This Week in Cardiology: Recent Episodes
Medscape
This podcast delivers Dr. John Mandrola’s summary and perspective on top news of the week that cardiologists can’t miss. This podcast is intended for US health professionals only.
Another failure of LA posterior wall isolation, first-line AF ablation, a revelation on EAST-AFNET 4 trial, an LAAC meta-analysis, and preventing AKI post-cardiac surgery are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- DAPT-MVD Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2517588
II Another Failure of Posterior Wall Isolation
- CORNERSTONE-AF Trial https://doi.org/10.1093/eurheartj/ehag486
- CAPLA Trial https://jamanetwork.com/journals/jama/fullarticle/2800186
- PVIOTAL IDE Trial 10.1016/j.hrthm.2025.08.018 External Link
III First Line AF ablation – One new study and a discovery about a second one
-
Catheter Ablation vs AAD for First-line Treatment of AF 10.1016/j.hrthm.2025.07.061 External Link
-
EAST-AFNET 4 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2019422
- Cardiology Trials Substack https://cardiologytrials.substack.com/p/summary-and-discussion-of-east-afnet
IV Left Atrial Appendage Closure Meta-analysis
- Long-Term Efficacy and Safety of LAAC vs OAC -- Meta-analysis https://academic.oup.com/europace/article/28/7/euag159/8739567
V Prevention of AKI after Cardiac Surgery: MERCURI-2
- MERCURI-2 Study https://jamanetwork.com/journals/jama/fullarticle/2852324
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The first oral PCSK9 inhibitor, another study finding safe MRI scanning in patients with nonconditional CIEDs, the PFA-SHAM trial, and the curious case of orthopedic injuries in cardiology are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Enlicitide Approved
First Oral PCSK9 Inhibitor Welcomed for Potential Primary Care Impact https://www.medscape.com/viewarticle/first-oral-pcsk9-inhibitor-welcomed-potential-primary-care-2026a1000own
- Dr Gregory Katz Substack https://gregorykatz.substack.com/p/are-we-sure-mercks-new-cholesterol
- CORALreef Lipids Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511002
- CORALreef HeFH Trial https://jamanetwork.com/journals/jama/fullarticle/2841258
- CORALreef Outcomes Trial https://clinicaltrials.gov/study/NCT06008756
II MRI Scans in Non-conditional CIEDs
Specialized Nurse Practitioners Safely Manage MRI in Patients With Cardiac Implantable Devices https://www.medscape.com/viewarticle/specialized-nurse-practitioners-safely-manage-mri-patients-2026a1000ozt
- Nurse Practitioner-Led CIED Monitoring During MRI 10.1016/j.hroo.2026.04.031 External Link
- MRI in Nonconditional Pacemakers and ICDs https://academic.oup.com/europace/article/22/2/288/5717383
- Heart Rhythm Society Consensus Document 10.1016/j.hrthm.2017.04.025 External Link
III PFA-SHAM trial
- PFA-SHAM Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.079484
- SHAM-PVI Trial https://jamanetwork.com/journals/jama/fullarticle/2823283
IV Orthopedic Injuries in Cardiology
What Will It Take to Make Fluoroscopy Labs Safer?
https://www.medscape.com/viewarticle/what-will-it-take-make-fluoroscopy-labs-safer-2026a1000ox6
- Expert Consensus Statement on Enhanced Radiation Protection https://www.jacc.org/doi/10.1016/j.jcin.2026.06.011
- 'Shed the Lead' and the Injuries. Should Cath Labs Go Lead-Free? https://www.medscape.com/viewarticle/shed-lead-and-injuries-should-cath-labs-go-lead-free-2024a1000hnb
- Health Hazards of Working in the Interventional Laboratory https://doi.org/10.1016/j.jacc.2014.11.056
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
DAPT back in the news, a practice-changing trial in VTE therapy, new knowledge in sudden cardiac death, heart failure definitions updated, and a dumb decision by NICE in the UK are the topics discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Antiplatelet Therapy After Stenting
- DAPT-MVD Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2517588
- HOST-EXAM Trial at 2 years https://pubmed.ncbi.nlm.nih.gov/34010616/
- HOST-EXAM Trial at 10 years 10.1016/S0140-6736(26)00422-8 External Link
- Nick Kurzen on X https://x.com/ncurzen/status/2077676739463922151
II Aspirin Proves Its Mettle After Hip and Knee Replacement
- EPCAT III Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2603649
- CRISTAL Trial https://jamanetwork.com/journals/jama/fullarticle/2795528
III New (and old) Knowledge in Sudden Cardiac Death
- Sudden Cardiac Death and its Relation to Cardiac Disease at Autopsy https://doi.org/10.1016/j.jacc.2026.01.029
- Sudden Cardiac Death Due to MI With Obstructive and Nonobstructive Coronary Arteries https://doi.org/10.1016/j.jacc.2026.01.030
- Frequency of Sudden Cardiac Death and Profiles of Risk https://www.ajconline.org/article/S0002-9149(97)00477-3/fulltext
IV Heart Failure Diagnosis
- AHA/ACC/ESC/WHF Expert Consensus Document http://jacc.org/doi/10.1016/j.jacc.2026.05.036
V NICE Makes a Dumb Decision
- NICE Recommends New Nonsteroidal MRA for Heart Failure
https://www.medscape.com/viewarticle/nice-recommends-new-nonsteroidal-mra-heart-failure-2026a1000nzv
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback on ICE vs TEE in AF ablation, fractional flow reserve without a wire or catheter, more bad news for ticagrelor, the POLY-HF trial, and oxygen targets after cardiac arrest are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
Oct 10, 2025 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1002990
- ICE vs TEE in Atrial Fibrillation Ablation https://jamanetwork.com/journals/jamacardiology/fullarticle/2839370
II FFR Without the Wire – Angiography-Derived FFR to Guide PCI
- ALL-RISE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600949
- FAST III Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2601841
- FAVOR III Trial 10.1016/S0140-6736(24)02175-5 External Link
- FAME 2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1205361
- Venk Murthy on X https://x.com/venkmurthy/status/2074849421452329456?s=20
III More Bad News for Ticagrelor
Jul 11, 2025 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1002704
- Prasugel, Ticagrelor, or Clopidogrel After PCI https://jamanetwork.com/journals/jamacardiology/fullarticle/2849614
IV The Polypill in Heart Failure
- POLY-HF trial https://www.nature.com/articles/s41591-026-04504-5
V Oxygen Targets After Cardiac Arrest
- LOGICAL Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2513814
- ICU-ROX Trial https://link.springer.com/article/10.1007/s00134-020-06196-y
- Secondary Analysis of the PILOT Trial https://journal.chestnet.org/article/S0012-3692(25)00553-7/fulltext
- Oxygen Targets in Comatose Survivors of Cardiac Arrest https://www.nejm.org/doi/10.1056/NEJMoa2208686
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback on valvular heart disease, statins and frailty, left atrial posterior wall ablation fails again, interpreting medical tests and AI ECG reading are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- PREVUE-VALVE Study https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5137
II Statins and Frailty
Statin Initiation Tied to Lower Frailty Risk in Older Adults https://www.medscape.com/viewarticle/statin-initiation-tied-lower-frailty-risk-older-adults-2026a1000lec
- Statins and Survival Free of Incident Frailty https://doi.org/10.1093/eurheartj/ehag451
III LA Posterior Wall Isolation Fails Again
- CORNERSTONE Trial https://doi.org/10.1093/eurheartj/ehag486
- CAPLA Trial https://jamanetwork.com/journals/jama/fullarticle/2800186
IV Does the Display of Test Results Improve Clinical Decisions?
- Interval Likelihood Ratios for Clinical Decsion-Making https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500249
- Making Sense of Health Statistics https://journals.sagepub.com/doi/full/10.1111/j.1539-6053.2008.00033.x
V AI and the ECG and Saving Doctors
- Case Report — AI-Enhanced Diagnostics https://www.nature.com/articles/s41591-026-04454-y
- The New York Times article https://www.nytimes.com/2026/06/22/health/artificial-intelligence-heart-damage.html
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, more long-term data on the TAVR/SAVR question, population prevalence of valvular heart disease in the US, and a CMS proposal to expand TAVR coverage are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- ICD Trends and Outcomes: 15-Year Analysis https://doi.org/10.1093/europace/euag110
- MADIT-RIT https://www.nejm.org/doi/full/10.1056/NEJMoa1211107
II More Long Term Data on TAVR vs SAVR
- PARTNER 2 Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.03.169
- 10-Year Outcomes of SAPIEN 3 TAVR or SAVR in Intermediate-Risk Patients https://doi.org/10.1016/j.jacc.2026.03.170
- TAVR at a Decade: Editorial https://doi.org/10.1016/j.jacc.2026.04.042
- EVOLUT Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063
- Updated 5-year Outcomes of TAVR vs SAVR in AS https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092
- NOTION Trial https://doi.org/10.1093/eurheartj/ehae043
- PARTNER 3 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509766
- NOTION 2 Trial https://academic.oup.com/eurheartj/article/45/37/3804/7673297
- TAVR vs SAVR Editorial : https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehag407/8708044
III The PREVUE-VALVE Study
- PREVUE-VALVE Study https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5137
IV CMS has Proposed New Coverage for TAVR
- CMS Proposal Document https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&ncaId=321
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, transcatheter tricuspid valve replacement, a new metabolic disease called CKM, the ARISE-FLUIDS Trial, the BIHCA trial, and temporal trends in ICD therapies are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- LOSE-AF Trial https://jamanetwork.com/journals/jama/fullarticle/2849335
- ARREST-AF Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2840225
- POP-AF Trial https://doi.org/10.1093/eurheartj/ehaf689
- PRAGUE-25 Trial https://www.jacc.org/doi/10.1016/j.jacc.2025.04.042
II Transcatheter Tricuspid Valve Replacement
- TRISCEND Cost Study https://doi.org/10.1016/j.shj.2026.101049
- TRISCEND II Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2401918
III More Disease Creation – the CKM Syndrome
ACC/AHA Release First-Ever Guideline for CKM Syndrome https://www.medscape.com/viewarticle/acc-aha-release-first-ever-guideline-ckm-syndrome-2026a1000jbs
- CKM Guideline in Circulation https://www.ahajournals.org/doi/10.1161/CIR.0000000000001447
IV Two Trials That Teach Important EBM Lessons
- ARISE-FLUIDS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2516225
- Dr Josh Farkas Post on X https://x.com/PulmCrit/status/2065064796270022845?s=20
V Bicarbonate for Inpatient Cardiac Arrest –The BIHCA trial
- BIHCA Trial https://jamanetwork.com/journals/jama/fullarticle/2850405
VI The Decline of VT in Heart Failure
- Trends and Outcomes in ICD Recipients: 15-Year Analysis https://doi.org/10.1093/europace/euag110
- Declining Risk of Sudden Death in HF https://www.nejm.org/doi/full/10.1056/NEJMoa1609758
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Chemical cardioversion in the ED, HF monitoring, weight loss in AF, and surgical LAA excision are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Chemical Cardioversion of AF in the ED: The FLECA-ED Trial
- FLECA-ED Rationale paper https://pmc.ncbi.nlm.nih.gov/articles/PMC10299428/
- FLECA-ED ESC Slides https://esc365.escardio.org/presentation/321209
- Review on Flecainide Use Despite CAST https://doi.org/10.1016/j.hrthm.2025.08.034
- RACE 7 ACWAS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1900353
II Heart Failure Monitoring – The ALLEVIATE-HF Trial
- ALLEVIATE-HF Trial https://doi.org/10.1016/j.jacc.2026.03.075
- CHAMPION Trial https://doi.org/10.1016/S0140-6736(11)60101-3
- GUIDE HF Trial https://doi.org/10.1016/S0140-6736(21)01754-2
-
ALLEVIATE-HF Editorial: Alerts Are Not Treatment https://doi.org/10.1016/j.jacc.2026.04.014
-
Steve Stiles Medscape report on CHAMPION https://www.medscape.com/viewarticle/755189
III A Negative Weight Loss Study in AF
- LOSE-AF Trial https://jamanetwork.com/journals/jama/fullarticle/2849335
IV Surgical LAA Excision
- OPINION Trial https://doi.org/10.1093/eurheartj/ehaf674
- LAAOS 3 trial https://www.nejm.org/doi/full/10.1056/NEJMoa2101897
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
A life-long treatment for high LDL, a VESALIUS subanalysis, tirzepatide beats semaglutide again, arrhythmia burden in cardiac amyloidosis, and a lipid guideline rebuttal are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Permanent Lipid Lowering therapy
- Verve 102 Therapy for FH https://www.nejm.org/doi/full/10.1056/NEJMoa2601283
II Vesalius Substudy on PCSK9i Use in Patients With Previous PCI
- VESALIUS Subgroup Analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.080616
- VESALIUS Study - NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2514428
III Tirzepatide looking to be best again
- SURPASS-EARLY Trial https://www.acpjournals.org/doi/10.7326/ANNALS-25-05602
- SURMOUNT-5 Trial https://www.nejm.org/doi/abs/10.1056/NEJMoa2416394
IV Arrhythmias in Cardiac Amyloidosis
Loop Recorders Reveal Arrhythmias in Cardiac Amyloidosis https://www.medscape.com/viewarticle/loop-recorders-reveal-arrhythmias-cardiac-amyloidosis-2026a1000gq9
- EXCALIBUR Study https://www.jacc.org/doi/10.1016/j.jacc.2026.04.030
V Lipid Guidelines
· In Defense of the 2026 Dyslipidemia Guideline https://www.medscape.com/viewarticle/defense-2026-dyslipidemia-guideline-2026a1000hd0
- Lipid Guidelines: Four Major Concerns https://www.medscape.com/viewarticle/lipid-guidelines-four-major-concerns-2026a1000fim
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Three more digoxin trials, yet another GLP-1 drug on the horizon, vagal nerve stimulation, trial inside baseball, and more on lipid guidelines are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I More About Low-dose Digoxin in HF — The DECISION Trial(s)
- DECISION Trial https://www.nature.com/articles/s41591-026-04406-6
- Digitalis Glycosides in HF — JAMA Meta-Analysis https://jamanetwork.com/journals/jama/fullarticle/2848972
- DIGIT-HF Trial https://www.nejm.org/doi/10.1056/NEJMoa2415471
- RADIANCE Trial (1993) https://www.nejm.org/doi/full/10.1056/NEJM199307013290101
- DECISION Withdrawal Study https://doi.org/10.1093/eurheartj/ehag385
- Digoxin Discontinuation vs Continuation in Chronic HF https://doi.org/10.1016/j.amjcard.2007.02.099
II Yet another GLP-1 Drug Announced this Week
Lillly News Release on Retatrutide https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
III A Big Story in HF Science – Vagal Nerve Stimulation in HFrEF
- ANTHEM HFrEF trial https://doi.org/10.1016/j.jacc.2026.03.040
- Editorials
An Unfinished ANTHEM https://doi.org/10.1016/j.jacc.2026.04.033
When Trials Stop Prematurely https://doi.org/10.1016/j.jacc.2026.03.039
IV Lipid Guideline News
Lipid Guidelines: Four Major Concerns
https://www.medscape.com/viewarticle/lipid-guidelines-four-major-concerns-2026a1000fim
- Editorial: Time to Move Beyond the Statin Nocebo Effect https://www.jacc.org/doi/10.1016/j.jacc.2026.04.002
- Correspondence: SAMSON N-of-1 Trial of Statin, Placebo, or No Treatment https://www.nejm.org/doi/full/10.1056/NEJMc2031173
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Another positive digoxin trial, another classic coronary physiology study from Imperial College London (ORBITA-FIRE), news in hypertrophic cardiomyopathy, and TAVR done in the wrong patients are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Digoxin in Rheumatic Heart Disease
- Dig-RHD Trial https://jamanetwork.com/journals/jama/fullarticle/2848973
- Safety and Efficacy of Digoxin: Meta-Analysis https://www.bmj.com/content/351/bmj.h4451.long
- DIGIT-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415471
- DIG Trial https://www.nejm.org/doi/full/10.1056/NEJM199702203360801
- RADIANCE Trial https://www.nejm.org/doi/full/10.1056/NEJM199307013290101
II The Physiologic Threshold for Angina
- ORBITA-FIRE Trial https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.125.078738
III Prediction in Hypertrophic Cardiomyopathy
- Predictors of Long-Term Outcomes in HCM https://jamanetwork.com/journals/jama/fullarticle/2848800#250998713
IV TAVR Trends in Young Patients
- Temporal Trends in AVR for Aortic Stenosis in Patients
- Wall Street Journal article https://www.wsj.com/health/healthcare/heart-valve-tavr-surgery-aorta-1e0eda70
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback from the DanGer Shock investigators, complete vs staged revascularization, polygenic risk scores, and quality improvement failure in an RCT are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- DanGer Shock Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2312572
- CHIP-BCIS 3 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2515704
II Immediate Complete vs Staged Revascularization in STEMI
- Meta-analysis: Timing of Complete Revasc in Patients with STEMI and Multivessel Disease https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.126.016601
- COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775 FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149
- iMODERN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2512918
III Polygenic Risk Scores for Prediction
- Polygenic Risk Report in US-Based Hospitals for 8 CV Conditions https://www.jacc.org/doi/10.1016/j.jacc.2026.03.035
IV Practice Improvement Policies Undergo the Proper Test – Randomization
- Quality Improvement on Hospitalizations and Health Outcomes for People with CHD https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012904
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Time to quadruple therapy, the disappointing AVANT GUARD trial, PFA risks, the TREAT-PVC trial, and NSTEMI care in the frail elderly are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Time to Quadruple Therapy in HFrEF
- Time to Quadruple Therapy After Diagnosis of HFrEF https://jamanetwork.com/journals/jamacardiology/fullarticle/2846899
II AVANT GUARD
PFA Bests Meds as First-Line Treatment for Persistent AF in Randomized Trial https://www.medscape.com/viewarticle/pulsed-field-ablation-bests-meds-first-line-treatment-2026a1000dsm
Pulsed Field Ablation of AF Disappoints in Setup for Success: AVANT GUARD https://www.medscape.com/viewarticle/pulsed-field-ablation-af-disappoints-setup-success-avant-2026a1000ddt
- AVANT GUARD Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600929
- Persistent AF: Meta-analysis of Invasive Strategies 10.1016/j.ijcard.2018.11.127 External Link
III Speaking of Scary News on PFA – The TIFFANY Study
-
Abstract - The TIFFANY Study https://www.heartrhythmjournal.com/article/S1547-5271(26)01747-9/fulltext
-
Delayed Myocardial Ischemia and Malignant Arrhythmias After PFA https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.077983
- Alberto Alfie Comment https://x.com/ALFIEEP1/status/2050029151315189774?s=20
IV TREAT PVC Trial
- TREAT-PVC Trial https://doi.org/10.1016/j.jacep.2026.01.011
- TREAT-AF Study 2020 https://doi.org/10.1016/j.jacep.2019.11.008
V NSTEMI In Frail Older Patients
- SENIOR-RITA Trial https://www.nejm.org/doi/10.1056/NEJMoa2407791
- Subanalysis of Senior RITA Trial https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2847995
- Timing of Invasive Strategy in Patients With Non-ST-Elevation Acute Coronary Syndrome -- Meta-analysis https://doi.org/10.1016/S0140-6736(17)31490-3
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
PCSK9 inhibitors in high-risk diabetes without ASCVD, the CAAN-AF trial, conduction system pacing vs biventricular pacing, PFA and stroke, and therapeutic fashion infects expert consensus are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I VESALIUS-CV
- VESALIUS-CV Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2514428
- JAMA Substudy https://jamanetwork.com/journals/jama/fullarticle/2847162
II How Best to Maximize CRT Benefit in Patients with AF
- CAAN-AF Trial https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag206/8654625?searchresult=1
- Role of AV Node Ablation: Meta-analysis of Observational Studies https://www.jacc.org/doi/10.1016/j.jacc.2011.10.891
III Stroke Rates in PFA vs Thermal Ablation
- Comparative Safety of RF versus PFA for AF in a High-Volume US Medical Center https://esc365.escardio.org/Ehra-congress/sessions/18281
IV Five New CSP Studies Presented and Published
- HeartSync-LBBP Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2845803
- PhysioSync-HF Trial
https://jamanetwork.com/journals/jamacardiology/fullarticle/2845802
- LEFT-BUNDLE-CRT Trial https://doi.org/10.1093/eurheartj/ehag225
- Long-Term Follow-up of His-Alternative I Trial https://www.jacc.org/doi/10.1016/j.jacep.2026.02.016
- LECART Trial https://esc365.escardio.org/Ehra-congress/sessions/17140
V New EP Training Document Published
- Advanced Training Statement on Clinical Cardiac Electrophysiology https://www.jacc.org/doi/10.1016/j.jacc.2026.01.074
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
SPIRIT-HF, another spironolactone trial in HFpEF; the ESSENCE imaging study of the drug olezarsen; the SirPAD trial in peripheral artery disease; and ultrasound-guided femoral venous access are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I ACC: SPIRIT-HF Trial
- FINEARTS-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2407107
-
TOPCAT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1313731
-
TOPCAT Americas Trial https://www.ahajournals.org/doi/10.1161/circulationaha.114.013255
II A New Class of Lipid Lowering Drug Has a Dubious Debut At ACC
- ESSENCE-TIMI 73b Imaging Study https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.080012
- ESSENCE-TIMI 73b Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2507227
- IMPROVE IT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1410489
III Drug-Coated Balloons Looked Quite Good in PAD interventions
Sirolimus-Coated Balloon Reduces Amputation Risk in Peripheral Artery Disease
https://www.medscape.com/viewarticle/sirolimus-coated-balloon-reduces-amputation-risk-peripheral-2026a1000a83
- SirPAD trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600360
IV Another Vascular Story from the European Heart Rhythm Association
- ULYSSES Trial https://doi.org/10.1093/eurheartj/ehag291
- ULTRA-FAST Trial https://doi.org/10.1093/europace/eux175
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Three imaging-guided PCI trials (two with surprising results), LDL targets, an oral PCSK9 inhibitor, and another beta-blocker withdrawal trial are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I IVUS-Guided PCI
- OPTIMAL Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600440
- IVUS-CHIP Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2601521
- ILUMIEN IV Trial https://www.nejm.org/doi/10.1056/NEJMoa2305861
- DKCRUSH VIII Trial https://doi.org/10.1016/j.jacc.2026.01.081
II Ez-PAVE Trial — Low vs Very Low LDL-targets
Does Ez-PAVE Support 'Lower Is Better' for LDL-C? https://www.medscape.com/viewarticle/does-ez-pave-support-lower-better-ldl-c-2026a1000akx
- Ez-PAVE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600283
- 2026 ACC/AHA Lipid Guidelines https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423
III CORALreef AddOn
- CORALreef AddOn Trial https://www.jacc.org/doi/abs/10.1016/j.jacc.2026.03.036
- This Week in Caardiology 2-6-26 https://www.medscape.com/viewarticle/1003240
- CORALreef Lipids Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511002
IV Another Post-MI Beta-blocker Withdrawal Study: SMART-DECISION
- SMART-DECISION Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2601005
- ABYSS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
John Mandrola offers an ACC recap of 5 big trials—Hi-PEITHO, PROTAVI, ORBITA-CTO, CHIPS-BCIS3 and CHAMPION AF
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Catheter Based Fibrinolysis of Pulmonary Embolism –Hi PEITHO
- Fibrinolysis Treatment Validated in Large Trial for Acute Intermediate-Risk PE https://www.medscape.com/viewarticle/fibrinolysis-treatment-validated-large-trial-acute-2026a10009im
- Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism (HI PEITHO) https://www.nejm.org/doi/full/10.1056/NEJMoa2516567
- National Early Warning Score (NEWS) https://www.england.nhs.uk/ourwork/clinical-policy/sepsis/nationalearlywarningscore/
II PRO-TAVI trial
- Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI) 10.1016/S0140-6736(26)00308-9 External Link
- PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation (Notion 3) https://www.nejm.org/doi/full/10.1056/NEJMoa2401513
III ORBITA CTO Sham vs PCI for Angina Relief
-
Tightly Blinded Trial Confirms PCI Reduces Angina in Obstructive Occlusion https://www.medscape.com/viewarticle/tightly-blinded-trial-confirms-pci-reduces-angina-2026a10009ob
-
A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina - ORBITA-CTO https://www.jacc.org/doi/10.1016/j.jacc.2026.03.027
- ORBITA 1 10.1016/S0140-6736(17)32714-9 External Link
- ORBITA 2 https://www.nejm.org/doi/full/10.1056/NEJMoa2310610
- DECISION CTO https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.031313
- EuroCTO https://doi.org/10.1093/eurheartj/ehy220
IV CHIPS BCIS3 Impella Supported High-Risk PCI
-
Adoption Before Evidence: CHIP-BCIS3 Humbles Impella https://www.medscape.com/viewarticle/adoption-before-evidence-chip-bcis3-humbles-impella-2026a10009jh
-
Left Ventricular Unloading in High-Risk PCI (CHIP BCIS3) https://www.nejm.org/doi/full/10.1056/NEJMoa2515704
- Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock (DanGer Shock) https://www.nejm.org/doi/full/10.1056/NEJMoa2312572
V CHAMPION AF – Watchman vs DOAC in Patients With AF
- CHAMPION-AF Trial Finds LAAC an Alternative for NOAC in Lower-Risk Patients https://www.medscape.com/viewarticle/champion-af-trial-finds-laac-alternative-noac-lower-risk-2026a10009ij
-
Six Reasons Why CHAMPION-AF Should Not Change Practice https://www.medscape.com/viewarticle/six-reasons-why-champion-af-should-not-change-practice-2026a10009i7
-
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation (CHAMPION AF) https://www.nejm.org/doi/full/10.1056/NEJMoa2517213
- Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation (CLOSURE AF) https://www.nejm.org/doi/full/10.1056/NEJMoa2513310
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Early aortic valve replacement in aortic stenosis, left atrial appendage occlusion in JAMA Cardiology, and a big preview of the upcoming American College of Cardiology meeting are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Early AVR
- RECOVERY Trial at 10 Years https://www.nejm.org/doi/full/10.1056/NEJMoa2511920
II Major Bleeding with Amulet and Watchman in JAMA Cardiology
- Amulet IDE Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2847047
- 5-year Results From Amulet IDE https://www.jacc.org/doi/10.1016/j.jacc.2024.10.101
III ACC Preview
Mandrola's Top 4 Trials from ACC 2026: Details Matter
https://www.medscape.com/viewarticle/mandrolas-top-4-trials-acc-2026-details-matter-2026a10008ti
- CHIB-BCIS3 Trial https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.123.013367
- Champion-AF Protocol https://doi.org/10.1016/j.ahj.2023.05.022
- ORBITA-CTO Protocol Paper https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1172763/full
- SPIRIT-HF Clinical Trials.gov https://clinicaltrials.gov/study/NCT04727073
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, the huge CLOSURE-AF trial of LAAC vs best medical therapy, previews of CHAMPION AF, and the controversial ACC/AHA lipid treatment guidelines are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- COBRRA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2510703
Closure AF published in NEJM
- CLOSURE-AF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2513310
- CHAMPION AF Rationale - Watchman FLX vs DOACs in Patients With AF https://pubmed.ncbi.nlm.nih.gov/37279840/
LIPID Guidelines
- ACC/AHA Joint Committee Guideline on Management of Dyslipidemia https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Beta-blocker in non-obstructive hypertrophic cardiomyopathy, a head-to-head apixaban vs rivaroxaban RCT, diltiazem vs metoprolol combined with DOAC, and the accuracy of smart watches for AF are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- EMPATICC trial https://academic.oup.com/eurheartj/article/47/9/1034/8242490
II Beta-blocker in Non-obstructive HCM
- BB vs Calcium Channel Blocker in Non-obstructive HCM https://doi.org/10.1016/j.jacc.2025.11.028
- RCT of Metoprolol in Patients With Obstructive HCM https://doi.org/10.1016/j.jacc.2021.07.065
III Apixaban vs Rivaroxaban for Bleeding Risk
- COBRRA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2510703
- AMPLIFY Trial (Apixaban) https://www.nejm.org/doi/10.1056/NEJMoa1302507
- EINSTEIN Trial (Rivaroxaban) https://www.nejm.org/doi/full/10.1056/NEJMoa1007903
IV Diltiazem vs Metoprolol When Combined with DOAC
- Risk for Bleeding in AF Patients Using Apixaban or Rivaroxaban With Diltiazem https://www.acpjournals.org/doi/10.7326/ANNALS-25-01408
V Actual Clinical Use of Smart Watches
- CIRCA-DOSE Original Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042622
- Wearable Smartwatches for AF Detection After Ablation https://doi.org/10.1093/europace/euaf280
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, urgent AF ablation, AF ablation as a stroke-reducing therapy, implantable loop recorder accuracy, and HF management in the setting of serious disease are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Urgent AF ablations
- Urgent vs Elective AF Ablation in the US https://www.jacc.org/doi/10.1016/j.jacep.2025.12.030
II AF Ablation Is Not Likely a Good Therapy for Stroke Reduction
- STABLED Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2845745
- Catheter Ablation for AF Associated With Lower Incidence of Stroke https://doi.org/10.1093/eurheartj/ehw087
III Loop Recorders
- ILR Accuracy - Multicenter, Multidevice Comparison https://doi.org/10.1016/j.jacep.2025.12.039
IV Heart Failure Therapy when there is Cancer
- EMPATICC Trial https://doi.org/10.1093/eurheartj/ehaf705
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
A superb note on CPR and DNR orders, patients' vs doctors' preferences for statins, more on GLP-1s, another LAAC story, and some closing cautionary notes on PFA are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- Addressing Inadequate Documentation of Unilateral DNR https://jamanetwork.com/journals/jama/fullarticle/2829203
- Video: Can We Talk About CPR? https://www.youtube.com/watch?v=yTCRfY3ETvI
- Personal Reminiscences of CPR's Origin https://www.ajconline.org/article/S0002-9149(03)00977-9/pdf
II Public Preferences for Statin Therapy
- Measuring Public Preferences for Statin Therapy https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2844660
III GLP-1 RA News
- ACHIEVE Trial https://doi.org/10.1016/S0140-6736(26)00202-3
IV New Trial in GLP-1 for Patients with AF
- Seminal-AF Trial https://clinicaltrials.gov/study/NCT06499857
V Relationship between Spontaneous Echo Contrast and LAAC Outcomes
- OCEAN-LAAC Trial https://doi.org/10.1016/j.jacep.2025.09.028
- News Release on Upcoming LAAOS-4 trial https://www.phri.ca/watchman/
- Reading the "Smoke" -- Editorial on OCEAN-LAAC https://www.jacc.org/doi/10.1016/j.jacep.2025.10.029
VI Concluding Remarks on My Talk at Western AF
- Delayed Myocardial Ischemia and Malignant Arrhythmias After PFA https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077983
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
EVOLUT Low Risk data, a provocative meta-analysis, DNR orders, targeted hypothermia, good news in HFpEF evidence, and GLP-1s as AF drugs are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I EVOLUT Low Risk 6-year Results and a 5-year Meta-Analysis of TAVR vs SAVR
- 6-Year Outcomes of TAVR vs SAVR https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063
- EVOLUT Low Risk Trial at 2 years https://www.nejm.org/doi/full/10.1056/NEJMoa1816885
- EVOLUT Low Risk Trial at 3 years https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017
- EVOLUT Low Risk Trial at 4 years https://www.jacc.org/doi/10.1016/j.jacc.2023.09.813
- Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials https://www.jacc.org/doi/10.1016/j.jacc.2019.08.1034
- TAVR vs SAVR 5-Year Outcomes - Systematic Review https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092
- TAVR vs SAVR Updated Meta-Analysis of RCTs https://www.jacc.org/doi/10.1016/j.jacc.2024.12.031
- UK TAVI Trial https://jamanetwork.com/journals/jama/fullarticle/2792251
- Dr David Cohen on X https://x.com/djc795/status/2023556582030852172?s=46&t=zXMCUoVjSsdyemzWlzeBjA
II DNR in the Hospital
- Inadequate Documentation of Unilateral DNR Orders https://jamanetwork.com/journals/jama/fullarticle/2829203
- GeriPal Blog Unilateral DNR Orders https://geripal.org/unilateral-dnr-gina-piscitello-erin-demartino-will-parker/
III Yet another failure of Targeted Hypothermia
- 2-Year Follow-Up of TTM2 Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2845193
- TTM2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2100591
IV Good news in HFpEF Evidence
- ALT-FLOW II Trial https://doi.org/10.1093/ejhf/xuaf016
V GLP-1 as AF drugs
- Semaglutide as Adjunctive Therapy in Obesity-Related PAF https://doi.org/10.1093/europace/euag018
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Ticagrelor vs prasugrel, a new LAAC device, pulsed field ablation AF results, lifestyle intervention in AF, the term "provider" vs "doctor," and coffee are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I TUXEDO-2 Trial
- TUXEDO-2 Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2844869
- ISAR-REACT 5 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1908973
II VERITAS Study of Dual-Seal LAAO
- VERITAS Study https://doi.org/10.1016/j.jacep.2026.01.021
III PFA vs RF over 4 years
- Advent-LTO study https://www.nature.com/articles/s41591-026-04246-4
- ADVENT Study https://www.nejm.org/doi/full/10.1056/NEJMoa2307291
- SPHERE PER-AF Study https://www.nature.com/articles/s41591-024-03022-6 SINGLE SHOT CHAMPION Study https://www.nejm.org/doi/full/10.1056/NEJMoa2502280
- BEAT PAROX-AF Trial https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf1115/8436829
IV What's in a Name — Use of the Term "Provider"
- Physicians Are Not Providers: The Ethical Significance of Names https://www.acpjournals.org/doi/10.7326/ANNALS-25-03852
V Coffee and Dementia Risk
- Coffee/Tea Intake and Dementia Risk https://jamanetwork.com/journals/jama/fullarticle/2844764
- Mandrola Commentary: Enough With the Coffee Research and Other Distractions https://www.medscape.com/viewarticle/883709
VI Lifestyle interventions Post AF ablation
- Improving Outcomes of AF by Lifestyle Interventions https://academic.oup.com/eurheartj/article/47/6/669/8243674
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Problems with the PREVENT score, a breakthrough in lipid-lowering therapy, a surprising benefit in stroke care, and more thoughts on statins and preventive care of heart disease are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I PREVENT Score
- PREVENT Equations in Young Adults https://doi.org/10.1016/j.jacc.2025.12.019
- Hospital Readmission Reduction Program for HF
https://pmc.ncbi.nlm.nih.gov/articles/PMC7664458/
II A New Breakthrough in LDL-C Management With an Oral PCSK9 Inhibitor
https://www.medscape.com/viewarticle/time-overcome-pcsk9i-inertia-new-data-future-options-2025a1000wf8
- CORALreef Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511002
- CORALreef Outcomes Trial https://clinicaltrials.gov/study/NCT06008756
III A Win for the Factor XI Inhibitor Asundexian – OCEANIC Stroke Trial
https://www.medscape.com/viewarticle/first-clear-win-factor-xia-inhibitors-stroke-reduced-2026a10003t0
- OCEANIC-STROKE Slide deck https://clinicaltrialresults.org/wp-content/uploads/2026/02/26-02-02_ISC_OCEANIC-STROKE-primary.pdf
- OCEANIC-AF Study Stopped Early https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficacy/
IV Statin Side Effects
-
Assessment of AEs Attributed to Statins -- Meta-analysis https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01578-8/fulltext
-
N-of-1 Trial to Assess AEs of Statins https://www.nejm.org/doi/full/10.1056/NEJMc2031173
- When to Start a Statin Is a Decision About Preference -- Editorial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029808
V Heart Disease Statistics
- CV Statistics in the US, 2026 https://www.jacc.org/doi/10.1016/j.jacc.2025.12.027
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, huge news in the rapidly expanding world of PFA AF Ablation, obesity, and a beautiful trial studying an AI-enhanced diagnostic tool in the office are the topics discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- Risk-Based TEE Omission in PVI 10.1016/j.hrthm.2025.04.056 External Link
II PFA News
- BEAT PAROX-AF trial https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf1115/8436829
- Life-Threatening Delayed Myocardial Ischemia and Malignant Arrhythmias Occurring After PFA https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.125.077983
-
Heart Rhythm TV: Life-Threatening Delayed Myocardial Ischemia and Malignant Arrhythmias https://www.youtube.com/watch?v=M-npoLKmRa4
-
MAUDE Adverse Event report https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=23733351&pc=QZI
III Obesity trends
- US State-Level Obesity Trends 1990-2022 and Forecasted to 2035 https://jamanetwork.com/journals/jama/fullarticle/2844495
IV New Tools in the Office
- TRICORDER Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02156-7/fulltext
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, the value of procedural volume for TAVR and MTEER, ventricular arrhythmia in older athletes, and the Goldilocks time horizon for predicting and modifying CV risk are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Procedural Volume and Outcomes for TAVI and M-TEER
- Operator Procedural Volumes and Outcomes for TAVR and MTEER https://jamanetwork.com/journals/jamacardiology/fullarticle/2843740
II Ventricular Arrhythmia in Older Male Endurance Athletes
Myocardial Fibrosis May Raise Arrhythmia Risk in Older Male Endurance Athletes
https://www.medscape.com/viewarticle/myocardial-fibrosis-may-raise-arrhythmia-risk-older-male-2026a10001y0
- Timing and Relationship of VA With Exercise Patterns in Older Male Endurance Athletes https://doi.org/10.1093/eurjpc/zwag021
III Predicting Cardiac Risk and Statin Use
- 30-Year ASCVD Risk Among US Adults Aged 30-59 https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012348
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Some great listener feedback, one of the best studies of the year in atrial fibrillation and heart failure, imaging to exclude left atrial thrombus, and a truly amazing first cardiac procedure are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
On Fish Oil and AF
- Links between omega-3 fatty acids and AF https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.058596
- Omega-3 and risk of AF https://doi.org/10.1016/j.pcad.2024.11.003
- DHA vs EPA in reducing vulnerability to AF https://www.ahajournals.org/doi/10.1161/CIRCEP.112.971515
II Withdrawal of HF Therapy AF rhythm control
The AF is Gone, the EF Is Up. Can You Stop the HF Meds?
https://www.medscape.com/viewarticle/af-gone-ef-can-you-stop-hf-meds-2024a1000h6o
- Effect of beta-blockers in patient with HF plus AF -- meta-analysis https://pubmed.ncbi.nlm.nih.gov/25193873/
- TRED HF Trial 10.1016/S0140-6736(18)32484-X External Link
- WITHDRAW-AF Trial https://academic.oup.com/eurheartj/article/47/2/250/8238240
III ICE or TEE Before AF Ablation
- ICE vs TEE in Atrial Fibrillation Ablation https://jamanetwork.com/journals/jamacardiology/fullarticle/2839370
IV The Vector Procedure
- Percutaneous Aorto-Coronary Bypass Graft: the VECTOR procedure https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.125.016130
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The limits of knowing coronary artery disease anatomy, fish oil and AF risk, a new drug for PSVT, and maybe I was wrong about a drug for AF conversion (the RAFF4 trial). These are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Prediction of CAD is hard — even if you have anatomy
- CCTA in Prediction of First Coronary Events https://jamanetwork.com/journals/jama/fullarticle/2841255
II Fish Oil and AF (and as a bonus we learn again about analytic flexibility)
- Are Fish Oils on the Hook for AF Risk?
https://www.medscape.com/viewarticle/995290
- Omega-3 and Fish Oil Use With Risk of AF https://www.ahajournals.org/doi/full/10.1161/JAHA.125.043031
- Effect of Long-Term Marine Omega-3 Fatty Acids on the Risk of AF https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055654
- RESPECT-EPA Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065520
- Association Between Omega-3 Fatty Acids and AF: Meta Analysis https://link.springer.com/article/10.1007/s10557-021-07204-z
- Fish Oil Supplements and Risk of AF https://academic.oup.com/eurjpc/article/29/14/1911/6679610
- Editorial: Fish Oil Supplements and AF Risk https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057464
III A New Drug for PSVT
- FDA Approval https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-type-abnormally-fast-heart-rhythm
- RAPID trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00776-6/fulltext
IV AF Conversion with Vernakalant
- RAFF4 Trial https://www.bmj.com/content/391/bmj-2025-085632.long
- Editorial: Rapid Cardioversion for Acute AF https://www.bmj.com/content/391/bmj.r2264
VI A Quick Note on HFpEF
Med Op-Ed: Avalanche Survival, HFpEF Skepticism, and More
https://www.medscape.com/viewarticle/med-op-ed-avalanche-survival-hfpef-skepticism-and-more-2026a1000012
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The MI paradox of risk scores, the CELEBRATE trial of a new subcutaneous glycoprotein IIb/IIIA inhibitor (with its funny endpoint), the SURPASS CVOT trial, and the bad story of andexanet alfa are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I What do risk scores mean for individuals? Or perhaps a better question: Is a first MI preventable?
- Limitations of Screening in Predicting First MI https://www.jacc.org/doi/10.1016/j.jacadv.2025.102361
- Sudden Death Due to Cardiac Arrhythmias https://www.nejm.org/doi/abs/10.1056/NEJMra000650
- UMC Amsterdam group (EHJ) https://academic.oup.com/eurheartj/article/46/38/3762/8181058
II CELEBRATE Trial
- CELEBRATE Trial https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500268
III SURPASS CVOT Trial Published
Aug 01, 2025 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1002781
- SURPASS-CVOT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2505928
- REWIND Trial 10.1016/S0140-6736(19)31149-3 External Link
IV FDA Pulls Andexanet Alfa From the Market
- ANNEXA 4 https://www.nejm.org/doi/10.1056/NEJMoa1814051
- ANNEXA I https://www.nejm.org/doi/full/10.1056/NEJMoa2313040
- Richard Buka Tweet https://x.com/richardbuka/status/2001045834050216327?s=20
V Mandrola's Top Cardiovascular Stories of 2025
https://www.medscape.com/viewarticle/mandrolas-top-10-cardiovascular-stories-2025-2025a1000yuh
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
An elegant study in post-TAVI atrioventricular block, a PSA for my structural colleagues, revascularization in women, and a CTO PCI trial are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I AV Block After TAVR
Heart Blocks During vs After TAVR Show Distinct Patterns
https://www.medscape.com/viewarticle/heart-blocks-during-vs-after-tavr-show-distinct-patterns-2025a1000ypp
- Mechanisms Underlying Alterations in Cardiac Conduction After TAVR https://jamanetwork.com/journals/jamacardiology/fullarticle/2842748
II Related PSA Announcement to My Structural Colleagues
III Revascularization Strategies in Women with Severe Chronic CAD
Women With Chronic Severe CAD Fare Better With CABG vs PCI
https://www.medscape.com/viewarticle/women-chronic-severe-cad-fare-better-cabg-vs-pci-2025a1000ygd
- PCI vs CABG in Women With Chronic CAD https://doi.org/10.1093/eurheartj/ehaf806
- PCI vs CABG - Meta-Analysis of 4 RCTs https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02334-5/abstract
- CABG vs Drug-Eluting Stent Implantation for CAD - Meta-Analysis https://www.jacc.org/doi/10.1016/j.jcin.2016.10.008
- RECHARGE trial https://therechargetrial.com/
IV A CTO PCI RCT – But don't get your hopes up
- Early vs Late-Staged PCI After Subintimal Tracking and Re-entry for CTO https://doi.org/10.1016/j.jacc.2025.09.1598
- DECISION CTO trial https://pubmed.ncbi.nlm.nih.gov/30813758/
- National Inpatient Sample Database PCI CTO Associated With Higher Mortality https://pubmed.ncbi.nlm.nih.gov/37356643/
V Mandrola's Top 10 Stories
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Less is more after PCI, the TARGET-FIRST trial, a negative blood pressure trial that is actually positive, aspirin vs OAC for bleeding, AEDs, and Factor XI is not dead yet are the topics discussed by John Mandrola, MD, on this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Less is More: TARGET-FIRST
- TARGET-FIRST Trial https://www.nejm.org/doi/10.1056/NEJMoa2508808
- STOPDAPT-2 ACS Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2789701
II A Negative Trial That Is Actually Positive
- The RETREAT-FRAIL Study https://www.nejm.org/doi/full/10.1056/NEJMoa2508157
III Major Bleeding With Aspirin vs Apixaban
- Subanalysis of ARTESiA https://jamanetwork.com/journals/jamacardiology/fullarticle/2841075
- ARTESiA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2310234
- AVERROES Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1007432
IV High Value Interventions – The AED
-
Experts Call for AED Placement on All Commercial Aircraft https://www.medscape.com/viewarticle/experts-call-aed-placement-all-commercial-aircraft-2025a1000xzf
-
In-Flight Sudden Cardiac Arrest and AED Use 10.1016/j.cjca.2025.10.010 External Link
V Factor XI Inhibitors – OCEANIC STROKE trial
- Bayer Press Release on Asundexian https://www.bayer.com/en/us/news-stories/oceanic-stroke
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, huge news in the world of carotid disease with the CREST-2 publication, prasugrel beats ticagrelor again, and a big coffee trial are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- Complete Revascularization for Acute MI Meta-analysis https://doi.org/10.1016/S0140-6736(25)02170-1
II A Sea Change in the Treatment of Carotid Artery Disease — CREST-2 Published
- ECST-2 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00107-3/fulltext
- SPACE-2 https://pubmed.ncbi.nlm.nih.gov/36115360/
- CREST-2 Trial www.nejm.org/doi/full/10.1056/NEJMoa2508800
- CREST Protocol paper https://pmc.ncbi.nlm.nih.gov/articles/PMC5987521/
III Prasugrel Beats Ticagrelor in High-Risk Patients With Diabetes After PCI https://www.medscape.com/viewarticle/prasugrel-beats-ticagrelor-high-risk-patients-diabetes-after-2025a1000wbt
- PLATO trial https://www.nejm.org/doi/full/10.1056/NEJMoa0904327
- Ticagrelor or prasugrel vs clopidogrel in PCI https://eurointervention.pcronline.com/article/ticagrelor-or-prasugrel-versus-clopidogrel-in-patients-undergoing-percutaneous-coronary-intervention-for-chronic-coronary-syndromes
- ISAR-REACT 5 trial https://www.nejm.org/doi/full/10.1056/NEJMoa1908973
IV Another Coffee and AF study
Can Coffee Cut the Risk for Atrial Fibrillation?
https://www.medscape.com/viewarticle/can-coffee-cut-risk-atrial-fibrillation-2025a1000w11
A Coffee a Day to Keep the AFib Away? The DECAF Trial Discussed https://www.medscape.com/viewarticle/coffee-day-keep-afib-away-decaf-trial-discussed-2025a1000v5z
- DECAF trial https://jamanetwork.com/journals/jama/fullarticle/2841253
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback on the PISCES trial, AHA news (including a big PCSK9i trial), beta-blockers post MI, LAAC, and post-AF ablation OAC use are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
Why I Believe Fish Oil's Big CV Benefit in Dialysis Patients https://www.medscape.com/viewarticle/why-i-believe-fish-oils-big-cv-benefit-dialysis-patients-2025a1000uzg
- PISCES trial https://www.nejm.org/doi/full/10.1056/NEJMoa2513032
II PCSK9 Inhibitor News
In Global Trial, PCSK9 Inhibitor Provides Major Protection Against First CV Event https://www.medscape.com/viewarticle/global-trial-pcsk9-inhibitor-provides-major-protection-2025a1000uzp
- VESALIUS-CV trial https://www.nejm.org/doi/full/10.1056/NEJMoa2514428
- ODYSSEY trial https://www.nejm.org/doi/full/10.1056/NEJMoa1801174
- FOURIER https://www.nejm.org/doi/full/10.1056/NEJMoa1615664
- Anish Koka Tweet on LDL-lowering https://x.com/anish_koka/status/1987280506937909326?s=20
III Beta-Blockers After MI and John Cleland
- Beta-Blockers after MI with normal EF https://www.nejm.org/doi/full/10.1056/NEJMoa2512686
- REBOOT-CNIC trial https://www.nejm.org/doi/full/10.1056/NEJMoa2504735
- REDUCE AMI trial https://academic.oup.com/ehjcvp/article/9/2/192/6895544?login=false
- ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204
- CAPITAL RCT trial https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199347
- Beta-Blockers after MI with mildly reduced EF https://pubmed.ncbi.nlm.nih.gov/40897190/
- John Cleland Clinical Outlook https://www.nature.com/articles/s41569-025-01228-w
IV Left Atrial Appendage Closure – The CLOSURE-AF trial
Percutaneous LAAC in AF Falls Short Again in CLOSURE-AF https://www.medscape.com/viewarticle/percutaneous-left-atrial-appendage-closure-af-falls-short-2025a1000uzu
- Prague-17 Trial https://www.jacc.org/doi/10.1016/j.jacc.2020.04.067
- OPTION trial https://www.nejm.org/doi/full/10.1056/NEJMoa2408308
V Oral AC after AF ablation – the OCEAN Trial
Anticoagulation After AF Ablation: The OCEAN Trial Still Leaves Questions https://www.medscape.com/viewarticle/anticoagulation-after-af-ablation-ocean-trial-still-leaves-2025a1000v4t
- OCEAN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509688
- ALONE-AF trial https://jamanetwork.com/journals/jama/fullarticle/2838294
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback on non-culprit PCI in STEMI, a major cardiac result in patients on hemodialysis, news on GLP-1 agonists, a dubious stroke trial, and an AHA preview are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- Meta-analysis of MI as a surrogate https://pubmed.ncbi.nlm.nih.gov/34694318/
- Compare Acute Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1701067
- DANAMI-3–PRIMULTI 10.1016/S0140-6736(15)60648-1 External Link
- CULPRIT-SHOCK https://www.nejm.org/doi/full/10.1056/NEJMoa1710261
II Huge Cardiac News for Patients with ESRD PISCES article EMBARGOED Till 1130 AM EST
- PISCES Trial www.nejm.org/doi/full/10.1056/NEJMoa2513032
- REDUCE-IT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
- STRENGTH Trial https://jamanetwork.com/journals/jama/fullarticle/2773120
- FISH trial https://jamanetwork.com/journals/jama/fullarticle/1150094
III Obesity Agents
- White House announces deal with Lilly and Novo on GLP-1 drugs https://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-shares-rise-trump-obesity-drug-deal-nears-2025-11-06/
Amylin Agonists
- Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial
https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf
- Eloralintide Phase 2 Study https://doi.org/10.1016/S0140-6736(25)02155-5
GLP-1 Comparisons
- SURMOUNT-5 Trial https://www.nejm.org/doi/10.1056/NEJMoa2416394
- Tirzepatide vs Semaglutide in 10-year CVD Risk Reduction https://doi.org/10.1093/ehjopen/oeaf117
IV A Problematic Trial in Stroke Care
- LAMP trial https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2840370
V AHA Preview
AHA 2025: Mandrola's Four Trials to Look For https://www.medscape.com/viewarticle/aha-2025-mandrolas-four-trials-look-2025a1000u80
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Four pillars of cardiology today, stable coronary artery disease, severe aortic stenosis, the evaluation of chest pain, and best therapies for atrial fibrillation are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Stable CAD Complete vs culprit-only revascularization at time of STEMI
- iMODERN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2512918
- PRAMI Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1305520
- COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775
- FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149
- PCI Revascularization Strategies After MI https://www.jacc.org/doi/10.1016/j.jacc.2024.04.051
- CULPRIT SHOCK Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1710261
- How a Meta-Analysis Can Mislead https://www.sensible-med.com/p/how-a-meta-analysis-can-misleadthe
II SEVERE Aortic Senosis
7-Year PARTNER 3 Results – TAVI vs SAVR
- 7-year results PARTNER 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2509766
- PARTNER 3 at 1 year https://www.nejm.org/doi/10.1056/NEJMoa1814052
- PARTNER 3 at 5 years https://www.nejm.org/doi/10.1056/NEJMoa2307447
III Functional vs Anatomic Assessment in Suspected CAD
- 10-year follow-up of PROMISE trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2838118
- PROMISE Trial https://www.nejm.org/doi/10.1056/NEJMoa1415516
- CCTA vs Functional Stress Test – Meta-Analysis https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2655243
IV ARREST AF
- ARREST AF trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2840225
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The PREVENT score in hypertension, GLP-1 mechanism of action in cardiovascular disease, CAD type and statin benefit, and the problem with hospitalization endpoints in HF trials are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Is the PREVENT Calculator Best for Determining CVD Risk? Insights From a Post Hoc Analysis of SPRINT Trial
https://www.medscape.com/viewarticle/prevent-calculator-best-determining-cvd-risk-insights-post-2025a1000svo
- PREVENT Calculator https://doi.org/10.1016/j.jacc.2025.07.037
- SPRINT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1511939
II GLP-1 Mechanism of Action in CV Disease
- Analysis of SELECT Trial 10.1016/S0140-6736(25)01375-3 External Link
- SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
III Statins and CAD Phenotype on CTA and Outcomes
- Interactions Between Statin Use, CAD Phenotypes on CTA https://www.jacc.org/doi/10.1016/j.jcmg.2025.05.018
- Statin Use for Primary Prevention of CVD https://jamanetwork.com/journals/jama/fullarticle/2795522
IV HHF Endpoints in Heart Failure Trials
- The Problem with Hospitalization Endpoints in HF Trials https://onlinelibrary.wiley.com/doi/10.1002/ejhf.70070
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Another knock against the antiplatelet/anticoagulant combo, polypills in HF, the physical exam of the future, and the problem of underpowered trials that even Bayesian analyses cannot rescue are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- Trends Study https://www.heartrhythmjournal.com/article/S1547-5271(11)00496-6/fulltext
II Another knock against the Antiplatelet/Anticoagulation combination
"Antiplatelet Plus Oral Anticoagulant Lowers Stroke, Raises Bleeding Risk" https://www.medscape.com/viewarticle/antiplatelet-plus-oral-anticoagulant-lowers-stroke-raises-2025a1000re0
- ATIS-NVAF Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2839511
- AQUATIC trial https://www.nejm.org/doi/abs/10.1056/NEJMoa2507532
III Polypill for HFrEF
- A Multilevel Polypill for Patients With HFrEF https://www.jacc.org/doi/10.1016/j.jacadv.2025.102195
IV The Physical Exam of the Future
- Point-of-Care Ultrasound https://doi.org/10.1016/j.jchf.2025.102707
V More on Underpowered Trials – GA vs Moderate Sedation in IV stroke
- SEGA Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2839838
- Bayesian Analyses of CV Trials https://doi.org/10.1016/j.cjca.2021.03.014
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
GLP-1 use in HFrEF, left atrial posterior wall isolation during AF ablation, peri-device leaks for LAAO, new findings in post-cardiac surgery AF, and imaging before AF ablation are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback
HYPERION trial https://www.nejm.org/doi/10.1056/NEJMoa2508170
ZENITH trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415160
II GLP1 Use in HFrEF
Effects of GLP-1s in Patients With HFrEF https://doi.org/10.1016/j.jchf.2025.102573
FIGHT Study https://jamanetwork.com/journals/jama/fullarticle/2540402
FIGHT Study Post-hoc Analysis https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.14862
Substudy of EXSCEL Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.041659
III LA Posterior Wall Isolation Saga
Failure of PW Wall Isolation by PFA with Epicardial Mapping https://doi.org/10.1016/j.jacep.2025.08.017
IV Peridevice Leaks After LAAO
IMPRESSION LAAC Study https://doi.org/10.1016/j.jacep.2025.08.014
V Post Cardiac Surgery AF
Monitoring of New-Onset AF After CABG https://jamanetwork.com/journals/jama/fullarticle/2839710
PACES trial https://clinicaltrials.gov/study/NCT04045665
VI TEE vs ICE Before AF ablation
ICE vs TEE Study https://jamanetwork.com/journals/jamacardiology/fullarticle/2839370
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Two great stories of translation science leading to beneficial drugs in terrible diseases of the heart and the Sisyphean task of predicting the need for pacing after TAVI are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Sotatercept
- HYPERION Trial https://www.nejm.org/doi/10.1056/NEJMoa2508170
- ZENITH Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415160
- Evidence report on treatment for PAH https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-on-treatment-for-pulmonary-arterial-hypertension/
- PAH Sotatercept Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2503944
II Acoramidis and ATTR Cardiomyopathy
- ATTRIBUTE-CM Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2305434?logout=true
- ATTRIBUTE-CM Analysis - Substudy https://www.jacc.org/doi/10.1016/j.jacc.2025.09.013
- Tafamadis Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1805689
III Pacing After TAVI
- Prophylactic pacemaker after TAVI https://www.jacc.org/doi/10.1016/j.jacep.2025.07.028
- PROMOTE study https://doi.org/10.1016/j.hrthm.2024.12.019
- Evaluation of ESC criteria on RBBB patients undergoing TAVI https://doi.org/10.1016/j.hrthm.2024.11.030
- Editorial on Heart Rhythm journal papers https://www.heartrhythmjournal.com/article/S1547-5271(25)00114-6/abstract
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
A bold trial in valvular heart disease, a CV prevention trial whose message is humility, VTE dogma challenged, more news on oral GLP-1 agonists, and a few public service announcements are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I DOUBLE-CHOICE: Minimalist Approach to TAVI May Be as Good as Standard of Care https://www.medscape.com/viewarticle/double-choice-minimalist-approach-tavi-may-be-good-standard-2025a1000pp7
- Patient & Physician Perspectives on CV Risk https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011837
II KP Vaccinate Trial
- KP Vaccinate Trial https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500208
- IAMI trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057042
- Increasing Flu Vaccinations in Patients With Chronic Disease https://jamanetwork.com/journals/jama/fullarticle/2824956
- MI FREEE Trial https://www.nejm.org/doi/full/10.1056/NEJMsa1107913
III Hi PRO Trial
- Apixaban for Extended Treatment of VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2509426
- Recurrent VTE in Patients with Provoked VTE https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/226140
IV Oral GLP-1 Agonists
- ATTAIN 1 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511774
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
More trials at ESC, including PARACHUTE HF, DAPA ACT HF-TIMI 68, AMALFI, and a super-interesting modeling study of when to start oral anticoagulants in AF, are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I PARACHUTE HF
First Evidence of Treatment Benefit in Chagas Heart Failure
https://www.medscape.com/viewarticle/first-evidence-treatment-benefit-chagas-heart-failure-2025a1000oem
- PARACHUTE-HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021
II SGLT2i Early Initiation — DAPA ACT HF-TIMI 68 Trial
Trial Data Support In-Hospital Initiation of SGLT2 Inhibitors for Heart Failure https://www.medscape.com/viewarticle/trial-data-support-hospital-initiation-sglt2-inhibitors-2025a1000o5q
- DAPA ACT HF-TIMI 68
https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076575
III AMALFI Trial of AF Screening
Remote ECG Screening Ups Atrial Fibrillation Detection 'Modestly' https://www.medscape.com/viewarticle/remote-ecg-screening-ups-atrial-fibrillation-detection-2025a1000myx
- AMALFI Trial https://jamanetwork.com/journals/jama/article-abstract/2838482
- STROKESTOP Trial https://www.thelancet.com/article/S0140-6736(21)01637-8/fulltext
- LOOP Trial 10.1016/S0140-6736(21)01698-6 External Link
IV Finding that Sweet Spot of Stroke Risk Threshold for Starting DOAC therapy
- Stroke Risk Threshold for non-Vitamin K Antagonist OAC in AF https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012090
- Variations in Rates of Stroke Across Patients With AF https://www.ahajournals.org/doi/10.1161/circulationaha.116.024057
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
More from ESC including: Valvular HD guidelines, a new drug class for HTN, myosin inhibition in HCM, vericiguat, and digoxin are the topic discussed by John Mandrola, MD.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I New European Valvular Heart Disease Guidelines
- 2025 ESC/EACTS Guidelines for the management of valvular heart disease https://doi.org/10.1093/eurheartj/ehaf194
- Debate: Does Asymptomatic Aortic Stenosis Warrant Early Intervention? https://exp.medscape.com/debates/does-asymptomatic-aortic-stenosis-warrant-early-intervention/
- Surgical Ablation of Atrial Fibrillation during Mitral-Valve Surgery https://www.nejm.org/doi/full/10.1056/NEJMoa1500528
- Surgical ablation of atrial fibrillation: a systematic review and meta-analysis https://doi.org/10.1093/europace/eux336
II New Drug for Resistant HTN
-
Baxdrostat: A 'Game Changer' for Hypertension? https://www.medscape.com/viewarticle/baxdrostat-game-changer-hypertension-2025a1000mz7
-
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension https://www.nejm.org/doi/full/10.1056/NEJMoa2507109
- Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension https://www.nejm.org/doi/10.1056/NEJMoa2501440
III HCM News at ESC
-
New Trials Clarify Role of Myosin Inhibitors for Hypertrophic Cardiomyopathy https://www.medscape.com/viewarticle/new-trials-clarify-role-myosin-inhibitors-hypertrophic-2025a1000myv
-
MAPLE HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2504654
- SEQUOIA HCM https://www.nejm.org/doi/10.1056/NEJMoa2401424
- ODYSSEY HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2505927
IV Vericiguat at ESC
-
New Data Said to Support Vericiguat as Standard Therapy for Heart Failurehttps://www.medscape.com/viewarticle/new-data-said-support-vericiguat-standard-therapy-heart-2025a1000mz9
-
VICTOR https://doi.org/10.1016/S0140-6736(25)01665-4
- VICTORIA https://www.nejm.org/doi/full/10.1056/NEJMoa1915928
- An individual participant data analysis of the VICTORIA and VICTOR trials https://doi.org/10.1016/S0140-6736(25)01682-4
V More on Digoxin
- RATE AF substudy https://doi.org/10.1002/ejhf.70022
- Main RATE-AF trial https://jamanetwork.com/journals/jama/fullarticle/2774407
- Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis https://doi.org/10.1016/S0140-6736(14)61373-8
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The big beta-blocker story from ESC, dual pathway therapy with aspirin and OAC, stopping OAC after successful AF ablation, and DANCAVAS II trial are the topics John Mandrola, MD, discusses on this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
This Week in Cardiology Podcast – August 29 https://www.medscape.com/viewarticle/1002877
II The Big Beta-blocker Story from ESC
Beta-Blockers Post-MI: A Clear Clinical Message https://www.medscape.com/viewarticle/beta-blockers-post-mi-clear-clinical-message-2025a1000mz0
- REBOOT https://www.nejm.org/doi/full/10.1056/NEJMoa2504735
-
BETAMI-DANBLOCK https://www.nejm.org/doi/abs/10.1056/NEJMoa2505985
-
REDUCE AMI https://www.nejm.org/doi/10.1056/NEJMoa2401479
- CAPITAL RCT https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199347
- Post Hoc Analysis From REBOOT Trial https://eurointervention.pcronline.com/article/effect-of-beta-blocker-withholding-or-withdrawal-after-myocardial-infarction-without-reduced-ejection-fraction-on-ischaemic-events-a-post-hoc-analysis-from-the-reboot-trial
- Beta-Blockers After MI With Mildly Reduced Ejection Fraction https://doi.org/10.1016/S0140-6736(25)01592-2
- CAPRICORN 10.1016/S0140-6736(00)04560-8 External Link
- BHAT https://jamanetwork.com/journals/jama/fullarticle/370103
- ISIS 1 https://pubmed.ncbi.nlm.nih.gov/2873379/
III Aspirin and OAC Combination Clearly Dangerous
Aspirin Plus Oral Anticoagulants Raises Mortality, Bleeding https://www.medscape.com/viewarticle/aspirin-plus-oral-anticoagulants-raises-mortality-bleeding-2025a1000nam
- AQUATIC https://www.nejm.org/doi/full/10.1056/NEJMoa2507532
- AFIRE https://www.nejm.org/doi/full/10.1056/NEJMoa1904143
- EPIC CAD https://www.nejm.org/doi/10.1056/NEJMoa2407362
- OAC-ALONE https://pubmed.ncbi.nlm.nih.gov/30586700/
IV Stop or Continue OAC after Successful AF Ablation
- ALONE-AF https://jamanetwork.com/journals/jama/fullarticle/2838294
- OCEAN trial protocol https://doi.org/10.1016/j.ahj.2017.12.007
V DANCAVAS II Trial
- DANCAVAS II https://doi.org/10.1093/eurheartj/ehaf704
- DANCAVAS I https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
CAC 0 takes a gut punch, ICD therapies cannot be surrogates for benefit, and two important trials from ESC are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I CAC 0
- LDL-C and CVD Risk With CAC Score 0 https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf497/8228645
II ICD Therapies
- Contemporary ICD Benefit https://www.jacc.org/doi/10.1016/j.jacep.2025.06.028
- PROFID Trial https://profid-project.eu/profid-ehra-trial/
- MADIT-RIT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1211107
- Declining Risk of Sudden Death in HF https://www.nejm.org/doi/full/10.1056/NEJMoa1609758
III Digit-HF
- DIGIT-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415471
- Digoxin–Mortality: Comparison in the DIG trial https://academic.oup.com/eurheartj/article/40/40/3336/5520008
IV POTCAST
- POTCAST trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509542
ESC Preview
IV HTN Guidelines
- New Blood Pressure Guidelines: 4 Things I Like and 2 Concerns https://www.medscape.com/viewarticle/new-blood-pressure-guidelines-4-thing-i-and-2-concerns-2025a1000m1x
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
John Mandrola discusses conduction system pacing vs standard pacing, withdrawing HF meds when AF is corrected and patient selection in LAAO.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Conduction System Pacing
- CSPACE trial https://doi.org/10.1016/j.jacc.2025.06.043
- BLOCK HF trial https://www.nejm.org/doi/full/10.1056/NEJMoa1210356
- BioPace trial https://doi.org/10.1093/europace/euaf029
II Withdrawing Meds After AF Corrected
- WITHDRAW AF https://doi.org/10.1093/eurheartj/ehaf563
- TRED HF https://pubmed.ncbi.nlm.nih.gov/30429050/
III Patient Selection in Left Atrial Appendage Occlusion
- Long-Term Outcomes Following LAAO in Medicare Beneficiaries: Outcomes From the National Cardiovascular Data Registry https://www.ahajournals.org/doi/10.1161/JAHA.124.039780
ESC Preview
IV HTN Guidelines
- New Blood Pressure Guidelines: 4 Things I Like and 2 Concerns https://www.medscape.com/viewarticle/new-blood-pressure-guidelines-4-thing-i-and-2-concerns-2025a1000m1x
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Big new hypertension guidelines, ultraprocessed foods, coronary sinus reduction and evidence-based medicine, and more news on pulsed field ablation for atrial fibrillation are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I HTN Guidelines
- BP Meds Should Begin Promptly, New ACC/AHA Guidelines Say
https://www.medscape.com/viewarticle/bp-meds-should-begin-promptly-new-acc-aha-guidelines-say-2025a1000lms
- Guideline for Management of High Blood Pressure https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356
- BPROAD trial https://www.nejm.org/doi/full/10.1056/NEJMoa2412006
- Trial Score Framework https://pmc.ncbi.nlm.nih.gov/articles/PMC6459598/
II UltraProcessed Foods
- AHA statement on Ultraprocessed Foods and Cardiometabolic Health
- https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001365
III Refractory Angina and the Coronary Sinus Reducer – A Lesson in EBM
-
Coronary Sinus Reducer Shows Promise, With Caveats https://www.medscape.com/viewarticle/coronary-sinus-reducer-shows-promise-caveats-2025a1000l76
-
Coronary Sinus Reducer — Meta-analysis https://www.jacc.org/doi/10.1016/j.jcin.2025.06.012
- COSIRA II Trial https://clinicaltrials.gov/study/NCT05102019
IV Pulsed Field Ablation Still Looking Strong
- Management of OACs After PFA 10.1016/j.hrthm.2025.03.1952 External Link
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback on SURPASS CVOT, AF ablation and the limits of meta-analyses, a Watchman alert from FDA, and oral anticoagulation choices in elderly patients are discussed by John Mandola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I SURPASS CVOT
- This Week in Cardiology Podcast, August 1 https://www.medscape.com/viewarticle/1002781
- Mounjaro Appears More Heart Protective Than Trulicity in Trial Of Eli Lilly Diabetes Drugs
https://www.medscape.com/s/viewarticle/mounjaro-proves-more-heart-protective-than-trulicity-trial-2025a1000kct
II Catheter and Surgical AF ablation
- Catheter and Surgical Ablation for AF: Meta-Analysis https://www.acpjournals.org/doi/10.7326/ANNALS-25-00253
III Watchman Air Embolism Alerts
- Looming Pay Cut to LAAO Triggers Objection From Card Groups
https://www.medscape.com/viewarticle/looming-pay-cut-laao-triggers-objection-card-groups-2025a1000l0j
- FDA Alert https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-watchman-access-system-issue-boston-scientific
IV Switching Oral Anticoagulants in Frail Older Adults Patients
- FRAIL AF Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066485
- COMBINE AF Substudy https://doi.org/10.1016/j.jacc.2025.05.060
- The Most Important Study From ESC: FRAIL-AF https://www.medscape.com/viewarticle/996063
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Exercise and CV outcomes, aldosterone modulation, AI for ECG reading, GLP-1 comparisons, end-of-life decisions, and another well-meaning policy that caused harm in veterans are discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Exercise and CV outcomes
II Aldosterone Modulation in Cardio-Kidney Disease
- Aldosterone and Aldosterone Modulation https://doi.org/10.1016/j.jacc.2025.06.012
- Randomized Aldactone Evaluation Study https://www.nejm.org/doi/full/10.1056/NEJM199909023411001
III AI vs MD ECG-Reading for Cath Lab Activation
- Accuracy of Cath Lab Activation Decisions https://doi.org/10.1016/j.ajem.2025.07.061
IV Tirzepatide vs Dulaglutide - SURPASS CVOT Study
- Eli Lilly Press Release https://investor.lilly.com/news-releases/news-release-details/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated
- REWIND Study 10.1016/S0140-6736(19)31149-3 External Link
V End-of-Life Decisions
Doctors' Own End-of-Life Choices Defy Common Medical Practice
https://www.medscape.com/viewarticle/doctors-own-end-life-choices-defy-common-medical-practice-2025a1000k01
- Physicians' Preferences for Their Own End of Life https://jme.bmj.com/content/early/2025/06/05/jme-2024-110192
- How US Doctors Die: A Cohort Study https://agsjournals.onlinelibrary.wiley.com/doi/full/10.1111/jgs.14112
VI Well-Meaning Policies That Make Sense
- The Mission Act and Cardiovascular Procedures https://jamanetwork.com/journals/jama/fullarticle/2837067
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The VENTOUX study of endurance athletes, the 10,000 step myth was not busted, rate vs rhythm control for AF, and GLP1 drugs and observational studies are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Endurance Athletes and Arrhythmia (again)
- VENTOUX trial
https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.125.018470
II Daily Step Count and Health — no myths were busted.
- Lancet Public Health: https://doi.org/10.1016/S2468-2667(25)00164-1
III Rate vs Rhythm Control of AF
Medscape: Everyone Deserves a Shot at the American Dream: Sinus Rhythm
https://www.medscape.com/viewarticle/everyone-deserves-shot-american-dream-sinus-rhythm-2025a1000jle
- This Week in Cardiology, July 11, 2025 https://www.medscape.com/viewarticle/1002704
- AFFIRM trial https://www.nejm.org/doi/full/10.1056/NEJMoa021328
- AFFIRM substudy https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/486560
IV GLP-1 Drugs and Observational Studies
- Neurodegeneration and Stroke After Semaglutide and Tirzepatide
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2836412
- SUSTAIN-6 https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
- SELECT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Finerenone, what not to consider when choosing treatment of AS, brain health after atrial fibrillation ablation, early rhythm control for AF, and Watchman reimbursement cuts are discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Finerenone FDA Widens Indication of Finerenone for Heart Failure Patients
https://www.medscape.com/viewarticle/fda-widens-indication-finerenone-heart-failure-patients-2025a1000ive
- FDA finerenone approval https://bayer2019tf.q4web.com/news/news-details/2025/U-S--FDA-Approves-KERENDIA-finerenone-to-Treat-Patients-With-Heart-Failure-With-Left-Ventricular-Ejection-Fraction-40-Following-Priority-Review/default.aspx
- FINEARTS-HF trial https://www.nejm.org/doi/full/10.1056/NEJMoa2407107
II Choosing TAVI or Surgical AVR
Carbon Emission when treating AS
- EHJ study https://doi.org/10.1093/eurheartj/ehaf379
III Brain Lesions and Visual Migraine After Left-Sided Ablations Post-Ablation Visual Auras a Sign of Transient Brain Injury?https://www.medscape.com/viewarticle/post-ablation-visual-auras-sign-transient-brain-injury-2025a1000iro
- TRAVERSE Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.071352
- TRAVERSE Migraine Substudy https://doi.org/10.1016/j.hrthm.2025.06.035
IV Early Rhythm Control for AF
- EHJ Rapid Communication https://doi.org/10.1093/eurheartj/ehaf397
- EAST-AFNET 4 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2019422
V Watchman Cuts
CMS Reduces LAAO Value in Proposed Fee Schedule https://www.acc.org/Latest-in-Cardiology/Articles/2025/07/15/20/08/CMS-Reduces-LAAO-Value-in-Proposed-2026
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Approval of first-generation devices, the ticagrelor controversy, ICD longevity, the PRAGUE-25 trial (one of the most important trials of the year), and some thoughts on the end of EP as a profession are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I More Ticagrelor Controversy
-
BMJ Investigation Finds More Concerns in Ticagrelor Trials https://www.medscape.com/viewarticle/investigation-bmj-raises-more-concerns-about-ticagrelor-2025a1000gh3
-
Ticagrelor PLATO study https://www.bmj.com/content/389/bmj.r1201
-
Ticagrelor vs Clopidogrel https://www.nejm.org/doi/full/10.1056/NEJMoa0904327
-
Review of the Ticagrelor Trials Evidence Base https://www.ahajournals.org/doi/10.1161/JAHA.123.031606
- The Plato Trial: Do you believe in magic? https://doi.org/10.1093/eurheartj/ehp545
- ONSET/OFFSET Antiplatelet Effects https://www.ahajournals.org/doi/10.1161/circulationaha.109.912550
- RESPOND Study https://www.ahajournals.org/doi/10.1161/circulationaha.109.919456
II ICD Battery Longevity
- Variability in ICD Battery Longevity https://doi.org/10.1016/j.hrthm.2025.05.031
PRAGUE-25 Trial of AF Ablation vs LFM
- PRAGUE-25 Trial https://www.jacc.org/doi/10.1016/j.jacc.2025.04.042
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
FDA approves triple-drug polypill, a change of opinion, a deep dive into invasive pulmonary embolism therapies, heart disease trends, and diabetes care is on fire are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I FDA News in HTN
- FDA announcement https://george-medicines.com/george-medicines-announces-fda-approval-of-widaplik-telmisartan-amlodipine-and-indapamide-a-new-single-pill-combination-treatment-for-hypertension-in-adults-including-initial-treatment/
- Lancet Study https://doi.org/10.1016/S0140-6736(24)01744-6
- JACC study vs placebo https://www.jacc.org/doi/abs/10.1016/j.jacc.2024.08.025
- JAMA Cardiology Meta-analysis https://jamanetwork.com/journals/jamacardiology/fullarticle/2804313
II Invasive PE Therapy
-
EHJ-Open review: https://academic.oup.com/ehjopen/article/5/3/oeaf071/8156689
-
PEITHO Trial https://www.nejm.org/doi/10.1056/NEJMoa1302097
- REAL PE Observational Study https://pmc.ncbi.nlm.nih.gov/articles/PMC11308131/
III Heart Disease Trends
- King et al https://www.ahajournals.org/doi/10.1161/JAHA.124.038644
IV Diabetes Coverage
- Medscape Link https://www.medscape.com/viewcollection/37830
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
A big, deep dive into CTA and fractional flow reserve CT, and a sobering report on the new EVOQUE valve are discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback and Correction
- CRAAFT HF https://clinicaltrials.gov/study/NCT06505798
II Imaging and Behavior Change
- SCOT HEART 1 https://www.nejm.org/doi/full/10.1056/NEJMoa1805971
- Five Reasons I Don't Believe an Imaging Test Improves Outcomes https://www.medscape.com/viewarticle/901204
- SCOT HEART 2 https://www.jacc.org/doi/10.1016/j.jcmg.2024.05.016
III. More on Imaging and CT FFR Symptoms Don't Always Indicate the Severity of Coronary Artery Disease https://www.medscape.com/viewarticle/symptoms-dont-always-indicate-severity-coronary-artery-2025a1000ge6
-
ADVANCE Registry Protocol https://www.journalofcardiovascularct.com/article/S1934-5925(16)30288-X/abstract
-
Research Letter JACC CV Imaging https://doi.org/10.1016/j.jcmg.2025.05.002
- ADVANCE Registry Paper 2018 https://doi.org/10.1093/eurheartj/ehy530
- Cook et al JAMA Card https://jamanetwork.com/journals/jamacardiology/fullarticle/2629072
- Low diagnostic yield Patel paper NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa0907272
- Venk Murthy thread https://x.com/venkmurthy/status/1033379922679660544
IV EVOQUE Real World Data
JACC has published a sobering research letter on the Transcatheter Tricuspid Valve Replacement called EVOQUE valve.
- Lupu et al JACC IV https://doi.org/10.1016/j.jcin.2025.03.019
- TRISCEND II https://www.nejm.org/doi/full/10.1056/NEJMoa2401918
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback on cardiac sarcoidosis, SA node ablation, surgical AF ablation, chronic kidney disease protection, and recruiting for clinical trials are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- EHJ paper Mathijssen et al https://doi.org/10.1093/eurheartj/ehaf338
- Nordenswan et al https://www.ahajournals.org/doi/full/10.1161/CIRCEP.117.006145#tab-contributors
II IST
- HR Case Reports https://doi.org/10.1016/j.hrcr.2025.05.017
- Lakkireddy et al https://doi.org/10.1016/j.hrthm.2021.07.010
III Survival After Surgical AF ablation during CABG
- McClure et al https://doi.org/10.1093/europace/eux336
- Schaffer et al https://doi.org/10.1016/j.athoracsur.2025.03.044
IV Finerenone with Empagliflozin in CKD and DM
- The Confidence Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2410659
V Recruiting for Important Trials and the Stature of EP as a Profession
Two UK Cardiology Trials Struggle to Recruit Patients
https://www.medscape.com/viewarticle/two-uk-cardiology-trials-struggle-recruit-patients-2025a1000ffs
- CRAFT HF https://clinicaltrials.gov/study/NCT06505798
- BRITISH https://doi.org/10.1016/j.ahj.2023.09.008
- PROFID https://profid-project.eu/profid-ehra-trial/
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback on cardiac sarcoidosis, out-of-hospital cardiac arrest, less is more when it comes to post-stent antiplatelets, lipoprotein(a), and atrial fibrillation in HFpEF are discussed by John Mandrola, MD, in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- Mathijssen https://doi.org/10.1093/eurheartj/ehaf338
- Poyhonen https://doi.org/10.1161/CIRCEP.124.013239
II News in out of hospital cardiac arrest
- AHA Press Release https://newsroom.heart.org/news/nfl-safety-justin-reid-expands-cpr-education-for-youth-through-summer-program
- Chan et al https://www.ahajournals.org/doi/abs/10.1161/CIRCOUTCOMES.124.011799
III Post-Stent Antiplatelet
- 4D ACS trial https://eurointervention.pcronline.com/article/one-month-dual-antiplatelet-therapy-followed-by-prasugrel-monotherapy-at-a-reduced-dose-the-4d-acs-randomised-trial
IV Lp(a) and the new PREVENT equation for Predicting cardiac events
-
Aug 02, 2024 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1001429
-
Bhatia et al https://jamanetwork.com/journals/jamacardiology/fullarticle/2835022
V AF in HFpEF
- Saksena et al https://doi.org/10.1093/europace/euad095
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, CRT vs CSP, important clues on the ECG, beta-blocker interruption after myocardial infarction, novel approaches to LDL-C lowering, and ICD decisions in cardiac sarcoidosis are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
II CRT vs CSP – CONSYST-CRT
• Trial JACC EP https://doi.org/10.1016/j.jacep.2025.03.024
III The Important QRS
• Kewcharoen et al https://www.ahajournals.org/doi/10.1161/CIRCEP.125.013809
IV ABYSS Trial of BB Interruption after MI Continues to be Mis-interpreted
• ABYSS Main https://www.nejm.org/doi/full/10.1056/NEJMoa2404204
• ABYSS substudy https://doi.org/10.1093/eurheartj/ehaf170
• REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479
V Oral PCSK9i and the PURSUIT Trial
• Koren et al https://www.jacc.org/doi/10.1016/j.jacc.2025.03.499
• Editorial https://doi.org/10.1016/j.jacc.2025.03.518
• Is Lifelong LDL-C Lowering Within Reach? The heart-1 Gene-Editing Trial https://www.medscape.com/viewarticle/998162
• Heart-1 Gene Therapy Trial Pauses Enrollment https://www.medscape.com/viewarticle/998162
• EHJ coverage VERVE https://academic.oup.com/ehjcvp/article/10/2/87/7455877
VI Cardiac Sarcoidosis and Risk of VT
• EHJ paper Mathijssen et al https://doi.org/10.1093/eurheartj/ehaf338
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback on sports “disqualification,” big digoxin news, Brugada syndrome, another positive finerenone study, and unblinded transcatheter trials are discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- JACC EP Paper https://www.jacc.org/doi/10.1016/j.jacep.2025.03.013
II Digoxin News
- DIGIT HF Baseline Characteristics paper https://doi.org/10.1002/ejhf.3679
- DIGIT HF Rationale paper https://pmc.ncbi.nlm.nih.gov/articles/PMC6607489/
- Dig trial https://www.nejm.org/doi/full/10.1056/NEJM199702203360801
- DECISION trial https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.3428
- Ziff et al BMJ meta-analysis https://www.bmj.com/content/351/bmj.h4451
III Brugada Syndrome
- Gomes et al https://doi.org/10.1093/europace/euaf091
IV Another Finerenone Substudy Published
- FINEARTS-HF trial substudy, Bhatt, A et al https://doi.org/10.1016/j.cardfail.2025.05.006
- FINEARTS HF Main paper https://www.nejm.org/doi/full/10.1056/NEJMoa2407107
- TOPCAT https://www.nejm.org/doi/full/10.1056/NEJMoa1313731
- TOPCAT regional variation Circ paper https://www.ahajournals.org/doi/10.1161/circulationaha.114.013255
V Another Opinion on Unblinded Transcatheter Intervention Trials
- Kaul https://eurointervention.pcronline.com/article/unblinded-trials-of-transcatheter-interventions-with-subjective-endpoints-what-are-the-implications
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The BedMed trial of nighttime BP meds, SURMOUNT-5, Troponin URL, gene tests in patients with no disease, and guideline-directed medical therapy for HF are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Timing of BP Meds – The BedMed RCT
- MAPEC https://doi.org/10.3109/07420528.2010.510230
- Hygia https://doi.org/10.1093/eurheartj/ehz754
- Turgeon et al https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.121.16501
- TIME trial https://doi.org/10.1016/S0140-6736(22)01786-X
- BedMed https://jamanetwork.com/journals/jama/fullarticle/2833860
- Time Antihypertensives Taken Doesn't Matter: New Trials https://www.medscape.com/viewarticle/time-antihypertensives-taken-doesnt-matter-new-trials-2024a1000g3z
- Timing of BP Dosing Doesn't Matter: BedMed and BedMed-Frail https://www.medscape.com/viewarticle/timing-blood-pressure-dosing-doesnt-matter-again-bedmed-and-2024a1000fz2
- Timing of Blood Pressure Meds Doesn’t Affect Outcomes: BedMed in Print https://www.medscape.com/viewarticle/timing-blood-pressure-meds-doesnt-affect-outcomes-bedmed-2025a1000cdm
II Tirzepatide vs Semaglutide
- SURMOUNT 5 https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
III Age-specific Troponins
- Coyle and McEvoy https://doi.org/10.1093/eurheartj/ehaf308
- Mandrola/Foy JAMA-IM https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2777967
IV Return to Play for Gene Positive Phenotype Negative athletes
- Martinez et al https://doi.org/10.1016/j.jacep.2025.03.013
V Rapid Titration of GDMT in HF
STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698
- JACC-HF Substudy https://doi.org/10.1016/j.jchf.2025.02.020
- STRONG HF https://doi.org/10.1016/S0140-6736(22)02076-1
- AVID https://www.nejm.org/doi/full/10.1056/NEJMoa013474
- EAST https://www.nejm.org/doi/full/10.1056/NEJMoa013474
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I The KETO-CTA Study
- JACC Advances Paper: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101686
- Meta-analysis https://doi.org/10.1016/j.ajcnut.2024.01.009
II Subclinical AF – Anticoagulate or Not?
Anticoagulation in Subclinical AF May Offer Little Benefit
https://www.medscape.com/viewarticle/anticoagulation-subclinical-af-may-offer-little-benefit-2025a1000b31
Treat AFib ‘Diagnosed’ by Smartwatch
https://www.medscape.com/viewarticle/treat-afib-diagnosed-smartwatch-2025a1000avp
- JAMA NO paper https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2833437
- NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
- ARTESIA https://www.nejm.org/doi/full/10.1056/NEJMoa2310234
- McIntyre meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512
- Singer et al https://pmc.ncbi.nlm.nih.gov/articles/PMC2777526/
- Stroke paper https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.123.045843
- American Journal of Medicine paper https://pubmed.ncbi.nlm.nih.gov/38331136/
III GLP1a for Treatment of Fatty Liver Disease
- ESSENCE trial https://www.nejm.org/doi/10.1056/NEJMoa2413258
Features
- CABG Still Superior to Stents Despite FAME 3 Endpoint Swap
https://www.medscape.com/viewarticle/cabg-still-superior-stents-despite-fame-3-endpoint-swap-2025a1000ao5
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The FDA approval of TAVR for asymptomatic AS, digital health, subcutaneous vs transvenous ICD, and cryptogenic stroke in young adults are discussed by John Mandrola, MD.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I FDA announces approval for TAVR in pts with asymptomatic AS
- Edwards Press Release https://www.edwards.com/newsroom/news/2025-05-01-edwards-tavr-receives-fda-approval-for-patients-with-asymptomatic-severe-aortic-stenosis
- Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis (EARLY TAVR) https://www.nejm.org/doi/full/10.1056/NEJMoa2405880
- EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec
- Asymptomatic Aortic Stenosis: 'Time to Act' or Not So Fast? https://www.medscape.com/viewarticle/asymptomatic-aortic-stenosis-time-act-or-not-so-fast-2025a10005o9
II PPG that Can Distinguish source of Tachycardia
- Machine-learning guided differentiation between photoplethysmography waveforms of supraventricular and ventricular origin https://doi.org/10.1016/j.cmpb.2025.108798
III PRAETORIAN -XL trial
- Device-related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-term Follow-up: the PRAETORIAN-XL Trial https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074576
- Subcutaneous or Transvenous Defibrillator Therapy (PRAETORIAN trial) https://www.nejm.org/doi/full/10.1056/NEJMoa1915932
- Subcutaneous or Transvenous Defibrillator Therapy Letter to Editor https://www.nejm.org/doi/full/10.1056/NEJMc2034917
- The PRAETORIAN Trial: Guarded Approach to Subcutaneous ICD Best https://www.medscape.com/viewarticle/937156
IV Stroke in Young People
- Burden of Modifiable Risk Factors in Young-Onset Cryptogenic Ischemic Stroke by High-Risk Patent Foramen Ovale https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.049855
- Migraine: A Key Factor in Young Adults With Unexplained Stroke https://www.medscape.com/viewarticle/migraine-key-factor-young-adults-unexplained-stroke-2025a10009jj
- U.S. stroke rate declining in adults 75 and older, yet rising in adults 49 and younger ASA statement https://newsroom.heart.org/news/u-s-stroke-rate-declining-in-adults-75-and-older-yet-rising-in-adults-49-and-younger
- Increasing stroke in the young https://doi.org/10.1016/j.ajpc.2020.100085
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
AI and ECGs, novel ways to treat hypertension, combined lipid-lowering therapy after myocardial infarction, PFA and silent stroke, a move toward accountability in AF ablation, and pacing issues in TTVR are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Help with ECGs in the ED
AI Shows Promise for Rapid NSTEMI Diagnosis
https://www.medscape.com/viewarticle/ai-shows-promise-rapid-nstemi-diagnosis-2025a10009pw
- Buscher et al https://doi.org/10.1093/eurheartj/ehaf254
II A Novel way to Treat HTN
A Pacemaker to Control BP Gets FDA Breakthrough Designation
https://www.medscape.com/viewarticle/pacemaker-control-bp-gets-fda-breakthrough-designation-2025a10009t3
- JAHA paper https://www.ahajournals.org/doi/10.1161/JAHA.120.020492
- Backbeat https://clinicaltrials.gov/study/NCT06059638
III Type of PFA may matter for Silent Cerebral Lesions
- Paper https://www.ahajournals.org/doi/10.1161/CIRCEP.125.013719
IV Accountability coming to US AF ablation
- Heart Rhythm Society Releases a Document on Establishing Centers of Excellence for AF ablation -- Press Release https://www.hrsonline.org/news/new-white-paper-on-atrial-fibrillation-centers-of-excellence/
V Pacing in Patients with Undergoing Transcatheter Tricuspid Valve Replacement
- Paper https://doi.org/10.1016/j.hrthm.2025.02.004
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The FAME 3 trial 5-year results, TAVR at 5 years, pacers after TAVR, and mavacamten not a wonder drug are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I FAME 3 at Five Years
Stents as Good as Surgery for Triple-Vessel Disease https://www.medscape.com/viewarticle/noninvasive-stents-good-surgery-triple-vessel-disease-2025a10007l4
- Main trial NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2112299
- Circulation 3-years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065770
- 5-year results Lancet 10.1016/S0140-6736(25)00505-7 https://linkinghub.elsevier.com/retrieve/pii/S0140673625005057
II TAVR in Low-Risk Patients at 5 years
5-Year TAVR, Surgery Outcomes Similar in Low-Risk Patients
https://www.medscape.com/viewarticle/5-year-tavr-surgery-outcomes-similar-low-risk-patients-2025a10007zl
- EVOLUT Low-Risk 5 years https://www.jacc.org/doi/10.1016/j.jacc.2025.03.004
- EVOLUT Editorial – We're Halfway There https://www.jacc.org/doi/10.1016/j.jacc.2025.03.428
- PARTNER 3 Low-Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2307447
- NOTION at 5 years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036606
III The Matter of Pacemakers After TAVI
- JACC IV Study Badertscher https://www.jacc.org/doi/10.1016/j.jcin.2025.03.028
- Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals
IV Mavacamten Looks to Have Specific Indications
- EXPLORER HCM 10.1016/S0140-6736(20)31792-X External Link
- VALOR HCM https://jamanetwork.com/journals/jamacardiology/fullarticle/2809050
- BMS Press Release https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-ODYSSEY-HCM-Trial/
FINAL THOUGHTS
- PRAGUE 25 https://bmjopen.bmj.com/content/12/6/e056522
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The TAP-IT, STRIDE, FreshUP, and SINGLE SHOT CHAMPION trials are discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I TAP IT
TAP IT trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.073521
II STRIDE
LANCET Ref 10.1016/S0140-6736(25)00509-4
SUMMIT HF https://www.nejm.org/doi/full/10.1056/NEJMoa2410027
III FRESH UP
No Need to Restrict Fluids in Stable Heart Failure
https://www.medscape.com/viewarticle/no-need-restrict-fluids-stable-heart-failure-2025a10008bu
Nature (Trial) https://www.nature.com/articles/s41591-025-03628-4
SODIUM HF https://pubmed.ncbi.nlm.nih.gov/35381194/
IV PFA for AF ablation
SINGLE SHOT CHAMPION https://www.nejm.org/doi/full/10.1056/NEJMoa2502280
ADVENT https://www.nejm.org/doi/full/10.1056/NEJMoa2307291
Foy et al https://pmc.ncbi.nlm.nih.gov/articles/PMC11852674/
MANIFEST REDO Study https://doi.org/10.1093/europace/euaf012
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Trials from the 2025 American College of Cardiology scientific sessions, including the WARRIOR, PROTECT TAVI, DAPATAVI, and SOUL are reviewed by John Mandrola, MD
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Thank you Comments
II WARRIOR Women’s IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
- Keep Fighting INOCA After Neutral WARRIOR Trial https://www.medscape.com/viewarticle/keep-fighting-inoca-after-neutral-warrior-trial-2025a10007uf
III Cerebral Embolic Protection in TAVI
- PROTECT TAVI https://www.nejm.org/doi/full/10.1056/NEJMoa2415120
- PROTECTED TAVR https://www.nejm.org/doi/full/10.1056/NEJMoa2204961
- Instrumental Variables in Randomized Trials https://evidence.nejm.org/doi/10.1056/EVIDctw2400204
IV DAPATAVI
-
SGLT2 Inhibitors Progressing to New Standard After TAVI https://www.medscape.com/viewarticle/sglt2-inhibitors-progressing-new-standard-after-tavi-2025a100081y
-
Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation https://www.nejm.org/doi/full/10.1056/NEJMoa2500366
V SOUL Study of Oral Semaglutide and CV outcomes in Diabetes
-
Oral GLP-1 Receptor Agonist Reduces CV Risk https://www.medscape.com/viewarticle/oral-glp-1-receptor-antagonist-reduces-cv-risk-2025a10007kr
-
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2501006
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Stopping oral anticoagulation after AF ablation, the core problem with paradoxes like the smoker’s paradox, chronic total occlusion PCI, and an ACC/EHRA preview are discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Oral Anticoagulation after Successful AF Ablation
- Iwawakie et al https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831851
- OCEAN protocol paper https://doi.org/10.1016/j.ahj.2017.12.007
II Smoker’s Paradox
- Presch et al https://www.jacc.org/doi/10.1016/j.jcin.2024.12.028
- Gupta et al https://doi.org/10.1161/JAHA.116.003370
III CTO PCI
- Main sub-analysis paper Bangalore et al https://doi.org/10.1016/j.jacc.2025.01.029
- DECISION CTO https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.031313
- Main EURO CTO trial https://doi.org/10.1093/eurheartj/ehy220
- 3-year MACE of EURO CTO https://eurointervention.pcronline.com/article/three-year-outcomes-of-eurocto-a-randomized-multicentre-trial-comparing-revascularization-and-optimal-medical-therapy-for-chronic-total-coronary-occlusions
- EXPLORE https://www.jacc.org/doi/abs/10.1016/j.jacc.2016.07.744
- ISCHEMIA CTO https://www.clinicaltrials.gov/study/NCT03563417
IV ACC and EHRA Preview
Mandrola’s 5 Trials to Look for at the 2025 American College of Cardiology Scientific Sessions https://www.medscape.com/viewarticle/mandrolas-5-trials-look-2025-american-college-cardiology-2025a10006zu
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
A large trial in cardiac pacing finally published, PVCs and cardiomyopathy, cannabis, CV risk and the danger of observational studies, and the tale of two disparate statin trials are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I BioPace Trial
- Trial manuscript https://doi.org/10.1093/europace/euaf029
II Another Belief Challenged in EP this week—PVCs and CM ‘
- UC Paper https://doi.org/10.1016/j.jacep.2025.01.004
- JACC Review https://doi.org/10.1016/j.jacc.2024.03.416
- Lee et al https://heart.bmj.com/content/105/18/1408
III Cannabis and CV Risk
- Cannabis and MACE in JACC Advances: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101698
- Zeraatkar –Grilling the data https://doi.org/10.1016/j.jclinepi.2024.111278
- PLOS-1 10.1371/journal.pone.0199705
IV Cardio-oncology
- Jacc Onc Substdy https://www.jacc.org/doi/10.1016/j.jaccao.2024.11.008
- Editorial https://www.jacc.org/doi/10.1016/j.jaccao.2025.01.006
- STOP CA JAMA 2023 https://jamanetwork.com/journals/jama/fullarticle/2807988
- PREVENT https://evidence.nejm.org/doi/10.1056/EVIDoa2200097
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, resistant hypertension, K-binders for MRA use in heart failure, nutritional epidemiology, and a positive study for vitamin D are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- Califf editorial https://www.jacc.org/doi/10.1016/j.jaccas.2020.01.003
II Resistant HTN
- Positive Topline Results for Lorundrostat in Hypertension
https://www.medscape.com/viewarticle/positive-topline-results-lorundrostat-hypertension-2025a100062e
III K-Binding
- REALIZE K Trial https://doi.org/10.1016/j.jacc.2024.11.014
- Packer Editorial https://doi.org/10.1016/j.jacc.2025.01.011
- Diamond Trial EHJ https://doi.org/10.1093/eurheartj/ehac401
- REALIZE K Commentary https://www.medscape.com/viewarticle/realize-k-new-potassium-binder-help-keep-spiro-board-2024a1000m2c
IV Butter vs Plant-based Oils and Mortality
- JAMA-IM Study https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2831265
- Is Red Meat Healthy? Multiverse Analysis Has Lessons Beyond Meat https://www.medscape.com/viewarticle/red-meat-healthy-multiverse-analysis-has-lessons-beyond-meat-2024a10008qv
- Cookbook Review https://doi.org/10.3945/ajcn.112.047142
V Vitamin D
- Impact Factor https://www.medscape.com/viewarticle/rare-win-vitamin-d-this-time-ms-2025a10005ul
- D-Lay trial https://jamanetwork.com/journals/jama/fullarticle/2831270
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback on asymptomatic aortic stenosis (AS), transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR), coronary artery calcium (CAC), and revascularization for patients with ischemic LV dysfunction are discussed by John Mandrola, MD, in today's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Aortic Valve Intervention for Asymptomatic AS
Asymptomatic Aortic Stenosis: “Time to Act” or Not So Fast?
https://www.medscape.com/viewarticle/asymptomatic-aortic-stenosis-time-act-or-not-so-fast-2025a10005o9
EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions
https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec
- Reddy et al: https://doi.org/10.1016/j.jacc.2024.12.031
- Wallach editorial https://doi.org/10.1016/j.jacc.2025.01.020
- Guerrero https://www.tctmd.com/slide/tavr-young-patients-current-treatment-patterns-us
II CAC - Coronary Artery Calcium
-
Coronary Artery Calcium Testing—Too Early, Too Late, Too Often https://jamanetwork.com/journals/jamacardiology/fullarticle/2830950
-
CAUGHT-CAD https://jamanetwork.com/journals/jama/fullarticle/2831115
III CABG, PCI or Meds for Ischemic LV Dysfunction
- STICH https://www.nejm.org/doi/full/10.1056/NEJMoa1100356
- STICHES https://www.nejm.org/doi/full/10.1056/NEJMoa1602001
- REVIVED BCIS https://www.nejm.org/doi/full/10.1056/NEJMoa2206606
- EHJ paper https://doi.org/10.1093/eurheartj/ehaf080
IV Preview
- https://www.medscape.com/viewarticle/shed-lead-and-injuries-should-cath-labs-go-lead-free-2024a1000hnb
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The treatment of asymptomatic aortic stenosis, the move to composite endpoints in trials, IFR vs FFR and high-frequency low tidal volume ventilation for AF ablation are the topics John Mandrola, MD, discusses in today's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Aortic valve intervention for Asymptomatic AS
- Lindman editorial https://jamanetwork.com/journals/jamacardiology/fullarticle/2829881
- Trends https://pmc.ncbi.nlm.nih.gov/articles/PMC11308430/
- Podcast EARLY TAVR Nov 8, 2024 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1001865
- Faith Healing and Subtraction Anxiety https://www.ahajournals.org/doi/10.1161/circoutcomes.118.004665
- Early TAVR trial https://www.nejm.org/doi/10.1056/NEJMoa2405880
- EVOLVED https://jamanetwork.com/journals/jama/fullarticle/2825540
- AVATAR https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057639
II Trial Endpoints
- Shepshelovich https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2830023
- Brown meta-analysis https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785560
III IFR vs FFR—a debate b/w RCTs and observational data
- 5-year DEFINE https://jamanetwork.com/journals/jamacardiology/fullarticle/2824470
- 5-year SwedeHeart IFR https://doi.org/10.1016/j.jacc.2021.12.030
- Eftekhari meta-analysis https://doi.org/10.1093/eurheartj/ehad582
- Gotberg SWEDEHEART Registry https://doi.org/10.1016/j.jcin.2024.12.003
- Editorial of SWEDEHEART-Registry https://doi.org/10.1016/j.jcin.2024.12.014
IV High-frequency low-tidal-volume ventilation for AF ablation
- Osorio et al https://doi.org/10.1016/j.hrthm.2024.07.094
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Blanking period after AF ablation, periprocedural MI after PCI in non-STEMI, predicting AF after ischemic stroke, and the proper standards for mitral valve repair in primary mitral regurgitation are the topics John Mandrola, MD, discusses in today’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I AF blanking period
- CIRCA DOSE Research letter https://www.ahajournals.org/doi/10.1161/CIRCEP.124.013232
- Circa-Dose https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042622
- COMPARE CRYO https://doi.org/10.1016/j.jacep.2024.03.021
- Mohanty et al 10.1016/j.hrthm.2024.08.011
- Ruzieh, Foy, Mandrola Patients’ Lives Don’t Pause for Blanking Periods https://doi.org/10.1016/j.ahjo.2024.100497
II Periprocedural MI and Future events
- Circulation paper https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.070729
III AI to detect AF related stroke
- eClinical Medicine Paper https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00050-1/fulltext
IV Mitral Valve Repair
- JACC paper -- https://doi.org/10.1016/j.jacc.2024.10.108
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Silent cerebral embolism after LAAC, AI in ECG rhythm analysis, anti-thrombotic strategies in patients with AF and CAD, and subclinical AF are the topics John Mandrola, MD, covers in today’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Silent Cerebral Embolism after LAAC
- JAHA Case Series https://www.ahajournals.org/doi/10.1161/JAHA.124.037968
- JACC https://doi.org/10.1016/j.jacc.2018.12.039
II. AI Transforming Rhythm Monitor Reading
- Johnson and colleagues RCT https://www.nature.com/articles/s41591-025-03516-x
III. Anticoagulation Alone or OAC plus antiplatelets in patients with CAD and AF
- Rashedi and colleagues Meta-analysis https://doi.org/10.1016/j.jacc.2024.12.030
- AQUATIC https://clinicaltrials.gov/study/NCT04217447
IV. DOAC for Subclinical AF – A Subgroup Analysis of ARTESIA
Anticoagulation Uncertainty in Embolic Stroke of Undetermined Source https://www.medscape.com/viewarticle/anticoagulation-uncertainty-embolic-stroke-undetermined-2024a1000h5e
- Lancet Neurology Subgroup Analysis of ARTESIA 10.1016/S1474-4422(24)00475-7
- ARTESIA https://www.nejm.org/doi/full/10.1056/NEJMoa2310234
- NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
- RE-SPECT ESUS https://www.nejm.org/doi/full/10.1056/NEJMoa1813959
- NAVIGATE ESUS https://www.nejm.org/doi/full/10.1056/NEJMoa1802686
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Sugar-sweetened beverages, the epidemiology of driving after an ICD, BP measurements, and massive EBM lesson in EVT for acute stroke are the topics John Mandrola, MD, discusses in today's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Sugar-Sweetened Beverages
Sugary Drinks Fuel Millions of Diabetes and CVD Cases https://www.medscape.com/viewarticle/sugary-drinks-fuel-millions-diabetes-and-cvd-cases-2025a10002wr
- Nature Medicin;e Epidemiologic Study https://www.nature.com/articles/s41591-024-03345-4
- JAMA-Network Open; Beverage Tax Observational Study https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829505
- Lancet Regional Health; Beverage Tax Philadelphia EHR 10.1016/j.lana.2024.100906
II. Driving With an ICD
- JACC Electrophysiology paper https://doi.org/10.1016/j.jacep.2024.12.002
- Earlier HEART paper https://heart.bmj.com/content/110/24/1401
III. Blood Pressure Measurements and Simple RCTs
BP Readings in Noisy Market as Good as Quiet Office?
https://www.medscape.com/viewarticle/bp-readings-noisy-market-good-quiet-office-2025a10002z0
- Annals of Internal Medicine Study https://www.acpjournals.org/doi/10.7326/ANNALS-24-00873
IV. A Big Shake-up in Interventional Stroke Care
- Endovascular Therapy Fails to Show Benefit in Distal Occlusion Stroke https://www.medscape.com/viewarticle/endovascular-therapy-fails-show-benefit-distal-occlusion-2025a100035u
- ESCAPE-MeVO https://www.nejm.org/doi/full/10.1056/NEJMoa2411668
- DISTAL trial https://www.nejm.org/doi/full/10.1056/NEJMoa2408954
- J. Mocco Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2500492
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Another negative AF ablation trial, predicting AF after stroke, the value of RCTs, troponin testing in the ED and surgical aortic valve choice are the topics John Mandrola, MD, discusses this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I AF ablation
- Coronary Sinus Isolation for High-Burden Atrial Fibrillation: A Randomized Clinical Trial https://doi.org/10.1016/j.jacep.2024.09.017
- Approaches to Catheter Ablation for Persistent Atrial Fibrillation (STAR AFII) https://www.nejm.org/doi/full/10.1056/NEJMoa1408288
- Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial https://doi.org/10.1001/jama.2020.16195
- Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation: Results of CONVERGE Clinical Trial https://www.ahajournals.org/doi/10.1161/CIRCEP.120.009288
II Post-Stroke AF monitoring
- Prediction of atrial fibrillation after a stroke event: a systematic review with meta-analysisMeta-analysis 10.1016/j.hrthm.2025.01.026
- Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source https://www.nejm.org/doi/full/10.1056/NEJMoa1813959
- Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source (Navigate ESUS https://www.nejm.org/doi/full/10.1056/NEJMoa1802686
- Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy (ARCADIA) https://jamanetwork.com/journals/jama/fullarticle/2814933
III RCTs
- Large simple randomized controlled trials—from drugs to medical devices: lessons from recent experience https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-025-08724-x
- Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction (TASTE) https://www.nejm.org/doi/full/10.1056/NEJMoa1405707
IV Troponin Testing in the ED
- Cardiac Biomarker Testing in US Emergency Departments https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2829344
- Updating Our Thinking on Troponin Use and Interpretation https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2777967
V Choice of AVR
- Bioprosthetic vs Mechanical Aortic Valve Replacement in Patients 40-75 Years https://doi.org/10.1016/j.jacc.2025.01.013
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Familial hypercholesterolemia, cardiac arrest therapy, Factor XI inhibition, and tricuspid valve interventions are the topics John Mandroa, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Familial hypercholesterolemia
- Danish Registry Study: https://doi.org/10.1093/eurheartj/ehae912
II. Cardiac Arrest
- Vallentin and Colleagues RCT https://www.nejm.org/doi/full/10.1056/NEJMoa2407616
III. Factor XI
- AZALEA https://www.nejm.org/doi/full/10.1056/NEJMoa2406674
- OCEANIC https://www.nejm.org/doi/full/10.1056/NEJMoa2407105
- VTE Study of Abelacimab 2021 https://www.nejm.org/doi/10.1056/NEJMoa2105872
IV. Tricuspid Valve Interventions
- TRILUMINATE 1-year Study https://doi.org/10.1016/j.jacc.2024.10.086
- Stone Editorial https://doi.org/10.1016/j.jacc.2024.11.045
- TRISCEND Main Paper https://www.nejm.org/doi/full/10.1056/NEJMoa2401918
- QOL Paper https://doi.org/10.1016/j.jacc.2024.10.067
- PASTE Registry https://doi.org/10.1016/j.jacc.2024.10.068
- AL-Lamee Editorial https://doi.org/10.1016/j.jacc.2024.10.085
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Renal denervation, the obesity paradox, JACC and the FINEARTS trial of finerenone in HFpEF, a setback for a PFA system, and coffee are the topics Jon Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. RDN
- CMS https://www.cms.gov/medicare-coverage-database/view/ncacal-tracking-sheet.aspx?ncaid=318
- Messerli https://doi.org/10.1016/j.jacc.2024.09.1244
- Filippone https://doi.org/10.1016/j.amjmed.2023.05.010
II. Finerenone
- FINEHEARTS -HF NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2407107
- FIDELIO-DKD https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
- FIGARO-DKD https://www.nejm.org/doi/full/10.1056/NEJMoa2110956
- Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF? https://doi.org/10.1016/j.jacc.2024.08.033
- Regional Variation TOPCAT https://www.ahajournals.org/doi/10.1161/circulationaha.114.013255
- Time from WHF Subanalysis https://doi.org/10.1016/j.jacc.2024.09.004
- REDEFINE - https://clinicaltrials.gov/study/NCT06008197
- Health status paper https://doi.org/10.1016/j.jacc.2024.09.023
- Obesity subanalysis https://doi.org/10.1016/j.jacc.2024.10.111
- Kidney outcomes https://www.sciencedirect.com/science/article/pii/S0735109724102525
- Kidney outcomes 2 https://doi.org/10.1016/j.jacc.2024.11.020
- Kaul editorial https://doi.org/10.1016/j.jacc.2024.11.024
III. PFA Setback
J&J Halts Varipulse Field Ablation for AFib
https://www.medscape.com/viewarticle/j-j-halts-varipulse-field-ablation-afib-2025a10000j8
IV. Coffee
Stop the Coffee Studies https://www.medscape.com/viewarticle/883709
- Coffee drinking timing and mortality in US adults
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Alcohol and cancer, GLP-1 trial representativeness, diagnosing CAD, changing stroke rates in patients with AF, blanking periods after AF ablation are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Surgeon General Causes Hoopla Regarding ETOH Warning
Dry January: Should Doctors Make It Year-Round?
https://www.medscape.com/viewarticle/dry-january-should-doctors-make-it-year-round-2025a100009t
- Surgeon General Warning https://www.hhs.gov/about/news/2025/01/03/us-surgeon-general-issues-new-advisory-link-alcohol-cancer-risk.html
- GBD 2016 Collaboration Lancet https://doi.org/10.1016/S0140-6736(18)31310-2
- RCT Voskobonik and colleagues https://www.nejm.org/doi/full/10.1056/NEJMoa1817591
- Marcus and colleagues; UCSF https://pubmed.ncbi.nlm.nih.gov/33516710/
- Review of ETOH AF https://doi.org/10.1016/j.jacc.2016.08.074
II. GLP-1 Agonists for Obesity –Trial vs Real World
- Generalizability of Trial Results https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2826335
- HRS Document ICD http://dx.doi.org/10.1016/j.hrthm.2014.03.041
III. Stress Testing and CAD Severity
- Reynolds and colleagues. Observational ISCHEMIA Sub-analysis https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.123.013743
- Foy Meta-analysis https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2655243
- ISCHEMIA https://www.nejm.org/doi/full/10.1056/NEJMoa1915922
IV. Changing Stroke Rates with AF
- Teppo and colleagues. Finnish Study https://doi.org/10.1016/j.jacep.2024.10.029
- Quinn and colleagues. https://www.ahajournals.org/doi/10.1161/circulationaha.116.024057
V. Patients’ Lives Don’t Pause for Blanking Periods
- Ruzieh and colleagues. https://doi.org/10.1016/j.ahjo.2024.100497
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, multiple studies in AF ablation,
a DANISH trial substudy of ICDs in NICM, and more data on eye complications of GLP-1 agonists are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. CCTA Feedback
- Foy meta-analysis https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2655243
- DANCAVAS https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
II. Listener Feedback on my negative take of the OPTION Trial.
- Option trial https://www.nejm.org/doi/pdf/10.1056/NEJMoa2408308
- My Preview https://www.medscape.com/viewarticle/mandrola-previews-option-trial-most-worrisome-study-aha-2024-2024a1000kmz
- 4 Reasons to Question Percutaneous Left Atrial Appendage Closure After AF Ablation
- https://www.medscape.com/viewarticle/4-reasons-question-percutaneous-left-atrial-appendage-2024a1000l0u
III. AF Ablation
PVI Add-Ons Provide Better Control of Persistent AF
https://www.medscape.com/viewarticle/pvi-add-ons-provide-better-control-persistent-af-2024a1000lcm
- VENUS https://jamanetwork.com/journals/jama/fullarticle/2772281
- PROMPT AF https://jamanetwork.com/journals/jama/fullarticle/2826710
- STAR AF 2 https://www.nejm.org/doi/full/10.1056/NEJMoa1408288
- CRRF-PeAF https://pmc.ncbi.nlm.nih.gov/articles/PMC9241129/
- CAVAC trial https://doi.org/10.1161/CIRCEP.124.012917
- CRRF-PeAF from multiple centers in Japan (not published)
IV. DANISH Trial Substudy
- Danish Trial Substudy https://www.ahajournals.org/doi/epdf/10.1161/CIRCULATIONAHA.124.071777
- Danish Main https://www.nejm.org/doi/full/10.1056/NEJMoa1608029
- MADIT-2 EF Substudy https://doi.org/10.1016/S0002-9149(01)01729-5
- SCD-HeFT subgroup https://www.nejm.org/doi/full/10.1056/NEJMoa043399
- Appraisal of ICD to Prevent SCD https://doi.org/10.1016/j.jacc.2008.05.058
V. Eye disease and GLP-1 Agonists
Jul 26, 2024 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1001384
- Semaglutide vs No Semagutide and Eye Disease https://link.springer.com/epdf/10.1186/s40942-024-00620-x
- Semaglutide vs SGLT- Inhibitors and Eye Disease https://www.medrxiv.org/content/10.1101/2024.12.09.24318574v1.full-text
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
US doc's pay, the ticagrelor controversy and new RCTs, clopidogrel beats ASA, holding antiplatelets for non-cardiac surgery, and Prof Cleland and ASA dogma are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. US Healthcare
Mandrola’s Top 10 Stories in 2024 https://www.medscape.com/viewarticle/mandrolas-top-10-stories-2024-2024a1000mxe?_gl=1dcvmkh_gcl_au*MTgzOTY2ODQ0Ni4xNzI5MjU4NjUz
- CMS Proposal
II. Ticagrelor Controversy
New Investigation Casts Doubt on Landmark Ticagrelor Trial
https://www.medscape.com/viewarticle/new-investigation-casts-doubt-landmark-ticagrelor-trial-2024a1000n1d
- Doshi Review https://www.bmj.com/content/387/bmj.q2550
- PLATO https://www.nejm.org/doi/full/10.1056/NEJMoa0904327
- ISAR REACT 5 https://www.nejm.org/doi/full/10.1056/NEJMoa1908973
- Bates Review https://www.ahajournals.org/doi/epub/10.1161/JAHA.123.031606
- Victor Serebuany and Dan Atar Editorial https://doi.org/10.1093/eurheartj/ehp545
III. New Ticagrelor vs Clopdiogrel trial
- Preprint: https://www.medrxiv.org/content/10.1101/2024.11.06.24316875v1.full-text
IV. Clopidogrel Better Than ASA Even in HBR
- Substudy Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity
- HOST-EXAM 10.1016/S0140-6736(21)01063-1
- HOST-EXAM-Extended https://doi.org/10.1161/CIRCULATIONAHA.122.062770
V. ASA During Non-Cardiac Surgery
- ASSURE DES https://doi.org/10.1016/j.jacc.2024.08.024
VII. Professor Cleland on ASA for Secondary Prevention
- Cleland Editorial https//jamanetwork.com/journals/jamacardiology/article-abstract/2827201
- ASA Meta-analysis 10.1016/S0140-6736(09)60503-1
- AMIS https://jamanetwork.com/journals/jama/fullarticle/368745
- SAPAT 10.1016/0140-6736(92)92619-Q
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Tirzepatide vs semaglutide in obesity; GLP1a use is complicated; HF outcomes; the misuse of meta-analyses in HF; and a breakthrough in HF care are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. SURMOUNT 5
- Clinicaltrials.gov https://clinicaltrials.gov/study/NCT05822830
- Press Release
II. Access to GLP-1 Agonist Drugs
- CMS statement https://www.cms.gov/newsroom/press-releases/biden-harris-administration-announces-medicare-advantage-and-medicare-part-d-prescription-drug
III. SUMMIT TRIAL commentary
Has Tirzepatide Scaled the HFpEF/Obesity SUMMIT?
https://www.medscape.com/viewarticle/has-tirzepatide-scaled-hfpef-obesity-summit-2024a1000m2h
IV. Blank Spot in HF Evidence – All cause hospitalizations
- Sayed and colleagues What Is Success in HF Trials? https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2827168
- EMPEROR-Preserved https://www.nejm.org/doi/full/10.1056/NEJMoa2107038
- Mayo Observational Study 10.1016/j.mayocp.2016.11.009
- DIG Trial https://jamanetwork.com/journals/jama/fullarticle/195990
V. Misuse of Meta-analysis by HF Community
- Lu and colleagues PARAGON/PARADIGM Meta-analysis https://jamanetwork.com/journals/jamacardiology/fullarticle/2823259
- Desai 2004 https://jamanetwork.com/journals/jama/fullarticle/199995
- PARADIGM HF https://www.nejm.org/doi/full/10.1056/NEJMoa1409077
- PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
VI Integration of Palliative Care Into HF Care
- Chuzi and colleagues Palliative Care in HF 10.1016/j.cardfail.2024.10.435
- Kotecha and colleagues Beta-blocker Metaanalysis 10.1016/S0140-6736(14)61373-8
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
An AHA review: the OPTION, SUMMIT, VANISH 2, SARAH, and CLEAR trials are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. OPTION Trial
For AF, LAA Rivals Anticoagulants After Ablation
https://www.medscape.com/viewarticle/af-laa-rivals-anticoagulants-after-ablation-2024a1000l7n
4 Reasons to Question Percutaneous Left Atrial Appendage Closure After AF Ablation
https://www.medscape.com/viewarticle/4-reasons-question-percutaneous-left-atrial-appendage-2024a1000l0u
- OPTION in NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2408308
II. SUMMIT Trial
Tirzepatide Reduces Heart Failure Events in HFpEF With Obesity
https://www.medscape.com/viewarticle/tirzepatide-reduces-heart-failure-events-hfpef-obesity-2024a1000kx5
- SUMMIT in NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2410027
III. VANISH Trial
New Trial Result Pushes Past Antiarrhythmic Therapy After MI
https://www.medscape.com/viewarticle/new-trial-result-pushes-past-antiarrhythmic-therapy-after-mi-2024a1000l08
- VANISH 2 https://www.nejm.org/doi/full/10.1056/NEJMoa2409501
- VANISH 1 https://www.nejm.org/doi/full/10.1056/NEJMoa1513614
IV. Cardioprotection
Common Heart Failure Drugs Ease Heart Damage During Chemo https://www.medscape.com/viewarticle/common-heart-failure-drugs-ease-heart-damage-during-chemo-2024a1000l14
- Strain Imaging Review Article https://www.jacc.org/doi/10.1016/j.jcmg.2024.07.011
V. CLEAR trial
Spironolactone Shows Mixed Results in Acute MI
https://www.medscape.com/viewarticle/spironolactone-shows-mixed-results-acute-mi-2024a1000l41
Routine Colchicine or MRA Post-MI: No CLEAR Benefit
https://www.medscape.com/viewarticle/routine-colchicine-or-mra-post-mi-no-clear-benefit-2024a1000la2
- CLEAR-Spironolactone https://www.nejm.org/doi/full/10.1056/NEJMoa2405923
- CLEAR-Colchicine https://www.nejm.org/doi/full/10.1056/NEJMoa2405922
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Tirzepatide, AF screening, and an AHA preview, including VT ablation, LAAC at the time of AF ablation, BP targets, and GLP1 agonists in HF are the topics John Mandrola, MD, covers in today's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Tirzepatide
- SURMOUNT 1 – Three-year results https://www.nejm.org/doi/full/10.1056/NEJMoa2410819
II. AF Screening
- GUARD AF https://www.jacc.org/doi/10.1016/j.jacc.2024.08.019
- LOOP 10.1016/S0140-6736(21)01698-6
- STROKE STOP 10.1016/S0140-6736(21)01637-8
III. LAAC with AF ablation
Mandrola Previews the OPTION Trial, the Most Worrisome Study at AHA 2024
https://www.medscape.com/viewarticle/mandrola-previews-option-trial-most-worrisome-study-aha-2024-2024a1000kmz
- The OPTION Trial Rationale https://doi.org/10.1016/j.ahj.2022.05.003
IV. Blood Pressure Targets
- BPROAD https://onlinelibrary.wiley.com/doi/10.1111/1753-0407.13411
- ACCORD - https://www.nejm.org/doi/full/10.1056/NEJMoa1001286
V. GLP1a for HFpEF
- SUMMIT at Clinicaltrials.gov https://clinicaltrials.gov/study/NCT04847557
VI. VT Ablation
- VANISH2 Rationale https://doi.org/10.1016/j.ahj.2024.04.009
- VANISH 1 https://www.nejm.org/doi/full/10.1056/NEJMoa1513614
VII. Spironolactone Results of CLEAR-SYNERGY
Nov 08, 2024 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1001865
'No Hint of Benefit' in Large Colchicine Trial
https://www.medscape.com/viewarticle/no-hint-benefit-large-colchicine-trial-2024a1000ko4
- CLEAR SYNERGY Rationale https://pubmed.ncbi.nlm.nih.gov/38936755/
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The EARLY TAVR trial, colchicine after MI, and the TRISCEND II trial of tricuspid valve replacement are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Early TAVR
- EARLY TAVR https://www.acc.org/latest-in-cardiology/clinical-trials/2024/10/24/14/42/early-tavr
- Rationale https://doi.org/10.1016/j.ahj.2023.11.019
- AVATAR https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057639
- RECOVERY https://www.nejm.org/doi/full/10.1056/NEJMoa1912846
- FAME 2 https://www.nejm.org/doi/full/10.1056/NEJMoa1205361
- Rajkumar; Faith Healing in Unblinded Trials https://pubmed.ncbi.nlm.nih.gov/29530888/
- PARTNER 3 trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307447
- EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec
II. Colchicine
- Meta-analysis https://doi.org/10.1016/j.eclinm.2024.102835
- Clear-Synergy Rationale https://pubmed.ncbi.nlm.nih.gov/38936755/
- COLCOT (post MI) https://www.nejm.org/doi/full/10.1056/NEJMoa1912388
- LoDoCo (Chronic CAD) https://www.nejm.org/doi/full/10.1056/NEJMoa2021372
III. TRISCEND II Trial
- TRISCEND II Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2401918
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback on PFA and STEMI/NSTEMI paradigm, oral semaglutide, symptomatic vs asymptomatic AF, and the win-ratio are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback
Oct 18, 2024 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1001769
- Pulsed Field Ablation
https://www.hrsonline.org/guidance/safety-alerts/boston-scientific-cardiac-cryoablation-system
- STEMI/NSTEMI https://doi.org/10.1016/j.jacadv.2024.101314
II. Oral Semaglutide
- Press Release: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=171480
- Rationale Paper SOUL trial
III. Symptomatic vs Asymptomatic AF
- Meta-analysis in EHJ
- Meta-analysis of rate vs rhythm-control strategies https://doi.org/10.1016/j.jacep.2024.03.006
IV. The Win Ratio
- Pocock and colleagues https://doi.org/10.1093/eurheartj/ehae647
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback on the c-statistic, atherosclerotic plaque imaging, WATCHMAN implant decisions in the US, and deprescribing are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I.Listener Feedback
Oct 11, 2024 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1001735
- Nancy Cook; C-statistic https://doi.org/10.1161/CIRCULATIONAHA.106.672402
II. Plaque Imaging
New Evidence That Plaque Buildup Shouldn't Be Ignored
https://www.medscape.com/viewarticle/new-evidence-plaque-buildup-shouldnt-be-ignored-2024a1000ihw
- Fuster and colleagues; Imaging vs CAC
III. WATCHMAN Decisions
- Zeitler and colleagues. Long-term Outcomes
IV. Deprescribing
Cognitive Decline and Antihypertensive Use: New Data
https://www.medscape.com/viewarticle/cognitive-decline-and-antihypertensive-use-new-data-2024a1000isw?form=fpf
- Jing and colleagues.
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Reader feedback on cardiac devices and PFA, a new paradigm in the language of MI, sudden cardiac death, and measuring blood pressure are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback
Sep 20, 2024 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1001631
- Cardiac Devices
https://www.acpjournals.org/doi/10.7326/ANNALS-24-00724
- Impact of PFA on Intraluminal Esophageal Temperature https://onlinelibrary.wiley.com/doi/10.1111/jce.16096
II. Towards a New Classification of MI
- McLaren and colleagues; From STEMI to OMI https://doi.org/10.1016/j.jacadv.2024.101314
III. Sudden Death After MI.
- EHJ Paper; SCD After MI https://doi.org/10.1093/eurheartj/ehae326
- Barsheshet and colleagues; Risk Score to Predict Benefit of ICD https://doi.org/10.1016/j.jacc.2012.02.036
- Zegard and colleagues; Myocardial Fibrosis and SCD 10.1016/j.jacc.2020.10.046
- MADIT RIT https://www.nejm.org/doi/full/10.1056/NEJMoa1211107
IV. BP Readings
Poor Arm Position May Significantly Skew BP Readings
https://www.medscape.com/viewarticle/poor-arm-position-may-significantly-skew-bp-readings-2024a1000icv?form=fpf
- ARMS Crossover RCT
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Reader feedback on LGE pre-ICDs, PFA for AF ablation, CTO-PCI, endovascular ablation of the greater splanchnic nerve in HFpEF, and data sharing are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback
Sept 27, 2024 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1001666
- JAMA Meta-analysis https://jamanetwork.com/journals/jama/fullarticle/2823869/
II. Pulsed Field Ablation for AF
Feb 02, 2024 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/999995
- ADMIRE Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.070333
- ADVENT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307291
III. PCI for CTO
- EuroCTO One Year SAQ Results https://doi.org/10.1093/eurheartj/ehy220
- EuroCTO Hard Outcomes https://eurointervention.pcronline.com/article/three-year-outcomes-of-eurocto-a-randomized-multicentre-trial-comparing-revascularization-and-optimal-medical-therapy-for-chronic-total-coronary-occlusions
- Faith Healing and Subtraction Anxiety https://doi.org/10.1161/CIRCOUTCOMES.118.004665
- DECISION CTO trial https://doi.org/10.1161/CIRCULATIONAHA.118.031313
- ISCHEMIA CTO Rationale and Design https://doi.org/10.1016/j.ahj.2022.11.016
IV. Greater Splanchnic Nerve Ablation for HFpEF
- REBALANCE HF https://jamanetwork.com/journals/jamacardiology/fullarticle/2823999
V. Data Sharing
The Pros and Cons of Clinical Trial Data Sharing
https://www.medscape.com/viewarticle/862815
- Kramer and Nallamothu, Caution in Data Sharing https://www.ahajournals.org/doi/full/10.1161/CIRCOUTCOMES.124.010257
- Nosek, Variability in Analytic Methods https://journals.sagepub.com/doi/10.1177/2515245917747646
- Zeraatker, Variability in Analytic Methods
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Surgical clearance, NICM assessment, dueling perspectives on PCI as first-line therapy for angina, GDMT in HFrEF are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. New ACC Peri-operative Guidelines Released
- ACC Guideline document https://www.jacc.org/doi/10.1016/j.jacc.2024.06.013
- J Vasc Surg https://www.jvascsurg.org/article/S0741-5214(21)00335-9/fulltext
- McFalls and colleagues; CARP https://www.nejm.org/doi/full/10.1056/NEJMoa041905
II. NICM – We may be doing it wrong in Selecting ICDs
- JAMA Meta-analysis https://jamanetwork.com/journals/jama/fullarticle/2823869/
- German CMR ICD Trial https://www.clinicaltrials.gov/study/NCT04558723
- BRITISH CMR trial https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/britishusing-cmr-scar-as-risk-indication-tool-in-nicm-and-severe-lvsd/
III. When Should PCI be Used in Chronic Stable CAD?
-
Rajkumar and Al-Lamee; PCI First https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011201
-
Boden and De Caterina; Meds First https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011268
- ORBITA 10.1016/S0140-6736(17)32714-9
- ORBITA 2 trial https://www.nejm.org/doi/full/10.1056/NEJMoa2310610
IV. GDMT Underuse in HFrEF
- Greene and colleagues https://doi.org/10.1016/j.jchf.2024.08.002
- DAPA HF https://www.nejm.org/doi/full/10.1056/NEJMoa1911303
- RALES https://www.nejm.org/doi/full/10.1056/NEJM199909023411001
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, K levels post cardiac surgery, cardiac device safety, disparities in preventive care, stopping trials early, and a SHAM-PVI update are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback
Sep 13, 2024 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1001596
- Sripal Bangalore Tweet on Yusef Meta-analysis https://x.com/SripalBangalore/status/1750116964893094125
II. Post Cardiac Surgery AF
- TIGHT K Trial https://jamanetwork.com/journals/jama/fullarticle/2823246
III. Evidence Base for New Cardiac Devices
- Annals of IM Survey Observational Study https://www.acpjournals.org/doi/10.7326/ANNALS-24-00724
IV. Disparities in Care
- JAMA Network Open Paper on Insurer Denials of Preventive Care https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823677
V. Stopping Trials Early
- Kaul and Butler; Insights on Recent CKD Trials https://doi.org/10.1016/j.jacc.2024.07.026
- Bassler Systematic Review https://jamanetwork.com/journals/jama/fullarticle/185591
VI. Sham PVI
AF Ablation Works…But: The Positive SHAM-PVI Trial
https://www.medscape.com/viewarticle/af-ablation-works-positive-sham-pvi-trial-2024a1000gzl?&icd=login_success_email_match_fpf
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
More from ESC: the SCOFF trial and fasting before cardiac cath, MATTERHORN, humbling data with AI, plus a reflection on the work of being a patient are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Fasting Before Cardiac Procedures
- The SCOFF Trial https://doi.org/10.1093/eurheartj/ehae573
II. MV repair for Functional MR
Large Trials Support Mitral Valve Repair in Heart Failure
- MATTERHORN https://www.nejm.org/doi/full/10.1056/NEJMoa2408739
III. AI in Medicine
- Rapidx AI Project https://healthtranslationsa.org.au/project/rapid-x-ai/
- PROTEUS Trial Rationale paper https://pubmed.ncbi.nlm.nih.gov/37192698/
IV. Time Toxicity
- Time Toxicity https://link.springer.com/article/10.1007/s00520-024-08844-1
- Thread X https://x.com/EnriqueSoto8/status/1833587144256065859
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Feedback on ABYSS and beta-blockers, more ESC recap, including SHAM-PVI, FINEARTS-HF, and RESHAPE HF2 trials are the topics John Mandrola, MD, discusses in today’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Feedback on ABYSS
Setbacks After Stopping Beta-Blockers
https://www.medscape.com/viewarticle/setbacks-after-stopping-beta-blockers-2024a1000fv7
Beta-Blockers Post-MI? No for Me, Even After the ABYSS Trial
https://www.medscape.com/viewarticle/beta-blockers-post-mi-no-me-even-after-abyss-trial-2024a1000fva
- ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204
- REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479
- QOL paper REDUCE AMI https://doi.org/10.1093/ehjcvp/pvae062
- Atenolol ED paper 10.1016/j.ehj.2003.08.016
II. SHAM-PVI
- JAMA SHAM-PVI paper https://jamanetwork.com/journals/jama/article-abstract/2823283
- Gupta QOL paper https://pubmed.ncbi.nlm.nih.gov/33952593/
III. FINEARTS HF
Finerenone Benefits Heart Failure With Preserved EF
https://www.medscape.com/viewarticle/finerenone-benefits-heart-failure-preserved-ef-2024a1000fza
Topline Finerenone Results Point to Advance in Heart Failure
https://www.medscape.com/viewarticle/topline-finerenone-results-point-advance-heart-failure-2024a1000fq2
- FINEHEARTS -HF NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2407107
- FIDELIO-DKD https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
- FIGARO-DKD https://www.nejm.org/doi/full/10.1056/NEJMoa2110956
- Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF? https://doi.org/10.1016/j.jacc.2024.08.033
IV. RESHAPE HF
TEER in Functional MR: Data Deluge, but No Easy Answers
https://www.medscape.com/viewarticle/teer-functional-mr-data-deluge-no-easy-answers-2024a1000fvg
- Mitra FR https://www.nejm.org/doi/full/10.1056/NEJMoa1805374
- COAPT https://www.nejm.org/doi/full/10.1056/NEJMoa1806640
- RESHAPE- HF2 https://www.nejm.org/doi/full/10.1056/NEJMoa2314328
- RESHAPE Subgroup paper https://doi.org/10.1016/j.jacc.2024.08.027
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
From ESC: post-MI beta blockers, a new therapy for ATTR-CM, holding RASi before non-cardiac surgery, good news in HFpEF, and an ESC preview are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. ABYSS
- ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204
- REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479
II. ATTR -CM HELIOS B
Positive Top Line Results for Vutrisiran in Cardiac Amyloidosis
https://www.medscape.com/viewarticle/positive-top-line-results-vutrisiran-cardiac-amyloidosis-2024a1000cjj
- HELIOS A https://www.tandfonline.com/doi/full/10.1080/13506129.2022.2091985
- HELIOS B https://www.nejm.org/doi/full/10.1056/NEJMoa2409134
III. STOP or NOT Trial
- Observational Study Showing Benefits of Holding RASi https://doi.org/10.1097/ALN.0000000000001404
- STOP or NOT Protocol Paper -- https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3247-1
- JAMA STOP or NOT https://jamanetwork.com/journals/jama/fullarticle/2823118
IV. GLP1a in HFpEF
The GLP-1 Agonist Semaglutide in HFpEF Cleared a Low Bar https://www.medscape.com/viewarticle/995872
- STEP-HFpEF https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
- STEP-HFpEF-DM https://www.nejm.org/doi/full/10.1056/NEJMoa2313917
- SELECT https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- FLOW https://www.nejm.org/doi/full/10.1056/NEJMoa2403347
- Lancet Meta-analysis https://doi.org/10.1016/S0140-6736(24)01643-X
V. ESC Preview
Mandrola's Five Big Trials to Look for at ESC 2024
https://www.medscape.com/viewarticle/mandrolas-five-big-trials-look-esc-2024-2024a1000fkt
Topline Finerenone Results Point to Advance in Heart Failure
https://www.medscape.com/viewarticle/topline-finerenone-results-point-advance-heart-failure-2024a1000fq2
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Suicidal ideation and GLP-1 agonists, a repeat of PARADIGM HF in Chagas CM, CASTLE HTx critical appraisal, and primary prevention of SCD in HF are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Suicidal ideation with GLP-1
Signal of Suicidality With GLP-1 RA Semaglutide, but Experts Urge Caution
https://www.medscape.com/viewarticle/signal-suicidality-glp-1-ra-semaglutide-experts-urge-caution-2024a1000fa7
- Disproportionality Analysis from World Health Organization Data on Semaglutide, Liraglutide, and Suicidality
- Variability in Disproportionality paper https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.668765/full
II. PARACHUTE HF: Repeating the Mistakes in PARADIGM HF
- PARACHUTE HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021
- SOLVD https://www.nejm.org/doi/full/10.1056/NEJM199108013250501
- CONSENSUS trial https://www.nejm.org/doi/full/10.1056/NEJM198706043162301
- Meta-analysis of Low vs High Dose ACE/ARB https://doi.org/10.1161/CIRCHEARTFAILURE.117.003956
- Meta-analysis of Sac/Val vs ARB/ACE Inhibitors https://link.springer.com/article/10.1007/s00228-024-03686-6
- PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508
III. CASTLE HTx Critical Appraisal
- Critical Appraisal of CASTLE HTx https://doi.org/10.1016/j.jacc.2024.06.020
- CASTLE HTx https://www.nejm.org/doi/10.1056/NEJMoa2306037
- CASTLE AF https://www.nejm.org/doi/full/10.1056/NEJMoa1707855
IV. More Data Suggesting Modest Benefits of the Primary Prevention ICD
- First and Recurrent ICD Shocks: JICE Paper from Denmark https://link.springer.com/article/10.1007/s10840-024-01873-0
- HF trialists https://www.nejm.org/doi/full/10.1056/NEJMoa1609758 PROFID Trial https://profid-project.eu/
- DANISH https://www.nejm.org/doi/full/10.1056/NEJMoa1608029
- SCD-HeFT https://www.nejm.org/doi/full/10.1056/NEJMoa043399
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Diuretic therapy in HFrEF, AF ablation, TACT 2 and the story of subgroups, and SGLT2 inhibitor underuse are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Diuretic Therapy in HF
- Dapa vs Metolazone Trial https://doi.org/10.1093/eurheartj/ehad341 ADVOR https://www.nejm.org/doi/10.1056/NEJMoa2203094
II. Rapid Medication Titration for Acute HF
- ACC Decision Pathway https://www.jacc.org/doi/10.1016/j.jacc.2024.06.002
III. SGLT2 Inhibitor Use in the US
- Shin and Colleagues; JACC https://www.sciencedirect.com/science/article/abs/pii/S0735109724076332
- Editorial https://doi.org/10.1016/j.jacc.2024.07.001
IV. AF Ablation: General Anesthesia vs Conscious Sedation
- Da Riis-Vestergaard and Colleagues https://doi.org/10.1093/europace/euae203
V. TACT 2 Published
- TACT 1 https://jamanetwork.com/journals/jama/fullarticle/1672238
- TACT 1 DM https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.113.000663
- TACT 2 https://jamanetwork.com/journals/jama/fullarticle/2822472
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Prediction models vs clinical judgement, CCTA quantification of atherosclerosis, AF ablation plus LAAO, atrial shunt devices, and HF medical therapy are topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I.Clinical Prediction Models vs Clinical Judgement
Did Statin Decision-Making Just Get Harder?
https://www.medscape.com/viewarticle/did-statin-decision-making-just-get-harder-2024a1000egl
- Colunga-Lozano and colleagues
- https://doi.org/10.1016/j.jclinepi.2023.10.016
- Aug 02, 2024 This Week in Cardiology Podcast
- https://www.medscape.com/viewarticle/1001429
II. CCTA Quantification of Atherosclerosis
- Atherosclerosis Quantification and Cardiovascular Risk: the ISCHEMIA Trial https://doi.org/10.1093/eurheartj/ehae471
- Circulation ISCHEMIA sub study 2021 – Severity of CAD and Outcomes https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.049755
- ISCHEMIA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1915922
III. Combined AF Ablation and LAAO
- Review from Mills and colleagues https://doi.org/10.1016/j.tcm.2023.11.003
- Link to CMS Rule on AF Ablation and LAAO https://hrs2.informz.net/z/cjUucD9taT05MjU3ODgyJnA9MSZ1PTkwMDQ2MTk4MCZsaT04NTU1OTQxMg/index.html
IV. Atrial Shunt Devices
No Net HF Benefit for Interatrial Shunt Device
https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk
- Original REDUCE-LAP-HF-II https://doi.org/10.1016/S0140-6736(22)00016-2
- Two-year results of REDUCE-LAP-HF-II https://doi.org/10.1016/j.jchf.2024.04.011
- Apr 19, 2024 This Week in Cardiology Podcast
V. Optimal HF Therapy
- Rao and colleagues; CHAMP HF https://doi.org/10.1016/j.jchf.2024.05.026
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Two downsides of PFA including autonomic tone and hemolysis, a bad surrogate in AF care, and controversies in defining cardiac risk are the topics John Mandrola, MD, covers in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I.PFA and Its (lack of) Effect on Autonomic Tone
Pulsed Field Ablation for AF: Are US Electrophysiologists Too Easily Impressed?
https://www.medscape.com/viewarticle/pulsed-field-ablation-af-are-us-electrophysiologists-too-2024a1000d2v
- Autonomic Tone Paper https://doi.org/10.1016/j.jacep.2024.05.005
- ADVENT https://www.nejm.org/doi/full/10.1056/NEJMoa2307291
II. Second PFA Study JACC-EP—on Hemolysis
- Hemolysis study https://doi.org/10.1016/j.jacep.2024.05.001
- MANIFEST 17K https://www.nature.com/articles/s41591-024-03114-3
- Defaye Editorial https://www.jacc.org/doi/abs/10.1016/j.jacep.2024.06.007
III. A Self-serving Surrogate Marker: Diagnosis to Ablation Time.
- CAPLA Study https://jamanetwork.com/journals/jama/fullarticle/2800186
- CAPLA Substudy https://doi.org/10.1016/j.jacep.2024.05.031
- EHJ RCT Early vs Late https://doi.org/10.1093/eurheartj/ehad247
- LOOP; Diederichsen and colleagues 10.1016/j.jacc.2019.09.050
- Groningen and Maastricht Group study https://heart.bmj.com/content/109/3/186
IV. Future Cardiac Risk
- Diao and colleagues Study of AHA PREVENT Risk Equations https://jamanetwork.com/journals/jama/fullarticle/2821624
- JAMA Editorial https://jamanetwork.com/journals/jama/fullarticle/2821542
- Another JAMA Editorial https://jamanetwork.com/journals/jama/fullarticle/2821628
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Health and income, high BP in the hospital, and more on subclinical AF and when to use anticoagulants are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Health and Income
A Cash Giveaway to Improve Health
https://www.medscape.com/viewarticle/cash-giveaway-improve-health-2024a1000dhf?form=fpf
- JAMA RCT https://jamanetwork.com/journals/jama/fullarticle/2821454
- NBER RCT https://www.nber.org/papers/w32711
- Have We Missed the Hidden Cause of Medical Overuse? https://www.medscape.com/viewarticle/908309
- Mar 17, 2023 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/989775
Other References
- Health Care Access and Management of Cardiovascular Risk Factors Among Working-Age Adults With Low Income by State Medicaid Expansion Status https://jamanetwork.com/journals/jamacardiology/article-abstract/2793120
- Rand Link https://www.rand.org/pubs/reports/R3055.html
- The Oregon Health Insurance Experiment https://www.healthaffairs.org/do/10.1377/hpb20150716.236899/full/
- Effect of Health Insurance in India: A Randomized Controlled Trial https://www.nber.org/papers/w29576
- Full Coverage for Preventive Medications after Myocardial Infarction https://www.nejm.org/doi/full/10.1056/nejmsa1107913
- Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial InfarctionThe ARTEMIS Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2720024
II. Elevated BP in the hospital
- JAMA-IM https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821364
III. Short-duration Subclinical AF
Apixaban Cuts Stroke but Ups Bleeding in Subclinical AF: ARTESIA
https://www.medscape.com/viewarticle/998379
- ARTESiA https://www.nejm.org/doi/full/10.1056/NEJMoa2310234
- ARTESiA CHADSVASC Subgroup https://www.jacc.org/doi/10.1016/j.jacc.2024.05.002
- NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
- EHJ NOAH subanalysis https://doi.org/10.1093/eurheartj/ehae225
- Stroke: Prolonged Heart Rhythm Monitoring After Stroke https://www.ahajournals.org/doi/10.1161/STROKEAHA.123.045843
- EHRA Analysis https://esc365.escardio.org/EHRA-Congress/sessions/10668
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Vulnerable plaque and scientific method; industry payments to trainees; tirzepatide or semaglutide; trial interpretation; and PFA are the topics John Mandrola, MD, covers in today’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Non-invasive Imaging for Vulnerable Plaque
PET Imaging Finds Vulnerable Plaques That Cause MI
https://www.medscape.com/viewarticle/pet-imaging-finds-vulnerable-plaques-cause-mi-2024a1000cm2
- JACC paper https://doi.org/10.1016/j.jacc.2024.03.419
- Original JAMA-Card paper https://jamanetwork.com/journals/jamacardiology/fullarticle/2806690
II. Industry Payments to Fellows
- JAMA Network Letter https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2821267
III. GLP-1a Class Effect?
Semaglutide Significantly Improves Chronic Kidney Disease
https://www.medscape.com/viewarticle/semaglutide-significantly-improves-chronic-kidney-disease-2024a10009w9
Mounjaro Beats Ozempic, So Why Isn’t It More Popular?
https://www.medscape.com/viewarticle/mounjaro-beats-ozempic-so-why-isnt-it-more-popular-2024a1000ckd
- JAMA-Internal Medicine: Semaglutide vs Tirzepatide https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080
- SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- FLOW trial https://www.nejm.org/doi/full/10.1056/NEJMoa2403347
- SURPASS-CVOT – Rationale https://doi.org/10.1016/j.ahj.2023.09.007
IV. Colchicine and Trial Interpretation in the Lancet
- CONVINCE https://doi.org/10.1016/S0140-6736(24)00968-1
V. PFA
Pulsed Field Ablation for AF: Are US Electrophysiologists Too Easily Impressed?
https://www.medscape.com/viewarticle/pulsed-field-ablation-af-are-us-electrophysiologists-too-2024a1000d2v
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Venous closure devices, GLP1-s linked to blindness and cancer, resisting the urge to do an ECG, and transcatheter edge-to-edge repair (TEER) for secondary mitral regurgitation are the topics discussed this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- Venous vascular closure system vs. figure-of-eight suture following atrial fibrillation ablation: the STYLE-AF Study https://doi.org/10.1093/europace/euae105
II GLP1-s and Blindness
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255
- Locke Twitter https://x.com/doc_BLocke/status/1808972226655629610
- When to Start a Statin Is a Preference-Sensitive Decision https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029808
III GLP1-s and Cancer
- Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820833
IV Screening ECG
- Routine Electrocardiogram Screening and Cardiovascular Disease Events in Adultshttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2820721
- Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP) https://doi.org/10.1016/S0140-6736(21)01637-8
- Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study) https://doi.org/10.1016/S0140-6736(21)01698-6
IV TEER for Secondary Mitral Regurgitation
- Randomized investigation of the MitraClip device in heart failure: Design and rationale of the RESHAPE-HF2 trial design https://doi.org/10.1002/ejhf.3247
- Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.3286
- Jun 21, 2024 This Week in Cardiology Podcast
- https://www.medscape.com/viewarticle/1001237
- Stats Blog https://www.r-bloggers.com/2023/07/the-benjamini-hochberg-procedure-fdr-and-p-value-adjusted-explained/
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Screening echo, multivitamins, wasteful research, another PA sensor for HF, vascular closure devices, and GLP-1 marketing as science research are the topics John Mandrola, MD, discusses this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Screening for Valvular HD in the Elderly
- EHJ-CV Imaging Paper https://doi.org/10.1093/ehjci/jeae127
II. Vitamins and Wasteful Research
Is Red Meat Healthy? Multiverse Analysis Has Lessons Beyond Meat https:// www.medscape.com/viewarticle/red-meat-healthy-multiverse-analysis-has-lessons-beyond-meat-2024a10008qv
May 10, 2024 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1000772
- Multivitamin Paper https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820369
- Physicians Health Study II https://jamanetwork.com/journals/jama/fullarticle/1389615
III. FDA Has Approved Another PA Sensor
- Link to slides https://c212.net/c/link/?t=0&l=en&o=4104690-1&h=4197477262&u=https%3A%2F%2Fendotronix.com%2FEndotronix-PROACTIVE-HF-LBCT-THT-2024.pdf&a=here
IV. Vascular Closure Devices in Electrophysiology.
- Vascular Closure Devices Study https://onlinelibrary.wiley.com/doi/full/10.1111/jce.16345
V. SURMOUNT-OSA
- SURMOUNT OSA Paper https://www.nejm.org/doi/full/10.1056/NEJMoa2404881
- SELECT https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- June 21, 2024 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1001237
- JAMA Systematic Review and Meta-analysis https://jamanetwork.com/journals/jama/fullarticle/2643307
- SAVE https://www.nejm.org/doi/full/10.1056/NEJMoa1606599
- Norwegian study https://doi.org/10.1016/j.hrthm.2022.06.016
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
MRAs in HF with renal dysfunction, coronary autoregulation, the hubris of US doctors, NSTEMI in older patients, survival after STEMI, and new leaders at JACC are discussed by John Mandrola, MD.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- Combined analysis (Matsumoto)
II Coronary artery autoregulation with increasing stenosis
- NEJM Paper https://www.nejm.org/doi/full/10.1056/NEJMc2402216
III RECOVER IV Trial
- Gregg Stone, MD Tweet https://x.com/GreggWStone/status/1803583552354742416
- DANGER-Shock Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2312572
- Impella Saves Lives in Cardiogenic Shock, but Patient Selection Key https://www.medscape.com/viewarticle/1000659
IV NSTEMI Elderly
- Main Paper
- Datamethods https://discourse.datamethods.org/t/random-vs-fixed-effects-meta-analysis/7361
- O’Fee Paper https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785560
V MI Survival
Danish Paper https://doi.org/10.1016/j.jacc.2024.04.025
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, statin eligibility and Yogi Berra, evidence-based medicine and heterogenous treatment effects, and MRAs in HF are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback
- ASPIRE AF https://classic.clinicaltrials.gov/ct2/show/NCT03968393
- Butala paper: Stroke After TAVR With and Without EPD https://www.ahajournals.org/doi/abs/10.1161/CIRCINTERVENTIONS.123.013697
- PROTECTED TAVR
- Heuts meta-analysis: EPD During TAVR https://heart.bmj.com/content/110/11/757
II. Statin Eligibility
- JAMA-IM: Data Analytic Choices and Predicting Vascular Events https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2819821
- Zeraatker Specification Analysis Paper https://doi.org/10.1016/j.jclinepi.2024.111278
- PCE https://www.mdcalc.com/calc/3398/ascvd-atherosclerotic-cardiovascular-disease-2013-risk-calculator-aha-acc
III. Heterogenous Treatment Effect
- Weisberg and Dailey-Higgs
- DANISH
IV. Heart Failure and MRAs
- RALES https://www.nejm.org/doi/full/10.1056/NEJM199909023411001
- EMPHASIS https://www.nejm.org/doi/full/10.1056/NEJMoa1009492
- Combined analysis (Matsumoto)
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Cannabis and CV outcomes, post-CABG AF, embolic protection devices, emulation of randomization, and a preview heterogenous treatment effects are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Cannabis
It Sure Looks Like Cannabis Is Bad for the Heart, Doesn't It?
https://www.medscape.com/viewarticle/1000250
Cannabis Use Tied to Increased Cardiovascular Risk
https://www.medscape.com/viewarticle/cannabis-use-tied-increased-cardiovascular-risk-2024a10003yr
Medical Cannabis for Chronic Pain Tied to Arrhythmia Risk
https://www.medscape.com/viewarticle/medical-cannabis-chronic-pain-tied-arrhythmia-risk-2024a10000sc
- Cannabis for Chronic Pain and CV Safety https://doi.org/10.1093/eurheartj/ehad834
- Editorial https://academic.oup.com/eurheartj/article/45/6/485/7500073
- Response to Letter https://doi.org/10.1093/eurheartj/ehae314
- UCLA paper https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2819559
- Lifetime Cannabis Use and Mortality https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2819635
II. Post Cardiac Surgery AF
- Meta-analysis https://doi.org/10.1093/eurheartj/ehae267
III. Embolic Protection devices
Clear Stroke Benefit Eludes Embolic Protection: PROTECTED TAVR
https://www.medscape.com/viewarticle/980978
- Embolic Protection and Stroke Prevention With TAVR https://www.ahajournals.org/doi/abs/10.1161/CIRCINTERVENTIONS.123.013697
- PROTECTED TAVR https://www.nejm.org/doi/full/10.1056/NEJMoa2204961
IV. Preview of HTE
Paper https://doi.org/10.1016/j.ahj.2024.04.020
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The FLOW trial of semaglutide, the DANCAVAS CV screening trial, non-invasive tests for chest pain, and conflicts of interest on social media are the topics John Mandrola, MD, discusses this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Semaglutide for CKD
Semaglutide Significantly Improves Chronic Kidney Disease
https://www.medscape.com/viewarticle/semaglutide-significantly-improves-chronic-kidney-disease-2024a10009w9
- FLOW Trial
II. CV Screening
Judicious CVD Screening May Work in Men: DANCAVAS
https://www.medscape.com/viewarticle/980153
- DANCAVAS 6-Year Outcomes https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004403
- DANCAVAS Main Trial NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
III. Non-invasive Cardiac Testing in Chest Pain
- Circulation Outcomes Paper https://www.ahajournals.org/doi/abs/10.1161/CIRCOUTCOMES.123.010457
- Scot Heart https://www.nejm.org/doi/full/10.1056/NEJMoa1805971
IV. COI and Social Media
- JAMA letter https://jamanetwork.com/journals/jama/fullarticle/2816900
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Clues in SCAF, a DOAC antidote trial, another negative lytic trial in stroke, JAMA changes to observational studies, and BP in stroke care are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. ARTESIA Substudy
Sadly, ARTESIA Doesn't Answer a Common Question in Cardiology
https://www.medscape.com/viewarticle/998215
- ARTESIA Substudy
- NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
- ARTESIA https://www.nejm.org/doi/10.1056/NEJMoa2310234
II. DOAC Reversal
- ANNEXA-1 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2313040
III. Lytic Therapy in Acute Stroke
Thrombolysis Offers No Benefit for Mild Stroke
https://www.medscape.com/viewarticle/iv-thrombolysis-offers-no-benefit-mild-stroke-2024a10009p7
- TEMPO-2 Trial https://doi.org/10.1016/S0140-6736(24)00921-8
- The Case Against Thrombolytic Therapy in Stroke
IV. Observational Research
- JAMA Special Communication https://jamanetwork.com/journals/jama/fullarticle/2818746
- JAMA editors note https://jamanetwork.com/journals/jama/fullarticle/2818747
V. Aggressive BP Control in Stroke
Guidelines on Rapid BP Reduction in Acute Ischemic Stroke Challenged
https://www.medscape.com/viewarticle/guidelines-rapid-bp-reduction-acute-ischemic-stroke-2024a10009pe
- TRUTH Trial https://doi.org/10.1016/S1474-4422(24)00177-7
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
An Impella update, another TAVI vs SAVR trial, two studies on angina and PCI, another null substudy from REVIVED-BCIS, and semaglutide are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Impella Update
- CHRIP BCIS 3 https://classic.clinicaltrials.gov/ct2/show/NCT05003817
- Danger-Shock Podcast https://www.medscape.com/viewarticle/1000675
II. TAVI vs SAVR
- Notion 2 Trial EHJ https://doi.org/10.1093/eurheartj/ehae331
- DEDICATE-DZHK6
III. Angina and PCI
- Orbita 2 Sub-analysis
- Orbita Star https://www.jacc.org/doi/10.1016/j.jacc.2024.04.001
IV. Complete Revascularization
- Main REVIVED trial https://www.nejm.org/doi/full/10.1056/NEJMoa2206606
- JACC Substudy https://www.jacc.org/doi/10.1016/j.jacc.2024.04.043
V. Semaglutide
Semaglutide CV Benefits Irrespective of Weight Loss: 4-Year SELECT Data
https://www.medscape.com/viewarticle/semaglutide-cv-benefits-irrespective-weight-loss-4-year-2024a100095z
- Nature Med substudy https://www.nature.com/articles/s41591-024-02996-7
- SELECT Main paper https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Inclisiran, sodium-channel blocker safety, analytic flexibility, the work-up of patients with HF, and BP in older patients are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Inclisiran Update
- ORION 4 https://classic.clinicaltrials.gov/ct2/show/NCT03705234
II. Sodium-Channel AADs
- UPenn Paper https://doi.org/10.1016/j.jacep.2024.01.021
- Three Questions Editorial https://www.ahajournals.org/doi/full/10.1161/circoutcomes.110.957381
- EAST Post-hoc Review https://doi.org/10.1093/europace/euae121
III. Analytic Flexibility
Is Red Meat Healthy? Multiverse Analysis Has Lessons Beyond Meat
https://www.medscape.com/viewarticle/red-meat-healthy-multiverse-analysis-has-lessons-beyond-meat-2024a10008qv
- Specification Curve Analysis of Red Meat Data https://doi.org/10.1016/j.jclinepi.2024.111278
IV. The Work-up of Patients With HF
- Durstenfeld and colleagues, UCSF https://www.ahajournals.org/doi/abs/10.1161/CIRCOUTCOMES.123.010800
- REVIVED BCIS2 https://www.nejm.org/doi/full/10.1056/NEJMoa2206606
V. BP Therapy in Older Patients
- Haring and colleagues; Women’s Health Initiative BP Study https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067302
- SPRINT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1511939
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The DEDICATE trial of TAVR vs SAVR, more on renal denervation, inclisiran, and marketing disguised as science are the topics John Mandrola, MD, discusses in today’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. TAVR vs SAVR
TAVI Comparable With SAVR in Lower-Risk Aortic Stenosis
https://www.medscape.com/viewarticle/tavi-comparable-savr-lower-risk-aortic-stenosis-2024a100074o?form=fpf
- DEDICATE https://www.nejm.org/doi/full/10.1056/NEJMoa2400685
- Partner 3 https://www.nejm.org/doi/full/10.1056/NEJMoa1814052
- Evolut Low Risk https://www.nejm.org/doi/full/10.1056/NEJMoa1816885
- Barili meta-analysis https://doi.org/10.1093/ejcts/ezab516
II. Renal Denervation
Alcohol-Mediated Renal Denervation Promising in Hypertension
https://www.medscape.com/viewarticle/alcohol-mediated-renal-denervation-promising-hypertension-2024a10007eg
- TARGET 1 https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.069291
III. Inclisiran
Earlier Inclisiran Gives Better Long-Term LDL Reductions
https://www.medscape.com/viewarticle/earlier-inclisiran-gives-better-long-term-ldl-reductions-2024a10007d6
- VICTORIAN INITIATE Trial https://www.jacc.org/doi/10.1016/j.jacc.2024.03.382
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
A listener defends colored boxes in guidelines; mysteries of non-culprit coronary lesions during PCI, and of AF ablation; and surrogate markers are the topics John Mandrola, MD, covers in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Mystery of What to Do in the Cath Lab after Fixing the Culprit Lesion – The FULL REVASC Trial
Complete Revascularization Not Superior to Culprit-Only PCI After MI
https://www.medscape.com/viewarticle/complete-revascularization-not-superior-culprit-only-pci-2024a10007ik
- FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149
- FIRE Trial https://www.nejm.org/doi/10.1056/NEJMoa2300468
- COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775
- Cohen Tweet on FULL REVASC https://x.com/djc795/status/1781361606238085532
II. AF Ablation Mysteries
New Expert Consensus on Ablation Strategies for AF
https://www.medscape.com/viewarticle/new-expert-consensus-ablation-strategies-af-2024a1000851
- Bern Study of Remapping https://doi.org/10.1016/j.jacep.2024.02.026
- Natural History of SCAF https://doi.org/10.1016/j.jacc.2019.09.050
- Liverpool Study: Thermal PV Isolation in Persistent AF https://doi.org/10.1016/j.hrthm.2024.04.061
III. Surrogate Markers
- JAMA: Surrugate Markers and Clinical Outcomes https://jamanetwork.com/journals/jama/fullarticle/2817850
- BP Surrogate Meta-analysis https://doi.org/10.1016/S0140-6736(21)00590-0
- JAMA: Nonfatal MI as Surrogate for Mortality https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785560
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
ACC Part 2: The TACT2 trial of chelation, inter-atrial shunts for HF, and triglyceride lowering; plus diltiazem and Factor Xa anticoagulants are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. TACT 2
Chelation Therapy Provides No Benefit Post-MI
https://www.medscape.com/viewarticle/chelation-therapy-provides-no-benefit-post-mi-2024a10006l5
Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit https://www.medscape.com/viewarticle/chelation-therapy-and-cv-risk-why-tact2-showed-no-benefit-2024a1000761?src=
- JAMA TACT 1 paper https://jamanetwork.com/journals/jama/fullarticle/1672238
- Diabetes Subgroup paper https://pubmed.ncbi.nlm.nih.gov/24254885/
- A New Look at P-values https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2300003
- PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
II. Interatrial Shunts for HF
No Net HF Benefit for Interarterial Shunt Device
https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk
- REDUCE LAP HF II https://doi.org/10.1016/S0140-6736(22)00016-2
III. Triglyceride Lowering
Early Olezarsen Results Show 50% Reduction in Triglycerides
https://www.medscape.com/viewarticle/early-olezarsen-results-show-50-reduction-triglycerides-2024a10006oz
Is It Time to Stop Treating High Triglycerides?
https://www.medscape.com/viewarticle/990126
- NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2402309
Substantial Triglyceride Reduction With Plozasiran
https://www.medscape.com/viewarticle/substantial-triglyceride-reduction-plozasiran-2024a10006wf?icd=login_success_email_match_norm
- JAMA Cardiology https://jamanetwork.com/journals/jamacardiology/article-abstract/2817469
IV. Diltiazem and Factor Xa inhibitors
- JAMA Vanderbilt University Paper https://jamanetwork.com/journals/jama/fullarticle/2817546
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
ACC Recap #1: DanGer Shock (plus a sobering JAMA research letter on Impella use), REDUCE-AMI, PREVENT, and EMPACT-MI are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. DanGer-Shock Trial
Impella CP Improves Survival in STEMI, Cardiogenic Shock https://www.medscape.com/viewarticle/impella-cp-improves-survival-stemi-cardiogenic-shock-2024a10006kz
Impella Saves Lives in Cardiogenic Shock, but Patient Selection Key https://www.medscape.com/viewarticle/1000659
- Published DanGer Shock Study https://www.nejm.org/doi/full/10.1056/NEJMoa2312572
- JAMA Research letter https://jamanetwork.com/journals/jama/article-abstract/2817457
II. REDUCE-AMI Trial
New Data Question Beta-Blockers Post-MI With Preserved EF https://www.medscape.com/viewarticle/new-data-question-beta-blockers-post-mi-preserved-ef-2024a10006y8
Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI https://www.medscape.com/viewarticle/1000663
- REDUCE-AMI paper https://www.nejm.org/doi/full/10.1056/NEJMoa2401479
- Meta-analysis: Beta Blockers for MI https://doi.org/10.1016/j.amjmed.2014.05.032
III. PREVENT Trial
Preventive PCI for Vulnerable Plaques Reduces Cardiac Events
https://www.medscape.com/viewarticle/preventive-pci-vulnerable-plaques-reduces-cardiac-events-2024a10006tc
Preventive Coronary Stents: Not There Yet
https://www.medscape.com/viewarticle/preventive-coronary-stents-not-there-yet-2024a10006yr
- PREVENT https://doi.org/10.1016/S0140-6736(24)00413-6
IV. EMPACT MI trial of Empagliflozin in the Post-MI setting
Empagliflozin Fails to Reduce Events After Acute MI
https://www.medscape.com/viewarticle/empagliflozin-fails-reduce-events-after-acute-mi-2024a10006kn
- EMPACT-MI: Another SGLT2 Inhibitor Miss in Post-MI Care https://www.medscape.com/viewarticle/1000684
- EMPACT MI https://www.nejm.org/doi/10.1056/NEJMoa2314051
- DAPA MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286
- PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508
- Kaul thread https://x.com/kaulcsmc/status/1776611935842165029
- Kaul paper https://www.ahajournals.org/doi/full/10.1161/circulationaha.116.022537
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Statins and diabetes, AAD in patients with heart disease, tricuspid valve interventions, and an ACC preview are the topics John Mandrola, MD, discusses in this week’s podcast.This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Statins and Diabetes
- Meta-analysis in Lancet-Diabetes https://doi.org/10.1016/S2213-8587(24)00040-8
- Editorial https://doi.org/10.1016/S2213-8587(24)00059-7
- NEJM Paper on Gene Variants and DM https://www.nejm.org/doi/full/10.1056/nejmoa1604304
- JAMA Paper on Gene Variants and DM https://jamanetwork.com/journals/jama/fullarticle/2565289
II. Anti-arrhythmic Drugs in Patients With Serious Heart Disease
- UPenn Paper on AADs for PVC Suppression https://doi.org/10.1016/j.jacep.2024.01.021
- Three Questions for Evidence-Based Cardiac EP https://www.ahajournals.org/doi/full/10.1161/circoutcomes.110.957381
- CAST trial https://www.nejm.org/doi/full/10.1056/NEJM199103213241201
III. Tricuspid Valve Interventions
FDA Clears TriClip for Tricuspid Regurgitation
https://www.medscape.com/viewarticle/fda-clears-triclip-tricuspid-regurgitation-2024a100068o
FDA Panel in Favor of TriClip for Tricuspid Regurgitation
https://www.medscape.com/viewarticle/fda-panel-favor-triclip-tricuspid-regurgitation-2024a100037n
- Slides for Trisend II
- TRILUMINATE https://www.nejm.org/doi/full/10.1056/NEJMoa2300525
IV. ACC Preview
Mandrola's Three Trials to Look for at the 2024 American College of Cardiology Scientific Sessions
https://www.medscape.com/viewarticle/1000613
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Intermittent fasting, anticoagulation decisions, heterogenous treatment effects, frailty in HF, the importance of the ECG, and industry conflicts are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Intermittent Fasting
No, Intermittent Fasting Won't Kill You
https://www.medscape.com/viewarticle/1000544
- NEJM Paper on Time-Restricted Eating https://www.nejm.org/doi/full/10.1056/NEJMoa2114833
- JAMA TREAT Clinical Trial https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771095
II. Stroke Prevention with OAC
- Shah Meta analysis of Vitamin K Agonists in AF https://www.ahajournals.org/doi/abs/10.1161/CIRCOUTCOMES.123.010269
III. Heterogenous Treatment Effects in Trials
Pivotal CV Trials May Not Apply to Complex Patients
https://www.medscape.com/viewarticle/989129
- Analysis of 8 Trials of Multimorbidity and Treatment Response https://doi.org/10.1016/j.amjmed.2024.01.028
IV. Frailty and HF
- Circulation Outcomes: Multidomain Frailty and Mode of Death in HF https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.123.010416
V. ECG in LBBB
- JAMA Cardiology: Revised Definition of LBBB https://jamanetwork.com/journals/jamacardiology/fullarticle/2816973
VI. Industry Payments to Doctors
- JAMA: Payments to US Physicians by Specialty https://jamanetwork.com/journals/jama/fullarticle/2816900
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
p>Obesity drugs as ASCVD-modifiers, HR monitors, when journals publish obvious facts, and effect scores and sorting out signals from RCTs are the topics John Mandrola, MD, covers in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Denmark Notes
II. FDA approval of Semaglutide
FDA Approves Semaglutide for Cardiovascular Risk Reduction
https://www.medscape.com/viewarticle/fda-approves-semaglutide-cardiovascular-risk-reduction-2024a10004ix
- Select Trial
III. PPG Monitor Accuracy
- Research Letter https://doi.org/10.1016/j.jacc.2024.01.024
IV. AAD and Bradycardia
Anti-arrhythmic Drugs Linked to Bradycardia in Patients With AF
https://www.medscape.com/viewarticle/anti-arrhythmic-drugs-linked-bradycardia-patients-af-2024a10004vw
- JACC paper on AAD Adverse Effects https://doi.org/10.1016/j.jacc.2024.01.013
V. Finding Signals in RCTs
- JAMA paper on Treatment Effects of Oxygen Targets
- DANISH trial https://www.nejm.org/doi/full/10.1056/nejmoa1608029
- LAFFLIN et al. Scoring System to Assess Generalizability of Trial Results https://doi.org/10.1177/2047487318815967
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Plastics and heart disease, MINT trial letters-to-the-editor and Bayes theorem, and Brugada syndrome are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Plastics and Heart Disease
Plastic Particles in Carotid Plaques Linked to CV Events
https://www.medscape.com/viewarticle/plastic-particles-carotid-plaques-linked-cv-events-2024a10004ge
- Plastics and ASCVD Study https://www.nejm.org/doi/full/10.1056/NEJMoa2309822
- Review https://www.nejm.org/doi/full/10.1056/NEJMra2300476
- Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2400683
II. MINT trial LTE and Bayes Theorem
In MI With Anemia, Results May Favor Liberal Transfusion: MINT https://www.medscape.com/viewarticle/998376
- The MINT Study https://www.nejm.org/doi/full/10.1056/NEJMoa2307983
- Letter-to-the-Editor https://www.nejm.org/doi/full/10.1056/NEJMc2400982
- Likelihood Ratio https://www.cebm.ox.ac.uk/resources/ebm-tools/likelihood-ratios
III. Brugada Syndrome
The EHJ paper: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae133/7623123
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The Western AF meeting, aspirin, cannabis use, LVEF in athletes, and shared decision making before ICD implantation are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. ASA in Primary Prevention
- Campbell Meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065420
- Swedish Observational study https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.028321
- ASPREE https://www.nejm.org/doi/full/10.1056/NEJMoa1805819
II. Cannabis
Cannabis Use Tied to Increased Cardiovascular Risk
https://www.medscape.com/viewarticle/cannabis-use-tied-increased-cardiovascular-risk-2024a10003yr
It Sure Looks Like Cannabis Is Bad for the Heart, Doesn’t It?
https://www.medscape.com/viewarticle/1000250
- Journal of the AHA Observational Study https://www.ahajournals.org/doi/full/10.1161/JAHA.123.030178
III. Low EF in Athletes
- Reduced Ejection Fraction in Elite Endurance Athletes: Clinical and Genetic Overlap With Dilated Cardiomyopathy https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.063777
IV. ICDs and Shared Decision-Making
- Association of a Medicare Mandate for Shared Decision-Making With Cardiac Device Utilization https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2815017
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Reading incidental CAC on chest CT scans, exercise benefits in women vs men, PCI with or without imaging, and trial non-reporting are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Incidental CAC on Chest CT
- Incidental CAC
- Tweet
- When Does a Calcium Score Equate to Secondary Prevention?: Insights From the Multinational CONFIRM Registry https://doi.org/10.1016/j.jcmg.2023.03.008
II. Exercise
Health Gains of Exercise Greater in Women?
https://www.medscape.com/viewarticle/health-gains-exercise-greater-women-2024a10003fv
- Sex Differences in Association of Physical Activity With All-Cause and Cardiovascular Mortality
III. PCI With or Without Imaging
Intravascular Imaging in PCI: Time for a Guideline Update?
https://www.medscape.com/viewarticle/995677
- Meta-analysis paper Lancet https://doi.org/10.1016/S0140-6736(23)02454-6
- Imaging uptake paper https://doi.org/10.1093/eurheartj/ehad430
IV. Trial Non-reporting
The Ghost Research Haunting Nordic Medical Trials
https://www.medscape.com/viewarticle/ghost-research-haunting-nordic-medical-trials-2024a10003gz
- Manuscript/preprint https://www.medrxiv.org/content/10.1101/2024.02.04.24301363v1#T10
- Nissen (Rosiglitazone) https://www.nejm.org/doi/10.1056/NEJMoa072761
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
An update in trial interpretation, CI, and P-values; percutaneous tricuspid Interventions; and news on HDL and humility in Medicine are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Evidence of Absence Is not Absence of Evidence
Feb 09, 2024 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1000101
- ARCADIA Trial https://jamanetwork.com/journals/jama/fullarticle/2814933
- FOURIER Trial https://www.nejm.org/doi/full/10.1056/nejmoa1615664
- Sample Size Calculator https://clincalc.com/stats/samplesize.aspx
II. Tricuspid Valve Interventions
FDA OKs First Transcatheter Tricuspid Valve Replacement
https://www.medscape.com/viewarticle/fda-oks-first-transcatheter-tricuspid-valve-replacement-2024a10002dq
FDA Panel in Favor of TriClip for Tricuspid Regurgitation
https://www.medscape.com/viewarticle/fda-panel-favor-triclip-tricuspid-regurgitation-2024a100037n
- Cardiothoracic Surgical Trials Network Study https://www.nejm.org/doi/full/10.1056/NEJMoa2115961
- TRILUMINATE https://www.nejm.org/doi/full/10.1056/NEJMoa2300525
- KAUL Tweet on ATTR Cardiomyopathy https://twitter.com/kaulcsmc/status/1753552603534016622?s=20
- APOLLO B trial https://www.nejm.org/doi/full/10.1056/NEJMoa2300757
- Al-Lamee Tweet on Sham Controls https://x.com/rallamee/status/1758236588570562736
III. HDL Cholesterol
- Rationale paper — AEGIS https://doi.org/10.1016/j.ahj.2020.10.052
- Press Release AEGIS II https://www.prnewswire.com/news-releases/csl-announces-top-line-results-from-the-phase-3-aegis-ii-trial-evaluating-the-efficacy-and-safety-of-csl112-apolipoprotein-a-i-human-302059156.html
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Beta-blocker withdrawal in HFpEF, the ARCADIA trial, food as medicine, and bariatric surgery are the topics John Mandrola, MD, discusses in today’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. HFpEF and Heart Rate
- PRESERVE HF Substudy https://jamanetwork.com/journals/jamacardiology/fullarticle/2814596
- PRESERVE HF Original https://doi.org/10.1016/j.jacc.2021.08.073
II. ARCADIA trial
- ARCADIA Main Paper: Apixaban vs ASA https://jamanetwork.com/journals/jama/fullarticle/2814933
- KAMEL’s AF and Stroke Paper 10.1161/STROKEAHA.115.012004
- AVERROES Substudy -- 10.1016/S1474-4422(12)70017-0
III. Food as Medicine
- Food-As-Medicine Trial results: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2812982
- NPR Story https://www.npr.org/sections/thesalt/2017/05/08/526952657/fresh-food-by-prescription-this-health-care-firm-is-trimming-costs-and-waistline
IV. Bariatric Surgery
Weight Loss Surgery Yields Long-Term BP Control in Obesity
https://www.medscape.com/viewarticle/weight-loss-surgery-yields-long-term-bp-control-obesity-2024a10002le
- Gateway RCT https://doi.org/10.1016/j.jacc.2023.11.032
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
FDA approves PFA for AF ablation, flawed comparisons of TEER vs MV surgery and PCI vs CABG, and cardiologists struggling with board exams are the topics John Mandrola, MD, covers in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. PFA
FDA Okays Boston Scientific PFA System for Paroxysmal AF
https://www.medscape.com/viewarticle/fda-okays-boston-scientific-pfa-system-paroxysmal-af-2024a1000275
Pulsed-Field Ablation for AF: The Promise and the Reality
https://www.medscape.com/viewarticle/995675
- ADVENT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307291
- EU-PORIA Registry https://doi.org/10.1093/europace/euad185
- Tomlinson/Mandrola Editorial https://www.jacc.org/doi/10.1016/j.jacc.2020.07.032
II. TEER vs MV Surgery
- EHJ Paper https://doi.org/10.1093/eurheartj/ehae046
III. ISCHEMIA Post-Hoc Studies
- JACC Post-Hoc ISCHEMIA Trialhttps://doi.org/10.1016/j.jacc.2023.11.002
- Main ISCHEMIA paper https://www.nejm.org/doi/full/10.1056/nejmoa1915922
- FAME 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2112299
IV. Board Exams
More Cardiologists Failing the Boards, Why and How to Fix?
https://www.medscape.com/viewarticle/more-cardiologists-failing-boards-why-and-how-fix-2024a10001oi
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
LAAO, more evidence that stable CAD is stable, CRT benefit over the long-term, and AF monitoring after stroke are the topics John Mandrola, MD, covers in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. LAAO
This Week in Cardiology Podcast, Dec 15, 2023 https://www.medscape.com/viewarticle/999282
- European Heart Journal paper https://academic.oup.com/eurheartj/article/45/3/214/7471675
- LAAOS 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2101897
II. CAD after Transcatheter Aortic Valve Implantation
- Cleveland Clinic Observational study https://doi.org/10.1093/eurheartj/ehae019
- ACTIVATION trial https://doi.org/10.1016/j.jcin.2021.06.041
III. Cardiac Resynchronization Therapy
- Original RAFT 2010 https://www.nejm.org/doi/full/10.1056/nejmoa1009540
- Long-term RAFT https://www.nejm.org/doi/full/10.1056/NEJMoa2304542
- Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2312419
IV. AF Monitoring After Stroke
- Japanese Observational Study https://www.ahajournals.org/doi/10.1161/JAHA.123.031508
- ARTESIA https://www.nejm.org/doi/full/10.1056/NEJMoa2310234
- NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
- LOOP substudy https://jamanetwork.com/journals/jamaneurology/fullarticle/2795865
- CRYSTAL AF https://www.nejm.org/doi/full/10.1056/nejmoa1313600
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback on antiplatelet therapy after PCI, bempedoic acid, off-Label PFO Closure, and palliative care are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback on Antiplatelet Therapy After PCI
Long-term Clopidogrel Has Advantages After Coronary Stenting
https://www.medscape.com/viewarticle/long-term-clopidogrel-has-advantages-after-coronary-stenting-2024a10000c8
- Host Exam Study; Extended FU of Host-Exam https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062770
II. Bempedoic Acid
This Week in Cardiology July 7, 2023 https://www.medscape.com/viewarticle/994089
-
NEJM: Bempedoic Acid and CV Outcomes
-
JAMA: Primary Prevention Analysis https://jamanetwork.com/journals/jama/fullarticle/2806646
-
JAMA-Cardiology: Total Events Analysis https://jamanetwork.com/journals/jamacardiology/fullarticle/2813647/
III. Off-Label PFO Closure
- Circulation Outcomes Paperhttps://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.123.010200
IV. Palliative Care
- JAMA: Palliative Care Consultation
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
GLP-1s and BaroStim Neo revisited, a new drug for transthyretin amyloid CM, clopidogrel vs ASA years after PCI and stent, and statins are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. GLP-1s and Obesity, BaroStim Neo Revisited
FDA Expands Label for CVRx Barostim System in HF https://www.medscape.com/viewarticle/fda-expands-label-cvrx-barostim-system-hf-2023a1000wsx
JAMA Cardiology Special Communication – BDP https://jamanetwork.com/journals/jamacardiology/fullarticle/2810726
II. ATTR Cardiomyopathy
ATTRibute-CM NEJM paper https://www.nejm.org/doi/full/10.1056/NEJMoa2305434
Circulation Review of TTR https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.111.078915
ATTR-ACT (Tafadimis) https://www.nejm.org/doi/10.1056/NEJMoa1805689
III. Clopidogrel vs ASA Years After PCI
Long-term Clopidogrel Has Advantages After Coronary Stenting
https://www.medscape.com/viewarticle/long-term-clopidogrel-has-advantages-after-coronary-stenting-2024a10000c8
Stop DAPT Original Trial
STOP DAPT at 5 Years https://doi.org/10.1016/j.jacc.2023.10.013
Network Meta-analysis of P2Y12-I vs ASA https://doi.org/10.1016/j.jcin.2022.08.009
IV. Statin Use
Statin Use Remains Low for At-Risk Patients
https://www.medscape.com/viewarticle/999043
Annals of Internal Medicine Observational Study https://doi.org/10.7326/M23-1915
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Neuro-modulation in HF, private equity owned hospitals, HCM, SCD and ICD re-evaluated, and peer review are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Neuromodulation for HFrEF
FDA Expands Label for CVRx Barostim System in HF
https://www.medscape.com/viewarticle/fda-expands-label-cvrx-barostim-system-hf-2023a1000wsx
BeAT HF trial https://doi.org/10.1016/j.jacc.2020.05.015
II. Private Equity Takeover of US Hospitals
Hospital Adverse Events Rise After Private Equity Acquisition
https://www.medscape.com/viewarticle/hospital-adverse-events-rise-after-private-equity-2023a1000wya
Changes in Hospital Adverse Events and Patient Outcomes Associated With Private Equity Acquisition: https://jamanetwork.com/journals/jama/article-abstract/2813379
RSS audio: https://bi.medscape.com/pi/editorial/studio/audio/2024/core/999557.mp3
III. Hypertrophic Cardiomyopathy
Positive Topline Results for SEQUOIA-HCM Trial in OHCM
https://www.medscape.com/viewarticle/positive-topline-results-sequoia-hcm-trial-ohcm-2023a1000wu9
IV. The ICD gets a ReLook
Study to Examine Routine ICD Implantation Post Heart Attack
https://www.medscape.com/viewarticle/study-examine-routine-icd-implantation-post-heart-attack-2023a1000wmd
PROFID Site https://profid-project.eu/profid-ehra-trial/
Declining Risk of Sudden Death in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa1609758
V. Peer Review
Prevalence of Short Peer Reviews in 3 Leading General Medical Journals -- https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2812883
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.n
FDA approves PFA, breakthrough in PAH, residual leaks after percutaneous LAAO, OAC in low to intermediate risk people are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. FDA Approves PFA
FDA Approves First Pulsed Field Ablation System for AF https://www.medscape.com/viewarticle/fda-approves-first-pulsed-field-ablation-system-af-2023a1000vit
-
PULSED AF https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064329
-
ADVENT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307291
-
MANIFEST https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064959
II. Pulmonary HTN
Positive Topline Data for Sotatercept in PAH: STELLAR
https://www.medscape.com/viewarticle/982407
-
STELLAR https://www.nejm.org/doi/10.1056/NEJMoa2213558
-
Editorial on STELLAR https://www.nejm.org/doi/full/10.1056/NEJMe2300324
III. Peri-Device Leaks
- Greek Meta-analysis https://doi.org/10.1093/eurheartj/ehad828
IV. Intermediate Risk AF – Norwegian Study
- Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study AFNOR Study https://doi.org/10.1093/eurheartj/ehad659
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Three aspects of the recent AF guideline documents and a possible new treatment of POTS are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I AF Guidelines
ACC/AHA Issue Updated Atrial Fibrillation Guideline
https://www.medscape.com/viewarticle/998956
-
Guideline doc: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001193
-
CASTLE AF https://www.nejm.org/doi/full/10.1056/nejmoa1707855
-
Analysis of US Inpatient Sample https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/1471-2261-14-73
-
RAFT AF https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057095
-
Beta Blockers in AF https://pubmed.ncbi.nlm.nih.gov/25193873/
Section 2 AF Guidelines – EARLY Rhythm Control Gets Emphasis
-
STOP AF https://www.nejm.org/doi/full/10.1056/NEJMoa2029554
-
EARLY AF https://www.nejm.org/doi/full/10.1056/nejmoa2029980
-
EAST https://www.nejm.org/doi/full/10.1056/NEJMoa2019422
-
Natural History of AF https://www.jacc.org/doi/abs/10.1016/j.jacc.2019.09.050
Section 3 AF Guidelines – Dubious Upgrade of percutaneous LAAC
-
PROTECT and PREVAIL Meta-analysis 5-year https://doi.org/10.1016/j.jacc.2017.10.021
-
PINNACLE FLX https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.120.050117
II. Postural Orthostatic tachycardia Syndrome
Vagus Nerve Stimulation Promising In POTS
https://www.medscape.com/viewarticle/998913
- Stavrakis et al. Noninvasive VNS for POTS https://doi.org/10.1016/j.jacep.2023.10.015
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
More from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. DAPA MI
Potential Dapagliflozin Benefit Post-MI Is Not a 'Mandate'
https://www.medscape.com/s/viewarticle/998378
- NEJM Evidence: Dapagliflozin After MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286
II. Blood Transfusion Strategy Post MI
In MI With Anemia, Results May Favor Liberal Transfusion: MINT
https://www.medscape.com/viewarticle/998376
-
MINT NEJM -- https://www.nejm.org/doi/full/10.1056/NEJMoa2307983
-
REALITY https://jamanetwork.com/journals/jama/fullarticle/2776201
-
PROTECTED TAVR - https://www.nejm.org/doi/full/10.1056/NEJMoa2204961
III. FACTOR XI
Impressive Bleeding Profile With Factor XI Inhibitor in AF: AZALEA
https://www.medscape.com/viewarticle/998418
Asundexian Phase 3 AF Study Halted for Lack of Efficacy
https://www.medscape.com/viewarticle/998665
- Abelacimab for VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2105872
IV. Renal Denervation
FDA Panel Split on Efficacy of Spyral Renal Denervation
https://www.medscape.com/viewarticle/995800
FDA OKs Symplicity Renal Denervation System for Hypertension
https://www.medscape.com/viewarticle/998664
-
SPYRAL HTN OFF MED -- https://doi.org/10.1016/S0140-6736(20)30554-7
-
SPRYAL HTN On Meds (Pilot Lancet 2018 ) https://doi.org/10.1016/S0140-6736(18)30951-6
-
SPRYAL HTN ON Meds (Expansion Pilot) https://doi.org/10.1016/j.jacc.2023.08.045
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
An AHA Recap: SELECT, ORBITA2, and ARTESIA are the trials John Mandrola, MD, reviews in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
American Heart Association 2023 on theHeart.org | Medscape Cardiology
https://www.medscape.com/viewcollection/37277
I. SELECT Trial
Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT
https://www.medscape.com/viewarticle/998373
Positive Results From SELECT Begins a New Era in Cardiology
https://www.medscape.com/viewarticle/998217
Is It Time for Cardiologists to Treat Obesity?
https://www.medscape.com/viewarticle/998391
-
SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
-
SUSTAIN 6 https://www.nejm.org/doi/full/10.1056/nejmoa1607141
II. ORBITA 2
Angioplasty Finally Proven Beneficial in Stable Angina: ORBITA-2
https://www.medscape.com/s/viewarticle/998375
ORBITA-2 Saves Interventional Cardiology and Challenges Current Guidance
https://www.medscape.com/viewarticle/998213
PCI, the Antianginal 'Pill': ORBITA-2 in Detail
https://www.medscape.com/viewarticle/997777
-
ORBITA-2; NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2310610
-
ORBITA 1 https://doi.org/10.1016/S0140-6736(17)32714-9
III. ARTESIA
Apixaban Cuts Stroke but Ups Bleeding in Subclinical AF: ARTESIA
https://www.medscape.com/viewarticle/998379
Sadly, ARTESIA Doesn't Answer a Common Question in Cardiology
https://www.medscape.com/viewarticle/998215
-
NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
-
ARTESIA https://www.nejm.org/doi/10.1056/NEJMoa2310234
-
AVERROES https://www.nejm.org/doi/full/10.1056/NEJMoa1007432
-
McIntyre Meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512
-
TRENDS https://www.ahajournals.org/doi/10.1161/circep.109.849638
-
ASSERT https://doi.org/10.1093/eurheartj/ehx042
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Renal denervation, a potential deadly decision in the ED, GLP-1 agonists, and an AHA preview are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Renal Denervation
FDA OKs Paradise Renal Denervation System for Hypertension
https://www.medscape.com/viewarticle/998237
-
Company Press Release https://www.recormedical.com/recor-medical-and-otsuka-medical-devices-announce-first-fda-approved-renal-denervation-system-for-the-treatment-of-hypertension/
-
Six-month Meta-analysis of RDN Studies https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.123.066941
-
March This Week in Cardiology with RDN Discussion https://www.medscape.com/viewarticle/989014
II. Potential Deadly Decisions in the ED
Even One Night in the ED Raises Risk for Death
https://www.medscape.com/viewarticle/998080
- JAMA Internal Medicine Study
III. Tirzepatide Approval
FDA Approves Tirzepatide for Treating Obesity
https://www.medscape.com/viewarticle/998225
-
SURMOUNT 2 https://doi.org/10.1016/S0140-6736(23)01200-X
-
SURMOUNT 1 https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
IV. AHA Preview
Mandrola's Top Trials to Look for at AHA 2023
https://www.medscape.com/viewarticle/998123
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Tricuspid regurgitation therapy, two more left atrial appendage trials, and reflections on being too soft on medical science are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Tricuspid Regurgitation
Trilogy TAVR Safe, Effective in Aortic Regurgitation
https://www.medscape.com/viewarticle/997782
The TRILUMINATE Transcatheter Tricuspid Repair Trial: Positive but No Benefit?
https://www.medscape.com/viewarticle/989105
Transcatheter Tricuspid Valve Repair Effective, Safe for Regurgitation: TRILUMINATE
https://www.medscape.com/s/viewarticle/989103
- TRILUMINATE NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2300525
II. LAA Occlusion
Different Strengths for LAA Closure Devices?
https://www.medscape.com/viewarticle/962893
- Swiss Apero – Original paper https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057859
- Swiss Apero – One-year https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067599
Peri-device Leaks After Watchman https://pubmed.ncbi.nlm.nih.gov/35902169/
TAVR With Left Atrial Appendage Occlusion Non-inferior to TAVR Plus Medical Therapy https://www.medscape.com/viewarticle/997725
- WATCH TAVR Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067312
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
More on the Million Hearts RCT, ENRICH AF, TAVI vs SAVR, the Partner 3 and Evolut-low-risk trials, and myocardial viability are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback Million Hearts
CMS 'Million Hearts' CVD Risk Reduction Model Works
https://www.medscape.com/viewarticle/997551
- RCT JAMA - https://jamanetwork.com/journals/jama/fullarticle/2810696
AC in ICH - ENRICH AF
Oral Anticoagulation in ICH Patients With AF: New Data https://www.medscape.com/viewarticle/997547
-
Lancet Neurology Meta-analysis https://doi.org/10.1016/S1474-4422(23)00315-0
-
ENRICH AF letter https://doi.org/10.1016/S0140-6736(23)02025-1
II. TAVI vs SAVR
Low-Risk TAVR Studies: Divergent Long-Term Results
https://www.medscape.com/viewarticle/997784
-
Partner 3 Main Results
-
Partner 3 – Five Year
-
Original EVOLUT -LR https://www.nejm.org/doi/10.1056/NEJMoa1816885
-
EVOLUT 3-year https://doi.org/10.1016/j.jacc.2023.02.017
-
EVOLUT -LR 4-year https://doi.org/10.1016/j.jacc.2023.09.813
III. Myocardial Viability
Viability-Guided PCI Doubted in Stable Severe CAD: REVIVED-BCIS2
https://www.medscape.com/viewarticle/989101
-
Revived BCIS – Original paper https://www.nejm.org/doi/10.1056/NEJMoa2206606
-
JAMA Cardiology Viability paper https://jamanetwork.com/journals/jamacardiology/fullarticle/2810727
-
STICH Viability Paper - https://www.nejm.org/doi/full/10.1056/NEJMoa1100358
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, oral anticoagulation in patients with ICH, an example of statistical significance but not clinical significance, and statins and diabetes are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback
October 13, 2023 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/997281
-
European Heart Journal: IVI for PCI https://doi.org/10.1093/eurheartj/ehad430
-
Elgendy Meta-analysis of Imaging in PCI: https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.116.003700
-
ULTIMATE: https://www.jacc.org/doi/10.1016/j.jacc.2018.09.013
-
ILUMEIN IV: https://www.nejm.org/doi/full/10.1056/NEJMoa2305861
-
OCTOBER: https://www.nejm.org/doi/full/10.1056/NEJMoa2307770
-
Main STEP-HFpEF paper
-
Letter to the Editor on Lack of Obesity Paradox https://doi.org/10.1016/j.amjcard.2019.04.037
II. Anticoagulation in ICH
Oral Anticoagulation in ICH Patients With AF: New Data https://www.medscape.com/viewarticle/997547
-
Lancet Neuro Meta-analysis https://doi.org/10.1016/S1474-4422(23)00315-0
-
ENRICH AF letter https://doi.org/10.1016/S0140-6736(23)02025-1
III. Million Hearts
CMS 'Million Hearts' CVD Risk Reduction Model Works https://www.medscape.com/viewarticle/997551
- RCT JAMA
IV. Statin Choice and Diabetes
April 7, 2023 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/990542
-
LODESTAR Main Study
-
LODESTAR Substudy
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Three stories regarding GLP-1 agonists, imaging during PCI, and the power of sham controls in procedure trials are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. FLOW Trial Positive
Novo Nordisk Stops Ozempic Kidney Trial After Early Signs of Success https://www.medscape.com/s/viewarticle/997237
- FLOW Trial – press release https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166327
II. STEP HFpEF
Semaglutide Win in HFpEF With Obesity Regardless of Ejection Fraction: STEP-HFpEF
https://www.medscape.com/viewarticle/997185
The GLP-1 Agonist Semaglutide in HFpEF Cleared a Low Bar
https://www.medscape.com/viewarticle/995872
-
STEP HFpEF substudy
-
STEP HFpEF main paper
III. GLP-1 Agonist Adverse Effects
GLP-1 Agonists Linked to Higher Risk for Rare but Serious GI Complications
https://www.medscape.com/viewarticle/997128
- GI Adverse Effects of GLP-1 Agonists https://jamanetwork.com/journals/jama/fullarticle/2810542
IV. Imaging in PCI
Intravascular Imaging in PCI: Time for a Guideline Update?
https://www.medscape.com/viewarticle/995677
-
Intravascular imaging during percutaneous coronary intervention: temporal trends and clinical outcomes in the USA https://academic.oup.com/eurheartj/article/44/38/3845/7226277
-
HEART Review of Studies of Intracoronary Imaging During PCI https://heart.bmj.com/content/107/9/755
V. The Power of Placebo (Sham) control
Hopeful Insights, No Overall HFpEF Gains From Splanchnic Nerve Ablation: REBALANCE-HF
https://www.medscape.com/viewarticle/997318
- Transvenous Right GSN Ablationin HFpEF https://doi.org/10.1016/j.jchf.2022.05.009
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Coated vs uncoated ASA, a new trial in CAD, conflicts of interest, first AF in the hospital, and changing HTN scoring and CHADSVASC are the topics John Mandrola, MD, covers in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. ASA
No Benefit of Enteric-Coated Aspirin vs Uncoated in CVD https://www.medscape.com/viewarticle/997119
-
JAMA Cardiology: Coated vs Uncoated ASA https://jamanetwork.com/journals/jamacardiology/fullarticle/2809795
-
ADAPTABLE https://www.nejm.org/doi/10.1056/NEJMoa2102137
II. RECHARGE
-
Revascularization Choices Among Under-Represented Groups Evaluation (The RECHARGE Program) https://www.pcori.org/research-results/2023/revascularization-choices-among-under-represented-groups-evaluation-recharge-program
-
Gaudino/Stone: Reconsidering Coronary Revascularization Trials
III. Conflicts of Interest
- Financial Conflicts of Interest in Public Comments on Medicare National Coverage Determinations of Medical Devices https://jamanetwork.com/journals/jama/fullarticle/2808721
IV. First AF in the Hospital
Decoding AFib Recurrence: PCPs' Role in Personalized Care https://www.medscape.com/viewarticle/997011
- Annals of Internal Medicine: AF Recurrence https://doi.org/10.7326/M23-1411
V. Changing CHADSVASC Score
- JAMA Network Open: HTN Guidelines and CHADSVASC Up-Scoring https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2809933
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Reader feedback, leadless pacing, ABIM, SGLT2 inhibitors, peri-operative MI after cardiac surgery, and. AHA late-breakers are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Reader Feedback
Sep 22, 2023 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/996694
-
ODYSSEY OUTCOMES trial https://www.nejm.org/doi/full/10.1056/nejmoa1801174
-
FOURIER https://www.nejm.org/doi/full/10.1056/nejmoa1615664
II. Leadless Pacing
- Leadless vs Transvenous Pacemaker Study https://doi.org/10.1093/europace/euad269
III. ABIM News
Heart Societies Ready to Split From ABIM Over Long-Standing MOC Disputes
https://www.medscape.com/viewarticle/996747
IV. SGLT2 inhibitors
Empagliflozin Gets FDA Nod for CKD Without T2D or HF
https://www.medscape.com/viewarticle/996873
- EMPA-Kidney https://www.nejm.org/doi/full/10.1056/NEJMoa2204233
V. Peri-Op MI after Cardiac Surgery
Cardiac Troponin Predicts Mortality Post Surgery
https://www.medscape.com/viewarticle/996877
-
Austrian Perioperative MI study https://doi.org/10.1016/j.jacc.2023.07.011
-
Vision https://www.nejm.org/doi/10.1056/NEJMoa2000803
VI. AHA Late Breakers
- Link to Late-Breakers https://professional.heart.org/en/meetings/scientific-sessions/programming/late-breaking-science#late-breaking
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Coronary calcium, cardiac arrest survival, Factor XI drug findings, APCs and a potential new board certification in cardiology are the topics discussed by John Mandrola, MD in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Coronary Artery Calcium
-
CONFIRM Registry - https://doi.org/10.1016/j.jcmg.2023.03.008
-
CURE -- https://www.nejm.org/doi/full/10.1056/nejmoa010746
II Cardiac Arrest
Cardiac Arrest Centers No Benefit in OHCA Without STEMI
https://www.medscape.com/viewarticle/995885
-
Cycling coverage https://velo.outsideonline.com/road/road-racing/nathan-van-hooydonck-forced-to-end-to-racing-career-due-to-heart-condition/
-
ARREST https://doi.org/10.1016/S0140-6736(23)01351-X
-
SCD in Athletes Bob Harrington and Manesh Patel https://www.medscape.com/viewarticle/995575
III Factor XI
Trial Halted for Bleeding Reduction With Abelacimab vs Rivaroxaban in AF
https://www.medscape.com/viewarticle/996587
-
Press Release - https://anthostherapeutics.com/wp-content/uploads/2023/09/2023-09-18-Anthos-Press-Release-final.pdf
-
Abelacimab, a Factor XI Inhibitor, Prevents VTE With Low Bleeding Risk in Knee Replacement
-
NEJM proof-of-concept https://www.nejm.org/doi/full/10.1056/NEJMoa2105872
-
OCEANIC-AF https://classic.clinicaltrials.gov/ct2/show/NCT05643573
-
Will Factor XI Be the Goldilocks Anticoagulant Target? https://www.medscape.com/viewarticle/979634
IV APC Care
NPs and PAs Handling Increasingly More Primary Care Visits: New Studies https://www.medscape.com/viewarticle/996709
BMJ paper -- https://www.bmj.com/content/382/bmj-2022-073933
V Possible Cardiology Board Certification Changes
- Heart Societies Ready to Split From ABIM Over MOC Disputes https://www.medscape.com/viewarticle/996747
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Reader feedback, imaging in the cath lab, AF ablation to relieve anxiety, and some possible help in hypertension are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Reader Feedback
Sep 08, 2023 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/996233
First Clinical Trial of CTO Procedures Fails to Deliver https://www.medscape.com/viewarticle/877405
- DanGerShock trial https://pubmed.ncbi.nlm.nih.gov/31176289/
II. Imaging in the Cath Lab
Should Intravascular Imaging Be Almost Routine in PCI? https://www.medscape.com/viewarticle/996375
-
ILUMIEN IV https://www.nejm.org/doi/full/10.1056/NEJMoa2305861
-
OCTOBER https://www.nejm.org/doi/full/10.1056/NEJMoa2307770
III. AF Ablation to Relieve Anxiety
-
REMEDIAL Trial https://jamanetwork.com/journals/jama/fullarticle/2809419
-
Sohaib and Francis; Meta analysis of Symptomatic Response Effect of CRT Pacing https://pubmed.ncbi.nlm.nih.gov/24259043/
IV. HTN
'New Dawn' for Aldosterone as Drug Target in Hypertension? https://www.medscape.com/viewarticle/996316
- TARGET HTN - https://jamanetwork.com/journals/jama/fullarticle/2809625
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
ESC Recap Part 2: ECLS-SHOCK, FIRE, MULTISTARS-AMI, HEART FID, and DANPACE II are the trials John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Cardiogenic Shock
ECMO for Shock in Acute MI Won't Help, May Harm: ECLS-SHOCK https://www.medscape.com/viewarticle/995882
-
ECLS-SHOCK trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307227
-
ECMO-CS trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062949
II. FIRE TRIAL
FIRE a Win for Physiology-Guided MI Complete Revascularization in Older Patients https://www.medscape.com/viewarticle/995875
-
FIRE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2300468
-
COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775
III. Immediate vs Staged Revascularization
Parity for Prompt vs Staged STEMI Complete Revascularization: MULTISTARS-AMI https://www.medscape.com/viewarticle/995961
-
MULTISTARS AMI trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307823
-
Complete Revascularization Now Compulsory? MULTISTARS-AMI and FIRE in Context https://www.medscape.com/viewarticle/995676
IV. Iron-Supplementation in Heart Failure
IV Iron Shows Only Modest Benefit in HF: HEART-FID https://www.medscape.com/viewarticle/995874
-
HEART-FID https://www.nejm.org/doi/full/10.1056/NEJMoa2304968
-
EHJ meta-analysis of Iron Supplementation https://doi.org/10.1093/eurheartj/ehad586
V. AF Prevention with Pacing
Minimizing Atrial Pacing No Benefit in Sinus Node Disease: DANPACE II https://www.medscape.com/viewarticle/996076
- DANPACE II https://doi.org/10.1093/eurheartj/ehad564
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine. https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
ESC Wrap-up 1: Obesity, heart failure with preserved EF and reduced EF, AF, frailty, evidence translation, and catheter ablation are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. FRAIL AF
-FRAIL-AF Study
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066485
-The Most Important Study From ESC: FRAIL-AF
https://www.medscape.com/viewarticle/996063
II. STEP-HFpEF
Wegovy Scores HFpEF Benefits in People With Obesity
https://www.medscape.com/viewarticle/995844
GLP-1 Agonist Semaglutide in HFpEF Cleared Low Bar
https://www.medscape.com/viewarticle/995872
Semaglutide’s Big Step in HFpEF With Obesity: Investigator Inteview
https://www.medscape.com/viewarticle/995673
-Semaglutide in Obese Patients With HFpEF
https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
III. NOAH AFNET 6
Anticoagulation No Benefit in Presumed AF Detected by Cardiac Devices
https://www.medscape.com/viewarticle/995861
How Much AF Warrants Anticoagulation? NOAH-AFNET 6 Provides Clues
https://www.medscape.com/viewarticle/995871
-NOAH AFNET-6 – NEJM
https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
IV. ADVENT
Pulsed Field Ablation Challenges Conventional Devices in AF
https://www.medscape.com/viewarticle/995884
Pulsed Field Ablation Noninferior but Underwhelming in ADVENT
https://www.medscape.com/viewarticle/995898
-PPFA vs Thermal Ablation for PAF
https://www.nejm.org/doi/10.1056/NEJMoa2307291
V. BUDAPEST CRT
Impact of RV Pacing in Heart Failure, CRT Benefit Shown in BUDAPEST-CRT
https://www.medscape.com/viewarticle/996035
Supporting Evidence for a Common Practice: BUDAPEST CRT
https://www.medscape.com/viewarticle/995880
-BUDAPEST CRT Study: European Heart Journal
https://doi.org/10.1093/eurheartj/ehad591
VI. CASTLE HTx
Advanced HF No Obstacle to AF Ablation Success: CASTLE-HTx
https://www.medscape.com/viewarticle/995897
AF Ablation in End-Stage HF: Is CASTLE-HTx Too Good to Be True?
https://www.medscape.com/viewarticle/995974
-CASTLE AF (2018)
https://www.nejm.org/doi/full/10.1056/nejmoa1707855
-CASTLE HTx
https://www.nejm.org/doi/full/10.1056/NEJMoa2306037
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
GLP-1 agonists in HFpEF, DOACs for subclinical AF, renal denervation, and the matter of remaining in the profession are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Obesity and HFpEF
GLP-1 Agonists in HFpEF With Obesity: Are We There Yet? https://www.medscape.com/viewarticle/993980
Wegovy Scores HFpEF Benefits in People With Obesity https://www.medscape.com/viewarticle/995844
- Semaglutide in Obese Patients With HFpEF https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
- Rationale/Protocol Paper https://doi.org/10.1016/j.jchf.2023.05.010
II. DOAC for Subclinical AF
- NOAH-AFNET 6 Rationale/Protocol https://doi.org/10.1016/j.ahj.2017.04.015
- NOAH-AFNET 6 Trial Results https://www.nejm.org/search?q=NOAH+AFNET
III. Renal Denervation
ReCor Renal Denervation System Safe, Effective: FDA Panel https://www.medscape.com/viewarticle/995741
FDA Panel Split on Efficacy of Spyral Renal Denervation https://www.medscape.com/viewarticle/995800
SPYRAL HTN-ON MED https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00455-X/fulltext
IV. Maintenance of Certification
As MOC Debate Heats Up, Cardiology Societies Weigh In https://www.medscape.com/viewarticle/moc-debate-heated-cardiology-societies-weigh-2023a1000jju
Features
Mandrola's 5 Things to Look for at the Upcoming ESC 2023
https://www.medscape.com/viewarticle/995614
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
ICD generator change, less is more in VT management, co-morbidity in HF, and SGLT2i after AF ablation are the topics discussed by John Mandrola, MD, in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. ICD Gen Change
- Patients’ Perspectives Regarding Generator Exchanges of Implantable Cardioverter Defibrillators https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.122.009827
- DEFINITE https://www.nejm.org/doi/10.1056/nejmoa033088
- SCD-HeFT https://www.nejm.org/doi/full/10.1056/nejmoa043399
- DANISH https://www.nejm.org/doi/10.1056/NEJMoa1608029
- Poole and colleagues; 11-year follow-up of SCD-HeFT https://doi.org/10.1016/j.jacc.2020.05.061
- Editorial – Howell/Stecker https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.123.010266
II. VT Therapy
Crossed Wires: Ischemia Testing and Monomorphic VT Storm
https://www.medscape.com/viewarticle/995401
- Cleveland Clinic Study
https://doi.org/10.1016/j.jacep.2023.04.030
III. Co-Morbidity in HF
- Hospital admissions in the last year of life of patients with heart failure
https://doi.org/10.1093/ehjqcco/qcad047
- Four Horsemen of Apocalypse Lecture
http://www.louisvillelectures.org/imblog/2017/10/5/whw8sf0m1k0wi6lm6kvjsx4nxzzjg5
IV. SGLT2i After Ablation for AF
SGLT2 Inhibitors Curb AF Post-Ablation Recurrences in Diabetes
https://www.medscape.com/viewarticle/995415
- Observational Study – Abu-Qaoud et al
https://www.jacc.org/doi/full/10.1016/j.jacep.2023.06.008
- Meta-analysis SGLT2i and AF
https://www.ahajournals.org/doi/full/10.1161/JAHA.121.022222
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Observational studies, another defense of digoxin, CTO-PCI, BP measurement, and a possible revolution in cardiovascular protection are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Observational Research
Yeh; Credibility in Observational Research https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064645
Hernan; Causal Language in Observational Research https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2018.304337
Wang; RCT Duplicate Initiative https://jamanetwork.com/journals/jama/fullarticle/2804067
II. Defense of Digoxin
Brophy; Beta Blockers, Digoxin, or Both https://doi.org/10.1016/j.cjca.2023.06.009
Dorian editorial https://doi.org/10.1016/j.cjca.2023.07.013
Ziff Digoxin Meta-analysis https://www.bmj.com/content/351/bmj.h4451.long
DIG trial https://www.nejm.org/doi/full/10.1056/nejm199702203360801
Davila Analysis of DIG Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801940/
Kotecha Meta-analysis of Beta Blockers https://pubmed.ncbi.nlm.nih.gov/25193873/
RATE-AF https://jamanetwork.com/journals/jama/fullarticle/2774407
III. CTO-PCI
PCI of Chronic Total Occlusions Improves Angina, Quality of Life in Trials https://www.medscape.com/viewarticle/994739
JAMA Network Open Meta-analysis
IV. BP Measurement
One Size Doesn’t Fit All in Blood Pressure Measurement https://www.medscape.com/viewarticle/995216
Ishigami Blood Pressure Measurement Comparison
https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2807853
V. GLP-1 SELECT Trial
Semaglutide Cuts Cardiovascular Events in Landmark Trial
https://www.medscape.com/viewarticle/995270
SELECT Protocol Paper
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback re observational studies, surgeons’ dissent from recent guidelines, aspirin for primary prevention, and fish oil are the topics discussed by John Mandrola.MD in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Heart Surgeons Dissent
Surgical Groups Push Back Against New Revascularization Guidelines
https://www.medscape.com/viewarticle/966153
New Revascularization Guidelines: Key Points and Navigating Controversies
https://www.medscape.com/viewarticle/972014
- AHA Guidelines - https://doi.org/10.1161/CIR.0000000000001168
- AATS statement 2023 https://doi.org/10.1016/j.jtcvs.2023.03.001
- Yusef and colleagues 1994 Meta-analysis - https://doi.org/10.1016/S0140-6736(94)91963-1
- 10-year SYNTAXES https://doi.org/10.1016/S0140-6736(19)31997-X
- Surgeons’ argument 2021 https://doi.org/10.1016/j.athoracsur.2021.12.003
- FAME 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2112299
- Gaudino Meta-analysis of Medical Therapy vs CABG https://doi.org/10.1016/j.jtcvs.2022.06.003
- NOBLE https://doi.org/10.1016/S0140-6736(19)32972-1
- EXCEL 5 years https://www.nejm.org/doi/full/10.1056/nejmoa1909406
II. ASA for Primary Prevention
Daily Aspirin Challenged in Primary Stroke Prevention: ASPREE
https://www.medscape.com/viewarticle/994963
- ASPREE – All-cause mortality
- ASPREE (MACE and Bleeding) https://www.nejm.org/doi/full/10.1056/NEJMoa1805819
- ASPREE (disability) https://www.nejm.org/doi/full/10.1056/NEJMoa1800722
- JAMA Network Open Subanalysis https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2807630
III. Fish Oil
- OMEMI Substudy https://doi.org/10.1016/j.clnu.2023.07.002
- Gencer and colleagues Meta-analysis - https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055654
- OMEMI Main Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.052209
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Antiarrhythmic drugs in patients with CAD, observational studies, GLP-1 agonists, and the subcutaneous ICD are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. AAD in Patients with CAD
- The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease****
https://doi.org/10.1016/j.jacep.2022.12.021
- Three Questions for Evidence-Based Cardiac Electrophysiology****
https://www.ahajournals.org/doi/full/10.1161/circoutcomes.110.957381
- The Cardiac Arrhythmia Suppression Trial (CAST) https://www.nejm.org/doi/full/10.1056/nejm198908103210608****
II. GLP-1 Agonists
Tirzepatide Powers Weight Loss in Two More Pivotal Trials https://www.medscape.com/viewarticle/994889
Semaglutide Use Surges in US Adults With Type 2 Diabetes https://www.medscape.com/viewarticle/994873
- Tirzepatide Once Weekly for the Treatment of Obesity****
https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial****
https://doi.org/10.1016/S0140-6736(23)01200-X
III. S-ICD
S-ICD Shows Virtues, Limits in 'Real World' Postmarket Study https://www.medscape.com/viewarticle/994851
- Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System https://doi.org/10.1016/j.jacc.2023.05.034****
- Subcutaneous or Transvenous Defibrillator Therapy https://www.nejm.org/doi/full/10.1056/NEJMoa1915932****
- Letter to the Editor https://www.nejm.org/doi/full/10.1056/NEJMc2034917****
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Listener feedback, conduction system pacing, eating fish vs fish pills, exercise, and an RCT for diet are the topics discussed by John Mandrola,.MD, in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback Monitor HF and AHA
Jun 02, 2023 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/992678
- Link to the ACC Email -- https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/07/18/17/21/monitor-hf
- Tweet From Anthony Pearson
https://twitter.com/skepcard/status/1681288604990189574
II. Conduction System Pacing
- Clinical Outcomes in Conduction System Pacing Compared to Right Ventricular Pacing in Bradycardia https://doi.org/10.1016/j.jacep.2022.10.016
- Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women https://www.acpjournals.org/doi/abs/10.7326/0003-4819-117-12-1016
III. Fish Oil
Omega-3s and AF: No Added Risk From Eating Fish but High-Dose Supplement Questions Persist https://www.medscape.com/viewarticle/994559
- Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation
https://www.jacc.org/doi/full/10.1016/j.jacc.2023.05.024
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia https://www.nejm.org/doi/full/10.1056/nejmoa1812792
- Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055654
IV. Exercise
Even Exercise by 'Weekend Warriors' Can Cut CV Risk
https://www.medscape.com/viewarticle/994617
- Accelerometer-Derived “Weekend Warrior” Physical Activity and Incident Cardiovascular Disease https://jamanetwork.com/journals/jama/article-abstract/2807286
V. Diet
Cognitive Benefit of Highly Touted MIND Diet Questioned
https://www.medscape.com/viewarticle/994550
- Trial of the MIND Diet for Prevention of Cognitive Decline in Older Persons
https://www.nejm.org/doi/full/10.1056/NEJMoa2302368
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
Carotid stents, the paclitaxel story now closed, inclisiran, DOAC failures, and primary vs secondary prevention are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Carotid Stenting CMS Proposal
Expanded Coverage of Carotid Stenting in CMS Draft Proposal
https://www.medscape.com/viewarticle/994315
No Added Benefit From Revascularization in Low-Risk CAS
https://www.medscape.com/viewarticle/992524
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with Stenting https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=311
- Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy
https://doi.org/10.1016/S0140-6736(21)01910-3
- SPACE-2 https://journals.sagepub.com/doi/10.1177/1747493019833017
- Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial 10.1161/STROKEAHA.120.030730
II. Paclitaxel
FDA: No Excess Mortality Risk From Paclitaxel Stents, Balloons for Peripheral Intervention https://www.medscape.com/viewarticle/994253
- FDA Statement https://www.fda.gov/medical-devices/letters-health-care-providers/update-paclitaxel-coated-devices-treat-peripheral-arterial-disease-unlikely-increase-risk-mortality?utm_medium=email&utm_source=govdelivery#_FDA_Actions
III. Inclisiran
FDA Expands Inclisiran Statin-Adjunct Indication to Include Primary Prevention https://www.medscape.com/viewarticle/994185
- ORION 10-11 Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol https://www.nejm.org/doi/10.1056/NEJMoa1912387
- Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
https://doi.org/10.1093/eurheartj/ehac615
- Inclisiran and cardiovascular events: a patient-level analysis of phase III trials https://pubmed.ncbi.nlm.nih.gov/36331326/
IV. DOAC Failure
Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant
https://doi.org/10.1212/WNL.0000000000207422
V. Primary or Secondary Prevention
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
European HTN Guidelines, vitamin D, bempedoic acid, and leadless pacing, with some critical appraisal techniques thrown in, are the topics John Mandrola, MD, tackles in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. European Hypertension Guidelines
New ESH Hypertension Guidelines Aim for Simplified Message
https://www.medscape.com/viewarticle/993913
- 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH)
https://pubmed.ncbi.nlm.nih.gov/37345492/
II. Vitamin D
CV Benefit From Vitamin-D Caps Hinted in Huge D-Health Trial
https://www.medscape.com/viewarticle/993996
- Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial
https://www.bmj.com/content/381/bmj-2023-075230
- Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials
https://jamanetwork.com/journals/jamacardiology/fullarticle/2735646
III. Bempedoic Acid
'Striking' Benefit of Lipid Lowering in Primary Prevention
https://www.medscape.com/viewarticle/993666
- Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients
https://jamanetwork.com/journals/jama/fullarticle/2806646
- Bempedoic Acid for High-Risk Primary Prevention of Cardiovascular Disease
https://jamanetwork.com/journals/jama/fullarticle/2806647
- Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
https://www.nejm.org/doi/full/10.1056/NEJMoa2215024
IV. Leadless Pacing
FDA Approves First Leadless Dual-Chamber Pacing System
https://www.medscape.com/viewarticle/994033
- A Dual-Chamber Leadless Pacemaker
https://www.nejm.org/doi/full/10.1056/NEJMoa2300080
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
Starting HF meds during hospitalization for HF, Impella, testosterone, and colchicine are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Starting HF Meds During Hospitalization for HF
Starting Indicated Heart Failure Meds In-Hospital: Progress, Opportunities https://www.medscape.com/viewarticle/993539
- Opportunities and Achievement of Medication Initiation Among Inpatients With Heart Failure With Reduced Ejection Fraction https://www.jacc.org/doi/full/10.1016/j.jchf.2023.04.015
II. Impella
- Comparative Effectiveness of Percutaneous Microaxial Left Ventricular Assist Device vs Intra-Aortic Balloon Pump or No Mechanical Circulatory Support in Patients With Cardiogenic Shock
https://jamanetwork.com/journals/jamacardiology/fullarticle/2806562
- Evidence Generation for Novel Cardiovascular Devices—Putting the Horse Back in Front of the Cart
https://jamanetwork.com/journals/jamacardiology/fullarticle/2806565
III. Testosterone
Big Trial Reassures on Heart Safety of Testosterone in Men
https://www.medscape.com/viewarticle/993322
- Cardiovascular Safety of Testosterone-Replacement Therapy
https://www.nejm.org/doi/full/10.1056/NEJMoa2215025
IV. Colchicine for CV Disease
Low-Dose Colchicine Approved for CVD: Now What?
https://www.medscape.com/viewarticle/993578
- Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
https://www.nejm.org/doi/full/10.1056/nejmoa1912388
- Colchicine in Patients with Chronic Coronary Disease
https://www.nejm.org/doi/full/10.1056/nejmoa2021372
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
AF screening, BNP, a new SGLT2 inhibitor, a sky-is-blue study, and the UK Mini Mitral surgical trial are discussed in this week's podcast
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I AF Screening
- Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064361
- Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01698-6
- Natural History of Subclinical Atrial Fibrillation Detected by Implanted Loop Recorders https://www.jacc.org/doi/full/10.1016/j.jacc.2019.09.050
- Prevalence and Prognostic Significance of Bradyarrhythmias in Patients Screened for Atrial Fibrillation vs Usual Care https://jamanetwork.com/journals/jamacardiology/fullarticle/2801362
- Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design https://doi.org/10.1093/europace/euw319
- Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068511/
II Frailty and GDMT of HFrEF
Frailty Linked to Lower Use of Guideline Treatments in HFrEF
https://www.medscape.com/viewarticle/993218
- Physical Frailty and Use of Guideline‐Recommended Drugs in Patients With Heart Failure and Reduced Ejection Fraction https://www.ahajournals.org/doi/10.1161/JAHA.122.026844
III Sotagliflozin
FDA Approves New Drug, Sotagliflozin, for Heart Failure
https://www.medscape.com/viewarticle/992518
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
https://www.nejm.org/doi/full/10.1056/NEJMoa2030186
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
https://www.nejm.org/doi/full/10.1056/NEJMoa2030183
IV Mini-Mitral
Support for Minimally Invasive Mitral Valve Repair: Mini Mitral Published
https://www.medscape.com/viewarticle/993191
- Minithoracotomy vs Conventional Sternotomy for Mitral Valve Repair
https://jamanetwork.com/journals/jama/article-abstract/2805908
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
Impella, digital health, low-value processes, are tricuspid valve interventions with pacing leads are the topics Dr. John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Impella Class I Recall
FDA Class I Recall for Some Abiomed Impella Heart Pumps
https://www.medscape.com/viewarticle/992845
- A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention
https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.112.098194
- Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction
https://doi.org/10.1016/j.jacc.2016.10.022
https://www.sciencedirect.com/science/article/pii/S0735109716367675?via%3Dihub
- The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support
https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.119.044007
- Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
https://jamanetwork.com/journals/jama/fullarticle/2761003
- Danish Cardiogenic Shock Trial (DanShock)
https://clinicaltrials.gov/ct2/show/NCT01633502
II. Wearable Devices
- Use of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805753 doi:10.1001/jamanetworkopen.2023.16634
- Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial
https://doi.org/10.1016/S0140-6736(21)01698-6
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01698-6/fulltext
- Prevalence and Prognostic Significance of Bradyarrhythmias in Patients Screened for Atrial Fibrillation vs Usual Care
https://jamanetwork.com/journals/jamacardiology/fullarticle/2801362
III. The Cost of Quality Measures
- The Volume and Cost of Quality Metric Reporting
https://jamanetwork.com/journals/jama/fullarticle/2805705
- Goodhart's law
https://en.wikipedia.org/wiki/Goodhart%27s_law
IV. Tricuspid Valve Interventions and Pacing Leads
Leadless Dual-Chamber Pacemaker Clears Early Safety, Performance Hurdles
https://www.medscape.com/viewarticle/992464
- Transcatheter Tricuspid Valve Replacement With the EVOQUE System: 1-Year Outcomes of a Multicenter, First-in-Human Experience
https://www.jacc.org/doi/10.1016/j.jcin.2022.01.280
- Effects of Implantable Cardioverter-Defibrillator Leads on the Tricuspid Valve and Right Ventricle: A Randomized Comparison of Transvenous versus Subcutaneous Leads
https://eppro01.ativ.me/src/EventPilot/php/express/web/planner.php?id=HRS23&utm_source=heartrhythm&utm_medium=nav-button&utm_campaign=hr23-webtracking
- Management and Outcomes of Transvenous Pacing Leads in Patients Undergoing Transcatheter Tricuspid Valve Replacement
https://www.jacc.org/doi/10.1016/j.jcin.2020.04.054
- TRILUMINATE trial -- Transcatheter Repair for Patients with Tricuspid Regurgitation
https://www.nejm.org/doi/full/10.1056/NEJMoa2300525
https://www.nejm.org/doi/full/10.1056/NEJMoa2300525
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
Listener feedback on the most important study in a decade, MONITOR-HF, a flawed paper and analysis, and the tension between pathos and logos are the topics John Mandrola, MD discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback
Earlier Anticoagulation Safe in Stroke With AF: ELAN
https://www.medscape.com/viewarticle/992411
- Early versus Later Anticoagulation for Stroke with Atrial Fibrillation
https://www.nejm.org/doi/full/10.1056/NEJMoa2303048
- Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction
https://www.nejm.org/doi/full/10.1056/nejmoa1301092
II. Monitor HF
CardioMEMS Boosts QoL, Curbs HF Hospitalizations: MONITOR-HF
https://www.medscape.com/viewarticle/992333
- Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial
https://doi.org/10.1016/S0140-6736(23)00923-6
- Remote pulmonary artery pressure monitoring in heart failure care: part of the new normal?
https://doi.org/10.1016/S0140-6736(23)01010-3
- Sowell’s A Conflict of Visions
https://en.wikipedia.org/wiki/A_Conflict_of_Visions
III. Intensive BP Treatment in Older Patients – Pathos vs Logos
- Clinical Outcomes of Intensive Inpatient Blood Pressure Management in Hospitalized Older
Adultshttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2805021
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
An HRS meeting recap, Impella failure, sacubitril/valsartan, the purpose of trials, and a major breakthrough in evidence generation are the topics discussed by John Mandrola, MD in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. HRS Meeting Recap
II. Impella in VT ablation
- First-in-human Experience with Impella 5.0/5.5 for High-Risk Patients with Advanced Heart Failure Undergoing VT Ablationhttps://www.jacc.org/doi/10.1016/j.jacc.2023.05.012
III. Sacubitril/Valsartan
ARNI Bests ARB to Reduce NT-proBNP in Stabilized Preserved-EF HF
https://www.medscape.com/viewarticle/992461
- Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure
https://www.jacc.org/doi/10.1016/j.jacc.2023.04.019
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
https://www.nejm.org/doi/full/10.1056/nejmoa1908655
- Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
https://doi.org/10.1093/eurheartj/ehad344
- Bogdan Tweet
https://twitter.com/bogdienache/status/1660356776204595201?s=20
IV. Big Change in Reporting of Medical Evidence – Elan Trial
-
Early versus Later Anticoagulation for Stroke with Atrial Fibrillationhttps://www.nejm.org/doi/full/10.1056/NEJMoa2303048
-
Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): Protocol for an international, multicentre, randomised-controlled, two-arm, open, assessor-blinded trial https://doi.org/10.1177/23969873221106043
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
When to use an ICD, risk stratification for HCM, blending EP and structural cardiology to improve care in post-TAVI patients, and hsTroponins are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. ICD in Patients with NICM
Simple Risk Score Predicts VT in Nonischemic Cardiomyopathy
https://www.medscape.com/viewarticle/992018
-
Declining Risk of Sudden Death in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa1609758
-
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa1608029
-
Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar https://doi.org/10.1093/eurheartj/ehy437
-
RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure (BRITISH) https://clinicaltrials.gov/ct2/show/NCT05568069
II. Risk Stratification in HCM
-
Changing Risk Stratification in Hypertrophic Cardiomyopathy? https://www.medscape.com/viewarticle/992014
-
NOAH–AFNET 6 trial terminates ahead of time (NOAH AFNET 6 trial) https://dzhk.de/en/news/latest-news/article/noah-afnet-6-trial-terminates-ahead-of-time-noah-afnet-6-trial/
III. Blending EP and Structural to Improve TAVI Care
- Impact of Right Ventricular Pacing in Patients With TAVR Undergoing Permanent Pacemaker Implantation https://www.jacc.org/doi/full/10.1016/j.jcin.2023.02.003
IV. Troponins
-
Age-Specific Cut-Offs Needed for Cardiac Troponin Tests? https://www.medscape.com/viewarticle/992167
-
Myocardial Injury Thresholds for 4 High-Sensitivity Troponin Assays in U.S. Adults https://www.jacc.org/doi/full/10.1016/j.jacc.2023.03.403
-
What Is a Normal Troponin Anyway? https://www.jacc.org/doi/10.1016/j.jacc.2023.03.404
-
Updating Our Thinking on Troponin Use and Interpretation https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2777967
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
Two new papers on left atrial appendage occlusion, the promise of DNA, statins in the elderly, and SGLT2 inhibitors are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback
- When to Start a Statin Is a Preference-Sensitive Decision
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029808
II. Left Atrial Appendage Closure
LAA Closure Outcomes Improve With CCTA: Swiss-Apero Subanalysis
https://www.medscape.com/viewarticle/991623
-
Impact of Preprocedural Computed Tomography on Left Atrial Appendage Closure Success: A Swiss-Apero Trial Subanalysis https://doi.org/10.1016/j.jcin.2023.02.027
-
Outcomes of percutaneous left atrial appendage occlusion device implantation in atrial fibrillation patients based on underlying stroke risk https://doi.org/10.1093/europace/euad049
III. Polygenic Risk Scores
-
Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease https://jamanetwork.com/journals/jama/fullarticle/2761086
-
Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program https://jamanetwork.com/journals/jamacardiology/article-abstract/2804439
-
Validity of polygenic risk scores: are we measuring what we think we are? https://doi.org/10.1093/hmg/ddz205
IV. Statins in Older Patients
High Cholesterol in Seniors: Use Statins for Primary Prevention?
https://www.medscape.com/viewarticle/991801
V. SGLT2 Inhibitors
FDA Expands Use of Dapagliflozin to Broader Range of HF
https://www.medscape.com/viewarticle/991736
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
https://www.nejm.org/doi/full/10.1056/NEJMoa2206286
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
Beta-blockers post MI, public perception of statins, trust in the medical profession, BMI, and TAVI are the topics John Mandrola, MD, covers in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Post-MI Beta Blockers
Long-term Beta-Blockers Not Needed After MI with Preserved Systolic Function? https://www.medscape.com/viewarticle/991542
-
Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes https://heart.bmj.com/content/early/2023/04/16/heartjnl-2022-322115
-
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure
https://www.nejm.org/doi/full/10.1056/nejmoa1608029
II. Statin Perceptions
Statin Misinformation on Social Media Flagged by AI
https://www.medscape.com/viewarticle/991585
- Artificial Intelligence–Enabled Analysis of Statin-Related Topics and Sentiments on Social Media
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2803988
III. BMI
BMI Is a Flawed Measure of Obesity. What Are Alternatives?
https://www.medscape.com/viewarticle/991210
IV. TAVI Access
Better Access to Transcatheter Aortic Valve Replacement Associated With Improved Outcomes
https://www.medscape.com/viewarticle/991573
- Regional Differences in Outcomes for Patients Undergoing Transcatheter Aortic Valve Replacement in New York State and Ontario https://doi.org/10.1016/j.cjca.2023.01.025
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
Two studies of cardiac device infections, observational studies, RCTs, and our ways of knowing in Medicine are the topics discussed by John Mandrola, MD in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Cardiac Device Infection
Mortality Climbs When CIED Infections Are 'Delayed' After Implant
https://www.medscape.com/viewarticle/990692
- Association of the Timing and Extent of Cardiac Implantable Electronic Device Infections With Mortality
https://jamanetwork.com/journals/jamacardiology/fullarticle/2803627
-
Low Utilization of Lead Extraction Among Patients With Infective Endocarditis and Implanted Cardiac Electronic Devices https://www.jacc.org/doi/full/10.1016/j.jacc.2023.02.042
-
Cardiac Implantable Electronic Devices and Infective Endocarditis: A Call to Arms...∗ https://www.jacc.org/doi/full/10.1016/j.jacc.2023.02.043
II. Can RCTs be Emulated with Real World Evidence?
-
Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses https://jamanetwork.com/journals/jama/fullarticle/2804067
-
Randomized Trials vs Real-world Evidence https://jamanetwork.com/journals/jama/fullarticle/2804092
-
Reanalyses of Randomized Clinical Trial Data
https://jamanetwork.com/journals/jama/fullarticle/1902230
III. Multi-Morbidity Effects in Trials
Pivotal CV Trials May Not Apply to Complex Patients
https://www.medscape.com/viewarticle/989129
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
John Mandrola, MD discusses early vs delayed AF ablation, a report on a devastating complication of AF ablation, and a potential crosswind for a major therapeutic fashion in electrophysiology.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I Early Vs Delayed Ablation
- Impact of Early Versus Delayed Atrial Fibrillation Catheter Ablation on Atrial Arrhythmia Recurrences
https://doi.org/10.1093/eurheartj/ehad247
- Diagnosis-to-Ablation Time and Recurrence of Atrial Fibrillation Following Catheter Ablation
https://www.ahajournals.org/doi/full/10.1161/CIRCEP.119.008128
- Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation
https://www.nejm.org/doi/full/10.1056/nejmoa2029980
- Progression of Atrial Fibrillation after Cryoablation or Drug Therapy
https://www.nejm.org/doi/full/10.1056/NEJMoa2212540
II Atrial-Esophageal Fistula
CT and Surgery Best Diagnose and Manage Esophageal Fistula
https://www.medscape.com/viewarticle/990933
-
A worldwide survey on incidence, management and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: The POTTER-AF study https://doi.org/10.1093/eurheartj/ehad250
-
Oesophageal Probe Evaluation in Radiofrequency Ablation of Atrial Fibrillation (OPERA): results from a prospective randomized trial https://doi.org/10.1093/europace/euaa209
-
Temperature monitoring and temperature-driven irrigated radiofrequency energy titration do not prevent thermally induced esophageal lesions in pulmonary vein isolation: A randomized study controlled by esophagoscopy before and after catheter ablation https://doi.org/10.1016/j.hrthm.2021.02.003
III High-Power Short-Duration Ablation
Short, High-Power Ablation on Par With Standard AF Ablation
https://www.medscape.com/viewarticle/972087
- Power-Fast Trial
https://clinicaltrials.gov/ct2/show/NCT04153747
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
SCAI consensus document on LAAC, semaglutide/tirzepatide disruption, NSAIDs, and interventional echocardiography are the topics discussed by John Mandrola, MD, on this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. SCAI Consensus Document
New Update on Left Atrial Appendage Closure Recommendations
https://www.medscape.com/viewarticle/990507
- SCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage Closure
https://doi.org/10.1016/j.jscai.2022.100577
- Transcatheter Left Atrial Appendage Closure Comes of Age
https://doi.org/10.1016/j.jscai.2023.100592
- EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update https://doi.org/10.1093/europace/euz258
II. Semaglutide and Tirzepatide Disruption
Tirzepatide Powers 'Unprecedented' Weight Loss in Obesity Trial
https://www.medscape.com/viewarticle/975061
- Obesity Management in Primary Care
https://reference.medscape.com/recap/982874
- The $76 Billion Diet Industry Asks: What to Do About Ozempic?
https://www.wsj.com/amp/articles/ozempic-wegovy-mounjaro-weight-loss-industry-89419ecb
III. NSAIDs and HF
NSAID Use in Diabetes May Worsen Risk for First HF Hospitalization
https://www.medscape.com/viewarticle/990642
- Heart Failure Following Anti-Inflammatory Medications in Patients With Type 2 Diabetes Mellitus
https://doi.org/10.1016/j.jacc.2023.02.027
IV. Interventional Echocardiography
New ASE Guideline on Interventional Echocardiography Training
https://www.medscape.com/viewarticle/990520
- Recommendations for Special Competency in Echocardiographic Guidance of Structural Heart Disease Interventions: From the American Society of Echocardiography
https://doi.org/10.1016/j.echo.2023.01.014
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
Chat GPT, a relatively unknown therapy for HFpEF, and two fun studies on statins and secondary prevention are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Artificial Intelligence and CHAT GPT
Can ChatGPT Replace Diabetes Educators? Perhaps Not Yet
https://www.medscape.com/viewarticle/990381
- Potential and Pitfalls of ChatGPT and Natural-Language Artificial Intelligence Models for Diabetes Education
https://doi.org/10.2337/dc23-0197
II. Exercise and HFpEF
AHA, ACC Advocate Supervised Exercise Training in HFpEF
https://www.medscape.com/viewarticle/990351
- Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology
https://doi.org/10.1016/j.jacc.2023.02.012
III. Statins and Muscles
Statins Don't Worsen Muscle Injury From Moderately Intense Exercise
https://www.medscape.com/viewarticle/990473
- Prolonged Moderate-Intensity Exercise Does Not Increase Muscle Injury Markers in Symptomatic or Asymptomatic Statin Users https://doi.org/10.1016/j.jacc.2023.01.043
IV. Statins in Secondary Prevention
Treat to LDL Target or High-Intensity Statin for All With Clinical CAD: LODESTAR
https://www.medscape.com/viewarticle/989884
- Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease
https://jamanetwork.com/journals/jama/article-abstract/2802214
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
Diets, coronary artery calcium, statins, basic CAD knowledge, and AF ablation are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Diet
Some Diets Better Than Others for Heart Protection https://www.medscape.com/viewarticle/990305
- Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: systematic review and network meta-analysis https://doi.org/10.1136/bmj-2022-072003
Plant-Based Diets Not Always Healthy; Quality Is Key https://www.medscape.com/viewarticle/990178
- Association of Healthful Plant-based Diet Adherence With Risk of Mortality and Major Chronic Diseases Among Adults in the UK https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802814
II. CAC and Statins
- Using the Coronary Artery Calcium Score to Guide Statin Therapy https://www.ahajournals.org/doi/full/10.1161/CIRCOUTCOMES.113.000799
III. Subclinical Atherosclerosis
Subclinical CAD by CT Predicts MI Risk, With or Without Stenoses https://www.medscape.com/viewarticle/990254
- Subclinical Coronary Atherosclerosis and Risk for Myocardial Infarction in a Danish Cohort
A Prospective Observational Cohort Study 0799 https://www.acpjournals.org/doi/10.7326/M22-3027
- A Prospective Natural-History Study of Coronary Atherosclerosis https://www.nejm.org/doi/10.1056/NEJMoa1002358?url_ver=Z39.88-2003
IV. AF ablation
-
Standard vs Augmented Ablation of Paroxysmal Atrial Fibrillation for Reduction of Atrial Fibrillation RecurrenceThe AWARE Randomized Clinical Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2802860
-
Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial FibrillationThe CAPLA Randomized Clinical Trial https://jamanetwork.com/journals/jama/article-abstract/2800186
-
Approaches to Catheter Ablation for Persistent Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/NEJMoa1408288
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine. https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Exercise, sudden cardiac death in sports, new TAVI data, behavioral psychology, EHR doing good things, maybe, and coffee are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Fitness and Longevity
Even Small Changes in Fitness Tied to Lower Mortality Risk https://www.medscape.com/viewarticle/989906
- Changes in Cardiorespiratory Fitness and Survival in Patients With or Without Cardiovascular Disease https://www.jacc.org/doi/full/10.1016/j.jacc.2023.01.027
II. SCD in Sports
Sports-Related Sudden Cardiac Arrest 'Extremely' Rare in Women https://www.medscape.com/viewarticle/990025
-
Incidence of Cardiac Arrest During Sports Among Women in the European Union https://www.jacc.org/doi/full/10.1016/j.jacc.2023.01.015
-
Sex-Related Differences in Sports-Related Sudden Cardiac Death Should Be Reflected in Guideline Screening Recommendations∗ https://www.jacc.org/doi/full/10.1016/j.jacc.2023.01.014
-
Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort https://doi.org/10.1093/eurheartj/ehz897
III. EVOLUT Three Year Data
Encouraging 3-Year Data for TAVR in Low-Risk Patients: EVOLUT
https://www.medscape.com/viewarticle/989144
-
Three-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017
-
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
https://www.nejm.org/doi/full/10.1056/nejmoa1816885
- Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk https://www.jacc.org/doi/10.1016/j.jacc.2020.12.052
IV. Behavioral Psychology
NUDGE-FLU: Electronic 'Nudges' Boost Flu Shot Uptake in Seniors https://www.medscape.com/viewarticle/989108
-
The Effect of Electronic Nudges on Influenza Vaccination Rate in Older Adults With Cardiovascular Disease: a Prespecified Analysis of the NUDGE-FLU Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064270
-
Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.121.057042
EHR Alerts Boosted MRA Prescribing in HFrEF: BETTER CARE-HF https://www.medscape.com/viewarticle/989110
-
Cluster-Randomized Trial Comparing Ambulatory Decision Support Tools to Improve Heart Failure Care https://doi.org/10.1016/j.jacc.2023.02.005
-
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure https://www.nejm.org/doi/full/10.1056/nejm199909023411001
V. Coffee
- Acute Effects of Coffee Consumption on Health among Ambulatory Adults https://www.nejm.org/doi/full/10.1056/NEJMoa2204737
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
ACC Recap No. 2: Pacing in HFpEF, Oral PCSK9 inhibitor, PAH, soft thinking on adherence, and so called metabolically healthy obese are discussed by John Mandrola, MD, in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Pacing in HFpEF
No Exercise Boost From Pacemaker in HFpEF With Impaired HR Response: RAPID-HF https://www.medscape.com/viewarticle/989681
-
Rate-Adaptive Atrial Pacing for Heart Failure With Preserved Ejection FractionThe RAPID-HF Randomized Clinical Trial https://jamanetwork.com/journals/jama/article-abstract/2802147
-
Accelerated Pacing a Possible Strategy for Preserved-EF Heart Failure? https://www.medscape.com/viewarticle/987815
-
Could a Breakthrough in Heart Failure With Preserved Ejection Fraction Just Take a Change of Pace? - https://www.medscape.com/viewarticle/988088
-
Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2801001
-
Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction https://doi.org/10.1016/j.jacc.2021.08.073
II Oral PCSK9i
Oral PCSK9 Inhibitor Shows Encouraging LDL Lowering https://www.medscape.com/viewarticle/989655
- Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial https://www.jacc.org/doi/10.1016/j.jacc.2023.02.018
III PAH
'Unheard of' PAH Improvement With Novel Drug: STELLAR https://www.medscape.com/viewarticle/989612
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension https://www.nejm.org/doi/full/10.1056/NEJMoa2213558
IV Medical Adherence
Waiving Co-Pays for CV Meds as Adherence Incentive Doesn't Cut Clinical Risk: ACCESS Trial https://www.medscape.com/viewarticle/989474
-
Eliminating Medication Copayments for Low-income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064188
-
Medicaid Expansion: Good First Step, but No Panacea for CV Care https://www.medscape.com/viewarticle/975141
-
Health Care Access and Management of Cardiovascular Risk Factors Among Working-Age Adults With Low Income by State Medicaid Expansion Status https://jamanetwork.com/journals/jamacardiology/article-abstract/2793120
-
Rand Link https://www.rand.org/pubs/reports/R3055.html
-
The Oregon Health Insurance Experiment https://www.healthaffairs.org/do/10.1377/hpb20150716.236899/full/
-
Effect of Health Insurance in India: A Randomized Controlled Trial https://www.nber.org/papers/w29576
-
Full Coverage for Preventive Medications after Myocardial Infarction https://www.nejm.org/doi/full/10.1056/nejmsa1107913
-
Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial InfarctionThe ARTEMIS Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2720024
-
Coronary CT Angiography and 5-Year Risk of Myocardial Infarction https://www.nejm.org/doi/full/10.1056/NEJMoa1805971
IV Metabolically Healthy Obese
'Metabolically Healthy Obesity' Rising, but Still Uncommon https://www.medscape.com/viewarticle/989398
- Trends in the Prevalence of Metabolically Healthy Obesity Among US Adults, 1999-2018 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802164
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
ACC Recap Part 1: Sports, bempedoic acid NASCARs, tricuspid regurgitation, and more on revascularization of stable CAD. are the topics discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Sports Cardiology
Even Vigorous Exercise Appears Safe for Patients With Hypertrophic Cardiomyopathy: LIVE-HCM https://www.medscape.com/viewarticle/989351
-
Lifelong endurance exercise and its relation with coronary atherosclerosis https://doi.org/10.1093/eurheartj/ehad152
-
Increased average longevity among the "Tour de France" cyclists https://pubmed.ncbi.nlm.nih.gov/21618162/
II. Clear Outcomes
Bempedoic Acid Cuts CV Events in Statin-Intolerant Patients: CLEAR Outcomes
https://www.medscape.com/viewarticle/989100
-
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients https://www.nejm.org/doi/full/10.1056/NEJMoa2215024
-
Bodgan Enache Tweet https://twitter.com/bogdienache/status/1632143539965509632?s=20
III. TRILUMINATE Trial
Transcatheter Tricuspid Valve Repair Effective, Safe for Regurgitation: TRILUMINATE https://www.medscape.com/viewarticle/989103
-
Transcatheter Repair for Patients with Tricuspid Regurgitation https://www.nejm.org/doi/full/10.1056/NEJMoa2300525
-
New Treatment Could Help Fix the Heart’s ‘Forgotten Valve.’ https://www.nytimes.com/2023/03/04/health/tricuspid-valve-clip-leakage.html
-
Rasha Al-Lamee Tweet https://twitter.com/rallamee/status/1632295242685612033?s=20
IV. REVIVED-BCIS
Viability-Guided PCI Doubted in Stable Severe CAD: REVIVED-BCIS2 https://www.medscape.com/viewarticle/989101
- Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/NEJMoa2206606
Features:
CLEAR Positives and Cautions With Bempedoic Acid for Statin Intolerance https://www.medscape.com/viewarticle/989098
The TRILUMINATE Transcatheter Tricuspid Repair Trial: Positive but No Benefit? https://www.medscape.com/viewarticle/989105
Three Surprising Studies on Exercise Restriction and an Exercise Sweet Spot https://www.medscape.com/viewarticle/989417
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Renal denervation, AF ablation, omecamtiv mecarbil, and an ACC Preview are the topics discussed by John Mandrola, MD, in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. AF Ablation
- Initial Findings From the National Cardiovascular Data Registry of Atrial Fibrillation Ablation Procedures https://www.jacc.org/doi/10.1016/j.jacc.2022.11.060
II. Renal Denervation
Consistent BP Cut With Renal Denervation: More on RADIANCE https://www.medscape.com/viewarticle/989006
-
Endovascular Ultrasound Renal Denervation to Treat HypertensionThe RADIANCE II Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2801849
-
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials https://jamanetwork.com/journals/jamacardiology/fullarticle/2802098
-
Is There a Role for Renal Denervation in the Treatment of Hypertension? https://jamanetwork.com/journals/jamacardiology/fullarticle/2802099
III. Omecamtiv Mecarbil
FDA Declines Approval for Omecamtiv Mecarbil in HFrEF https://www.medscape.com/viewarticle/988948
IV. ACC Preview
ACC Scientific Session Returns Live, Virtually to New Orleans https://www.medscape.com/viewarticle/988803
- ‘Faith Healing’ and ‘Subtraction Anxiety’ in Unblinded Trials of Procedures https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.118.004665
Features
Mandrola's 5 Things to Look for at ACC 23 https://www.medscape.com/viewarticle/988808
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Reporting on potential fraud in medicine, AF, stroke, a possible new cholesterol-lowering drug, and the tone of debate in medical science are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Potential Fraud in Medicine
Inside the Big Business of Clogged Arteries https://www.medscape.com/viewarticle/988448
II. AF Screening and Stroke
STROKE AF at 3 Years: High AF Rate After Atherosclerotic Stroke https://www.medscape.com/viewarticle/988076
Severity and Etiology of Incident Stroke in Patients Screened for Atrial Fibrillation vs Usual Care and the Impact of Prior Stroke https://jamanetwork.com/journals/jamaneurology/fullarticle/2795865
III. Bempedoic Acid
New Studies Give Bempedoic Acid a Bump as Lipid-Lowering Agent https://www.medscape.com/viewarticle/911100
-
Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance https://doi.org/10.1016/j.ahj.2020.10.060
-
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol https://www.nejm.org/doi/full/10.1056/NEJMoa1803917
-
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease https://jamanetwork.com/journals/jama/fullarticle/2754792
-
N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects https://www.nejm.org/doi/full/10.1056/NEJMc2031173
-
Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment https://www.jacc.org/doi/10.1016/j.jacc.2021.07.022
IV. The Technique of Critical Appraisal
Why Evidence-Based Medicine Enthusiasts Could Use a Lesson in Persuasion https://www.medscape.com/viewarticle/988227
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Bradyarrhythmia during AF screening, thrombolysis in stroke, NP vs MD care, and the most biased paper this year — on LAAO — are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Screening with ILR
-
Ade Adamson Tweet https://twitter.com/AdeAdamson/status/1625878856820482048?s=20
-
The Rapid Rise in Cutaneous Melanoma Diagnoses
https://www.nejm.org/doi/full/10.1056/NEJMsb2019760
-
Loop Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01698-6/fulltext
-
Prevalence and Prognostic Significance of Bradyarrhythmias in Patients Screened for Atrial Fibrillation vs Usual Care https://jamanetwork.com/journals/jamacardiology/fullarticle/2801362
II. Thrombolysis in Mild Stroke
Thrombolysis Not Necessary in Mild Nondisabling Stroke: ARAMIS
https://www.medscape.com/viewarticle/988381
-
PRISMS Trial https://jamanetwork.com/journals/jama/fullarticle/2687354
-
Risk of selection bias assessment in the NINDS rt-PA stroke study https://pubmed.ncbi.nlm.nih.gov/35705913/
-
Tissue Plasminogen Activator for Acute Ischemic Stroke https://www.nejm.org/doi/full/10.1056/NEJM199512143332401
-
Effects of alteplase for acute stroke; Hacke et al meta-analysis https://journals.sagepub.com/doi/10.1177/1747493017744464
-
Methodological survey of missing outcome data in an alteplase for ischemic stroke meta-analysis
https://onlinelibrary.wiley.com/doi/full/10.1111/ane.13656
-
ECASS; Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke https://www.nejm.org/doi/full/10.1056/nejmoa0804656
-
Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances https://pubmed.ncbi.nlm.nih.gov/32430395/
III. NP vs MD Care
This Doc Still Supports NP/PA Led Care ... With Caveats https://www.medscape.com/viewarticle/967073
-
The Productivity of Professions: Evidence from the Emergency Department https://www.nber.org/papers/w30608
-
Independent Nurse Practitioners and Physician Assistants: A Doc's View https://www.medscape.com/viewarticle/924047
IV. LAAO vs OAC
- Comparative Effectiveness of Left Atrial Appendage Occlusio Versus Oral Anticoagulation by Sex
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062765
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Drug and non-drug therapies for HFpEF, the search for AF, and exercise as medicine are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. SGLT2 Inhibitors in HFpEF
Dapagliflozin Gets Expanded Heart Failure Indication in Europe https://www.medscape.com/viewarticle/988034
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2206286
II. HFpEF and Heart Rate
Accelerated Pacing a Possible Strategy for Preserved-EF Heart Failure? https://www.medscape.com/viewarticle/987815
III. Stroke and AF
STROKE AF at 3 Years: High AF Rate After Atherosclerotic Stroke https://www.medscape.com/viewarticle/988076
- Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease https://jamanetwork.com/journals/jama/fullarticle/2780490
- Cryptogenic Stroke and Underlying Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/nejmoa1313600
- Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT https://pubmed.ncbi.nlm.nih.gov/28329139/
- Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke https://www.nejm.org/doi/full/10.1056/NEJMoa2101897
IV. Exercise as Medicine
Trending Clinical Topic: Exercise Prescription https://reference.medscape.com/viewarticle/985373
- Effect of Moderate and Vigorous Aerobic Exercise on Incident Diabetes in Adults With Obesityhttps://pubmed.ncbi.nlm.nih.gov/36716009/
Features
Could a Breakthrough in Heart Failure With Preserved Ejection Fraction Just Take a Change of Pace? https://www.medscape.com/viewarticle/988088
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
A possible major breakthrough in thinking about diastolic dysfunction and HFpEF, MRI scanning and cardiac devices, and AF and dementia are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. New Thinking in HFpEF
Accelerated Pacing a Possible Strategy for Preserved-EF Heart Failure? https://www.medscape.com/viewarticle/987815
-
Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2801001
-
Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction https://doi.org/10.1016/j.jacc.2021.08.073
-
A Targeted Treatment Opportunity for HFpEF: Taking Advantage of Diastolic Tone https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056412
-
Lenient versus Strict Rate Control in Patients with Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/nejmoa1001337
II. MRI and ICD Function
Legacy ICDs Exposed to MRI Still Shock, Pace as Needed https://www.medscape.com/viewarticle/987729
-
Implantable Defibrillator System Shock Function, Mortality, and Cause of Death After Magnetic Resonance Imaging https://doi.org/10.7326/M22-2653
-
2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices https://pubmed.ncbi.nlm.nih.gov/28502708/
III. AF and Dementia
Atrial Fibrillation and Dementia: What Do We Know?
https://www.medscape.com/viewarticle/985900
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Exercise for AF, drugs have more than one effect, AI bots and the future of medicine, and the good and bad news about prognosis in HF are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. AF and Exercise
- Aerobic Exercise Can Reduce AF Frequency, Severity: ACTIVE-AF https://www.medscape.com/viewarticle/957322
- An Exercise and Physical Activity Program in Patients With Atrial Fibrillation: The ACTIVE-AF Randomized Controlled Trial https://www.jacc.org/doi/full/10.1016/j.jacep.2022.12.002
- Early Rhythm-Control Therapy in Patients with Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/NEJMoa2019422
II. GLP-1 Inhibitors and Retinopathy
- Eye Check Important Before Starting Semaglutide for Diabetes https://www.medscape.com/viewarticle/987418
- Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes? https://doi.org/10.1016/j.dsx.2022.102696
III. AI Bot Passes USMLEs
- AI Bot ChatGPT Passes US Medical Licensing Exams Without Cramming – Unlike Students https://www.medscape.com/viewarticle/987549
- Performance of ChatGPT on USMLE: Potential for AI-Assisted Medical 2 Education Using Large Language Models https://www.medrxiv.org/content/10.1101/2022.12.19.22283643v2.full.pdf
- Tyler Cowen Comments -- GPT and my own career trajectory https://marginalrevolution.com/marginalrevolution/2023/01/gpt-and-my-own-career-trajectory.html
IV. HF Prognosis
- Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study https://doi.org/10.1093/eurheartj/ehac797
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The loop diuretic duels, adverse events during hospital admissions, BP accuracy, and, again, left main revascularization strategies (again) are the topics John Mandrola discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. TRANSFORM HF
Clarity on Torsemide vs Furosemide in HF: TRANSFORM-HF Published https://www.medscape.com/viewarticle/987128
• Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure https://jamanetwork.com/journals/jama/fullarticle/2800428
• RANSFORM-HF—Can We Close the Loop on Diuretics in Heart Failure? https://jamanetwork.com/journals/jama/fullarticle/2800445
II. Adverse Events in the Hospital
Adverse Events Reported in One Quarter of Inpatient Admissions https://www.medscape.com/viewarticle/987091
• The Safety of Inpatient Health Care https://www.nejm.org/doi/full/10.1056/NEJMsa2206117
III. BP Accuracy
Experts Demand Validation of Automatic Blood Pressure Devices
https://www.medscape.com/viewarticle/987032
IV. Left Main Coronary Artery Disease
Real-World Examination of Revascularization Strategies for Left Main Coronary Disease in Ontario, Canada
https://doi.org/10.1016/j.jcin.2022.10.016
Management of Left Main Coronary Artery Disease in Nonemergent Settings: The Heart of Multidisciplinary Teamwork https://doi.org/10.1016/j.jcin.2022.11.024
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
FOURIER authors’ response, a possible practice-changing paper in electrophysiology, and the ATLAS and CAPLA trials are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. FOURIER Authors Respond
Recount of FOURIER Data Finds Higher Mortality With Evolocumab; Trialists Push Back https://www.medscape.com/viewarticle/986634
- Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data https://bmjopen.bmj.com/content/12/12/e060172
- Letter to the Editor RE: "Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data". BMJ Open https://bmjopen.bmj.com/content/12/12/e060172.responses#letter-to-the-editor-re-restoring-mortality-data-in-the-fourier-cardiovascular-outcomes-trial-of-evolocumab-in-patients-with-cardiovascular-disease-a-reanalysis-based-on-regulatory-data-bmj-open-2022123060172
- Risk of selection bias assessment in the NINDS rt-PA stroke study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202115/
- Methodological survey of missing outcome data in an alteplase for ischemic stroke meta-analysis https://doi.org/10.1111/ane.13656
II. A Potential Practice-Changing Paper in Cardiac Pacing
Novel 'Cure' May Avert Lead Extraction in CIED Pocket Infections https://www.medscape.com/viewarticle/986762
- Regional Antibiotic Delivery for Implanted Cardiovascular Electronic Device Infections https://doi.org/10.1016/j.jacc.2022.10.022
- Treatment of Localized Implantable Cardiac Device Pocket Infections https://doi.org/10.1016/j.jacc.2022.11.018
III. ATLAS Trial
- Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations https://doi.org/10.7326/M22-1566
- Subcutaneous or Transvenous Defibrillator Therapy https://www.nejm.org/doi/full/10.1056/NEJMoa1915932
- Subcutaneous or Transvenous Defibrillator Therapy https://www.nejm.org/doi/10.1056/NEJMc2034917
IV. CAPLA Published
CAPLA Shows Limits of Further Ablation Post PVI in Persistent AF https://www.medscape.com/viewarticle/986901
- Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation https://jamanetwork.com/journals/jama/fullarticle/2800186
- Catheter Ablation for Persistent Atrial Fibrillation https://jamanetwork.com/journals/jama/fullarticle/2800200
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
Damar Hamlin, obesity and semaglutide, Open Data and PCSK9 inhibitors, and TAVI vs SAVR trials are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Damar Hamlin
Five Thoughts on the Damar Hamlin Collapse
https://www.medscape.com/viewarticle/986550
II. Semaglutide and Obesity in Adolescents
FDA Approves Wegovy (Semaglutide) for Obesity in Teens 12 and Up
https://www.medscape.com/viewarticle/986403
• Once-Weekly Semaglutide in Adolescents with Obesity https://www.nejm.org/doi/full/10.1056/NEJMoa2208601
III. Open Data and PCSK9 inhibitors
Evolocumab Added to Statins Cuts CV Events in FOURIER Trial
https://www.medscape.com/viewarticle/877348
• Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
https://bmjopen.bmj.com/content/12/12/e060172
• Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
https://www.nejm.org/doi/full/10.1056/nejmoa1615664
• PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction https://pubmed.ncbi.nlm.nih.gov/34252181/
• Bendary Tweet https://twitter.com/DrBendary/status/1609849852979986432?s=20&t=FDDhGIofS_HQ4jxf8aHwBA
IV. Open Data and TAVI vs SAVR Trials
Risk of Bias in Randomized Clinical Trials Comparing Transcatheter and Surgical Aortic Valve Replacement https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799937
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The top ten stories of the year plus a few honorary mentions. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I Annual Wrap Ups on Medscape
-
Mandrola’s Top 10 Cardiology Stories of 2022 https://www.medscape.com/viewarticle/985607
-
2022 in Review Through a Cardiology Lens https://www.medscape.com/viewarticle/984505
-
Top Cardiology Trials of 2022 https://www.medscape.com/viewarticle/985647
II REVIVED BCIS2
-
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/nejmoa2206606
-
PCI Fails in Stable Disease Again: REVIVED-BCIS https://www.medscape.com/viewarticle/979862
-
PCI Fails to Beat OMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 https://www.medscape.com/viewarticle/979853
III GUIDE HF
-
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01754-2
-
CardioMEMS Remote HF Monitoring: Resist the Spin and FOMO https://www.medscape.com/viewarticle/970278
-
GUIDE-HF: CardioMEMS-Guided Meds Fall Short in Mild to Moderate Heart Failure https://www.medscape.com/viewarticle/957390
IV DECAAF II
-
Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation The DECAAF II Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2793452
-
DECAAF II: AF, Fibrosis Ablation Technique Falls Short, but Signs of Hope https://www.medscape.com/viewarticle/957469
V DANCAVAS
-
Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
-
DANCAVAS Misses Primary Endpoint but Hints at Benefit from Comprehensive CV Screening https://www.medscape.com/viewarticle/979854
-
Judicious CVD Screening May Work in Men: DANCAVAS https://www.medscape.com/viewarticle/980153
-
DANCAVAS: Might Cardiovascular Screening Extend Men's Lives? https://www.medscape.com/viewarticle/979632
VI SODIUM HF
-
Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial https://doi.org/10.1016/S0140-6736(22)00369-5
-
Low-Sodium Diet Did Not Cut Clinical Events in Heart Failure Trial https://www.medscape.com/viewarticle/971482
-
Sodium Restriction in Heart Failure: Another Dogma Felled by Randomization https://www.medscape.com/viewarticle/971697
-
SODIUM-HF Simplifies Message to Patients on Diet https://www.medscape.com/viewarticle/971547
VII STRONG-HF
-
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial https://doi.org/10.1016/S0140-6736(22)02076-1
-
Rapidly, Fully Optimize HF Meds After Hospital Discharge: STRONG-HF https://www.medscape.com/viewarticle/983870
-
STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698
VIII Health Insurance Access
-
Health Care Access and Management of Cardiovascular Risk Factors Among Working-Age Adults With Low Income by State Medicaid Expansion Status https://doi.org/10.1001/jamacardio.2022.1282
-
Medicaid Expansion: Good First Step, but No Panacea for CV Care https://www.medscape.com/viewarticle/975141
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
BP control over the long term, omecamtiv mecarbil, incentives and Goodhart’s law, and open science are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Long-Term BP Control
-
Final SPRINT Data Confirm Lower BP Is Better https://www.medscape.com/viewarticle/951572
-
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control https://jamanetwork.com/journals/jamacardiology/fullarticle/2797064
-
Let's Not SPRINT to Judgment About New Blood Pressure Goals https://www.acpjournals.org/doi/full/10.7326/M15-3123
-
Should We SPRINT Toward New Blood Pressure Goals or Let the Dust Settle? https://doi.org/10.1016/j.amjmed.2016.04.022
II. Omecamtiv Mecarbil
-
FDA Panel Votes No on Omecamtiv Mecarbil for Heart Failure https://www.medscape.com/viewarticle/985593
-
Omecamtiv Mecarbil Fails to Improve Exercise Capacity in HFrEF https://www.medscape.com/viewarticle/978355
-
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2025797
-
Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction https://jamanetwork.com/journals/jama/fullarticle/2794362
-
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial https://doi.org/10.1093/eurheartj/ehac293
III. Measuring Quality of Care
-
MIPS Quality Scores Don't Reflect Quality of Care: Study https://www.medscape.com/viewarticle/985396
-
Association Between Individual Primary Care Physician Merit-based Incentive Payment System Score and Measures of Process and Patient Outcomes https://jamanetwork.com/journals/jama/article-abstract/2799153
-
Pay for Performance When Slogans Overtake Science in Health Policy https://jamanetwork.com/journals/jama/fullarticle/2799177
-
Goodhart's law https://en.wikipedia.org/wiki/Goodhart%27s_law
IV. Open Science
-
Radial Artery Outlasts SVG as Second CABG Conduit, Cuts 5-Year Clinical Risk https://www.medscape.com/viewarticle/896122
-
Many Analysts, One Data Set: Making Transparent How Variations in Analytic Choices Affect Results https://doi.org/10.1177/2515245917747646
-
Radial artery versus saphenous vein versus right internal thoracic artery for coronary artery bypass grafting https://academic.oup.com/ejcts/article/62/1/ezac345/6604735?login=false
-
Do all roads lead to Rome? Critical reassessment of the individual patient meta-analysis on bypass grafts by Gaudino et al. https://doi.org/10.1093/ejcts/ezac564
-
Editorial: Radial artery versus saphenous vein versus right internal thoracic artery for coronary artery bypass grafting: Different conduits or different trials? https://doi.org/10.1093/ejcts/ezac562
Features
- Mandrola’s Top 10 Cardiology Stories of 2022 https://www.medscape.com/viewarticle/985607
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Nudges, statins, AI, less-is-more in the ICU, myocarditis, exercise as medicine, and December in the hospital are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Nudges and Statin Prescribing
EHR Alerts to Both Doc and Patient May Boost Statin Prescribing
https://www.medscape.com/viewarticle/984944
Effect of Nudges to Clinicians, Patients, or Both to Increase Statin Prescribing
https://jamanetwork.com/journals/jamacardiology/article-abstract/2798971
Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia
https://jamanetwork.com/journals/jama/fullarticle/2719307
Lack of Efficacy of a Salience Nudge for Substituting Selection of Lower-Calorie for Higher-Calorie Milk in the Work Place https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488787/
II. AI and Chest X-Ray
Single Chest X-Ray Could Predict 10-Year CVD Risk
https://www.medscape.com/viewarticle/984910
III. BOX Trial
Shorter Fever Prevention Duration Effective After Cardiac Arrest
https://www.medscape.com/viewarticle/984852
Duration of Device-Based Fever Prevention after Cardiac Arrest
https://www.nejm.org/doi/10.1056/NEJMoa2212528
Oxygen Targets in Comatose Survivors of Cardiac Arrest
https://www.nejm.org/doi/full/10.1056/NEJMoa2208686
Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest
https://www.nejm.org/doi/full/10.1056/NEJMoa2208687
Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure
https://www.nejm.org/doi/full/10.1056/NEJMoa2032510
IV. Myocarditis
Mortality Higher in Myocarditis After Virus Than After COVID Vax
https://www.medscape.com/viewarticle/985045
Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination
https://link.springer.com/article/10.1007/s00392-022-02129-5#Tab2
Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults
https://jamanetwork.com/journals/jamapediatrics/fullarticle/2798866
Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis
https://www.jacc.org/doi/full/10.1016/j.jacc.2022.09.049
V. Exercise as Medicine
Just 8 Minutes of Exercise a Day Is All You Need
https://www.medscape.com/viewarticle/984684
Vigorous physical activity, incident heart disease, and cancer: how little is enough? https://doi.org/10.1093/eurheartj/ehac572
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
John M Mandrola, MD
SGLT2 inhibitors, publishing choices, second and third order effects of interventions, decision support, and patient selection for preventive procedures are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. EMPA Kidney
-
EMPA-Kidney Seals SGLT2 Inhibitors as 'Foundational' for CKD https://www.medscape.com/viewarticle/984439
-
EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease https://www.medscape.com/viewarticle/983521
-
Empagliflozin in Patients with Chronic Kidney Disease https://www.nejm.org/doi/pdf/10.1056/NEJMoa2204233
-
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://www.nejm.org/doi/10.1056/NEJMoa1811744
-
Dapagliflozin in Patients with Chronic Kidney Disease https://www.nejm.org/doi/full/10.1056/NEJMoa2024816
-
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials https://doi.org/10.1016/S0140-6736(22)02074-8
II. Publishing Choices
-
Motorcycle Rallies Linked to Spike in Organ Transplants https://www.medscape.com/viewarticle/984623
-
Organ Donation and Transplants During Major US Motorcycle Rallies https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2798550
III. Second and Third Order Effects
- Heart Disease Deaths Spiked During COVID After 10-Year Decline https://www.medscape.com/viewarticle/984605
IV. Decision Support
-
Patient App Aids Decisions on Anticoagulants: ENHANCE-AF https://www.medscape.com/viewarticle/984253
-
A Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision‐Making Pathway https://www.ahajournals.org/doi/10.1161/JAHA.122.028562
V. Percutaneous Left Atrial Appendage Closure
-
Consider Life Expectancy When Referring for LAA Closure? https://www.medscape.com/viewarticle/981117
-
Transcatheter Left Atrial Appendage Occlusion: A Multi-Center Real Life Experience https://www.mdpi.com/2077-0383/11/23/6944
-
Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure https://www.jacc.org/doi/full/10.1016/j.jacep.2022.06.012
-
Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO Registry https://www.ahajournals.org/doi/full/10.1161/CIRCOUTCOMES.121.008418
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
AHA 2022, Part 2: IRONMAN, ECMO-CS, CTS-AMI, and PROGRESSIVE AF are the trials John Mandrola, MD, reviews in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Pushback on PROMINENT
Zimerman Thread: https://twitter.com/AndreZimerman/status/1593019800036708353
II. IRONMAN
IRONMAN Galvanizes Case for IV Iron Repletion in Heart Failure
https://www.medscape.com/viewarticle/984030
Is Iron Replacement in Heart Failure Worth the Trouble?
https://www.medscape.com/viewarticle/983622
- Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial https://doi.org/10.1016/S0140-6736(22)02083-9
III. ECMO-CS
Avoid Routine Early ECMO in Severe Cardiogenic Shock: ECMO-CS
https://www.medscape.com/viewarticle/983618
-
Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062949
-
Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock and Cardiac Arrest https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.118.004905
IV. CTS-AMI
Chinese Herbal Medicine May Offer Benefits in STEMI: CTS-AMI
https://www.medscape.com/viewarticle/983619
V. PROGRESSIVE AF
First-Line AF Ablation Cuts Risk of Progression vs Drug Therapy
https://www.medscape.com/viewarticle/983882
Role of Ablation Type and Risk Factors in Paroxysmal AF: PROGRESSIVE-AF Interview https://www.medscape.com/viewarticle/983474
- Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation
https://www.nejm.org/doi/full/10.1056/nejmoa2029980
- Progression of Atrial Fibrillation after Cryoablation or Drug Therapy
https://www.nejm.org/doi/10.1056/NEJMoa2212540
- Natural History of Subclinical Atrial Fibrillation Detected by Implanted Loop Recorders
https://pubmed.ncbi.nlm.nih.gov/31779791/
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
AHA 2022 Part 1: ISCHEMIA-EXTEND, STRONG-HF, chlorthalidone vs HCTZ, experts vs practitioners; torsemide vs furosemide; and TG lowering are discussed by John Mandrola, MD, in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. AHA Meta-comments
II. ISCHEMIA-Extended
-
ISCHEMIA-EXTEND: Conservative Stable CAD Management Holds Up https://www.medscape.com/viewarticle/983657
-
Survival After Invasive or Conservative Management of Stable Coronary Disease https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062714
III. STRONG-HF
-
Rapidly, Fully Optimize HF Meds After Hospital Discharge: STRONG-HF https://www.medscape.com/viewarticle/983870
-
STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698
-
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial https://doi.org/10.1016/S0140-6736(22)02076-1
IV. DCP
-
Diuretic Agents Equal to Prevent CV Events in Hypertension: DCP https://www.medscape.com/viewarticle/983608
-
HCTZ vs Chlorthalidone -- A Win for Practicing Doctors and Science https://www.medscape.com/viewarticle/983614
V. TRANSFORM HF
- No Survival Advantage for Either Torsemide or Furosemide in HF: TRANSFORM-HF https://www.medscape.com/viewarticle/983611
VI. PROMINENT
-
Triglyceride Lowering Fails to Show CV Benefit in Large Fibrate Trial https://www.medscape.com/viewarticle/983610
-
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2210645
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
AF conversion in the ED, HRT, a shining example of evidence-based medicine and less-is-more, multimorbidity, and what’s coming at AHA are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. AF Conversion
-
IV Potassium and Magnesium an Acute Treatment for AF? https://www.medscape.com/viewarticle/983137
-
Association of Intravenous Potassium and Magnesium Administration With Spontaneous Conversion of Atrial Fibrillation and Atrial Flutter in the Emergency Department https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797474
II. HRT
-
USPSTF Doesn't Change Postmenopausal Hormone Recommendations https://www.medscape.com/viewarticle/983349
-
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women https://doi.org/10.7326/0003-4819-117-12-1016
-
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal WomenPrincipal Results From the Women's Health Initiative Randomized Controlled Trial https://jamanetwork.com/journals/jama/fullarticle/195120
-
Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal PersonsUS Preventive Services Task Force Recommendation Statement https://jamanetwork.com/journals/jama/fullarticle/2797867
-
Menopausal Hormone Therapy for Prevention of Chronic Conditions https://jamanetwork.com/journals/jama/fullarticle/2797897
III. BP Targets After Stroke Intervention
-
Intensive BP Lowering Harmful in Acute Ischemic Stroke: ENCHANTED2/MT https://www.medscape.com/viewarticle/983176
-
Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial https://doi.org/10.1016/S0140-6736(22)01882-7
IV. Multimorbidity
-
ACC Issues Guidance on Integrating ASCVD and Multimorbidity Care https://www.medscape.com/viewarticle/983123
-
2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care: A Report of the American College of Cardiology Solution Set Oversight Committee https://www.jacc.org/doi/10.1016/j.jacc.2022.08.754
V. AHA Preview
-
AHA 2022 to Recapture In-Person Vibe but Preserve Global Reach https://www.medscape.com/viewarticle/983315
-
Mandrola's Top 5 Picks From AHA 2022 Previewed https://www.medscape.com/viewarticle/983237
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
ERASE AF follow-up, recreational drugs and AF, etripamil, misuse of science, and diabetes as a cardiovascular risk factor are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Follow-up on ERASE AF
II. Recreational Drugs
Four Commonly Abused Drugs Linked With Atrial Fibrillation
https://www.medscape.com/viewarticle/983052
III. Etripamil
RAPID: Positive Data for Etripamil Nasal Spray in Paroxysmal SVT
https://www.medscape.com/viewarticle/982787
- Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia https://investors.milestonepharma.com/news-releases/news-release-details/milestone-pharmaceuticals-announces-positive-results-phase-3
IV. Misuse of Science
When Bad Actors Hijack Good Research
https://www.medscape.com/viewarticle/982936
- Level and Prevalence of Spin in Published Cardiovascular Randomized Clinical Trial Reports With Statistically Nonsignificant Primary Outcomes: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/31050775/
V. Diabetes as a Risk Factor
Diabetes Becoming Less Potent Risk Factor for CVD Events
https://www.medscape.com/viewarticle/982801
- Trends in the Association Between Diabetes and Cardiovascular Events, 1994-2019 https://jamanetwork.com/journals/jama/fullarticle/2797494
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
ERASE AF follow-up, recreational drugs and AF, etripamil, misuse of science, and diabetes as a cardiovascular risk factor are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Follow-up on ERASE AF
II. Recreational Drugs
Four Commonly Abused Drugs Linked With Atrial Fibrillation
https://www.medscape.com/viewarticle/983052
III. Etripamil
RAPID: Positive Data for Etripamil Nasal Spray in Paroxysmal SVT
https://www.medscape.com/viewarticle/982787
- Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia https://investors.milestonepharma.com/news-releases/news-release-details/milestone-pharmaceuticals-announces-positive-results-phase-3
IV. Misuse of Science
When Bad Actors Hijack Good Research
https://www.medscape.com/viewarticle/982936
- Level and Prevalence of Spin in Published Cardiovascular Randomized Clinical Trial Reports With Statistically Nonsignificant Primary Outcomes: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/31050775/
V. Diabetes as a Risk Factor
Diabetes Becoming Less Potent Risk Factor for CVD Events
https://www.medscape.com/viewarticle/982801
- Trends in the Association Between Diabetes and Cardiovascular Events, 1994-2019 https://jamanetwork.com/journals/jama/fullarticle/2797494
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
The ERASE AF ablation trial, left bundle pacing, finerenone, and perceptions of cardiology are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. AF Ablation
-
Low-Voltage Myocardium-Guided Ablation Trial of Persistent Atrial Fibrillation https://evidence.nejm.org/doi/10.1056/EVIDoa2200141
-
Approaches to Catheter Ablation for Persistent Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/NEJMoa1408288
-
Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation https://jamanetwork.com/journals/jama/fullarticle/2793452
-
Circumferential Pulmonary Vein Isolation Plus Low-Voltage Area Modification in Persistent Atrial Fibrillation: The STABLE-SR-II Trial https://www.jacc.org/doi/full/10.1016/j.jacep.2022.03.012
-
Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation https://jamanetwork.com/journals/jama/fullarticle/2772281
-
Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation https://www.ahajournals.org/doi/full/10.1161/CIRCEP.120.009288
II. Left Bundle Branch Area Pacing
-
FDA OKs Medtronic Lead for Left Bundle Branch Pacing https://www.medscape.com/viewarticle/982577
-
Left bundle branch area pacing outcomes: the multicentre European MELOS study https://academic.oup.com/eurheartj/article/43/40/4161/6671019
-
Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy https://www.jacc.org/doi/full/10.1016/j.jacc.2022.07.019
-
Early sudden distal conductor fracture of a stylet-driven lead implanted for left bundle branch area pacing https://doi.org/10.1016/j.hrcr.2022.10.004
-
Repositioning and extraction of stylet-driven pacing leads with extendable helix used for left bundle branch area pacing https://pubmed.ncbi.nlm.nih.gov/33825263/
-
Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2289126
III. Finerenone
-
Finerenone Benefits T2D Across Spectrum of Renal Function https://www.medscape.com/viewarticle/982626
-
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes https://www.nejm.org/doi/10.1056/NEJMoa2110956
-
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis https://academic.oup.com/eurheartj/article/43/6/474/6433104
-
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes https://www.jacc.org/doi/10.1016/j.jchf.2022.07.013
IV. Perceptions of Cardiology
- IM Residents Rate Cardiology Low on Work-Life Balance https://www.medscape.com/viewarticle/982578
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Chest pain evaluation in the ED, peer review, the NordICC trial, and a surgeon lost too early are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Chest Pain Consensus Pathway
-
ACC Issues Guidance on ED Evaluation of Acute Chest Pain https://www.medscape.com/viewarticle/982302
-
2022 ACC Expert Consensus Decision Pathway on the Evaluation and Disposition of Acute Chest Pain in the Emergency Department: A Report of the American College of Cardiology Solution Set Oversight Committee https://www.jacc.org/doi/10.1016/j.jacc.2022.08.750
-
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines https://www.ahajournals.org/doi/10.1161/CIR.0000000000001030#d20522356e1
II. Peer Review
-
Big Name Researchers May Get Special Treatment, Limiting New Science https://www.medscape.com/viewarticle/982193
-
Nobel and Novice: Author Prominence Affects Peer Review https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4190976
-
Editorial peer review for improving the quality of reports of biomedical studies https://www.cochrane.org/MR000016/METHOD_editorial-peer-review-for-improving-the-quality-of-reports-of-biomedical-studies
III. NordICC
-
Colonoscopy Lowers CRC Risk and Death, but Not by Much: NordICC https://www.medscape.com/viewarticle/982143
-
Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death https://www.nejm.org/doi/full/10.1056/NEJMoa2208375
-
The arrogance of preventive medicine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC117852/
-
Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
IV. Domenico Pagano
- Surgeon Domenico Pagano Has Died, EACTS Announces https://www.medscape.com/viewarticle/982351
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Post-PCI antiplatelet therapy, palliative care in patients with HF, Watchman information on hospital websites, and HCM in athletes are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Post-Stent Antiplatelet Therapy
SMART-CHOICE 3-Year Results Support Dropping Aspirin After PCI
https://www.medscape.com/viewarticle/981741
- Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention https://jamanetwork.com/journals/jamacardiology/fullarticle/2796902
- The Smart(est) Choice for Dual Antiplatelet Therapy is a Patient-Directed One https://jamanetwork.com/journals/jamacardiology/fullarticle/2796904
- Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention https://jamanetwork.com/journals/jama/fullarticle/2736564
II. Palliative Care in HF
Home-Based Palliative Care Improves Heart Failure Outcomes https://www.medscape.com/viewarticle/981715
- Regional collaborative home-based palliative care and health care outcomes among adults with heart failure https://doi.org/10.1503/cmaj.220784
III. Watchman Info on Hospital Websites
Concern Over US Hospital Patient Information on LAA Closure https://www.medscape.com/viewarticle/981961
- Analysis of Patient-Focused Information About Left Atrial Appendage Occlusion on US Hospital Web Pages https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2797102
IV. HCM and Exercise in Athletes
Athletes With Mild HCM Can Likely Continue Competitive Sports https://www.medscape.com/viewarticle/981782
- Impact of Exercise on Outcomes and Phenotypic Expression in Athletes With Nonobstructive Hypertrophic Cardiomyopathy https://www.jacc.org/doi/full/10.1016/j.jacc.2022.08.715
- A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD) https://pubmed.ncbi.nlm.nih.gov/24126876/
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
Pulmonary embolism, coffee, when DOACs don’t work, lipoprotein (a), and the marginal benefits of current CV therapy are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Pulmonary Embolism
-
Positive Data on Thrombectomy Catheter That Avoids Thrombolytics in Acute PE https://www.medscape.com/viewarticle/981322
-
Acute Outcomes for the Full US Cohort of the FLASH Mechanical Thrombectomy Registry in Pulmonary Embolism https://eurointervention.pcronline.com/article/acute-outcomes-for-the-full-us-cohort-of-the-flash-mechanical-thrombectomy-registry-in-pulmonary-embolism
-
PEERLESS Study https://clinicaltrials.gov/ct2/show/NCT05111613
-
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (HI-PEITHO) https://clinicaltrials.gov/ct2/show/NCT04790370
-
A Prospective, Single-Arm, Multicenter Trial of Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary Embolism: The FLARE Study https://doi.org/10.1016/j.jcin.2018.12.022
II. Coffee Again
- Coffee Linked to Reduced Cardiovascular Disease and Mortality https://www.medscape.com/viewarticle/981518
Enough With the Coffee Research and Other Distractions https://www.medscape.com/viewarticle/883709
- The impact of coffee subtypes on incident cardiovascular disease, arrhythmias, and mortality: long-term outcomes from the UK Biobank https://doi.org/10.1093/eurjpc/zwac189
III. DOAC and Mechanical Valves
-
PROACT Xa Trial of Apixaban With On-X Heart Valve Stopped https://www.medscape.com/viewarticle/981644
-
Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial https://investors.artivion.com/news-releases/news-release-details/artivion-follows-recommendation-stop-proact-xa-clinical-trial
-
PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban https://clinicaltrials.gov/ct2/show/NCT04142658
-
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves https://www.nejm.org/doi/full/10.1056/nejmoa1300615
IV. Lipoprotein(a)
-
Aspirin Primary Prevention Benefit in Those With Raised Lp(a)? https://www.medscape.com/viewarticle/981602
-
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes https://www.jacc.org/doi/full/10.1016/j.jacc.2022.07.027
-
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women https://www.nejm.org/doi/full/10.1056/nejmoa050613
-
Effect of Aspirin on Disability-free Survival in the Healthy Elderly https://www.nejm.org/doi/full/10.1056/NEJMoa1800722
-
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly https://www.nejm.org/doi/full/10.1056/NEJMoa1805819
-
Effect of Aspirin on All-Cause Mortality in the Healthy Elderly https://www.nejm.org/doi/full/10.1056/NEJMoa1803955
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
In this week’s podcast, John Mandrola, MD, discusses the PROTECTED TAVR trial, renal denervation, left atrial appendage closure and deprescribing aspirin.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I Cerebral Embolic Protection After TAVI
-
Clear Stroke Benefit Eludes Embolic Protection: PROTECTED TAVR https://www.medscape.com/viewarticle/980978
-
Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement https://www.nejm.org/doi/10.1056/NEJMoa2204961
-
Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement https://doi.org/10.1016/j.jacc.2016.10.023
-
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
-
Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
-
Randomised Trial Of Intravenous Streptokinase, Oral Aspirin, Both, Or Neither Among 17 187 Cases Of Suspected Acute Myocardial Infarction: Isis-2 https://doi.org/10.1016/S0140-6736(88)92833-4
II Renal Denervation
-
Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
-
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial https://doi.org/10.1016/S0140-6736(22)01787-1
-
A systematic review, meta-analysis, and meta regression of the sham controlled renal denervation randomized controlled trials https://doi.org/10.1016/j.tcm.2022.05.009
-
Legacy of Neutral Renal Denervation Trial Recast by Long-term Outcomes: SYMPLICITY HTN-3 https://www.medscape.com/viewarticle/981062
-
A Controlled Trial of Renal Denervation for Resistant Hypertension https://www.nejm.org/doi/10.1056/NEJMoa1402670
III Percutaneous Left Atrial Appendage Occlusion (LAAO)
-
Amulet, Watchman 2.5 LAAO Outcomes Neck and Neck at 3 Years https://www.medscape.com/viewarticle/981199
-
Consider Life Expectancy When Referring for LAA Closure? https://www.medscape.com/viewarticle/981117
-
Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure https://www.jacc.org/doi/full/10.1016/j.jacep.2022.06.012
IV Deprescribing Aspirin
-
Deprescribing Aspirin for Warfarin Patients May Reduce Bleeding https://www.medscape.com/viewarticle/981243
-
Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796492
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The safety of very low LDL-C, the win-ratio analytic method, sacubitril/valsartan, SGLT2 inhibitors, and percutaneous left atrial appendage closure are discussed in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I PCSK9I
Evolocumab Benefits Accrue With Longer Follow-up: FOURIER OLE
https://www.medscape.com/viewarticle/979950
-
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
https://www.nejm.org/doi/full/10.1056/nejmoa1615664 -
Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061620
II Analytic Methods and Re-Analysis of Old Trials
-
PARADISE-MI Results Obscured As Post Hoc Analysis Finds Flaws
https://www.medscape.com/viewarticle/980776 -
Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction
https://www.nejm.org/doi/10.1056/NEJMoa2104508 -
Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057429 -
The Year’s Most Important Study Adds to Uncertainty in Science
https://www.medscape.com/viewarticle/904286
III SGLT2i Post MI
-
Early Signal of Benefit for Empagliflozin in Acute MI: EMMY
https://www.medscape.com/viewarticle/980180 -
Empagliflozin in acute myocardial infarction: the EMMY trial
https://doi.org/10.1093/eurheartj/ehac494
IV Percutaneous Left Atrial Appendage Closure
-
Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure
https://www.jacc.org/doi/10.1016/j.jacep.2022.06.012 -
Cost‐Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5‐Year, Long‐Term Data
https://www.ahajournals.org/doi/10.1161/JAHA.118.011577 -
Baseline Comorbidities And Bleeding Events Of Patients Undergoing Percutaneous Left Atrial Appendage Occlusion Among Medicare Beneficiaries
https://www.jacc.org/doi/10.1016/S0735-1097%2822%2901158-5
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
A potential new anticoagulant, surveillance stress testing, a trial misinterpretation, an old diuretic, and AI in cardiology are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Factor XI inhibitors
-
Factor XIa Inhibitor After MI, Stroke Encouraging in Early Phase 2 Studies https://www.medscape.com/viewarticle/979942
-
AXIOMATIC-SSP: Cautious Optimism on Factor XI Inhibitor in Stroke https://www.medscape.com/viewarticle/979860
II. Surveillance Stress Testing
-
No Benefit of Routine Stress Test POST-PCI in High-Risk Patients https://www.medscape.com/viewarticle/979866
-
Routine Functional Testing or Standard Care in High-Risk Patients after PCI https://www.nejm.org/doi/full/10.1056/NEJMoa2208335
III. New Diuretic for Acute Heart Failure
-
Vintage Drug Atop IV Loop Diuretics Boosts Decongestion in ADHF: ADVOR https://www.medscape.com/viewarticle/979851
-
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload https://www.nejm.org/doi/full/10.1056/NEJMoa2203094
IV. AI in Cardiology
-
In Blinded Trial, Artificial Intelligence Beats Sonographers for Echo Accuracy https://www.medscape.com/viewarticle/979857
-
Video-based AI for beat-to-beat assessment of cardiac function https://www.nature.com/articles/s41586-020-2145-8
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
A second ESC review covering REVIVED, the DANCAVAS CV screening trial, DELIVER on dapagliflozin in HF with mildly reduced EF, and the INVICTUS trial of rivaroxaban in rheumatic heart disease. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I REVIVED BCIS
-
PCI Fails to Beat OMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 https://www.medscape.com/viewarticle/979853
-
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/NEJMoa2206606
-
Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/nejmoa1100356
II DANCAVAS
-
DANCAVAS Misses Primary Endpoint but Hints at Benefit from Comprehensive CV Screening https://www.medscape.com/viewarticle/979854
-
Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
-
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa1608029
III DELIVER Trial
-
Dapagliflozin's HFpEF Benefit Recasts Heart Failure Treatment: DELIVER https://www.medscape.com/viewarticle/979855
-
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2206286
-
Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2107038
-
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials https://doi.org/10.1016/S0140-6736(22)01429-5
IV Rheumatic Heart Disease
-
Rivaroxaban Outmatched by VKAs for AF in Rheumatic Heart Disease https://www.medscape.com/viewarticle/979861
-
Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/NEJMoa2209051
-
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve https://www.nejm.org/doi/full/10.1056/NEJMoa2029603
-
Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis https://www.jacc.org/doi/full/10.1016/j.jacc.2018.12.047
Features:
-
Do SGLT2 Inhibitors DELIVER in All Patients With Heart Failure? https://www.medscape.com/viewarticle/979852
-
PCI Fails in Stable Disease Again: REVIVED-BCIS https://www.medscape.com/viewarticle/979862
-
DANCAVAS: Might Cardiovascular Screening Extend Men's Lives? https://www.medscape.com/viewarticle/979632
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Early rhythm control in AF, treating coronary artery disease before transcatheter aortic valve implantation, and an ESC 2022 preview are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Early Rhythm Control
-
Early AF Rhythm-Control Advantage Climbs With Comorbidity Burden: EAST-AFNET4 https://www.medscape.com/viewarticle/979627
-
Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.122.060274
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/NEJMoa2019422
II. CAD and Aortic Stenosis
-
No Survival Gains Seen From Pre-TAVR PCI of Complex CAD https://www.medscape.com/viewarticle/979408
-
The Effect of Coronary Lesion Complexity and Preprocedural Revascularization on 5-Year Outcomes After TAVR https://doi.org/10.1016/j.jcin.2022.06.019
-
Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Meta‐Analysis https://www.ahajournals.org/doi/10.1161/JAHA.117.005960
-
ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic Valve implantaTION): A Randomized Clinical Trial https://www.jacc.org/doi/full/10.1016/j.jcin.2021.06.041
III. ESC Trials
- Mandrola Previews His Top 5 Trials From ESC 2022 https://www.medscape.com/viewarticle/979560
TIME
-
Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension https://pubmed.ncbi.nlm.nih.gov/35983870/
-
Empirical Evaluation of Very Large Treatment Effects of Medical Interventions https://jamanetwork.com/journals/jama/fullarticle/1386610
SECURE
- Polypill Strategy in Secondary Cardiovascular Prevention http://www.nejm.org/doi/full/10.1056/NEJMoa2208275
CAPLA
- Catheter ablation for persistent atrial fibrillation: A multicenter randomized trial of pulmonary vein isolation (PVI) versus PVI with posterior left atrial wall isolation (PWI) - The CAPLA study http://www.sciencedirect.com/science/article/pii/S0002870321002453?via%3Dihub
IV. ESC Preview
- Barcelona Beckons for First Hybrid ESC Congress https://www.medscape.com/viewarticle/979477
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The obesity paradox in AF and paradoxes in general, digital health gets whacked again, and direct-to-consumer ads are the topics discussed by John Mandrola, MD in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Collider Bias and the Obesity Paradox
-
'Obesity Paradox' in Atrial Fibrillation Challenged as Mortality Climbs With BMI https://www.medscape.com/viewarticle/979150
-
Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF https://openheart.bmj.com/content/9/2/e002038
-
Collider bias https://catalogofbias.org/biases/collider-bias/
-
Pediatric obesity appears to lower the risk of diabetes if selection bias is ignored https://pubmed.ncbi.nlm.nih.gov/29374028/
-
Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2480484
II. Digital Health
-
Blood Pressure Smartphone App Fails to Beat Standard Self-Monitoring https://www.medscape.com/viewarticle/979341
-
Effectiveness of Standard vs Enhanced Self-measurement of Blood Pressure Paired With a Connected Smartphone Application https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2794971
III. Direct-to-Consumer Ads
-
Does DTC Heart Drug Advertising Discourage Lifestyle Changes? https://www.medscape.com/viewarticle/979404
-
Association of Direct-to-Consumer Advertising of Prescription Drugs With Consumer Health-Related Intentions and Beliefs Among Individuals at Risk of Cardiovascular Disease https://jamanetwork.com/journals/jama-health-forum/fullarticle/2794995
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
AF screening; sodium, potassium, BP, and CV outcomes; drug prices; and cardio-respiratory fitness are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. AF Screening
-
Using Wearable Devices to Detect AF Is 'Cost Effective' https://www.medscape.com/viewarticle/978861
-
Cost-effectiveness of Screening for Atrial Fibrillation Using Wearable Devices https://jamanetwork.com/journals/jama-health-forum/fullarticle/2794835
-
Screening for Atrial Fibrillation in Asymptomatic Older Adults https://www.nejm.org/doi/full/10.1056/NEJMclde2203726
II. Salt Substitutes
-
More Evidence Salt Substitutes Lower Risk of CVD and Death https://www.medscape.com/viewarticle/978999
-
Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis https://heart.bmj.com/content/early/2022/07/21/heartjnl-2022-321332
-
Effect of Salt Substitution on Cardiovascular Events and Death https://www.nejm.org/doi/10.1056/NEJMoa2105675
-
Settling the controversy of salt substitutes and stroke: sodium reduction or potassium increase? https://doi.org/10.1093/eurheartj/ehac160
-
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia https://www.nejm.org/doi/full/10.1056/nejmoa1812792
-
Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention https://www.nejm.org/doi/full/10.1056/nejmoa0807611
III. Drug Prices
- House Could Soon Give Biden Win on Medicare Drug Negotiations, Insulin Costs https://www.medscape.com/viewarticle/978988
IV. Fitness is Under-rated
-
Cardiorespiratory Fitness Key to Longevity for All? https://www.medscape.com/viewarticle/978854
-
Cardiorespiratory Fitness and Mortality Risk Across the Spectra of Age, Race, and Sex https://www.jacc.org/doi/full/10.1016/j.jacc.2022.05.031
-
Cardiorespiratory fitness, obesity and left atrial function in patients with atrial fibrillation https://doi.org/10.1016/j.ijcha.2022.101083
You also may like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Hyperkalemia in heart failure, CV health in America, primary prevention ICDs, and a debate about posters at medical meetings are the topics discussed by John Mandrola, MD in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I. Hyperkalemia in Heart Failure
-
DIAMOND: Adding Patiromer Helps Optimize HF Meds, Foils Hyperkalemia https://www.medscape.com/viewarticle/971616
-
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial https://doi.org/10.1093/eurheartj/ehac401
-
Potassium Binders for Patients With Heart Failure? The Real Enlightenment of the DIAMOND Trial https://doi.org/10.1093/eurheartj/ehac399
-
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure https://www.nejm.org/doi/full/10.1056/nejm199909023411001
-
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms https://www.nejm.org/doi/full/10.1056/nejmoa1009492
-
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial https://pubmed.ncbi.nlm.nih.gov/21208974/
II. CV Health in America
-
‘Staggering’ CVD Rise Projected in US, Especially in Minorities https://www.medscape.com/viewarticle/978366
-
Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates https://www.jacc.org/doi/10.1016/j.jacc.2022.05.033
III. Primary Prevention ICDs in Modern Era
-
Do ICDs Still ‘Work’ in Primary Prevention Given Today’s Recommended HF Meds? https://www.medscape.com/viewarticle/978254
-
Guideline-Directed Medical Therapy and the Risk of Death in Primary Prevention Defibrillator Recipients https://doi.org/10.1016/j.jacep.2022.05.001
-
Declining Risk of Sudden Death in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa1609758
-
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa1608029
IV. Medical Meetings and Posters
- As Digital Posters Take Over, Traditionalists Push Back https://www.medscape.com/viewarticle/978384
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
A big new HF and EP trial, doctors and probability, LV assist devices in cardiogenic shock, vitamin D, and exercise in PAD are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Left vs Left RCT
Taking Cardiac Pacing From Boring to Super-Cool https://www.medscape.com/viewarticle/973615
Conduction-System Pacing Shines vs BiV Pacing for CRT in Early Studies https://www.medscape.com/viewarticle/974173
• Baylor led research awarded $31 Million for Resynchronization Therapy in Patients with Heart Failure https://www.bcm.edu/news/baylor-led-research-awarded-31-million-for-resynchronization-therapy-in-patients-with-heart-failure
II. Probability and Conjunction Fallacy
Is What You Call Probable...Impossible?
https://www.medscape.com/viewarticle/976451
• Analysis of Physicians’ Probability Estimates of a Medical Outcome Based on a Sequence of Events
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793624
III. LV Assist Devices
Impella Pump for MI With Cardiogenic Shock Again Fares Poorly vs IABP in Study
https://www.medscape.com/viewarticle/977994
• Clinical Outcomes and Cost Associated With an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump in Patients Presenting With Acute Myocardial Infarction Complicated by Cardiogenic Shock
https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2794390
• Intravascular Microaxial Left Ventricular Assist Device for Acute Myocardial Infarction With Cardiogenic Shock—A Call for Evidence of Benefit https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2794394
• Intra-aortic Balloon Pump Therapy for Acute Myocardial InfarctionA Meta-analysis https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2210888
IV. Vitamin D
Vitamin D Supplements Do Not Lower Risk of Fractures
https://www.medscape.com/viewarticle/978108
Why Is Vitamin D Hype So Impervious to Evidence? https://www.medscape.com/viewarticle/968682
• Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults
https://www.nejm.org/doi/full/10.1056/NEJMoa2202106
V. Peripheral Artery Disease
For Patients With Peripheral Artery Disease, Pain Can Be Gain
https://www.medscape.com/viewarticle/978053
• Effects of Walking Exercise at a Pace With Versus Without Ischemic Leg Symptoms on Functional Performance Measures in People With Lower Extremity Peripheral Artery Disease: The LITE Randomized Clinical Trial
https://www.ahajournals.org/doi/10.1161/JAHA.121.025063
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact mailto:news@medscape.net
Therapeutic fashion and conduction system pacing, early rhythm control in AF, statins in CKD, and salt intake in HF are the topics discussed by John Mandrola, MD, in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – Therapeutic Fashion and Conduction System Pacing
-
Medical Necessity vs Therapeutic Fashion: How Evidence-Based Is Your Field of Medicine? https://www.medscape.com/viewarticle/977358
-
Conduction System Pacing Noninferior to Biventricular Pacing for HF With Wide QRS https://www.medscape.com/viewarticle/971740
-
His Corrective Pacing or Biventricular Pacing for Cardiac Resynchronization in Heart Failure https://www.jacc.org/doi/full/10.1016/j.jacc.2019.04.026
II – Early Rhythm Control
-
Benefit of Early Rhythm Control Questioned in Newly Diagnosed Atrial Fibrillation https://www.medscape.com/viewarticle/977584
-
Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy https://doi.org/10.1016/j.jacc.2022.04.058
-
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/NEJMoa2019422
III – Statins and CKD
-
Rosuvastatin Again Linked With Risks to Kidneys https://www.medscape.com/viewarticle/977646
-
Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria https://doi.org/10.1681/ASN.2022020135
-
Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis https://www.nejm.org/doi/10.1056/NEJMoa043545
-
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis https://www.nejm.org/doi/full/10.1056/nejmoa0810177
IV – Sodium and HF
-
Overly Tight Sodium Restriction May Worsen HFpEF Outcomes https://www.medscape.com/viewarticle/977441
-
Salt restriction and risk of adverse outcomes in heart failure with preserved ejection fraction https://heart.bmj.com/content/early/2022/06/07/heartjnl-2022-321167
-
Spironolactone for Heart Failure with Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/nejmoa1313731
-
Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial https://doi.org/10.1016/S0140-6736(22)00369-5
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The LIFE study, multimorbidity and evidence translation, cardiac arrest and therapeutic fashion, diabetes and cardiology, and EP cuts are the topics John Mandrola, MD, tackles in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – LIFE Study and Substudy
-
LIFE: ARNI Does Not Best Valsartan in Advanced Heart Failure https://www.medscape.com/viewarticle/952681
-
Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the LIFE Trial Run-In https://www.jacc.org/doi/10.1016/j.jchf.2022.04.013
-
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection FractionA Randomized Clinical Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2785700
II – Early Angiography and Therapeutic Fashion
-
Emergency Angiography for Cardiac Arrest Without ST Elevation? https://www.medscape.com/viewarticle/975434
-
Emergency vs Delayed Coronary Angiogram in Survivors of Out-of-Hospital Cardiac ArrestResults of the Randomized, Multicentric EMERGE Trial https://jamanetwork.com/journals/jamacardiology/article-abstract/2793310
-
Immediate Coronary Angiography in Survivors of Out-of-Hospital Cardiac Arrest https://www.nejm.org/doi/full/10.1056/NEJM199706053362302
-
Coronary Angiography after Cardiac Arrest without ST-Segment Elevation https://www.nejm.org/doi/10.1056/NEJMoa1816897
-
Randomized Pilot Clinical Trial of Early Coronary Angiography Versus No Early Coronary Angiography After Cardiac Arrest Without ST-Segment Elevation https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.049569
-
Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation https://www.nejm.org/doi/10.1056/NEJMoa2101909
-
Most healthcare interventions tested in Cochrane Reviews are not effective according to high quality evidence: a systematic review and meta-analysis https://www.jclinepi.com/article/S0895-4356(22)00100-7/fulltext
III – Diabetes and Cardiology
-
Medicare Advantage Tied to Less Use of Pricey Diabetes Drugs https://www.medscape.com/viewarticle/977181
-
Diabetes Care Among Older Adults Enrolled in Medicare Advantage Versus Traditional Medicare Fee-For-Service Plans: The Diabetes Collaborative Registry https://doi.org/10.2337/dc21-1178
IV – EP Cuts
- EP Ablation Rate Changes in 2022 Physician Fee Schedule https://www.acc.org/Latest-in-Cardiology/Articles/2021/11/18/01/44/EP-Ablation-Rate-Changes-in-2022-Physician-Fee-Schedule
You also may like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
On this week’s podcast, John Mandrola, MD discusses fish oil, America’s heart health, pharmacists and prescribing and statins This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - Fish Oil
-
New Biomarker Data Add to Concerns Over REDUCE-IT Trial https://www.medscape.com/viewarticle/976490
-
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.059410
-
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia https://www.nejm.org/doi/full/10.1056/nejmoa1812792
-
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular RiskThe STRENGTH Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2773120
-
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial https://academic.oup.com/eurheartj/article/41/40/3925/5898836
II - US Heart Health
-
New AHA Checklist: Only 1 in 5 Adults Have Optimal Heart Health https://www.medscape.com/viewarticle/976519
-
Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association https://www.ahajournals.org/doi/10.1161/CIR.0000000000001078
-
Status of Cardiovascular Health in US Adults and Children Using the American Heart Association's New "Life's Essential 8" Metrics: Prevalence Estimates from the National Health and Nutrition Examination Survey (NHANES), 2013-2018 https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.060911
III - Pharmacist Prescribing
-
Paxlovid Is Here: A Pharmacist's Prescribing Pearls https://www.medscape.com/viewarticle/973260
-
Coronavirus (COVID-19) Update: FDA Authorizes Pharmacists to Prescribe Paxlovid with Certain Limitations https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pharmacists-prescribe-paxlovid-certain-limitations
IV - Statin Eligibility
-
New European Guidelines ‘Drastically’ Reduce Statin Eligibility https://www.medscape.com/viewarticle/976715
-
Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines https://jamanetwork.com/journals/jamacardiology/article-abstract/2793729
-
Time to Revisit Using 10-Year Risk to Guide Statin Therapy https://jamanetwork.com/journals/jamacardiology/article-abstract/2793732
-
Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps https://doi.org/10.1097/mol.0000000000000247
You May Also Like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
A non-significant but wonderful trial in AF, smoking and HF, vitamins, and pre-op risk screening are the topics discussed by John Mandrola, MD, in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I – DECAAF II Trial
DECAAF II: AF, Fibrosis Ablation Technique Falls Short, but Signs of Hope
https://www.medscape.com/viewarticle/957469
• Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation https://jamanetwork.com/journals/jama/article-abstract/2793452
• Association of Atrial Tissue Fibrosis Identified by Delayed Enhancement MRI and Atrial Fibrillation Catheter Ablation
https://jamanetwork.com/journals/jama/fullarticle/1820433
II – Smoking and HF
Cigarettes Linked to HF With Preserved or Reduced EF https://www.medscape.com/viewarticle/976066?src=
• Cigarette Smoking, Cessation, and Risk of Heart Failure With Preserved and Reduced Ejection Fraction https://www.jacc.org/doi/full/10.1016/j.jacc.2022.03.377
III – Vitamins
Evidence Still Lacking That Vitamins Prevent CVD, Cancer: USPSTF https://www.medscape.com/viewarticle/975965
• Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: US Preventive Services Task Force Recommendation Statement https://jamanetwork.com/journals/jama/fullarticle/2793446
IV – Pre-Op Risk
Add Atrial Fibrillation to Pre-Noncardiac Surgery Risk Evaluation: New Support
https://www.medscape.com/viewarticle/975926
• Preoperative Atrial Fibrillation and Cardiovascular Outcomes After Noncardiac Surgery
https://doi.org/10.1016/j.jacc.2022.04.021
• Patterns and Determinants of Low-Value Preoperative Testing in Michigan
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2779744
• Coronary-Artery Revascularization before Elective Major Vascular Surgery
https://www.nejm.org/doi/full/10.1056/nejmoa041905
• Stress testing before abdominal aortic aneurysm repair does not lead to a reduction in perioperative cardiac events https://doi.org/10.1016/j.jvs.2021.02.032
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
Statin Intolerance, external validity of trials, contrast shortage, and expansion of cardiology into diabetes and nephrology are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I - Statin Intolerance
-
New National Lipid Association Statement on Statin Intolerance https://www.medscape.com/viewarticle/975674
-
What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. https://academic.oup.com/eurjpc/article/21/4/464/5926070
-
Unblinded and Blinded N-of-1 Trials Versus Usual Care: A Randomized Controlled Trial to Increase Statin Uptake in Primary Care. https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.120.007793
-
Role of Blinding in N-of-1 Trials https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.122.008914
-
N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects https://www.nejm.org/doi/full/10.1056/NEJMc2031173
II - External Validity
-
Is Paxlovid, the Covid Pill, Reaching Those Who Most Need It? The Government Won't Say https://www.medscape.com/viewarticle/973906
-
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2118542
-
PFE Press Release on EPIC SR https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting
III - Contrast Shortage
- Global Contrast Media Shortage Blamed on COVID Lockdown in China https://www.medscape.com/viewarticle/973810
IV - Cardiology Expands
-
Experts Elevate New Drugs for Diabetic Kidney Disease https://www.medscape.com/viewarticle/975724
-
SGLT2 Inhibitors Cut AFib Risk in Real-Word Analysis https://www.medscape.com/viewarticle/975542
-
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
-
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa2110956
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
More ISCHEMIA controversy, health Insurance and CV outcomes, testosterone, and flawed observational studies are the topics discussed by John Mandrola, MD in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – More Ischemia Controversy
-
Data Concerns Mount Despite ISCHEMIA Substudy Correction https://www.medscape.com/viewarticle/974974
-
ISCHEMIA Substudy Data Just Don't Add Up, Cardiac Surgeons Say https://www.medscape.com/viewarticle/974107
-
Initial Invasive or Conservative Strategy for Stable Coronary Disease https://www.nejm.org/doi/full/10.1056/nejmoa1915922
-
Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.049755
-
Link to Bakaeen and Sabik Second letter (agree to terms to download the letter): https://protect-us.mimecast.com/s/nfDdCwp5G6HLjLO9GHV9Cnm?domain=wetransfer.com
II – Health Insurance and CV outcomes
-
Medicaid Expansion: Good First Step, but No Panacea for CV Care https://www.medscape.com/viewarticle/975141
-
Health Care Access and Management of Cardiovascular Risk Factors Among Working-Age Adults With Low Income by State Medicaid Expansion Status https://jamanetwork.com/journals/jamacardiology/article-abstract/2793120
-
Rand Link https://www.rand.org/pubs/reports/R3055.html
-
The Oregon Health Insurance Experiment https://www.healthaffairs.org/do/10.1377/hpb20150716.236899/full/
-
Effect of Health Insurance in India: A Randomized Controlled Trial https://www.nber.org/papers/w29576
III – Testosterone
-
Jury Still Out on Cardiovascular Safety of Testosterone https://www.medscape.com/viewarticle/975273
-
Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis https://doi.org/10.1016/S2666-7568(22)00096-4
-
Adverse events associated with testosterone administration. https://www.nejm.org/doi/full/10.1056/NEJMoa1000485
IV – Voting and Mortality
-
Blue Counties Enjoy Dramatic Mortality Edge https://www.medscape.com/viewarticle/975217
-
Political environment and mortality rates in the United States, 2001-19: population based cross sectional analysis https://www.bmj.com/content/377/bmj-2021-069308
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Devices for HF, Twitter for disseminating science, HDL levels, and dubious post-hoc studies are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – Interatrial Shunts for HF
-
Interatrial Shunt in HF Hints at Heart Structural, Functional Benefits https://www.medscape.com/viewarticle/974776
-
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial https://doi.org/10.1016/S0140-6736(22)00016-2
-
Reducing Lung CongestIon Symptoms in Advanced Heart Failure (RELIEVE-HF) https://clinicaltrials.gov/ct2/show/NCT03499236
II – Twitter for Science Communication
-
Twitter Promotion Boosts Visibility, Citation for CV Research https://www.medscape.com/viewarticle/974653
-
Twitter promotion is associated with higher citation rates of cardiovascular articles: the ESC Journals Randomized Study https://doi.org/10.1093/eurheartj/ehac150
-
A Randomized Trial of Social Media From Circulation https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.114.013509
III – HDL Level
-
Very High HDL-C: Too Much of a Good Thing? https://www.medscape.com/viewarticle/974651
-
Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations https://jamanetwork.com/journals/jamacardiology/article-abstract/2792282
-
Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889017/
IV – Dubious Sub-Studies: Omecamtiv Mecarbil
-
Myosin Inhibitor May Benefit Data-Deprived Patients With Heart Failure and Low Blood Pressure https://www.medscape.com/viewarticle/974960
-
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2025797
-
METEORIC-HF: Omecamtiv Mecarbil Does Not Improve Exercise Capacity in HFrEF Patients https://www.acc.org/Latest-in-Cardiology/Articles/2022/04/02/13/22/Sun-945am-METEORIC-HF-acc-2022
-
Effects of Omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehac293/6590348
You might also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
Ischemia vs anatomic testing for CAD, UK-TAVI trial, TAVI for AR? and post-PCI anti-thrombotics are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – Ischemic vs Anatomic Evaluation for CAD
-
ISCHEMIA Substudy Data Just Don't Add Up, Cardiac Surgeons Say https://www.medscape.com/viewarticle/974107
-
Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.120.049755
-
Initial Invasive or Conservative Strategy for Stable Coronary Disease https://www.nejm.org/doi/full/10.1056/nejmoa1915922
-
Forget Ischemia: It’s All About the Plaque https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.054102
-
Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.107.743963
-
Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention https://doi.org/10.1016/j.ahj.2012.05.018
-
Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease https://www.nejm.org/doi/full/10.1056/nejmoa1415516
-
Coronary CT Angiography and 5-Year Risk of Myocardial Infarction https://www.nejm.org/doi/full/10.1056/NEJMoa1805971
-
Five Reasons I Don't Believe an Imaging Test Improves Outcomes https://www.medscape.com/viewarticle/901204
II – UK-TAVI Trial
-
UK TAVI: Similar Outcomes to Surgery in Real World https://www.medscape.com/viewarticle/927729
-
Effect of Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement on All-Cause Mortality in Patients With Aortic Stenosis https://jamanetwork.com/journals/jama/fullarticle/2792251
III – TAVI for AI?
- JenaValve Trilogy Takes Another Step Forward in Severe AR https://www.medscape.com/viewarticle/974304
IV – Post PCI DAPT
-
One-Month DAPT Enough for Complex PCI if Bleeding Risk High https://www.medscape.com/viewarticle/974224
-
Duration of Antiplatelet Therapy After Complex Percutaneous Coronary Intervention In Patients at High Bleeding Risk: a MASTER DAPT trial sub-analysis https://doi.org/10.1093/eurheartj/ehac284
-
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2108749
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
Obstructive hypertrophic cardiomyopathy and mavacamten, SGLT2 inhibitors, the triple whammy, espresso, and clinician burnout are the topics John Mandrola, MD, covers in today’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – Mavacamten
-
FDA Clears Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy https://www.medscape.com/viewarticle/972945
-
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial https://doi.org/10.1016/S0140-6736(20)31792-X
-
FDA approves new drug to improve heart function in adults with rare heart condition https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-improve-heart-function-adults-rare-heart-condition
II – Dapagliflozin in HFpEF
-
Positive Topline Results for Dapagliflozin in HFpEF: DELIVER https://www.medscape.com/viewarticle/973490
-
Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2107038
III – Triple Whammy for AKI
- Mixing BP Meds With NSAID May Be 'Triple Whammy' for Kidneys https://www.medscape.com/viewarticle/973885
IV – Espresso
-
Espresso Coffee Associated With Increased Total Cholesterol https://www.medscape.com/viewarticle/973819
-
Association between espresso coffee and serum total cholesterol: the Tromsø Study 2015–2016 https://openheart.bmj.com/content/9/1/e001946
-
Is everything we eat associated with cancer? A systematic cookbook review https://pubmed.ncbi.nlm.nih.gov/23193004/
-
Enough With the Coffee Research and Other Distractions https://www.medscape.com/viewarticle/883709
V – Clinician Burnout
- Administrative Hassle Hacks: Strategies to Curb Physician Stress https://www.medscape.com/viewarticle/973597
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
HRS meeting presentations: conduction system pacing, AF in the ED, a possible new treatment for vagal bradycardia, and women in EP are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I – HRS Comments
II – Conduction System Pacing
Conduction System Disease Recast as Preventive Therapy Target
https://www.medscape.com/viewarticle/973488
• Rescue Left Bundle Branch Area Pacing in Coronary Venous Lead Failure or Non-response to Biventricular Pacing: Results From International LBBAP Collaborative Study Group
https://doi.org/10.1016/j.hrthm.2022.04.024
• Clinical Outcomes Of Conduction System Pacing Compared To Biventricular Pacing In Patients Requiring Cardiac Resynchronization Therapy
https://doi.org/10.1016/j.hrthm.2022.04.023
III – Emergency Triage of AF
Early Arrhythmia-Specialist Consult, Ordered in the ER, a Boon to AF Outcomes: ER2EP Study
https://www.medscape.com/viewarticle/973250
• ClinicalTrials.gov Reference
https://clinicaltrials.gov/ct2/show/NCT04476524
• George Bernard Shaw Reference:
https://jamanetwork.com/journals/jama/fullarticle/2623628
IV – Cardioneural Ablation
Can Ablation Abolish Vasovagal Syncope? Early Series Promising
https://www.medscape.com/viewarticle/973346
V – Women in EP
Why Are Numbers of Women, Minorities So Low in Cardiac EP?
https://www.medscape.com/viewarticle/972968
• Temporal and geographical trends in women operators of electrophysiology procedures in the United States
https://doi.org/10.1016/j.hrthm.2022.02.015
• Quantification of Female and Underrepresented Minority Applicants to Clinical Cardiac Electrophysiology Fellowship
https://www.jacc.org/doi/full/10.1016/j.jacep.2022.04.001
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Aspirin for primary prevention, time-restricted feeding, renal denervation, and a potential new obesity drug are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – ASA for Primary Prevention:
-
USPSTF Final Recommendation on Aspirin for Primary CV Prevention https://www.medscape.com/viewarticle/972761
-
Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement https://jamanetwork.com/journals/jama/fullarticle/2791399
-
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly https://www.nejm.org/doi/10.1056/NEJMoa1805819
-
Effect of Aspirin on All-Cause Mortality in the Healthy Elderly https://www.nejm.org/doi/full/10.1056/NEJMoa1803955
II – Time Restricted Feeding
-
Is There a Benefit to Fasting Plus Calorie Counting? https://www.medscape.com/viewarticle/972579
-
Calorie Restriction with or without Time-Restricted Eating in Weight Loss https://www.nejm.org/doi/full/10.1056/NEJMoa2114833
-
Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity. The TREAT Randomized Clinical Trial https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771095
III – Renal Denervation
-
Renal Denervation BP Benefits Remain at 3 Years: SPYRAL HTN-ON https://www.medscape.com/viewarticle/971883
-
Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial https://doi.org/10.1016/S0140-6736(22)00455-X
IV – Tirzepatide for Obesity
-
Tirzepatide Excites in Obesity Now Too, Says Lilly https://www.medscape.com/viewarticle/972936
-
Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 https://www.prnewswire.com/news-releases/lillys-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-obesity-or-overweight-in-surmount-1--301534871.html
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Critiques of last week’s comments on VT ablation and a review of EHRA presentations, including new ways to ablate atrial myocardium and pace the ventricle, are discussed by John Mandrola, MD, in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – VT ablation
-
VT Ablation After First ICD Shock Boosts Survival: PARTITA https://www.medscape.com/viewarticle/971969
-
Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.122.059598
-
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia https://www.jacc.org/doi/10.1016/j.jacc.2022.01.050
-
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs https://www.nejm.org/doi/full/10.1056/NEJMoa1513614
II – Pulsed-Field Ablation
-
Pulsed Field Ablation Treats AF With Few Complications https://www.medscape.com/viewarticle/972147
-
Pulsed Field Ablation for Persistent Atrial Fibrillation (PersAFOne): Hope or Hype? https://www.jacc.org/doi/10.1016/j.jacc.2020.07.032
III – High-Power Short Duration Ablation
- Short, High-Power Ablation on Par With Standard AF Ablation https://www.medscape.com/viewarticle/972087
IV – LBB-Area Pacing
- MELOS: LBB Area Pacing Promising for Bradyarrhythmias, HF https://www.medscape.com/viewarticle/972270
Also of interest...
- Conduction System Pacing Noninferior to Biventricular Pacing for HF With Wide QRS https://www.medscape.com/viewarticle/971740
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
ACC Recap, Part 2: VT ablation, HF care, three-vessel disease, and patiromer are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I – VT ablation
VT Ablation After First ICD Shock Boosts Survival: PARTITA
https://www.medscape.com/viewarticle/971969
• Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.122.059598
• Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia https://www.jacc.org/doi/10.1016/j.jacc.2022.01.050
• Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs https://www.nejm.org/doi/full/10.1056/NEJMoa1513614
II – HF Care
Alerts Improve Prescribing of HF Quadruple Therapy: PROMPT-HF https://www.medscape.com/viewarticle/972079
• Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial https://www.jacc.org/doi/10.1016/j.jacc.2022.03.338
• Reassessing Quality Assessment — The Flawed System for Fixing a Flawed System https://www.nejm.org/doi/full/10.1056/NEJMms2200976
III – Three-Vessel Disease
FAME 3 Subanalysis Adds Twist to Negative Primary Results
https://www.medscape.com/viewarticle/971495
• Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery https://www.nejm.org/doi/10.1056/NEJMoa2112299
• Quality of Life After Fractional Flow Reserve-Guided PCI Compared with Coronary Bypass Surgery https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.122.060049
IV – Treating Drug Side Effects with More Drugs
DIAMOND: Adding Patiromer Helps Optimize HF Meds, Foils Hyperkalemia https://www.medscape.com/viewarticle/971616
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
ACC Recap: John Mandrola, MD, provides part 1 of an ACC recap in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – HTN in Pregnancy
-
Hypertension Control During Pregnancy Validated in Large Trial https://www.medscape.com/viewarticle/971486
-
Treatment for Mild Chronic Hypertension during Pregnancy https://www.nejm.org/doi/full/10.1056/NEJMoa2201295
II – Prevention of Bleeding in Non-Cardiac Surgery
-
POISE-3 Backs Wider Use of Tranexamic Acid in Noncardiac Surgery https://www.medscape.com/viewarticle/971483
-
Tranexamic Acid in Patients Undergoing Noncardiac Surgery https://www.nejm.org/doi/full/10.1056/NEJMoa2201171
III – HCM
- VALOR-HCM: Novel Drug May Delay, Avert Invasive Therapy in OHCM https://www.medscape.com/viewarticle/971484
IV – Left Atrial Appendage Occlusion
- Small Leaks After LAAO Linked to Thromboembolism, Bleeding https://www.medscape.com/viewarticle/971709
V – Low Sodium Diet for HF
-
Low-Sodium Diet Did Not Cut Clinical Events in Heart Failure Trial https://www.medscape.com/viewarticle/971482
-
Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial https://doi.org/10.1016/S0140-6736(22)00369-5
VI – Flu Vaccine and Heart Failure
- Flu Vaccines Cut Seasonal Death in Patients With Heart Failure https://www.medscape.com/viewarticle/971619
VII – New Anticoagulant?
- Less Bleeding With Factor XI Inhibitor Anticoagulant? PACIFIC-AF https://www.medscape.com/viewarticle/971702
Features:
-
Sodium Restriction in Heart Failure: Another Dogma Felled by Randomization https://www.medscape.com/viewarticle/971697
-
Percutaneous Left Atrial Appendage Occlusion: ACC Data Challenge Promise vs Reality https://www.medscape.com/viewarticle/971512
-
Mavacamten in Hypertrophic Cardiomyopathy: Reasons for Both Optimism and Caution https://www.medscape.com/viewarticle/971485
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
Coronary CTA, semaglutide, coronary artery calcium, exercise, and an ACC and EHRA preview are the topics discussed by John Mandrola, MD, in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – Coronary CTA Feedback
- Coronary Computed Tomography Angiography vs Functional Stress Testing for Patients With Suspected Coronary Artery Disease https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2655243
II – Semaglutide
-
FDA Okays Semaglutide Higher Dose, 2 mg/Week, for Type 2 Diabetes https://www.medscape.com/viewarticle/971156
-
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial https://doi.org/10.1016/S2213-8587(21)00174-1
-
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
-
Once-Weekly Semaglutide in Adults with Overweight or Obesity https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
III – CAC and SCD
-
Calcium Scores Predict Sudden-Death Risk in Preclinical CAD in Large Cohort Study https://www.medscape.com/viewarticle/971056
-
Coronary Artery Calcium for Risk Stratification of Sudden Cardiac Death: The Coronary Artery Calcium Consortium https://www.jacc.org/doi/10.1016/j.jcmg.2022.02.011
IV – Exercise and COVID-19
-
More Exercise Linked to Lower Chance of Severe COVID-19: Study https://www.medscape.com/viewarticle/949468
-
Small steps, strong shield: directly measured, moderate physical activity in 65 361 adults is associated with significant protective effects from severe COVID-19 outcomes http://dx.doi.org/10.1136/bjsports-2021-105159
V – ACC Preview
-
Hybrid ACC.22 Resurrects the Live Scientific Session https://www.medscape.com/viewarticle/971083
-
Mandrola Previews the 2022 American College of Cardiology Scientific Sessions https://www.medscape.com/viewarticle/971084
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
AF ablation vs rate control in HF, TAVI vs SAVR, atherosclerosis, and surrogate endpoints in observational studies are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I – AF ablation vs Rate Control
RAFT-AF, Despite Itself, Hints at Advantage for Ablation Rhythm Control in Heart Failure With AF https://www.medscape.com/viewarticle/951326
• Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients with Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.121.057095
• Catheter Ablation for Atrial Fibrillation with Heart Failure
https://www.nejm.org/doi/full/10.1056/nejmoa1707855
• Lenient versus Strict Rate Control in Patients with Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/nejmoa1001337
II – TAVI vs SAVR
Surgery Groups Push Back on VARC-3 Valve Trial Definitions https://www.medscape.com/viewarticle/970753
• Joint Surgical Associations (EACTS, LACES, ASCVTS, AATS, and STS) Position Statement Regarding the VARC-3 Definitions for Aortic Valve Clinical Researchhttps://doi.org/10.1093/ejcts/ezac110
III – Atherosclerosis
Medical Management Best for Atherosclerotic Stroke: New AAN Guidance
https://www.medscape.com/viewarticle/970886
• Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory https://n.neurology.org/content/98/12/486
IV – ECHO parameters with Rhythm Control
Global Gains in Heart Function From Early AF Rhythm Control
https://www.medscape.com/viewarticle/970329
• Restoring Sinus Rhythm Reverses Cardiac Remodeling and Reduces Valvular Regurgitation in Patients With Atrial Fibrillation https://doi.org/10.1016/j.jacc.2021.12.029
• Effects of Atrial Fibrillation and Sinus Rhythm on Cardiac Remodeling and Valvular Regurgitation https://doi.org/10.1016/j.jacc.2021.12.028
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
AF screening, CTA, stroke prevention and broken observational studies, and medical writing are the topics John Mandrola, MD discusses in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - AF Screening
-
Handheld ECGs Ease A-Fib Screening in the Very Elderly https://www.medscape.com/viewarticle/969846
-
Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: the VITAL-AF Randomized Controlled Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057014
II - CTA
-
DISCHARGE: CTA Shows Safety Edge vs Cath in Intermediate-Risk Stable Chest Pain https://www.medscape.com/viewarticle/969732
-
CT or Invasive Coronary Angiography in Stable Chest Pain https://www.nejm.org/doi/full/10.1056/NEJMoa2200963
III - Stroke Prevention post TAVI
-
Silver Lining Emerges for Embolic Protection in Post-TAVR Stroke https://www.medscape.com/viewarticle/969992
-
Cerebral Embolic Protection and Stroke-Related Mortality Following Transcatheter Aortic Valve Replacement https://www.jacc.org/doi/full/10.1016/j.jcin.2022.01.007
-
Safety and efficacy of cerebral protection devices in transcatheter aortic valve replacement: A clinical end-points meta-analysis https://pubmed.ncbi.nlm.nih.gov/29550047/
-
Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results From the Transcatheter Valve Therapy Registry https://pubmed.ncbi.nlm.nih.gov/33619968/
IV - Medical Writing
- Writing Program Asks Physicians to Explore Their Experiences https://www.medscape.com/viewarticle/969973
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
An update to CardioMEMs post, ARBs and cancer, troponins, empagliflozin, and low-value care are the topics discussed by John Mandrola, MD, in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – Invasive Monitoring for HF
-
FDA Expands Eligibility for CardioMEMS Heart Failure System https://www.medscape.com/viewarticle/969004
-
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01754-2
II – ARBs and Cancer
-
ARBs and Cancer Risk: New Meta-Analysis Raises Questions Again https://www.medscape.com/viewarticle/969510
-
Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials https://doi.org/10.1371/journal.pone.0263461
-
Marciniak Meta-analysis in FDA Medical Review 206316Orig1Orig2s000 https://rb.gy/myhlvy
III – Troponins and Cardiac Surgery
-
What Troponin Level Indicates Injury After Cardiac Surgery? https://www.medscape.com/viewarticle/969617?src=
-
High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality https://www.nejm.org/doi/full/10.1056/NEJMoa2000803
-
Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease https://www.nejm.org/doi/full/10.1056/nejmoa1909406
IV – Empagliflozin in HFpEF
-
FDA Okays Empagliflozin for HF Regardless of Ejection Fraction https://www.medscape.com/viewarticle/969118
-
Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2107038
-
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
V – Low-Value Care
-
AHA Targets 'Low-Value' Heart Care in New Scientific Statement https://www.medscape.com/viewarticle/969107
-
Strategies to Reduce Low-Value Cardiovascular Care: A Scientific Statement From the American Heart Association https://www.ahajournals.org/doi/abs/10.1161/HCQ.0000000000000105
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
FDA approval of CardioMEMS, statins, VT storm, and fish oil and AF are the topics covered by John Mandrola, MD, in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - Invasive Monitoring for HF
-
FDA Expands Eligibility for CardioMEMS Heart Failure System https://www.medscape.com/viewarticle/969004
-
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01754-2
-
Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial https://doi.org/10.1016/S0140-6736(11)60101-3
II - Statin Use in Primary Prevention
-
USPSTF Tweaks Primary Prevention Statin Recommendations in New Draft Guidance https://www.medscape.com/viewarticle/968963
-
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication https://www.uspreventiveservicestaskforce.org/uspstf/document/draft-evidence-review/statin-use-primary-prevention-cardiovascular-disease-adults
-
The Case Against Coronary Artery Calcium Scoring for Cardiovascular Disease Risk Assessment https://www.aafp.org/afp/2019/1215/p734.html
III - VT-Storm
-
Transcutaneous Magnetic Stimulation Promising Against VT Storm https://www.medscape.com/viewarticle/968955
-
Effect of Transcutaneous Magnetic Stimulation in Patients With Ventricular Tachycardia Storm https://jamanetwork.com/journals/jamacardiology/fullarticle/2788915
IV - Fish Oil and AF risk
- Fish Oil Supplements May Increase the Risk for Atrial Fibrillation: What Does This Mean? https://www.medscape.com/viewarticle/967159
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Spinal cord stimulation to prevent post-cardiac surgery AF, statin intolerance, heart failure with preserved ejection fraction, and Vitamin D are discussed by John Mandrola, MD, in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com//twic
I Post-Cardiac Surgery AF
Spinal Cord Stimulation May Cut AF After Cardiac Surgery
https://www.medscape.com/viewarticle/968478
• Autonomic Neuromodulation for Atrial Fibrillation Following Cardiac Surgery: JACC Review Topic of the Week https://www.jacc.org/doi/10.1016/j.jacc.2021.12.010
• Temporary Spinal Cord Stimulation to Prevent Postcardiac Surgery Atrial Fibrillation: 30-Day Safety and Efficacy Outcomes https://www.jacc.org/doi/10.1016/j.jacc.2021.08.078
II – Statin Intolerance
Statin Intolerance 'Overestimated and Overdiagnosed' https://www.medscape.com/viewarticle/968627
• Prevalence of statin intolerance: a meta-analysis https://doi.org/10.1093/eurheartj/ehac015
III – HFpEF
Risk in Preserved-EF HF Varies With Normal vs High Natriuretic Peptides https://www.medscape.com/viewarticle/968748
• Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality https://doi.org/10.1093/eurheartj/ehab911
• Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association https://pubmed.ncbi.nlm.nih.gov/33605000/
Features:
Why Is Vitamin D Hype So Impervious to Evidence? https://www.medscape.com/viewarticle/968682
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact: news@medscape.net
LDL equations, stroke interventions, post-PCI antiplatelets, the transitive function and network meta-analysis, and lipoprotein(a) are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - LDL-C Equations:
-
Standard LDL Equations Yield Discordant Results https://www.medscape.com/viewarticle/968112
-
Discordance Between Standard Equations for Determination of LDL Cholesterol in Patients With Atherosclerosis https://www.jacc.org/doi/10.1016/j.jacc.2021.11.042
-
LDL-C Estimation: The Perils of Living With Imperfection https://www.jacc.org/doi/10.1016/j.jacc.2021.12.005
II - Acute Stroke Care
-
Endovascular Therapy Benefits Stroke With Larger Ischemic Core? https://www.medscape.com/viewarticle/968203
-
Endovascular Therapy for Acute Stroke with a Large Ischemic Region https://www.nejm.org/doi/full/10.1056/NEJMoa2118191
III - Post PCI Antiplatelet Regimens
-
Study Parses Out Merits of Short DAPT, De-escalation in ACS https://www.medscape.com/viewarticle/968050
-
Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes https://www.jacc.org/doi/10.1016/j.jcin.2021.11.028
IV - Lipoprotein (a)
- Positive Topline Results for siRNA in Raised Lipoprotein(a) https://www.medscape.com/viewarticle/968278
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Interatrial shunt therapy, the power of the RCT, chronic stress, anxiety and cardiometabolic risk, and TAVR, are the topics covered by John Mandrola, MD, in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - Interatrial Shunt
-
Interatrial Shunt Falters in Preserved, Mid-Range LVEF Heart Failure: REDUCE LAP-HF 2 https://www.medscape.com/viewarticle/967792
-
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial https://doi.org/10.1016/S0140-6736(22)00016-2
II - Chronic Stress
-
Chronic Stress Accelerates Aging: Epigenetic Evidence https://www.medscape.com/viewarticle/967828
-
Psychological and biological resilience modulates the effects of stress on epigenetic aging https://www.nature.com/articles/s41398-021-01735-7
-
DNA methylation GrimAge strongly predicts lifespan and healthspan https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366976/
III – Anxiety, Neuroticism, and CardioMetabolic Risk Factors
-
Anxiety in Men Tied to Risk Factors for CVD, Diabetes https://www.medscape.com/viewarticle/967811
-
Neuroticism, Worry, and Cardiometabolic Risk Trajectories: Findings From a 40‐Year Study of Men https://www.ahajournals.org/doi/full/10.1161/JAHA.121.022006
IV - TAVR Implant Success
-
VARC-3 TAVR Technical Failure Definition 'Highly Clinically Relevant https://www.medscape.com/viewarticle/967717
-
Validation of the Valve Academic Research Consortium 3 Technical Success Definition in Patients Undergoing TAVR https://www.jacc.org/doi/full/10.1016/j.jcin.2021.11.013
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
AF Screening, alcohol, sports-related sudden death, non-MD-led healthcare, and CPR are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - AF Screening
-
USPSTF Says Evidence Still Lacking for AF Screening in Asymptomatic Patients https://www.medscape.com/viewarticle/967275
-
Screening for Atrial Fibrillation US Preventive Services Task Force Recommendation Statement https://jamanetwork.com/journals/jama/fullarticle/2788340
-
Screening for Atrial Fibrillation—New Devices, Same Challenges https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2788475
-
Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01698-6
II - Vaccine Induced Myocarditis
- Hong Kong, US, Israeli Data Illuminate COVID Vaccine Myocarditis https://www.medscape.com/viewarticle/967355
III - Alcohol and Heart
- No Amount of Alcohol Safe for the Heart: WHF https://www.medscape.com/viewarticle/967124
IV - Sports Related Sudden Cardiac Arrest
-
Survival Improving in Sports-Related Sudden Cardiac Arrest https://www.medscape.com/viewarticle/967061
-
Evolution of Incidence, Management, and Outcomes Over Time in Sports-Related Sudden Cardiac Arrest https://www.jacc.org/doi/full/10.1016/j.jacc.2021.11.011
V - Non MD vs MD-led Care
- This Doc Still Supports NP/PA Led Care ... With Caveats https://www.medscape.com/viewarticle/967073
VI - CPR
- Should We Always Offer CPR? https://www.medscape.com/viewarticle/966886
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Olive oil, breastfeeding and CV health, informed consent during stroke, and controversy regarding revascularization guidelines are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – Olive Oil
-
Olive Oil Intake Tied to Reduced Mortality https://www.medscape.com/viewarticle/966366
-
Consumption of Olive Oil and Risk of Total and Cause-Specific Mortality Among U.S. Adults https://www.jacc.org/doi/full/10.1016/j.jacc.2021.10.041
-
Can Small Amounts of Olive Oil Keep the Death Away? https://www.jacc.org/doi/10.1016/j.jacc.2021.11.006
II – Breastfeeding and CV Maternal Health
-
Breastfeeding Linked to Lower CVD Risk in Later Life https://www.medscape.com/viewarticle/966767
-
Breastfeeding Is Associated With a Reduced Maternal Cardiovascular Risk: Systematic Review and Meta‐Analysis Involving Data From 8 Studies and 1 192 700 Parous Women https://www.ahajournals.org/doi/10.1161/JAHA.121.022746
-
Meta-analysis: pitfalls and hints https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868184/
III – Informed Consent
-
New Guidance on Consent in Acute Ischemic Stroke https://www.medscape.com/viewarticle/966889
-
Consent Issues in the Management of Acute Ischemic Stroke https://n.neurology.org/content/98/2/73
-
The Case Against Thrombolytic Therapy in Stroke https://www.medscape.com/viewarticle/895159
-
tPA in Stroke: 'The Facts Are Clear' https://www.medscape.com/viewarticle/895370
IV – Controversy in Revascularization Guidelines
-
'Incomprehensible' CABG Recommendation Raises Concerns https://www.medscape.com/viewarticle/966819
-
Surgical Groups Push Back Against New Revascularization Guidelines https://www.medscape.com/viewarticle/966153
-
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration https://doi.org/10.1016/S0140-6736(94)91963-1
-
Ten-Year Follow-Up Survival of the Medicine, Angioplasty, or Surgery Study (MASS II) https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.109.911669
-
What constitutes an appropriate empirical trial of antianginal therapy in patients with stable angina before referral for revascularisation? https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02045-6/fulltext
-
Initial Invasive or Conservative Strategy for Stable Coronary Disease https://www.nejm.org/doi/full/10.1056/nejmoa1915922
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Xeno-transplantation, weight loss drugs, DOAC coverage, vitamin D, LAAC and frailty, and recalled LVADs are the topics John Mandrola, MD, discusses in this week’s podcast. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – Xenotransplantation
-
Pig Heart Successfully Transplanted to Man https://www.medscape.com/viewarticle/966367
-
What Does a Pig-to-Human Heart Transplant Mean for Medicine? https://www.medscape.com/viewarticle/966488
II – Weight Loss Drugs
-
Wegovy Tops Sibling Saxenda for Weight Loss https://www.medscape.com/viewarticle/966376
-
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes https://jamanetwork.com/journals/jama/article-abstract/2787907
III – DOAC Coverage
- CVS Caremark Formulary Change Freezes Out Apixaban https://www.medscape.com/viewarticle/966588
IV – Vitamin D
-
More Vitamin D Not Better for Reducing Cancer or CVD Incidence https://www.medscape.com/viewarticle/966333
-
The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality https://doi.org/10.1016/S2213-8587(21)00345-4
-
Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial—a randomized controlled trial https://doi.org/10.1093/ajcn/nqab419
-
Association between vitamin D supplementation and mortality: systematic review and meta-analysis https://www.bmj.com/content/366/bmj.l4673
V – LAAC and Frailty
-
Frailty in patients undergoing percutaneous left atrial appendage closure https://doi.org/10.1016/j.hrthm.2022.01.007
-
Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies https://pubmed.ncbi.nlm.nih.gov/31752643/
VI – LVAD recall
- A High-Risk Medical Device Didn't Meet Federal Standards. The Government Paid Millions for More. https://www.medscape.com/viewarticle/966255
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
This podcast is intended for US health professionals only.
Causes of sudden death, inclisiran, DOAC choices, and alcohol and VT/VF are the topics discussed by John Mandrola, MD, in this week’s podcast.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – Causes of Sudden Death
-
Cardiac Device Interrogation After Death 'Richly Informative' https://www.medscape.com/viewarticle/965730
-
Postmortem Interrogation of Cardiac Implantable Electronic Devices: A 15-Year Experience https://www.jacc.org/doi/full/10.1016/j.jacep.2021.10.011
-
Sudden Death in Patients With Cardiac Implantable Electronic Devices https://pubmed.ncbi.nlm.nih.gov/26098676/
-
Cardiac Implantable Electronic Device Interrogation at Forensic Autopsy https://www.ahajournals.org/doi/full/10.1161/circulationaha.117.032367
II – Inclisiran
-
FDA Approves First-in-Class Inclisiran to Lower LDL-C https://www.medscape.com/viewarticle/965464
-
ORION: Inclisiran Phase 3 Trials Published https://www.medscape.com/viewarticle/927107
-
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia https://pubmed.ncbi.nlm.nih.gov/32892993/
-
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease https://www.nejm.org/doi/full/10.1056/nejmoa1615664
-
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome https://www.nejm.org/doi/10.1056/NEJMoa1801174
III – DOAC Choice
-
Apixaban: The 'Anticoagulant of Choice' for AF https://www.medscape.com/viewarticle/965390
-
Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation https://jamanetwork.com/journals/jama/fullarticle/2787319
IV – Alcohol and VT/VF and SCD
-
Some Good News on Alcohol and 'Holiday Heart Syndrome' https://www.medscape.com/viewarticle/965498
-
Alcohol consumption and risk of ventricular arrhythmias and sudden cardiac death: An observational study of 408,712 individuals https://www.heartrhythmjournal.com/article/S1547-5271(21)02215-3/fulltext
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
PFO closure, trans-mitral procedures, yoga as therapy, and a year-end-review are the topics John Mandrola, MD, covers in this week’s podcast. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – PFO Closure
-
Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke https://jamanetwork.com/journals/jama/fullarticle/2787115
-
Patent Foramen Ovale Closure—Harnessing Clinical Trial Evidence to Inform Individualized Treatment Decisions https://jamanetwork.com/journals/jama/fullarticle/2787132
-
Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects https://pubmed.ncbi.nlm.nih.gov/30530757/
-
Lord’s Paradox by Stephen Senn https://www.linkedin.com/pulse/cause-concern-stephen-senn/
II – Trans-Mitral Procedures
-
Transcatheter Mitral Valve Procedures Up Tenfold Since 2014 https://www.medscape.com/viewarticle/964657
-
Transcatheter Mitral Valve Therapy in the United States: A Report From the STS-ACC TVT Registry https://www.jacc.org/doi/full/10.1016/j.jacc.2021.07.058
-
Percutaneous Repair or Surgery for Mitral Regurgitation https://www.nejm.org/doi/full/10.1056/nejmoa1009355
-
Transcatheter Mitral-Valve Repair in Patients with Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa1806640
-
Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation https://www.nejm.org/doi/full/10.1056/NEJMoa1805374
III – Yoga for Vasovagal Syncope
-
Yoga Effective Adjunct Therapy in Recurrent Vasovagal Syncope https://www.medscape.com/viewarticle/964644
-
Effect of Yoga on Clinical Outcomes and Quality of Life in Patients With Vasovagal Syncope (LIVE-Yoga) https://www.jacc.org/doi/full/10.1016/j.jacep.2021.09.007
-
Effect of Yoga on Arrhythmia Burden, Anxiety, Depression, and Quality of Life in Paroxysmal Atrial Fibrillation: The YOGA My Heart Study https://www.jacc.org/doi/full/10.1016/j.jacc.2012.11.060
-
Effects of yoga in patients with paroxysmal atrial fibrillation - a randomized controlled study https://pubmed.ncbi.nlm.nih.gov/26976659/
IV – Top Ten of 2021
-
Mandrola's Top 10 Cardiology Stories of 2021 https://www.medscape.com/viewarticle/964818
-
Top Cardiology Trials of 2021 https://www.medscape.com/viewarticle/963475
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
AF triggers, rising BP during the pandemic, long COVID, cardiac arrest care, and social media are the topics John Mandrola, MD discusses in this week’s podcast. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – AF Triggers
-
Alcoholic Drinks Stand Out in Novel Trial Exploring AF Triggers https://www.medscape.com/viewarticle/962911
-
Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation https://jamanetwork.com/journals/jamacardiology/article-abstract/2786196
II – BP Increase During the Pandemic
-
Blood Pressure Control Worsened During COVID Pandemic https://www.medscape.com/viewarticle/964329
-
Rise in Blood Pressure Observed Among US Adults During the COVID-19 Pandemic https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057075
III – DOAC after VTE
-
Apixaban Outmatches Rivaroxaban for VTE in Study https://www.medscape.com/viewarticle/964301
-
Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data https://www.acpjournals.org/doi/full/10.7326/M21-0717
-
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes https://www.nejm.org/doi/full/10.1056/NEJMoa1908973
IV – Long Covid
-
In Long COVID, CPET Finds Abnormalities Other Tests Don't https://www.medscape.com/viewarticle/964250
-
Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post–Coronavirus Disease https://doi.org/10.1016/j.jchf.2021.10.002
V – Cardiac Arrest Care
-
Calcium Does Not Benefit Patients in Cardiac Arrest https://www.medscape.com/viewarticle/964059
-
Effect of Intravenous or Intraosseous Calcium vs Saline on Return of Spontaneous Circulation in Adults With Out-of-Hospital Cardiac Arrest https://jamanetwork.com/journals/jama/fullarticle/2786819
VI – Social Media
- Online Reviews Most Important Factor in Choosing a Doctor: Survey https://www.medscape.com/viewarticle/964264
Features:
- Booze Out, Coffee Okay to Outsmart Atrial Fibrillation? https://www.medscape.com/viewarticle/961993
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The AMAZE trial of left atrial appendage isolation, non-statin oral lipid lowering drugs, EHR alerts, non-MD care, and obesity are the topics John Mandrola, MD, discusses in this week’s podcast. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I – aMAZE Trial
-
No Advantage Shown for LAA Ligation as Adjunct to Pulmonary Vein Isolation https://www.medscape.com/viewarticle/962954
-
Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2289126
-
Left Atrial Appendage Isolation in Patients With Longstanding Persistent AF Undergoing Catheter Ablation: BELIEF Trial https://pubmed.ncbi.nl m.nih.gov/27788847/
II – Non-Statin Lipid Lowering
-
Obicetrapib: CETP Inhibitor Impresses in LDL Lowering https://www.medscape.com/viewarticle/963611
-
Daily Oral PCSK9 Inhibitor Encouraging in Phase 1 Trials https://www.medscape.com/viewarticle/963550
III – EHR Alerts and Prognosis
-
EHR Alerts Have No Impact on Inpatient HF Treatment or Outcomes https://www.medscape.com/viewarticle/963002
-
REVeAL-HF: Design and Rationale of a Pragmatic Randomized Controlled Trial Embedded Within Routine Clinical Practice https://www.jacc.org/doi/full/10.1016/j.jchf.2021.03.006
IV – Non-MD Care Models
-
Remote Non-Physician Care Helps BP, LDL Control https://www.medscape.com/viewarticle/963783
-
A Remotely Delivered Hypertension and Lipid Program in 10,000 Patients Across a Diverse Health Care Network https://www.abstractsonline.com/pp8/?_ga=2.141042993.2042594723.1635046736-1021258137.1633710264#!/9349/presentation/18153
V – Obesity in the Young
-
Obesity Rates Soar in Early Adulthood in the US https://www.medscape.com/viewarticle/963511
-
Trends in Obesity Prevalence Among Adults Aged 18 Through 25 Years, 1976-2018 https://jamanetwork.com/journals/jama/article-abstract/2786516
Features
- Doubting the BELIEF Trial on LAA Isolation https://www.medscape.com/viewarticle/850822
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
In AHA 2021 Part 1, John Mandrola, MD, reports on selected sessions from the virtual American Heart Association meeting.
To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - AVATAR
-
Early SAVR Tops Watchful Waiting in Severe, Asymptomatic Aortic Stenosis: AVATAR https://www.medscape.com/viewarticle/962904
-
Aortic Valve ReplAcemenT versus Conservative Treatment in Asymptomatic SeveRe Aortic Stenosis: The AVATAR Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057639
-
Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis https://www.nejm.org/doi/full/10.1056/NEJMoa1912846
II - TCV Repair
-
Concomitant Tricuspid-Mitral Surgery Beneficial but With a Tradeoff https://www.medscape.com/viewarticle/962899
-
Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation https://www.nejm.org/doi/full/10.1056/NEJMoa2115961
III - PALACS
-
Procedure Reduces Postop AF After Cardiac Surgery: PALACS https://www.medscape.com/viewarticle/962907
-
Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial https://doi.org/10.1016/S0140-6736(21)02490-9
IV - Left Main CAD
-
Left-Main PCI, CABG Mortality Similar; Choice Remains Complex https://www.medscape.com/viewarticle/963198
-
Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis https://doi.org/10.1016/S0140-6736(21)02334-5
Features:
-
Questions Remain on Tricuspid Repair at Time of Mitral Surgery https://www.medscape.com/viewarticle/962902
-
Despite Positive Trials, Early Surgery in Asymptomatic AS Should Wait https://www.medscape.com/viewarticle/962926
-
Can New Meta-analysis of PCI vs CABG for Left Main CAD Settle the Debate? https://www.medscape.com/viewarticle/963295
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Left atrial appendage closure vs DOACs, TAVR vs SAVR, renal denervation, and an AHA 2021 preview are the topics John Mandrola, MD, discusses in this week’s podcast. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - LAAC
-
PRAGUE-17: LAA Closure Holds Up Against DOACs Out to 4 Years https://www.medscape.com/viewarticle/962608
-
LAAO vs DOAC: PRAGUE-17 Falls Short https://www.medscape.com/viewarticle/933641
-
Left Atrial Appendage Closure versus Non-Warfarin Oral Anticoagulation in Atrial Fibrillation: 4-Year Outcomes of PRAGUE-17 https://www.jacc.org/doi/10.1016/j.jacc.2021.10.023
-
Does Percutaneous Left Atrial Appendage Closure Stand the Test of Time? https://www.jacc.org/doi/10.1016/j.jacc.2021.10.022
II - SURTAVI (TAVR vs SAVR)
-
SURTAVI at 5 Years Reinforces TAVR but Was It Long-term Enough? https://www.medscape.com/viewarticle/962484
-
Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients https://www.nejm.org/doi/full/10.1056/NEJMoa1700456
III - Renal Denervation
-
Renal Denervation Adds Clout to BP Meds in Resistant HTN: RADIANCE-HTN TRIO https://www.medscape.com/viewarticle/962508
-
Renal Denervation Remains Only Promising in Meta-Analysis https://www.medscape.com/viewarticle/962369
-
Renal Denervation for Hypertension: A Systematic Review and Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials https://doi.org/10.1016/j.jcin.2021.09.020
IV - AHA Preview
-
AHA 2021 Puts Scientific Dialogue, Health Equity Center Stage https://www.medscape.com/viewarticle/962524
-
Mandrola Previews the Virtual AHA 2021 https://www.medscape.com/viewarticle/962468
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
FFR-guided PCI, ISCHEMIA trial challenged, QFR, and one of the most important studies of 2021 are discussed by John Mandrola, MD, in this week’s podcast. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - FFR-Guided PCI
-
FFR-Guided PCI Falls Short vs CABG in Multivessel CAD: FAME 3 https://www.medscape.com/viewarticle/962274
-
Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery https://www.nejm.org/doi/full/10.1056/NEJMoa2112299
-
The fallacies of fractional flow reserve https://pubmed.ncbi.nlm.nih.gov/31889563/
II - ISCHEMIA-Trial Challenged
-
How Applicable is ISCHEMIA Trial to US Clinical Practice? https://www.medscape.com/viewarticle/962233
-
Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population https://www.jacc.org/doi/full/10.1016/j.jcin.2021.08.047
-
The Glass Is at Least Half Full https://www.jacc.org/doi/10.1016/j.jcin.2021.08.054
-
Initial Invasive or Conservative Strategy for Stable Coronary Disease https://www.nejm.org/doi/full/10.1056/nejmoa1915922
III - QFR
-
FAVOR III China: QFR-Guided PCI Shows Advantage Over Angiography https://www.medscape.com/viewarticle/962328
-
Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial https://doi.org/10.1016/S0140-6736(21)02248-0
Features:
-
The MI–Mortality Mismatch: When Lowering MI Doesn't Extend Life https://www.medscape.com/viewarticle/962276
-
Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2785560
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
ESUS, CAC 0, Takotsubo syndrome, and chest pain are the topics John Mandrola, MD, covers in today’s podcast. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I – ESUS
Anticoagulation May Benefit Stroke Patients With LV Dysfunction https://www.medscape.com/viewarticle/961815
- Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs AspirinA Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial
https://jamanetwork.com/journals/jamaneurology/article-abstract/2785030
- Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
https://www.nejm.org/doi/10.1056/NEJMoa1802686
- Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
https://www.nejm.org/doi/10.1056/NEJMoa1813959
II – CAC
CAC Score 0 Unreliable to Rule Out Stenosis in Younger Patients https://www.medscape.com/viewarticle/961801
-
Association of Age With the Diagnostic Value of Coronary Artery Calcium Score for Ruling Out Coronary Stenosis in Symptomatic Patients https://jamanetwork.com/journals/jamacardiology/fullarticle/2785586
-
The Case Against Coronary Artery Calcium Scoring for Cardiovascular Disease Risk Assessment
https://www.aafp.org/afp/2019/1215/p734.html
III – Takotsubo Cardiomyopathy
Broken Heart Syndrome: On the Rise, Especially in Women 50-74
https://www.medscape.com/viewarticle/961307
- Sex‐ and Age‐Based Temporal Trends in Takotsubo Syndrome Incidence in the United States
https://www.ahajournals.org/doi/10.1161/JAHA.120.019583
IV- Chest Pain Guidelines
AHA/ACC Issues First Comprehensive Guidance on Chest Pain
https://www.medscape.com/viewarticle/961806
- 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines https://www.jacc.org/doi/10.1016/j.jacc.2021.07.052
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Aspirin for primary prevention, induced hypothermia, half-dose DOAC, and social media, are the topics John Mandrola, MD, discusses in this week’s podcast. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - ASA for Primary Prevention
-
USPSTF Rules Out Aspirin for Over 60s in Primary CVD Prevention https://www.medscape.com/viewarticle/960745
-
Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication https://www.uspreventiveservicestaskforce.org/uspstf/document/draft-evidence-review/aspirin-use-to-prevent-cardiovascular-disease-preventive-medication
-
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31924-X/fulltext
-
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus https://www.nejm.org/doi/full/10.1056/nejmoa1804988
-
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly https://www.nejm.org/doi/full/10.1056/NEJMoa1805819
-
Effect of Aspirin on All-Cause Mortality in the Healthy Elderly https://www.nejm.org/doi/full/10.1056/nejmoa1803955
II - Induced Hypothermia
-
No Benefit From Lower Temps for Out-of-Hospital Cardiac Arrest https://www.medscape.com/viewarticle/961191
-
The CAPITAL CHILL Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2785263
-
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest https://www.nejm.org/doi/10.1056/NEJMoa1310519
-
Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest https://www.nejm.org/doi/full/10.1056/NEJMoa2100591
III - Half-dose DOAC
-
Half-Dose DOACs Cut Bleeding, Thrombus Risk Post-Watchman LAA Closure https://www.medscape.com/viewarticle/960974
-
Half-Dose Direct Oral Anticoagulation Versus Standard Antithrombotic Therapy After Left Atrial Appendage Occlusion https://www.jacc.org/doi/full/10.1016/j.jcin.2021.07.031
IV - Social Media
-
Navigating Benefits, Pitfalls of Social Media as a Female Doctor https://www.medscape.com/viewarticle/961150
-
Gender Differences in Physician Use of Social Media for Professional Advancement https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779868
Features:
- USPSTF Statement on Aspirin: Poor Messaging at Best https://www.medscape.com/viewarticle/961118
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Two NEJM papers on mRNA-related myocarditis, AF and stroke, intensifying BP meds, and CCTA and high-sensitivity troponin are the topics John Mandrola, MD, covers in this week's podcast. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I -- Vaccine-Induced Myocarditis
New Reports Help Nail Down Myocarditis Risk With COVID-19 Vaccine
https://www.staging.medscape.com/viewarticle/960537
• Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
https://www.nejm.org/doi/full/10.1056/NEJMoa2109730
• Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
https://www.nejm.org/doi/full/10.1056/NEJMoa2110737
II – AF and Stroke
AF a Stroke Cause or Innocent Bystander? The Debate Continues
https://www.medscape.com/viewarticle/960224
• Temporal Association Between Episodes of Atrial Fibrillation and Risk of Ischemic Stroke
https://jamanetwork.com/journals/jamacardiology/fullarticle/2784332
• It's Time to Rethink (and Retrial) Our Framework for Stroke Prevention in Atrial Fibrillation
https://jamanetwork.com/journals/jamacardiology/fullarticle/2784335
III- Intensification of BP Control
Adding New Hypertensive May Be More Potent Than Upping Doses
https://www.medscape.com/viewarticle/960454
• Adding a New Medication Versus Maximizing Dose to Intensify Hypertension Treatment in Older Adults
https://doi.org/10.7326/M21-1456
IV- Hs-troponin and CAD
Troponin Levels Tied to Increased CAD Risk, May Guide Imaging /viewarticle/960146
• Troponin-Guided Coronary Computed Tomographic Angiography After Exclusion of Myocardial Infarction
https://doi.org/10.1016/j.jacc.2021.07.055
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
Coronary artery calcification and exercise, translating clinical trials, the question of metabolically healthy obesity, and Watchman complications are the topics John Mandrola, MD, discusses in this week’s podcast. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - CAC and Physical Activity
-
Physical Activity Paradoxically Tied to Higher Coronary Calcium https://www.medscape.com/viewarticle/959366
-
Physical activity and the progression of coronary artery calcification http://dx.doi.org/10.1136/heartjnl-2021-319346
II - Translating Clinical Trials
-
SYNTAX Score II 2020 Wobbles in Real-World Validation https://www.medscape.com/viewarticle/958834
-
Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation https://doi.org/10.1016/S0140-6736(20)32114-0
-
External Validation of the SYNTAX Score II 2020 https://www.jacc.org/doi/full/10.1016/j.jacc.2021.07.027
III - Healthy and Obesity
-
‘Metabolically Healthy Obesity’ Has Heart Risks. Is it a Misnomer? https://www.medscape.com/viewarticle/959994
-
Metabolically healthy obesity and cardiovascular events: A nationwide cohort study https://doi.org/10.1111/dom.14492
-
Relation of Obesity to New-Onset Atrial Fibrillation and Atrial Flutter in Adults https://pubmed.ncbi.nlm.nih.gov/29501206/
-
Paediatric obesity appears to lower the risk of diabetes if selection bias is ignored https://pubmed.ncbi.nlm.nih.gov/29374028
IV - Watchman Complications
- FDA Investigating Potential Sex Differences in LAAO Adverse Outcomes https://www.medscape.com/viewarticle/959806
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Dual antiplatelet therapy after PCI, statin side effects, nightshift work and AF, and a cautionary note regarding therapeutic enthusiasm in HF care are the topics John Mandrola, MD, discusses in this week’s podcast. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - COVID
- Alaska Sets Record for Daily COVID Cases https://www.medscape.com/viewarticle/958999
II - MASTER DAPT
-
MASTER DAPT: 1 Month DAPT Enough After High-Bleeding-Risk PCI https://www.medscape.com/viewarticle/957463
-
Antiplatelets and Anticoagulation Post-PCI: More on MASTER DAPT https://www.medscape.com/viewarticle/958002
-
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2108749
-
Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056680
III - Statins and Side Effects
-
Most Muscle Pain on Statins Not a Drug Effect: SAMSON in Print https://www.medscape.com/viewarticle/958877
-
Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment https://doi.org/10.1016/j.jacc.2021.07.022
IV - Nightshift Work and AF
-
Regular Nightshift Work Linked to Atrial Fibrillation, CHD https://www.medscape.com/viewarticle/959346?src=
-
Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease https://doi.org/10.1093/eurheartj/ehab505
V - Enthusiasm for HF Therapy
- Empagliflozin's HFpEF Efficacy Catalyzes Redefinition of HF https://www.medscape.com/viewarticle/959249
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Cardiac arrest care, finerenone, carotids, meds post TAVI: less is more and the new may not be as grand as the tried and true. John Mandrola, MD, provides a third ESC review. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - Cardiac Arrest Care
-
Angiography Can Wait for Cardiac Arrest Without ST-Elevation https://www.medscape.com/viewarticle/957471
-
Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation https://www.nejm.org/doi/full/10.1056/NEJMoa2101909
-
Coronary Angiography after Cardiac Arrest without ST-Segment Elevation https://www.nejm.org/doi/full/10.1056/NEJMoa1816897
II - Finerenone
-
FIDELITY: Finerenone Cuts CV Risk in T2D Across CKD Spectrum https://www.medscape.com/viewarticle/957470
-
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2110956
-
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
III - Carotid Intervention
-
ACST-2: Carotid Stenting, Surgery on Par in Asymptomatic Patients https://www.medscape.com/viewarticle/957474
-
Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy https://doi.org/10.1016/S0140-6736(21)01910-3
IV - Post TAVI DOAC
-
'Less Is More' for Edoxaban in Post-TAVI Anticoagulation: ENVISAGE-TAVI AF https://www.medscape.com/viewarticle/957466
-
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR https://www.nejm.org/doi/full/10.1056/NEJMoa2111016
-
ATLANTIS Hints at How to Choose Post-TAVR Antithrombotics https://www.medscape.com/viewarticle/951234
-
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement https://www.nejm.org/doi/full/10.1056/NEJMoa1911425
Features:
-
What Are the Implications of ACST-2 for Patients With Asymptomatic Carotid Stenosis? https://www.medscape.com/viewarticle/957502
-
Top 5 Studies From ESC 2021 https://www.medscape.com/viewarticle/958598
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
ESC Wrap-up Part II: EMPEROR-Preserved, and the STEP, Guide-HF, and IAMI trials, are discussed by John Mandrola, MD, in this week’s podcast. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I - HFpEF
-
EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough https://www.medscape.com/viewarticle/957405
-
Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2107038
II - BP Targets
-
STEP: Lowering Blood Pressure Below 130 mm Hg Shows CV Benefit https://www.medscape.com/viewarticle/957566
-
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension https://www.nejm.org/doi/full/10.1056/NEJMoa2111437
III- PA Catheter Monitoring
-
GUIDE-HF: CardioMEMS-Guided Meds Fall Short in Mild to Moderate Heart Failure https://www.medscape.com/viewarticle/957390
-
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01754-2
-
Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial https://doi.org/10.1016/S0140-6736(11)60101-3
IV - Influenza Vaccine
-
Seasonal Flu Vax Cuts Post-MI Mortality in IAMI Trial https://www.medscape.com/viewarticle/957575
-
Influenza Vaccination after Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial https://doi.org/10.1161/CIRCULATIONAHA.121.057042
-
Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis https://pubmed.ncbi.nlm.nih.gov/20332404/
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine. https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
EMPEROR-Preserved, the LOOP study, ablate-and-pace for AF, and salt substitute and stroke: John Mandrola, MD provides a first of two ESC reviews. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
1 - HFpEF
-
EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough https://www.medscape.com/viewarticle/957405
-
Empagliflozin in Heart Failure with a Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa2107038
-
Empagliflozin and Major Renal Outcomes in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMc2112411
-
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2022190
2 - AF Screening
-
LOOP Trial Undercuts Value of Long-term Continuous ECG Screening for Atrial Fibrillation https://www.medscape.com/viewarticle/957473
-
Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01698-6/fulltext
-
Subclinical Atrial Fibrillation and the Risk of Stroke https://www.nejm.org/doi/full/10.1056/nejmoa1105575
3 - Ablate and Pace for AF and HF
-
APAF-CRT: 'Ablate and Pace' Cuts Mortality in Narrow-QRS HF, Permanent AF https://www.medscape.com/viewarticle/957467
-
A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS https://academic.oup.com/eurheartj/article/39/45/3999/5078460
-
AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial https://doi.org/10.1093/eurheartj/ehab569
4 - Salt Substitute and Stroke
-
Salt Substitute Shows Clear Reduction in Stroke, CV Events, and Death https://www.medscape.com/viewarticle/957472
-
Effect of Salt Substitution on Cardiovascular Events and Death https://www.nejm.org/doi/full/10.1056/NEJMoa2105675
Features:
-
Incremental, Not Monumental, Win for Empagliflozin in Heart Failure With Preserved Ejection Fraction https://www.medscape.com/viewarticle/957465
-
Empagliflozin in HFpEF: Putting EMPEROR-Preserved in Context https://www.medscape.com/viewarticle/957388
-
Lessons on AF Screening From the LOOP Study https://www.medscape.com/viewarticle/957512
-
Ablate-and-Pace Delivers a Huge Win for Those Sick With AF https://www.medscape.com/viewarticle/958033
-
Will the Positive Findings From the SSaSS Trial on Salt Substitution Silence the Salt Skeptics? https://www.medscape.com/viewarticle/957510
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID-19, NEJM vaccine safety paper, full-dose anticoagulation in COVID-19, AF and Exercise, and early results on EMPEROR-Preserved are the studies John Mandrola, MD, discusses in this week’s podcast. https://www.medscape.com/twic
1 - COVID-19
-
Heart Inflammation More Common After COVID Than After Vaccination https://www.medscape.com/viewarticle/957343
-
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting https://www.nejm.org/doi/full/10.1056/NEJMoa2110475
2 - Full dose AC in COVID-19
-
Heparin's COVID-19 Benefit Greatest in Moderately Ill Patients https://www.medscape.com/viewarticle/956630
-
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2105911
-
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2103417
3 - AF and Exercise
- Aerobic Exercise Can Reduce AF Frequency, Severity: ACTIVE-AF https://www.medscape.com/viewarticle/957322
4 - EMPEROR AF
- EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough https://www.medscape.com/viewarticle/957405
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID-19, Simpson’s Paradox, LAA appendage closure, multimorbidity, and an ESC preview are the topics John Mandrola, MD discusses in today’s podcast. https://www.medscape.com/twic
1 - COVID-19
-
Lacking Beds, Hospitals Ship COVID-19 Patients to Other States https://www.medscape.com/viewarticle/956917
-
Efficacy and Safety of Same-Day Discharge for Atrial Fibrillation Ablation https://pubmed.ncbi.nlm.nih.gov/32553209/
2 - Simpson’s Paradox
-
Israeli data: How can efficacy vs. severe disease be strong when 60% of hospitalized are vaccinated? https://www.covid-datascience.com/post/israeli-data-how-can-efficacy-vs-severe-disease-be-strong-when-60-of-hospitalized-are-vaccinated
-
Simpson’s Paradox and Interpreting Data https://towardsdatascience.com/simpsons-paradox-and-interpreting-data-6a0443516765
-
How SIMPSON'S PARADOX explains weird COVID19 statistics https://www.youtube.com/watch?v=t-Ci3FosqZs
3 - Left Atrial Appendage Closure
-
FDA Approves Abbott's Amplatzer Amulet for Atrial Fibrillation https://www.medscape.com/viewarticle/956726
-
Chronic Kidney Disease Tied to Worse LAAO Outcomes https://www.medscape.com/viewarticle/956778
-
The Association of Chronic Kidney Disease With Outcomes Following Percutaneous Left Atrial Appendage Closure https://www.jacc.org/doi/full/10.1016/j.jcin.2021.06.008
-
Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.119.039818
4 - ESC Preview
-
SGLT2 inhibitors in HFpEF
-
EMPEROR-Preserved: Positive Top-Line Results for Empagliflozin in HFpEF https://www.medscape.com/viewarticle/954284
-
AF Screening
-
Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial https://pubmed.ncbi.nlm.nih.gov/28454796/
5 - Coming soon
The anticoagulation in COVID-19 trial is one of the hardest I have seen in years. Stay tuned.
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID-19, vaccine-induced myocarditis, Watchman complications, SGLT2 inhibitors, and cardiogenic shock are the topics John Mandrola, MD, discusses in this week’s podcast. https://www.medscape.com/twic
1 - COVID-19
- 18 Months Later, the COVID-19 Memories Won’t Go Away https://www.medscape.com/viewarticle/956335
2 - Vaccine-Myocarditis
-
Myocarditis in Adolescents After COVID-19 Vaccine Typically Mild https://www.medscape.com/viewarticle/956359
-
Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
3 - Watchman
-
'Striking' Difference in Adverse Events in Women With Watchman LAAO https://www.medscape.com/viewarticle/956593
-
Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion https://jamanetwork.com/journals/jamacardiology/fullarticle/2782726
4 - SGLT2 Inhibitors
-
EU Approves Dapagliflozin for Kidney Disease, Regardless of Diabetes https://www.medscape.com/viewarticle/956345
-
Dapagliflozin in Patients with Chronic Kidney Disease https://www.nejm.org/doi/full/10.1056/NEJMoa2024816
5 - Cardiogenic Shock
-
No Win for Milrinone Over Dobutamine in Cardiogenic Shock https://www.medscape.com/viewarticle/956222
-
Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock https://www.nejm.org/doi/full/10.1056/NEJMoa2026845
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The COVID-19 surge, vaccine-induced myocarditis, Heart Rhythm news, the state of medical evidence, and doctors in unions are discussed by John Mandrola, MD, in this week's podcast.
https://www.medscape.com/twic
1- COVID-19
Texas COVID-19 Wave Is Climbing More Steeply Than Past Waves https://www.medscape.com/viewarticle/956104
White House Says US Can Provide COVID-19 Boosters if Needed https://www.medscape.com/viewarticle/956016
2- Vaccine-Myocarditis
Myocarditis Tied to COVID-19 Shots More Common Than Reported? https://www.medscape.com/viewarticle/956089
3- Heart Rhythm News
The Three Big Stories from the Heart Rhythm Society's 2021 Meeting https://www.medscape.com/viewarticle/955989
4- Medical Evidence
Despite Retraction, Study Using Fraudulent Surgisphere Data Still Cited https://www.medscape.com/viewarticle/956090
Ongoing Citations of a Retracted Study Involving Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19 https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2782460
5- Doctors in Unions?
Physicians Need to Unionize Now https://www.medscape.com/viewarticle/955888
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Two studies on alcohol and AF incidence and an important paper on stable CAD are the topics John Mandrola discusses in this week’s podcast. https://www.medscape.com/twic
1 - COVID-19
New Vaccinations Increasing in COVID Hot Spots https://www.medscape.com/viewarticle/955680
2 - Alcohol
-
Moderate Drinking Protective After MI, Stroke in 'Flawed' Study https://www.medscape.com/viewarticle/955474
-
Risk Thresholds for Total and Beverage-Specific Alcohol Consumption and Incident Atrial Fibrillation https://doi.org/10.1016/j.jacep.2021.05.013
-
Can a Drink a Day Keep the Electrophysiologist Away? https://doi.org/10.1016/j.jacep.2021.06.010
-
Association of alcohol consumption with morbidity and mortality in patients with cardiovascular disease: original data and meta-analysis of 48,423 men and women https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-021-02040-2
3 - Coronary Artery Disease
- CLARIFY Confirms Meds, Watchful Waiting in Angina, Stable CAD https://www.medscape.com/viewarticle/955313
- International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational Observational CLARIFY Study https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.121.054567
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID-19 messaging, coffee, CTA and statins, and Watchman problems are the topics discussed by John Mandrola, MD, in this week’s podcast. https://www.medscape.com/twic
1- COVID-19:
-
COVID-19 Cases in US Triple Over 2 Weeks Amid Misinformation https://www.medscape.com/viewarticle/955269
-
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant https://www.nejm.org/doi/full/10.1056/NEJMoa2108891
-
What Really Happened With that Weird Yankees COVID Outbreak https://nymag.com/intelligencer/2021/05/what-really-happened-with-that-weird-yankees-covid-outbreak.html
2- Coffee:
-
Coffee Not Linked to Increased Arrhythmia Risk in New Study https://www.medscape.com/viewarticle/954992
-
Coffee Consumption and Incident Tachyarrhythmias https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2782015
-
Another Cup of Coffee Without an Arrhythmia, Please https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2782021
3- CTA and Statins:
-
CTA May Guide Primary Prevention Statins in Nonobstructive CAD https://www.medscape.com/viewarticle/955030
-
Reduction of Myocardial Infarction and All-Cause Mortality Associated to Statins in Patients Without Obstructive CAD https://www.jacc.org/doi/full/10.1016/j.jcmg.2021.05.022
4- Left Atrial Appendage Closure:
-
Five Risk Factors May Predict Thrombus on LAA Occlusion Implants https://www.medscape.com/viewarticle/955131
-
Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion https://www.jacc.org/doi/full/10.1016/j.jacc.2021.04.098
-
Device-Related Thrombus After Left Atrial Appendage Occlusion https://www.jacc.org/doi/10.1016/j.jacc.2021.05.028
Features:
-
Does Coffee Make Your Heart Flutter? https://www.medscape.com/viewarticle/954996
-
Enough With the Coffee Research and Other Distractions https://www.medscape.com/viewarticle/883709
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID-19, Ivermectin, a dissolving pacer, clinician well-being, and finerenone are discussed this week.
1 COVID-19
US 'Losing Time' Against Delta Variant, NIH Chief Says https://www.medscape.com/viewarticle/954882
Ivermectin for COVID: How Do We Know What to Believe? https://www.medscape.com/viewarticle/954681
2 Dissolving Pacemaker
Dissolving Pacemaker Impressive in Early Research https://www.medscape.com/viewarticle/954774
3 Clinician Well-being
Global Heart Organizations Unite to Promote Clinician Well-Being https://www.medscape.com/viewarticle/954803
Clinician Well-Being: Addressing Global Needs for Improvements in the Health Care Field A Joint Opinion From the American College of Cardiology, American Heart Association, European Society of Cardiology, and the World Heart Federation https://www.jacc.org/toc/jacc/0/0
From Triple to Quadruple Aim: Care of the Patient Requires Care of the Provider https://www.annfammed.org/content/12/6/573.full
Bullying in Academic Medicine Rife, Underreported https://www.medscape.com/viewarticle/954709
4 Finerenone
FDA Approves Finerenone (Kerendia) for Slowing CKD in Type 2 Diabetes https://www.medscape.com/viewarticle/954606
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID-19, mRNA-vaccine-induced myocarditis, type 2 diabetes in kids, optimal medical therapy for CAD, and Alcohol are the topics discussed by John Mandrola, MD, in this week’s podcast. https://www.medscape.com/twic
1-COVID
-
Fast-spreading Delta Variant, Vaccination Rates, Reintroduction of Indoor Masks: COVID-19 Global Weekly Highlights https://www.medscape.com/viewarticle/940446
-
Health care 'breaking point': Cox confirms some Springfield COVID-19 patients transferred to St. Louis, Kansas City https://www.news-leader.com/story/news/local/ozarks/2021/06/29/springfield-covid-delta-variant-missouri-hospitals-cox-some-patients-transferred-vaccines/7787970002/
2- COVID Vaccine-Induced Myocarditis
-
New Details of Myocarditis Linked to COVID Vaccines https://www.medscape.com/viewarticle/954061
-
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601
-
Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602
3- Diabetes in the Clinic
- 'Staggering' Doubling of Type 2 Diabetes in Kids During Pandemic https://www.medscape.com/viewarticle/953816
4- Optimal Medical Therapy
-
OMT 'Best Insurance' for Extended Survival After Revascularization https://www.medscape.com/viewarticle/953959
-
Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization https://doi.org/10.1016/j.jacc.2021.04.087
-
Defining the Proper SYNTAX for Long-Term Benefit of Myocardial Revascularization With Optimal Medical Therapy https://doi.org/10.1016/j.jacc.2021.04.088
-
Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. https://www.nejm.org/doi/full/10.1056/nejmoa0804626
-
Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial https://doi.org/10.1016/S0140-6736(19)31997-X
5- Alcohol
- The Sick-Quitter Effect: How Alcohol Can Seem Cardioprotective When It Isn't https://www.medscape.com/viewarticle/953696
Features:
- Vaccine-Induced Myocarditis Concerns Demand Respect, Not Absolutism https://www.medscape.com/viewarticle/954038
You may also like:
-
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
-
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Myocarditis and the COVID vaccine, lipid lowering guidelines, financial toxicity, and deprescribing statins are the topics covered by John Mandrola, MD, in this week’s podcast. https://www.medscape.com/twic
1 – COVID
Varied COVID Vaccination Rates May Lead to 'Two Americas' https://www.medscape.com/viewarticle/953658
Nearly All COVID Deaths in US Are Now Among Unvaccinated https://www.medscape.com/viewarticle/953703
2 - COVID Vaccine Myocarditis
FDA to Add Myocarditis Warning to mRNA COVID-19 Vaccines https://www.medscape.com/viewarticle/953647
3 – Lipid Guidelines
Clinicians Slow to Implement Lipid-Lowering Guidelines: GOULD Registry https://www.medscape.com/viewarticle/953688
- Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US https://jamanetwork.com/journals/jamacardiology/fullarticle/2780713
4 - Financial Toxicity
Financial Burden Higher With CVD Than Cancer https://www.medscape.com/viewarticle/953687
- Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States https://www.jacc.org/doi/10.1016/j.jaccao.2021.02.006
5 - Deprescribing Statins
Stopping Statins Linked to Death, CV Events in Elderly https://www.medscape.com/viewarticle/953545
-
Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780952
-
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61240-4/fulltext
-
Rosuvastatin in Older Patients with Systolic Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa0706201
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID vaccine myocarditis, Christian Eriksen and sudden cardiac death, therapeutic hypothermia, and revascularization of stable CAD are the topics John Mandrola, MD, discusses in this week’s podcast.
https://www.medscape.com/twic
1- COVID-Vaccine-Myocarditis
AHA: Don't Delay COVID Shot While CDC Reviews Myocarditis Cases https://www.medscape.com/viewarticle/953233
Myocarditis after BNT162b2 and mRNA-1273 Vaccination https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055913
2- Christian Eriksen
Christian Eriksen: un survivant qui doit nous inspirer
https://francais.medscape.com/voirarticle/3607279
Danish Soccer Player Suffered Cardiac Arrest During Euro Match
https://www.webmd.com/news/20210614/danish-soccer-player-suffered-cardiac-arrest-during-euro-match
Point/Counterpoint on Halting Implantation of the Subcutaneous ICD https://www.jacc.org/doi/10.1016/j.jacep.2021.03.006
3- Therapeutic Hypothermia
Trial Supports Therapeutic Hypothermia in Nonshockable Cardiac Arrest https://www.medscape.com/viewarticle/919855
Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest
https://www.nejm.org/doi/full/10.1056/NEJMoa2100591
PulmCrit – A history of hypothermia for cardiac arrest, 2002-2021 (RIP)
https://emcrit.org/pulmcrit/ttm2/
4 - Revascularization of Stable CAD
Meta-analysis Muses Over ISCHEMIA Message Had Trial Lasted Longer https://www.medscape.com/viewarticle/951498
Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis https://doi.org/10.1093/eurheartj/ehab246
Impact of revascularisation on outcomes in chronic coronary syndromes: a new meta-analysis with the same old biases?
https://doi.org/10.1093/eurheartj/ehab330
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
COVID vaccine myocarditis, AF post-stroke, semaglutide, and iPhones and cardiac devices are the topics John Mandrola, MD, discusses in this week’s podcast. https://www.medscape.com/twic
COVID-Vaccine-Myocarditis
More Evidence Links COVID Vaccines to Rare Cases of Myocarditis in Youth https://www.medscape.com/viewarticle/952905
-
Symptomatic Acute Myocarditis in Seven Adolescents Following the Pfizer-BioNTech COVID-19 Vaccination https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-052478
-
At Least 18 Cases of Apparent Heart Problems in Young People in CT After COVID-19 Vaccine https://www.nbcconnecticut.com/news/coronavirus/connecticut-confirms-at-least-18-cases-of-apparent-heart-problems-in-young-people-after-covid-19-vaccination/2494534/
-
C.D.C. Is Investigating a Heart Problem in a Few Young Vaccine Recipients https://www.nytimes.com/2021/05/22/health/cdc-heart-teens-vaccination.html
-
EMA Statement: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-may-2021
-
Is the Second Shot Giving Young Men a Dangerous Heart Condition? https://nymag.com/intelligencer/2021/06/israel-detects-link-between-myocarditis-and-covid-vaccine.html
-
Report to FDA https://www.fda.gov/media/150054/download
AF and Stroke
Evidence Mounts for Implantable AF Monitoring After Stroke https://www.medscape.com/viewarticle/952325
-
The STROKE-AF Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2780490
-
The PER DIEM Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2780491
Obesity
FDA Approves 'Game Changer' Semaglutide for Weight Loss https://www.medscape.com/viewarticle/952441
iPhone 12 and Cardiac Device
Evidence Builds for iPhone 12 Interference With Cardiac Devices https://www.medscape.com/viewarticle/952780
-
Magnetic Interference on Cardiac Implantable Electronic Devices From Apple iPhone MagSafe Technology https://www.ahajournals.org/doi/10.1161/JAHA.121.020818
-
Letter to the Editor—Lifesaving therapy inhibition by phones containing magnets https://www.heartrhythmjournal.com/article/S1547-5271(20)31227-3/fulltext
-
Smart wearable device accessories may interfere with implantable cardiac devices https://www.heartrhythmcasereports.com/article/S2214-0271(20)30274-8/fulltext
Features:
Feb 26, 2021 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/946476
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
John Mandrola, MD, presents an ACC 2021 recap. https://www.medscape.com/twic
ACC 2021 Reveiw
I -- Left Atrial Appendage Closure
LAAOS III: Surgical LAA Closure Cuts AF Stroke Risk by One Third https://www.medscape.com/viewarticle/951232
- Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke https://www.nejm.org/doi/full/10.1056/NEJMoa2101897
Watchman Registry: 1-Year Stroke Estimates Reassuringly Low https://www.medscape.com/viewarticle/951235
II - Angiotensin-Neprilysin Inhibition
PARADISE-MI: Sacubitril/Valsartan Can't Beat Ramipril in Patients With Acute MI https://www.medscape.com/viewarticle/951236
Life Trial
Rationale Paper: https://doi.org/10.1016/j.jchf.2020.05.005
III - Renal Denervation
Ultrasound Renal Denervation Drops BP in Patients on Triple Therapy https://www.medscape.com/viewarticle/951248
IV -- Clopidogrel vs ASA post Stent
HOST-EXAM: Clopidogrel Beats Aspirin as Monotherapy After Stenting https://www.medscape.com/viewarticle/951294
- Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial https://doi.org/10.1016/S0140-6736(21)01063-1
V -- AF Ablation in HF
RAFT-AF, Despite Itself, Hints at Advantage for Ablation Rhythm Control in Heart Failure With AF. https://www.medscape.com/viewarticle/951326
VI -- Rivaroxaban in COVID-19 – ACTION Trial
Therapeutic Rivaroxaban Dose: Risk Outweighs Benefit in Stable COVID https://www.medscape.com/viewarticle/951475
VII -- REHAB-HF Trial
Novel Rehab Program Fights Frailty, Boosts Capacity in Advanced HF https://www.medscape.com/viewarticle/951244
- Physical Rehabilitation for Older Patients Hospitalized for Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2026141
VIII – ASA 81 vs 325 – ADAPTABLE Trial
ADAPTABLE: Low-Dose Aspirin as Good as High-Dose in CHD? https://www.medscape.com/viewarticle/951230
- Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease https://www.nejm.org/doi/full/10.1056/NEJMoa2102137
Perspectives:
Eight Things to Know About the Surgical Left Atrial Appendage Occlusion (LAAOS III) Trial https://www.medscape.com/viewarticle/951229
PARADISE-MI Makes Me Question the Benefits of Sacubitril/Valsartan https://www.medscape.com/viewarticle/951239
Sacubitril/Valsartan: Trending Toward PARADISE Post MI https://www.medscape.com/viewarticle/950300
Renal Denervation for Resistant Hypertension Is Not Back on Track https://www.medscape.com/viewarticle/951497
Acute Alcohol Consumption Raises Risk for Atrial Fibrillation https://www.medscape.com/viewarticle/950938
Does ADAPTABLE Inform Aspirin Dosing for Secondary Prevention? https://www.medscape.com/viewarticle/950969
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
The upcoming ACC meeting, polypharmacy, finerenone, and ethics and professionalism are the topics covered by John Mandrola, MD, in this week’s podcast. https://www.medscape.com/twic
ACC Preview:
ACC.21 Looks to Repeat Success Despite Pandemic Headwinds https://www.medscape.com/viewarticle/950836
- Level and Prevalence of Spin in Published Cardiovascular Randomized Clinical Trial Reports With Statistically Nonsignificant Primary Outcomes: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/31050775/
Polypharmacy
Hypertension Worsened by Commonly Used Prescription Meds https://www.medscape.com/viewarticle/950724
Finerenone
Finerenone Scores Second Pivotal-Trial Success in Diabetic Kidney Disease https://www.medscape.com/viewarticle/951027
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
Ethics and Professionalism
AHA/ACC Guidance on Ethics, Professionalism in Cardiovascular Care https://www.medscape.com/viewarticle/951018
- 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report https://www.ahajournals.org/doi/10.1161/CIR.0000000000000963
Features:
Mandrola Previews the 2021 (Virtual) American College of Cardiology Scientific Sessions https://www.medscape.com/viewarticle/950797
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID-19 and BMI, TAVR vs SAVR, subcutaneous ICD, SGLT2 inhibitors, and physician-Moms are the topics John Mandrola, MD, discusses in this week’s podcast. https://www.medscape.com/twic
COVID-19
COVID-19 Severity Starts in Normal BMI Range, Especially in Young https://www.medscape.com/viewarticle/950568
- Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00089-9/fulltext
TAVR vs SAVR
VARC-3 Sets Goalpost for Future Aortic Valve Trials https://www.medscape.com/viewarticle/950012
- Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa799/6237954
TAVR Availability
Patchy Growth of TAVR Programs Leaves Poorer Communities Behind https://www.medscape.com/viewarticle/950316
S-ICD
Trade-offs Between Subcutaneous, Transvenous ICDs on Display in EFFORTLESS https://www.medscape.com/viewarticle/950328
-
Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study https://doi.org/10.1016/j.jacc.2017.06.040
-
Reduction in Inappropriate Therapy and Mortality through ICD Programming https://www.nejm.org/doi/full/10.1056/NEJMoa1211107
-
Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results https://doi.org/10.1016/j.hrthm.2015.01.017
Dapagliflozin and CKD
FDA Approves Dapagliflozin (Farxiga) for Chronic Kidney Disease https://www.medscape.com/viewarticle/950329
Features
New Physician Moms Need More Resources and Less Guilt in the Workplace https://www.medscape.com/viewarticle/949765
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID-19 and global vaccinations, AF screening, conduction-system pacing, FDA ban on menthol tobacco, and a heartfelt essay are the topics John Mandrola, MD, discusses in this week’s podcast. https://www.medscape.com/twic
COVID-19
Indians Rush for COVID-19 Vaccines as Death Toll Passes 200,000 https://www.medscape.com/viewarticle/950095
- Vaccine Breakthrough Infections with SARS-CoV-2 Variants https://www.nejm.org/doi/full/10.1056/NEJMoa2105000
AF Screening:
Modest Clinical Gain for AF Screening of Asymptomatic Elderly: STROKESTOP https://www.medscape.com/viewarticle/949950
- Mass Screening for Untreated Atrial Fibrillation
The STROKESTOP Study https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.114.014343
-
Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials https://pubmed.ncbi.nlm.nih.gov/25596211/
-
Toward evidence-based medical statistics. 2: The Bayes factor https://pubmed.ncbi.nlm.nih.gov/10383350
Conduction System Pacing
Keeping Pace: His-Bundle CRT for Heart Failure Impresses in Second Randomized Trial https://www.medscape.com/viewarticle/950037
-
A Randomized Trial of His pacing versus Biventricular pacing in Symptomatic Heart Failure Patients with left bundle branch block (His-Alternative) https://www.jacc.org/doi/10.1016/j.jacep.2021.04.003
-
His Corrective Pacing or Biventricular Pacing for Cardiac Resynchronization in Heart Failure https://www.jacc.org/doi/full/10.1016/j.jacc.2019.04.026
FDA
FDA Moves to Ban Menthol in Tobacco Products https://www.medscape.com/viewarticle/950223
Features:
Losing Both Parents During COVID: A Physician's 'Unwitnessed Grief' https://www.medscape.com/viewarticle/949490
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Cardiac status post COVID-19 in athletes, AF ablation, and bias against procedural doctors are the topics covered by John Mandrola, MD, in this week’s podcast https://www.medscape.com/twic
COVID-19
COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program — Kentucky, March 2021 https://www.cdc.gov/mmwr/volumes/70/wr/mm7017e2.htm
Professor Zeynep Tufekci Newsletter: https://www.theinsight.org/p/facts-are-pieces-of-a-puzzle-not
Post-COVID-19 Cardiac Involvement in NCAA athletes
SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.054824
AF and Durable PV isolation
Paroxysmal AF Can Recur but Burden Plunges After 'Durable' Ablation https://www.medscape.com/viewarticle/949566
Radiofrequency vs. Cryoballoon Catheter Ablation for Paroxysmal Atrial Fibrillation: Durability of Pulmonary Vein Isolation and Effect on AF Burden: The RACE-AF Randomized Controlled Trial https://www.ahajournals.org/doi/10.1161/CIRCEP.120.009573
Bias Against Procedures:
Apr 9, 2021 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/949000
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID-19 vaccine-related clotting, vitamin D, anticoagulation strategies before PCI, and a good intervention at end of life are the topics John Mandrola, MD, discusses in this week’s podcast. https://www.medscape.com/twic
COVID-19:
How Some COVID-19 Vaccines Could Cause Rare Blood Clots https://www.medscape.com/viewarticle/949262
FAQ: What to Know About the J&J Vaccine Pause https://www.medscape.com/viewarticle/949231
Vitamin D Screening:
Don't Screen for Vitamin D in General Population, Says US Task Force https://www.medscape.com/viewarticle/949167
Pre-PCI AC Decisions:
Parity Whether Anticoagulation Is Halted or Not for Unplanned Cath https://www.medscape.com/viewarticle/949064
Uninterrupted Oral Anticoagulant Therapy in Patients Undergoing Unplanned Percutaneous Coronary Intervention https://doi.org/10.1016/j.jcin.2021.01.022
Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation https://www.nejm.org/doi/full/10.1056/nejmoa1302946
Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2) https://doi.org/10.1093/eurheartj/ehy413
A Superb Intervention at End of Life:
Use of Comfort Care Increasing After Stroke, May Reduce Costs https://www.medscape.com/viewarticle/949297
Decade‐Long Nationwide Trends and Disparities in Use of Comfort Care Interventions for Patients With Ischemic Stroke https://doi.org/10.1161/JAHA.120.019785
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID-19, COVID-19 vaccines, hybrid AF ablation TAVR and who gets to be called a doctor are the topics by John Mandrola, MD, in this week’s podcast. https://www.medscape.com/twic
COVID-19
UK Regulators to Offer Under-30s Alternative to AZ COVID Vaccine https://www.medscape.com/viewarticle/948934
- News - Communicating the potential benefits and harms of the Astra-Zeneca COVID-19 vaccine https://wintoncentre.maths.cam.ac.uk/news/communicating-potential-benefits-and-harms-astra-zeneca-covid-19-vaccine/
Hybrid Ablation for Persistent AF
-
Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation https://www.ahajournals.org/doi/10.1161/CIRCEP.120.009288
-
Converge trial Rationale Paper https://doi.org/10.1016/j.ahj.2020.02.016
-
Approaches to Catheter Ablation for Persistent Atrial Fibrillation https://www.nejm.org/doi/full/10.1056/NEJMoa1408288
-
Toward evidence-based medical statistics. 2: The Bayes factor https://pubmed.ncbi.nlm.nih.gov/10383350/
TAVR
-
TAVR Feasible, Comparable to Surgery in Rheumatic Heart Disease https://www.medscape.com/viewarticle/948832
-
Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Rheumatic Aortic Stenosis https://doi.org/10.1016/j.jacc.2021.02.032
-
Upsides, Downsides for TAVR, Minimally Invasive AVR https://www.medscape.com/viewarticle/946104
-
Minimally invasive surgery versus transcatheter aortic valve replacement: a systematic review and meta-analysis https://openheart.bmj.com/content/8/1/e001535#ref-9
Who Should Get to Be Called 'Doctor'? https://www.medscape.com/viewarticle/948887
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID-19, long-COVID, the language of medicine, childhood obesity, and open notes are the topics covered by John Mandrola, MD, in this week's podcast.
https://www.medscape.com/twic
COVID-19
AstraZeneca COVID Vaccine: Clotting Disorder Mechanism Revealed?
https://www.medscape.com/viewarticle/948560
Long COVID
Long COVID Brings Welcome Attention to POTS
https://www.medscape.com/viewarticle/948174
Keep Both 'Renal' and 'Nephro' in Glossary of Kidney Disease
https://www.medscape.com/viewarticle/948451
'Striking' Increase in Childhood Obesity During Pandemic
https://www.medscape.com/viewarticle/948350
COVID-19 and Changes in Child Obesity. https://pediatrics.aappublications.org/content/early/2021/03/01/peds.2021-050123
Starting Monday, Patients Can Read Your Notes:
5 Key Things https://www.medscape.com/viewarticle/948508
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
COVID-19, AF detection post stroke, new measures of heart function, and structural racism in quality measures are the topics covered by John Mandrola, MD, in this week’s podcast. https://www.medscape.com/twic
COVID-19
NIH Rebukes AstraZeneca Vaccine Interim Data: 'Incomplete' https://www.medscape.com/viewarticle/947954
Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination https://jamanetwork.com/journals/jama/fullarticle/2777898
AF and Stroke
Insertable Cardiac Monitors Improve AF Detection After Stroke https://www.medscape.com/viewarticle/947986
Perfection in LV Function Measurement
Adding Strain Measure to LVEF Better Predicts Later HF https://www.medscape.com/viewarticle/948114
Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life https://jamanetwork.com/journals/jamacardiology/fullarticle/2777414
Is the Left Ventricular Ejection Fraction Measurement Still Preeminent?—New Measures to Quantify Subclinical Systolic Dysfunction https://jamanetwork.com/journals/jamacardiology/fullarticle/2777412
Structural Racism in Pay for Performance
Association Between the Proportion of Black Patients Cared for at Hospitals and Financial Penalties Under Value-Based Payment Programs https://jamanetwork.com/journals/jama/fullarticle/2777701
Twitter Thread from Rishi Wadhera https://twitter.com/rkwadhera/status/1374380385560186883
References:
Sowell, Thomas A Conflict of Visions https://en.wikipedia.org/wiki/A_Conflict_of_Visions
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID-19, Fish Oil and AF risk, SGLT2 inhibitors and renal outcomes, and TAVR vs SAVR are the topics discussed by John Mandrola, MD, in this week’s podcast. https://www.medscape.com/twic
COVID-19
EMA Launches Review of Clot Risk With AstraZeneca COVID Vaccine https://www.medscape.com/viewarticle/947393
AZ Vaccine Safe Overall but Questions Remain over Unusual Clots https://www.medscape.com/viewarticle/947733
Fish Oil and AF
Dose-Related AF Risk With Omega-3 Fatty Acids? https://www.medscape.com/viewarticle/947542
Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation https://jamanetwork.com/journals/jama/fullarticle/2777469
Omega-3 Fatty Acids and Atrial Fibrillation https://jamanetwork.com/journals/jama/fullarticle/2777450
SGLT2i and Renal Outcomes
Ertugliflozin: Renal Benefits in Additional VERTIS CV Analyses https://www.medscape.com/viewarticle/947668
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2004967
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial https://link.springer.com/article/10.1007/s00125-021-05407-5
TAVR vs SAVR
TAVR vs SAVR in Low-Risk Patients: What We Do and Don't Know https://www.medscape.com/viewarticle/946173
Mortality in trials on transcatheter aortic valve implantation versus surgical aortic valve replacement: a pooled meta-analysis of Kaplan-Meier-derived individual patient data https://pubmed.ncbi.nlm.nih.gov/32236543/
Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk https://www.jacc.org/doi/full/10.1016/j.jacc.2020.12.052
Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement https://www.nejm.org/doi/full/10.1056/NEJMoa1910555
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact
news@medscape.net
COVID-19, heart failure classifications, DOAC after bioprosthetic valves, and Medicare spending in the pandemic year Are the topics discussed by John Mandrola, MD, in this week’s podcast. https://www.medscape.com/twic
I. COVID-19 Vaccination in Israel
COVID-19 Vaccination Linked to Less Mechanical Ventilation https://www.medscape.com/viewarticle/946568
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting https://www.nejm.org/doi/full/10.1056/NEJMoa2101765
II. Heart Failure Classification
Heart Failure Redefined With New Classifications, Staging https://www.medscape.com/viewarticle/947048
Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure https://doi.org/10.1016/j.cardfail.2021.01.022
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction https://www.nejm.org/doi/full/10.1056/NEJMoa1908655
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044586
III. DOACs In Bioprosthetic Valves --
DOACs Offered After Heart Valve Surgery Despite Absence of Data https://www.medscape.com/viewarticle/947193
Off-label Use of Direct Oral Anticoagulants in Patients Receiving Surgical Mechanical and Bioprosthetic Heart Valves https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2777141
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves https://www.nejm.org/doi/full/10.1056/nejmoa1300615
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document.... https://academic.oup.com/europace/article/19/11/1757/4098134
IV. Pandemic Slices Medicare Physician Spending in First Half of 2020: AMA https://www.medscape.com/viewarticle/946984
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Cardiac studies in professional athletes after COVID-19 infection, percutaneous valve repair, AF screening, and social media are the topics discussed by John Mandrola, MD, in this week’s podcast. To read a partial transcript or to comment https://www.medscape.com/twic
COVID and the Athletic Heart
Incidence of Cardiac Pathology Post-COVID in Pro Athletes < 1% https://www.medscape.com/viewarticle/946902
Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening https://jamanetwork.com/journals/jamacardiology/fullarticle/2777308
Percutaneous Valve Repair
Delirium Common, Costly After Mitral, Tricuspid Valve Repair https://www.medscape.com/viewarticle/946736
Prevalence and Impact of Post-Procedural Delirium After Percutaneous Repair of Mitral and Tricuspid Valves https://www.jacc.org/doi/full/10.1016/j.jcin.2020.11.031
AF Screening
AF Screening in Asymptomatic Older Individuals Shows Promise https://www.medscape.com/viewarticle/946844
Screening for Atrial Fibrillation in the Older Population A Randomized Clinical Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2776728
Social Media
JAMA Podcast on Racism in Medicine Faces Backlash https://www.webmd.com/sex-relationships/news/20210304/jama-podcast-on-racism-in-medicine-faces-backlash
Time's Up Founder Choo Accused in Harassment Mishandling https://www.medscape.com/viewarticle/946678
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Risk factors for COVID-19, CMR after COVID-19, and two important obesity studies are discussed in this week’s podcast. To read a partial transcript or to comment https://www.medscape.com/twic
Cardiometabolic Conditions and COVID19
Most Severe COVID Tied to Four Cardiometabolic Conditions https://www.medscape.com/viewarticle/946488
Coronavirus Disease 2019 Hospitalizations Attributable to Cardiometabolic Conditions in the United States: A Comparative Risk Assessment Analysis https://www.ahajournals.org/doi/10.1161/JAHA.120.019259
CMR after COVID19
Myocardial Injury Seen on MRI in 54% of Recovered COVID https://www.medscape.com/viewarticle/946287
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance https://doi.org/10.1093/eurheartj/ehab075
Obesity Trials
Semaglutide for Weight Loss? A Good First STEP, With Caveats https://www.medscape.com/viewarticle/945630
Once-Weekly Semaglutide in Adults with Overweight or Obesity https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Major Breakthrough in Weight Loss With Semaglutide? https://www.medscape.com/viewarticle/940841
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity https://jamanetwork.com/journals/jama/fullarticle/2777025
Features
Fired for Good Judgment a Sign of Physicians' Lost Respect https://www.medscape.com/viewarticle/946286
A Tribute to Bernard Lown https://www.medscape.com/viewarticle/946447
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Bernard Lown, Type 2 MI, Sacubitril/Valsartan and COVID19 anticoagulation are discussed in this week’s podcast. To read a partial transcript or to comment https://www.medscape.com/twic
COVID
Israeli Study Finds Pfizer Vaccine 95% Effective Against COVID-19 https://www.medscape.com/viewarticle/945962
Bernard Lown
Cardiologist, Antiwar Activist Bernard Lown Dies at 99 https://www.medscape.com/viewarticle/945966
Type 2 MI
New Light Cast on Type-2 MI Aims to Sharpen Diagnosis, Therapy https://www.medscape.com/viewarticle/946075
Early AC in COVID19
More Evidence Supports Early Anticoagulation in COVID-19 https://www.medscape.com/viewarticle/945902
Sacubitril/Valsartan
FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF https://www.medscape.com/viewarticle/945936
Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF https://www.medscape.com/viewarticle/944168
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Prediabetes, AI and ECGs, HFpEF, and observational studies are the topics discussed by John Mandrola, MD in this week’s podcast. To read a partial transcript or to comment http://www.medscape.com/twic
Pre-diabetes
'Prediabetes' Unlikely to Progress to Diabetes in Older Adults https://www.medscape.com/viewarticle/945511
Mobile QT Interval Measurement
Using AI, Mobile ECG Aims to Expand QTc Screening Horizons https://www.medscape.com/viewarticle/945484 Giudicessi JR et al.
Artificial Intelligence-Enabled Assessment of the Heart Rate Corrected QT Interval Using a Mobile Electrocardiogram Device | Circulation (ahajournals.org) https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.120.050231
HFpEF
Exercise Quandary in HFpEF: Training Regimens Fall Short in Trial https://www.medscape.com/viewarticle/945621
Observational Study Follies
Statins Linked to Reduced Postop Adhesions, Bowel Obstruction https://www.medscape.com/viewarticle/945686
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Carotid screening, AF and alcohol, subcutaneous ICD, and medical education are the topics discussed by John Mandrola, MD, in this week’s podcast. To read a partial transcript or to comment http://www.medscape.com/twic
Carotid Screening
USPSTF Again Recommends Against Carotid Stenosis Screening https://www.medscape.com/viewarticle/945202
Subcutaneous ICD Recall
FDA Recalls Subcutaneous-ICD Leads Due to Fracture Risk https://www.medscape.com/viewarticle/945168
Alcohol and AF
Alcohol and the Electric Atrium, Part 2: When BAC Exceeds the Legal Limit https://www.medscape.com/viewarticle/945297
Medical Education
USMLE Stuns Again: Clinical Skills Test Permanently Ended https://www.medscape.com/viewarticle/944756
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
AF and COVID-19, microthrombi in COVID-19 autopsies, vericiguat, and POTS are the topics covered by John Mandrola, MD, in this week’s podcast. To read a partial transcript or to comment: http://www.medscape.com/twic
AF and COVID
AF at COVID-19 Admission Predicts Mortality, Demands Vigilance https://www.medscape.com/viewarticle/944802
Microthrombi and COVID
Microthrombi, Necrosis Seen in COVID-19 Hearts on Autopsy https://www.medscape.com/viewarticle/944783
Vericiguat
FDA Approval Adds Vericiguat (Verquvo) to HF Treatment Options https://www.medscape.com/viewarticle/944434
POTS:
Lower-Body Compression Trims Orthostatic Tachycardia in POTS https://www.medscape.com/viewarticle/944791
Postural Orthostatic Tachycardia Syndrome (POTS): A critical assessment https://doi.org/10.1016/j.pcad.2020.03.010
Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance https://www.onlinecjc.ca/article/S0828-282X(19)31550-8/fulltext#secsectitle0130
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
COVID myocarditis, the Polypill, low-value care, and edge-to-edge tricuspid valve repair are discussed by John Mandrola, MD, in this week’s podcast.
COVID, ACE/ARBs, left atrial appendage closure, SGLT2 inhibitors, and a clue in AF mechanisms are the topics discussed by John Mandrola, MD, in this week’s podcast.
COVID vaccine schedules, trial translation, valve guidelines, and physician harassment on social media are the topics discussed by John Mandrola, MD, in this week’s podcast.
COVID, sacubitril/valsartan and spironolactone in patients with HFpEF, year-end comments are the topics discussed by John Mandrola, MD in this week’s podcast.
COVID, the clogged pipe frame of CAD, paclitaxel, and AF performance measures and Goodhart’s law are the topics John Mandrola, MD, covers in this week’s podcast.
COVID vaccines, tocilizumab, finerenone, type 2 MI care, coronary CTA, and sotagliflozin are the topics discussed by John Mandrola, MD, in this week’s podcast.
COVID-19 vaccines and virtual AHA presentations on statins and the nocebo effect, high dose omega-3s, and AF ablation are the topics John Mandrola, MD, discusses on this week’s podcast.
COVID19 vaccines, thrombolysis in stroke, industry payments to doctors, and the upcoming AHA are topics covered by John Mandrola, MD, in this week’s podcast.
COVID, AF ablation, pediatric “do not dos” from AAP, heart failure performance measures, and a brief AHA preview are the topics discussed by John Mandrola, MD on this week’s podcast.
Remdesivir, the athletic heart, troponin and echo abnormalities in patients with COVID-19, and a novel MRA drug are the topics John Mandrola, MD, discusses in this week's podcast
COVID, tocilizumab, hypertrophic cardiomyopathy, cerebral microbleeds, and surrogate endpoints are the topics discussed by John Mandrola, MD, in this week’s podcast
COVID drug trials and science news, BNP, polypharmacy in heart failure, and in-patient CPR are the topics john Mandrola, MD, discusses in this week’s podcast
COVID-19, scientific philosophy, left main coronary artery disease, empagliflozin and the SGLT2 inhibitors are the topics discussed by John Mandrola, MD in this week’s podcast
Scientific trust, publishing incentives, and the EXCEL trial, Vitamin D and COVID, and time-restricted eating are discussed by John Mandrola, MD, in this week’s podcast.
COVID sport participation guidelines, beta-blockers after MI, and low-dose DOAC therapy in AF are the topics covered by John Mandrola, MD, in this week’s podcast.
COVID, CMR after COVID, ISCHEMIA trial substudy, valvular heart disease and AF are the topics John Mandrola, MD, discusses in this week’s podcast.
COVID, icosapent ethyl, sudden death, and antiplatelet choices in the elderly are topics John Mandrola, MD, discusses in this week’s podcast.
COVID, trust in the FDA, and ESC Recap: Part 1 are the topics John Mandrola, MD, covers in this week’s podcast.
COVID and the heart, convalescent plasma, PCI in the VA system, and the upcoming ESC meeting are discussed by John Mandrola, MD, in this week’s podcast.
COVID, diversity, clinical research, the S-ICD, and ECGs are the topics discussed by John Mandrola, MD in this week’s podcast.
COVID, obesity, heart failure, Impella, and fitness are the topics John Mandrola, MD, discusses in this week’s podcast.
COVID, cardiac effects of COVID, AF ablation safety, and SGLT2i are the topics discussed by Dr John Mandrola in this week’s podcast.
COVID vaccines, T-cells, ICDs, Watchman, and two features are the topics John Mandrola, MD, discusses in this week’s podcast.
COVID, the EXCEL trial, AF ablation, and pacemaker techniques are the topics discussed by John Mandrola, MD in this week’s podcast.
COVID, sacubitril/valsartan, left atrial appendage occlusion, and statins are the topics Dr John Mandrola discusses in this week’s podcast.
COVID, science communication breakthrough, tricuspid valve disease, and AF ablation are the topics discussed by John Mandrola, MD, in this week’s podcast.
COVID19, corticosteroids, CAC, SGLT2i, and vericiguat are the topics discussed by Dr. John Mandrola in this week’s podcast.
ISCHEMIA, COVID-19 statistics, and racial justice are discussed by Dr John Mandrola in this week’s podcast.
COVID19, protests, Impella, Excel, Bayesian statistics, and journal retractions are discussed by John Mandrola, MD, in this week’s podcast.
COVID-19, nursing homes, evidence based medicine, hydroxychloroquine and VT, and remdesivir are the topics discussed by John Mandrola, MD, in this week’s podcast.
COVID-19, medical education, collider bias, Watchman, and VT are the topics John Mandrola, MD, discusses in this week’s podcast.
COVID-19 stats, anticoagulation in acute COVID-19 illness, ICD trials, and left bundle branch pacing are the topics discussed by John Mandrola, MD, in this week’s podcast.
COVID-19, the angiotensin receptor blocker, TAVR, and acute stroke care are covered by John Mandrola, MD, in this week’s podcast.
COVID-19, social distancing, ECG monitoring, thrombosis, and TAVR are discussed by John Mandrola, MD, in this week’s podcast.
New epidemiologic studies, pitfalls of testing, and treatments for COVID-19 are the topics discussed by John Mandrola, MD in this week’s podcast.
The COVID-19 crisis—epidemiology, viral therapeutics, pulmonary management, and coagulopathy—is the topic discussed by John Mandrola, MD in this week’s podcast.
The COVID-19 crisis—epidemiology, ventilation protocols, telemedicine, and humanity in these dark days—are the topics discussed by John Mandrola, MD in this week’s podcast.
The COVID19 crisis—heroes, viral spread, betrayals, and intolerance of ideas—are discussed by John Mandrola, MD in this week’s podcast.
The COVID-19 crisis—ethics, hydroxychloroquine, and angiotensin drugs—are among the topics discussed by John Mandrola, MD in this week’s podcast.
The newest developments in COVID-19 are discussed by John Mandrola, MD, in this week’s podcast.
COVID-19, left main coronary diseases, and cascades are the topics covered by Dr John Mandrola in this week’s podcast.
Social media tension, bempedoic acid, hopeful news from CMS, and carotid interventions are the topics discussed by Dr John Mandrola in this week’s podcast.
More fuel piled onto the EXCEL trial controversy, GI bleeds in AF, medical education, and revascularization procedures are covered by Dr John Mandrola in this week’s podcast.
Cardiac stents, cardio-oncology, VT ablation, acute AF are the topics discussed by Dr John Mandrola in this week's podcast.
The NEJM retraction, TAVR 5-year results, ICD selection, long QT reversals, and lung cancer screening are the topics discussed by John Mandrola, MD in this week's podcast.
Executive physicals, coconut fat, leadless pacemakers, coils, and independent nurse practitioners and physician assistants are the topics discussed by Dr. John Mandrola in this week’s podcast.
EXCEL, amyloid cardiomyopathy, drug prices, palliative care in cardiology, and gender bias are the topics covered by Dr John Mandrola in this week’s podcast.
The Excel trial, peripartum cardiomyopathy, marathoning, hot-spotting, and leadership in innovation are the topics discussed by Dr. John Mandrola in this week’s podcast.
The EXCEL debate, the NOBLE trial, alcohol and AF, cardiac devices, and hospital consolidation are the topics covered by John Mandrola, MD, in this week’s podcast.
A risk score for device infection, conflicts of interest, the Fragility Index, rhythm vs rate control for AF in HFpEF, and year-end highlights are discussed by John Mandrola, MD, in this week's podcast.
The EXCEL trial controversy, and Dr John Mandrola's experience with vernakalant at FDA are the topics covered in this week's podcast.
Vernakalent, CV death in cancer patients, dapagliflozin, and sacubitril/valsartan are the topics Dr. John Mandrola discusses in this week’s podcast.
Highlights from the 2019 AHA meeting are analyzed by Dr John Mandrola in this week’s podcast.
Interruption of oral anticoagulation, marijuana and stroke, ORBITA substudy, ISCHEMIA medical therapy targets, and more on AHA are the topics discussed by Dr. John Mandrola in this week’s podcast.
Words that harm, statins, thyroid replacement, and the ISCHEMIA trial are the topics discussed by Dr John Mandrola in this week’s podcast.
Mortality after AF ablation, cardiac rehab programs, hypertrophic cardiomyopathy, and clinician wellness are the topics Dr. John Mandrola discusses in this week’s podcast.
AF after TAVR, opioids after cardiac devices, hypertension in black adults, and post-cardiac surgery AF are the topics Dr John Mandrola discusses in this week’s podcast.
The Nobel Prize, more on the EXCEL trial, the costs of cardiac tests, familial hypercholesterolemia, and burnout are the topics discussed by Dr John Mandrola in this week’s podcast.
Left main PCI vs CABG trials and TAVR vs SAVR—in this week’s podcast, Dr John Mandrola takes a deeper dive.
Social effects of medicine, SGLT2 inhibitors, CIED infections, equity in cardiology, and post-PCI anti-thrombotic therapy are the topics discussed by Dr John Mandrola in this week’s podcast.
The polypill, dapagliflozin, TAVR, and video games are discussed by John Mandrola, MD, in this week’s podcast.
More from ESC: Antiplatelets and NOACs, blood glucose control, high sensitivity troponin tests, and ICD trials are all covered by John Mandrola, MD, in this week’s podcast.
Six major trials from the ESC meeting in Paris are reviewed by John Mandrola, MD, in this week’s podcast.
Digital health, a new LDL-c lowering drug, PCSK9i outcomes in higher risk patients, and an ESC preview are discussed by John Mandrola in this week’s podcast.
TAVR, baroreflex activation for heart failure, dapagliflozin for HF, and myocardial viability are the topics discussed by John Mandrola in this week’s podcast.
AI for AF detection, syncope and PE, thoracentesis, fish oil, and why doctors should organize are the topics covered by John Mandrola in this week’s podcast.
Digoxin, acupuncture and angina, heart failure with preserved ejection fraction, bariatric surgery, and cardiac device complications are the topics John Mandrola covers in this week's podcast.
CRT in patients with non-LBBB, ezetimibe, lifestyle diseases in the young, end of life care, and diabetes for the cardiologist are the topics John Mandrola, MD discusses in this week's podcast
Deprescribing beta bockers, interrupting oral anticoagulants, sudden death, quality measures, and acute stroke care are the topics John Mandrola, MD discusses in this week’s podcast.
High-sensitivity troponin assays, nursing education, negative risk markers, valve-in-valve TAVRs, and the use of AI in medical practice are covered in this week’s podcast.
Medical reversals, conflict of interest in the cardiac cath lab, cardiologist burnout, and changes in TAVR rules are discussed by John Mandrola, MD, in this week's podcast.
FDA hearings on paclitaxel devices in PAD, health news spin, myocarditis, difficult conversations, and TAVR in patients with end stage renal disease (ESRD) are discussed in this week’s podcast.
Vitamin D, ICD in patients on dialysis, aspirin, type 2 diabetes, and paclitaxel in PAD are the topics covered by John Mandrola in this week’s podcast.
Complications of PCI, health hubs, AV block after TAVR, VTE prevention, and rivaroxaban use in patients with heart failure are the topics discussed by Dr John Mandrola in this week's podcast.
Tricuspid valve repair, aortic stenosis, His-bundle pacing, deprescribing loop diuretics, and ‘leakage’ are covered in this week’s podcast.
Aspirin and ICH, late tPA for stroke, public reporting of outcomes, Impella, grapefruit juice and QT interval, and ICDs for primary prevention are discussed in this week’s podcast.
Renal and AF ablation in combination, infection risk of devices, neuromodulation of AF, pulsed field ablation and stroke of unknown source are covered in a HRS-heavy podcast.
Spin in the cardiovascular literature, palliative care for cardiac patients, tPA for acute stroke, and whether institutional volume affects AF ablation complications are the topics discussed this week.
Bike commuting and obesity, CMR for NSTEMI, Niacin in secondary prevention, cardiologists’ pay, and end-of-life conversations are in this week’s podcast.
Anticoagulation for embolic stroke of unknown origin, added-sugar labels, AF-patient knowledge, LDL-C and hemorrhagic stroke, and genetic signals in cancer-care cardiomyopathy are discussed this week.
Super-saturated oxygen in STEMI, Medicaid expansion and CV mortality, pacemakers in patients with HFpEF, HF readmissions, and exercise vs diet for weight loss are discussed in this week’s podcast.
ARB recalls, bystander compression-only CPR, renal denervation for hypertension, LDL cholesterol targets, and pre-op frailty are the topics discussed in this week’s podcast.
Catheter ablation for atrial fibrillation, eggs, booze, and anti-thrombotic agents for double vs triple therapy in patients with ACS and AF are discussed in this week’s podcast.
From ACC.19 and EHRA: The Apple Heart study, TAVR for low-surgical-risk AS, preventing cardiac device infections, COACT, VF arrest, and AF cardioversion are discussed in this week's podcast.
Obesity paradox studies and collider bias, the ISCHEMIA trial baseline findings, expanded indications for the MIitraClip, and an ACC preview are covered in this week’s podcast.
N of 1 hypertension trials, heart failure readmissions and HRRP, insulin, CTA vs functional stress testing, and the ongoing paclitaxel PAD controversy are discussed in this week’s podcast.
Lead extraction, AF triggers, cognitive decline and CV risk factors, low-value care, and secondary prevention in the real world are discussed in this week’s podcast.
Factor Xa reversal agent Andexa, PTSD, gender transition hormones and CVD, primary care physician shortage, and a commentary from a young interventional cardiologist are discussed this week.
The cost of cardiac care, statin adherence and mortality, syncope, ultra-processed food, and heart failure survival are discussed in this week's podcast.
Statins in the elderly, donor hearts and the opioid crisis, Impella, coronary calcium in exercisers, and the plateau in heart disease deaths are discussed in this week’s podcast.
New guidelines for atrial fibrillation, PFO closure for stroke prevention, fried chicken, skipping breakfast and e-cigarettes are discussed in this week’s podcast.
Aspirin for primary prevention, alcohol and Afib, high-sensitivity troponin, and women in interventional cardiology are discussed in this week’s podcast.
Burnout, aspiration thrombectomy, fish intake, insurance coverage, and the gout drug febuxostat are discussed in this week’s podcast.
Appropriate use criteria for imaging, HRRP efficacy, medical marijuana, radiation exposure in the cath lab, and hormone therapy are the topics discussed this week’s podcast.
The cost of treating high blood pressure, heart-failure readmission policies, abdominal fat, low flow/low gradient aortic stenosis and hypertensive disorders of pregnancy are discussed this week.
Dr John Mandrola discusses upcoding for PCI, hypertension, a pacing lead issue, a PAD trial discovery, and an FDA warning on fluoroquinolones in this week’s podcast.
Carotid stents, more stem-cell retractions, AHA statement on statin safety, flu vaccine rules, medication errors, veterans care, and wasteful NIH research on golfing are discussed in this week’s podcast.
Measures of hospital quality, statin under- or over-use, Botox for AF, smoking cessation and translating trial evidence to clinical practice are discussed in this week’s podcast.
TAVR vs surgery for high-risk aortic stenosis, conflicts of interest for physicians and societies, spin in the CV literature, and low-carb diets are discussed in this week’s podcast.
The top 5 studies from the recent American Heart Association meeting and the new cholesterol guidelines are discussed in this week’s podcast.
ODYSSEY PCSK9 inhibitor trial in print, new bradycardia guidelines, echocardiography, and an AHA preview are the topics discussed in this week’s podcast.
CV outcomes in patients with type 2 diabetes, canagliflozin, cardiorespiratory fitness, the value of randomized trials, and the most important paper of 2018 are reviewed in this week’s podcast.
Oxygen supplementation, PCSK9 inhibitor pricing, rapid troponin testing, cardio-oncology and joint commission accreditation are discussed in this week’s podcast.
Low-dose rivaroxaban for CAD/PAD, hypertension management in the community, research misconduct, cyber-security in cardiac devices, and bariatric surgery are discussed in this week’s podcast.
Timing of aortic valve replacement, rivaroxaban failure post TAVR, statins beyond CVD, conflicts of interest, and post-stent antithrombotic management are discussed in this week’s podcast.
The COAPT MitraClip trial, high dose omega-3 fatty acids, the VEST trial in print, renal denervation for resistant hypertension, and competing coronary stents are discussed in this TCT-heavy podcast.
ASA, polypharmacy, statins and obesity treatments are the topics discussed by Dr John Mandrola in this week’s podcast
The Apple Watch EKG, ablate/pace strategies, chronic total occlusion-PCI, assisted reproduction strategies and CV health, and remembering Ron Victor, MD are the topics for this week’s podcast.
High sensitivity troponin, radial access (a good news story!), stroke care, rivaroxaban in CAD and PAD, and the components of a healthy diet are discussed in this week’s podcast.
The salt wars, drug costs and vaule, Takotsubo syndrome, carb intake, and the upcoming European Society of Cardiology congress are discussed in this week’s podcast
Screening athletes, AF ablation complications, physician gender and MI mortality, the rise of chronic kidney disease, and the rosuvastatin lawsuit are discussed in this week's podcast.
AF screening, atrial flutter, palliative care in heart failure, and LDL-C lowering are discussed in this week's podcast
Aspirin dosing, a potential new drug for SVT, apixaban in patients with ESRD, TAVR, and saunas, are discussed in this week's podcast
Leadless pacing, AF detection, coronary calcium, BP control and omega-3 fatty acids are discussed in this week's podcast.
Questionable ICD use, ambulatory blood pressure monitoring, multivitamins and cardiovascular health, and end-of-life care are discussed in this week's podcast
Dr John Mandrola discusses controversy over the ISCHEMIA trial, AAA screening, PCSK9i in diabetes, cardiac arrest and Twitter in this week’s podcast
PREDIMED (again), malpractice concerns in CAD testing, alcohol, stroke care in the elderly, and genetic testing are the topics discussed by Dr John Mandrola in this week’s podcast
Nutrition education for docs, PREDIMED retraction, recommendations for ECG screening of healthy adults, and MOC studies are discussed in this week's podcast.
Better equations for CV risk prediction, a drug for bradycardia, illicit drugs and MI in the young, EHR woes, and vitamins for CV risk reduction are discussed in this week's podcast.
Surgical left atrial appendage occlusion, renal denervation, a substudy of ORBITA, FFR and hypertension guidelines are discussed in this week's podcast.
Device-related thrombosis with Watchman left atrial appendage closure, debulking atrial fibrillation after ablation, rivaroxaban for stroke prevention, alteplase, and Lp(a) are discussed this week.
The CABANA trial on catheter ablation in patients with atrial fibrillation is discussed in this week’s podcast recorded at the Heart Rhythm Scientific Sessions.
AHA rescinds sections of the stroke guidelines, thrombectomy for pulmonary embolism, Mitra-clip, nuts and AF, and blood pressure measurements are discussed in this week's podcast.
Lipid-lowering and baseline LDL-C, the CV safety of NSAIDs, 'metabolically healthy' obesity, PCI for chronic total occlusions, and wearable tech are discussed in this week's podcast.
Ambulatory BP measurements, advanced practice providers, medical marijuana for sleep apnea, Barbara Bush's comfort care, and apixaban for cardioversion are the topics discussed in this week's podcast.
Atrial fibrillation after cardiac surgery, long QT syndrome, exercise for CV prevention, a new risk factor for mothers, and coronary obstruction post TAVR are discussed in this week's podcast.
Beta-blockers in diabetes, ACE inhibitors vs ARBs, cardiac implantable electronic device infections, alcohol and AF, and strengthening the p value threshold are discussed in this week's podcast.
Dr. John Mandrola discusses heart failure care, methamphetamine, AF ablation, lead extraction, and myocardial injury after noncardiac surgery in this week's podcast.
His-bundle pacing, Factor Xa reversal, heart failure quality measures, predicting prognosis after cardiac arrest, and myocarditis after cancer immunotherapy are discussed in this week's podcast.
ODYSSEY, VEST, mSTOPS, CANTOS, and the Black barbershop blood pressure study are among the presentations from the 2018 American College of Cardiology meeting reviewed in this week's podcast.
Obesity in young people, type-2 diabetes, the risks of varicose veins, on-pump vs off-pump coronary artery bypass surgery and an ACC preview are the topics discussed in this week's podcast.
Vegetarian vs Mediterranean diets, a clarithromycin alert, a new stent, best choice of IV fluid, and early work in prevention Type I diabetes are discussed in this week's podcast.
Atrial fibrillation after cardiac surgery, radial vs ulnar cath access, aspirin for heart failure, VTE prophylaxis and low-fat vs high-carb diets are discussed in this week's podcast.
ICD use in patients with CKD, PFO and peri-operative stroke, LV assist devices, guideline-directed medical therapy after revascularization, and upcoming trials in 2018 are discussed in this week's podcast.
Genetic risk scores and early onset CAD, ECGs in athletes, the ripple effect of weight loss, troponin in sepsis, and fish oil for CVD prevention are the topics discussed in this week's podcast.
Loperamide abuse, heart failure quality measures, and the CASTLE-AF ablation study are discussed in this week's podcast.
Surgical left atrial appendage closure, the effects of smoking and influenza on CV risk, acute stroke care, and why cardiologists are an unhappy bunch are discussed by Dr Mandrola this week.
MRI in patients with cardiac devices, bariatric surgery, statins, the LifeVest wearable defibrillator, and spontaneous coronary dissection are the topics discussed in this week's podcast.
Exercise effects on left ventricular compliance, CT in stable angina, MRI in patients with cardiac devices, a win for pharma, and ECG screening in adults are discussed in this week's podcast.
Noninvasive VT ablation, Riata leads, NOAC/DOAC therapies, HDL-C and infection risk, and fibrosis in triathletes are discussed in this week's podcast.
Mobile ECGs, PFO closure for migraine, AF care, lytic and mechanical removal of VTE and the PSCK9 inhibitor evolocumab are discussed in this week's podcast.
Sports preparticipation screening, cell therapy in PAD, exercise, supplements, and US healthcare policy are reviewed in this week’s podcast.
New hypertension guidelines, BP measurement, DOACs during device surgery, a CANTOS substudy, and conflicting data on the heart-failure readmissions reduction program are discussed this week.
Dr John Mandrola discusses PCI in stable CAD, MR, exercise, AHA preview, and celebrities at medical meetings in this week's podcast.
The ORBITA sham-control PCI study, Watchman, revascularization in cardiogenic shock, Absorb BVS, quality-of-life outcomes after PCI or bypass, and chronic total occlusion PCI are discussed in this week's podcast.
Statins tied to diabetes risk and reduced bacterial infections, a novel use for hs-troponin, mitral-regurgitation management, and His-bundle pacing are reviewed in this week's podcast.
Secondary AF, Heart failure statistics, DOAC bleeding rates, uncontrolled hypertension and stroke risk factors are discussed by John Mandrola in this week's podcast.
Noninvasive tests for chest pain evaluation, the obesity epidemic, the costs of cardiac device recalls, and DOAC-drug interactions are reviewed in this week's podcast.
Stopping aspirin, TAVR durability, meditation, triathlon risk, and BP control in low-income patients are discussed by Dr Mandrola in this week's podcast.
Oxygen therapy in stroke, physical activity, hospital rankings, MRI labeling of cardiac devices, and PFO closure are discussed in this week's podcast.
PCSK9 drugs and diabetes, allegations against St Jude Medical, trends in carotid interventions, food as medicine, and death with dignity are discussed by Dr John Mandrola in this week's podcast.
PFO closure for recurrent stroke prevention, hormone replacement in women, DAPT, obesity, and fentanyl are discussed in this week's podcast.